{"4bbcea8f14eb49b7e673efd140db38112b218617": [["The authors warn that, in the context of Yemen, the closure of humanitarian lifesaving programmes and shifting support toward health security, i.e. to support COVID-19 response, at the expense of primary health care support, will undermine existing health system strengthening efforts, worsen the humanitarian crisis and will accentuate the impact of COVID-19.", [["COVID-19", "CHEMICAL", 351, 359], ["humanitarian lifesaving programmes", "TREATMENT", 63, 97], ["shifting support", "TREATMENT", 102, 118], ["primary health care support", "TREATMENT", 196, 223], ["the humanitarian crisis", "PROBLEM", 293, 316], ["COVID", "TEST", 351, 356]]], ["The authors urge the international community and the Government of Yemen to carefully consider a more comprehensive approach to support Yemen's COVID-19 response while maintaining, and strengthening, essential public health services.Key words:COVID-19; UHC; humanitarian aid; health system; conflict; fragility; Yemen; outbreak.Key words:In 2018, Ooms and colleagues flagged the conflicting agendas in global health: universal health coverage (UHC), health security and health promotion as a challenge to achieving the sustainable development goals and UHC.", [["Yemen's COVID", "TEST", 136, 149], ["fragility", "PROBLEM", 301, 310], ["outbreak", "PROBLEM", 319, 327]]], ["1 This fragmentation affects the health system in Yemen; while the country reports its first COVID-19 confirmed case on April 10th, 2020 and is intensifying its efforts to contain the pandemic, it is worrying to witness the shortcoming of public health programmes' funding, which will force the United Nations in Yemen to phase out or close more than 30 lifesaving humanitarian and health projects by the end of April.", [["fragmentation", "OBSERVATION", 7, 20]]], ["2 In this commentary, we highlight the devastating impact of withdrawing and decreasing support to humanitarian operations and primary health care (PHC) in Yemen in the context of COVID-19 and conflict.Key words:Yemen has been struggling with a protracted conflict that shocked its vulnerable population.", [["humanitarian operations", "TREATMENT", 99, 122], ["COVID", "TEST", 180, 185], ["devastating", "OBSERVATION_MODIFIER", 39, 50]]], ["The humanitarian situation in Yemen continues to deteriorate, where nearly half of the population are in an acute need for health care.", [["health care", "TREATMENT", 123, 134], ["acute", "OBSERVATION_MODIFIER", 108, 113]]], ["4 On top of the most massive cholera epidemic in modern history, vaccinepreventable outbreaks such as diphtheria and measles continue to spread.", [["cholera", "DISEASE", 29, 36], ["diphtheria", "DISEASE", 102, 112], ["measles", "DISEASE", 117, 124], ["vaccinepreventable outbreaks", "PROBLEM", 65, 93], ["diphtheria", "PROBLEM", 102, 112], ["measles", "PROBLEM", 117, 124], ["massive", "OBSERVATION_MODIFIER", 21, 28]]], ["5 Poor health indicators are predominant, with suboptimal vaccine coverage, high maternal and child mortality, and increasing prevalence of acute and chronic malnutrition, to name a few.", [["malnutrition", "DISEASE", 158, 170], ["suboptimal vaccine coverage", "TREATMENT", 47, 74], ["acute and chronic malnutrition", "PROBLEM", 140, 170], ["predominant", "OBSERVATION_MODIFIER", 29, 40], ["acute", "OBSERVATION_MODIFIER", 140, 145], ["chronic", "OBSERVATION_MODIFIER", 150, 157], ["malnutrition", "OBSERVATION", 158, 170]]], ["6 The ongoing conflict, huge displacement, natural disasters, inflated economy and the fragile, fragmented health system will accentuate the impact of COVID-19 outbreak at all levels.", [["huge displacement", "PROBLEM", 24, 41], ["inflated economy", "TREATMENT", 62, 78], ["the fragile, fragmented health system", "PROBLEM", 83, 120], ["COVID", "TEST", 151, 156], ["huge", "OBSERVATION_MODIFIER", 24, 28], ["displacement", "OBSERVATION_MODIFIER", 29, 41], ["inflated", "OBSERVATION_MODIFIER", 62, 70], ["economy", "OBSERVATION_MODIFIER", 71, 78], ["fragile", "OBSERVATION_MODIFIER", 87, 94], ["fragmented", "OBSERVATION_MODIFIER", 96, 106]]], ["In a country where only 50% of the health facilities being fully functional and UHC service coverage index of 39 out of 100 (60, 63 in Syria and Iraq, respectively), 7 the consequences will be disastrous if policymakers and donors shifted their priorities and funding to COVID-19 response without strengthening PHC along with its community and preventative components.Key words:The humanitarian response plan provides a glimpse of hope in restoring some public health services in Yemen.", [["donors", "ORGANISM", 224, 230], ["coverage index", "TEST", 92, 106], ["COVID", "TEST", 271, 276], ["strengthening PHC", "PROBLEM", 297, 314]]], ["For instance, the health stakeholders are working with the Ministry of Public Health and Population (MOPHP) to deliver priority health services, including nationwide malnutrition treatment programmes.", [["malnutrition", "DISEASE", 166, 178], ["malnutrition treatment programmes", "TREATMENT", 166, 199]]], ["8 Nevertheless, the recent announcement by the United Nations Office for the Coordination of Humanitarian Affairs (OCHA) 2 on shutting down lifesaving interventions in Yemen, including health, due to lack of funds, is alarming and needs due revision by donor countries.Key words:Furthermore, in light of COVID-19 and conflict, we believe that the international community should look at Yemen differently for two reasons.", [["lifesaving interventions", "TREATMENT", 140, 164], ["revision", "TREATMENT", 241, 249]]], ["However, Yemen has 24.1 million people in need for humanitarian aid with more than two thirds at high risk for contracting diseases, 3 making the people of Yemen extremely vulnerable to COVID-19 and communicable diseases.", [["communicable diseases", "DISEASE", 199, 220], ["people", "ORGANISM", 32, 38], ["people", "ORGANISM", 146, 152], ["people", "SPECIES", 32, 38], ["people", "SPECIES", 146, 152], ["humanitarian aid", "TREATMENT", 51, 67], ["contracting diseases", "PROBLEM", 111, 131], ["COVID", "TEST", 186, 191], ["communicable diseases", "PROBLEM", 199, 220], ["diseases", "OBSERVATION", 123, 131]]], ["Secondly, while global evidence shows that children are less affected by COVID-19 in some countries, 9 it is essential to notice that these countries, unlike Yemen, are not facing conflict, displacement, exhausted health system, food insecurity, or major economic crisis.", [["food insecurity", "DISEASE", 229, 244], ["children", "ORGANISM", 43, 51], ["children", "SPECIES", 43, 51], ["major economic crisis", "PROBLEM", 249, 270], ["economic crisis", "OBSERVATION", 255, 270]]], ["Around 2 million under-five children in Yemen are severely malnourished and 12 times at higher risk of death due to infectious diseases, compared to non-malnourished children.", [["death", "DISEASE", 103, 108], ["infectious diseases", "DISEASE", 116, 135], ["children", "ORGANISM", 28, 36], ["children", "ORGANISM", 166, 174], ["children", "SPECIES", 28, 36], ["children", "SPECIES", 166, 174], ["severely malnourished", "PROBLEM", 50, 71], ["death", "PROBLEM", 103, 108], ["infectious diseases", "PROBLEM", 116, 135], ["infectious", "OBSERVATION", 116, 126]]], ["10 We fear that pooling financial and technical resources toward COVID-19 response at the expense of essential public health services will have a drastic impact on Yemen's PHC and will nurture an environment for more severe outbreaks, i.e. another wave of cholera.", [["cholera", "DISEASE", 256, 263], ["COVID", "TEST", 65, 70], ["Yemen's PHC", "TREATMENT", 164, 175], ["more severe outbreaks", "PROBLEM", 212, 233], ["cholera", "PROBLEM", 256, 263]]], ["Therefore, intensifying efforts to combat COVID-19 in Yemen should run in tandem with maintaining and strengthening core health services across the continuum of care so that no one is left behind.", [["COVID", "TREATMENT", 42, 47], ["left", "ANATOMY_MODIFIER", 184, 188]]], ["This approach is in line with WHO guidance on prioritisation of basic health services in the context of COVID-19.", [["COVID", "TEST", 104, 109]]], ["11 There is a value in adopting this approach, as strengthening PHC at the facility and community level will benefit the current MOPHP mitigation and containment measures against COVID-19 and vice versa.Key words:We urge the international community and the Yemeni Government to continue and expand their leverage to sustain essential health services and to revisit the decision to shut down some aid programmes.", [["COVID-19", "CHEMICAL", 179, 187], ["this approach", "TREATMENT", 32, 45], ["the current MOPHP mitigation", "TREATMENT", 117, 145], ["containment measures", "TREATMENT", 150, 170], ["COVID", "TEST", 179, 184]]], ["This action will prevent a worsening humanitarian crisis and emerging outbreaks and will support Yemen's overstretched health system in its fight against COVID-19 and the progress toward UHC.", [["UHC", "CANCER", 187, 190], ["a worsening humanitarian crisis", "PROBLEM", 25, 56], ["worsening", "OBSERVATION_MODIFIER", 27, 36], ["humanitarian crisis", "OBSERVATION", 37, 56]]]], "cf4267556daa18262b0f7727f325b94a53b2f2b1": [["INTRODUCTIONDuchenne muscular dystrophy (DMD) is a severe muscle degenerative disorder characterized by mutations that disrupt the reading frame in the dystrophin (DMD) gene leading to the absence of functional protein (1) .", [["muscular", "ANATOMY", 21, 29], ["muscle", "ANATOMY", 58, 64], ["muscular dystrophy", "DISEASE", 21, 39], ["DMD", "DISEASE", 41, 44], ["muscle degenerative disorder", "DISEASE", 58, 86], ["muscle", "ORGAN", 58, 64], ["dystrophin", "GENE_OR_GENE_PRODUCT", 152, 162], ["DMD", "GENE_OR_GENE_PRODUCT", 164, 167], ["reading frame", "DNA", 131, 144], ["dystrophin (DMD) gene", "DNA", 152, 173], ["INTRODUCTIONDuchenne muscular dystrophy", "PROBLEM", 0, 39], ["DMD", "PROBLEM", 41, 44], ["a severe muscle degenerative disorder", "PROBLEM", 49, 86], ["mutations", "PROBLEM", 104, 113], ["the dystrophin (DMD", "PROBLEM", 148, 167], ["muscular dystrophy", "OBSERVATION", 21, 39], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["muscle", "ANATOMY", 58, 64], ["degenerative", "OBSERVATION", 65, 77]]], ["A related allelic disorder, Becker muscular dystrophy (BMD), is caused by mutations that give rise to shortened but in-frame transcripts resulting in the production of truncated but partially functional protein.", [["muscular", "ANATOMY", 35, 43], ["allelic disorder", "DISEASE", 10, 26], ["Becker muscular dystrophy", "DISEASE", 28, 53], ["Becker muscular", "TISSUE", 28, 43], ["A related allelic disorder", "PROBLEM", 0, 26], ["Becker muscular dystrophy", "PROBLEM", 28, 53], ["mutations", "PROBLEM", 74, 83], ["partially functional protein", "PROBLEM", 182, 210], ["allelic disorder", "OBSERVATION", 10, 26], ["muscular dystrophy", "OBSERVATION", 35, 53]]], ["Such partially functional protein retains the critical amino terminal, cysteine rich and C-terminal domains but usually lacks elements of the central rod domains which are of less functional significance (2) .", [["amino", "CHEMICAL", 55, 60], ["cysteine", "CHEMICAL", 71, 79], ["C", "CHEMICAL", 89, 90], ["cysteine", "AMINO_ACID", 71, 79], ["amino terminal, cysteine rich and C-terminal domains", "PROTEIN", 55, 107], ["central rod domains", "PROTEIN", 142, 161], ["C-terminal domains", "PROBLEM", 89, 107], ["the central rod domains", "PROBLEM", 138, 161], ["functional protein", "OBSERVATION", 15, 33], ["cysteine rich", "OBSERVATION", 71, 84], ["central rod", "OBSERVATION", 142, 153], ["less functional", "OBSERVATION_MODIFIER", 175, 190]]], ["As a consequence, BMD phenotypes range from mild DMD to virtually asymptomatic, depending on the precise mutation and the level of dystrophin produced.INTRODUCTIONAntisense oligonucleotide (AO)-mediated splice modification of out-of-frame dystrophin transcripts has been demonstrated to exclude specific dystrophin exons, thereby restoring the open reading frame and resulting in the production of Becker-like, shortened but partially functional dystrophin protein (3 -13) .", [["DMD", "DISEASE", 49, 52], ["dystrophin", "GENE_OR_GENE_PRODUCT", 131, 141], ["dystrophin", "GENE_OR_GENE_PRODUCT", 239, 249], ["dystrophin", "GENE_OR_GENE_PRODUCT", 304, 314], ["dystrophin", "GENE_OR_GENE_PRODUCT", 446, 456], ["dystrophin", "PROTEIN", 131, 141], ["dystrophin transcripts", "RNA", 239, 261], ["dystrophin exons", "DNA", 304, 320], ["open reading frame", "DNA", 344, 362], ["dystrophin protein", "PROTEIN", 446, 464], ["BMD phenotypes range", "PROBLEM", 18, 38], ["mild DMD", "PROBLEM", 44, 52], ["virtually asymptomatic", "PROBLEM", 56, 78], ["the precise mutation", "PROBLEM", 93, 113], ["INTRODUCTIONAntisense oligonucleotide (AO)-mediated splice modification", "TREATMENT", 151, 222], ["out-of-frame dystrophin transcripts", "TREATMENT", 226, 261], ["specific dystrophin exons", "PROBLEM", 295, 320], ["partially functional dystrophin protein", "PROBLEM", 425, 464], ["mild", "OBSERVATION_MODIFIER", 44, 48], ["DMD", "OBSERVATION", 49, 52]]], ["Utilizing 2 0 O-methyl modified oligonucleotides delivered by direct intramuscular injection, Lu et al. (8) demonstrated molecular correction of a dystrophin transcript in mdx mice bearing a nonsense mutation in exon 23, resulting in local dystrophin production and functional improvement.", [["intramuscular", "ANATOMY", 69, 82], ["O-methyl", "CHEMICAL", 14, 22], ["2 0 O-methyl modified oligonucleotides", "SIMPLE_CHEMICAL", 10, 48], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 69, 82], ["dystrophin", "GENE_OR_GENE_PRODUCT", 147, 157], ["mdx mice", "ORGANISM", 172, 180], ["dystrophin", "GENE_OR_GENE_PRODUCT", 240, 250], ["dystrophin transcript", "RNA", 147, 168], ["exon 23", "DNA", 212, 219], ["dystrophin", "PROTEIN", 240, 250], ["mice", "SPECIES", 176, 180], ["mice", "SPECIES", 176, 180], ["2 0 O-methyl modified oligonucleotides", "TREATMENT", 10, 48], ["direct intramuscular injection", "TREATMENT", 62, 92], ["a dystrophin transcript", "TREATMENT", 145, 168], ["a nonsense mutation", "PROBLEM", 189, 208], ["local dystrophin production", "PROBLEM", 234, 261], ["dystrophin transcript", "OBSERVATION", 147, 168], ["local dystrophin production", "OBSERVATION", 234, 261], ["functional", "OBSERVATION_MODIFIER", 266, 276], ["improvement", "OBSERVATION_MODIFIER", 277, 288]]], ["Proof-of-principle for this therapeutic approach has also been successfully shown in human subjects using a similar local intramuscular AO-injection protocol (11) .INTRODUCTIONTo develop AO-mediated exon-skipping as an effective therapy for DMD will require systemic correction of the molecular defect, including in cardiac muscle.", [["intramuscular", "ANATOMY", 122, 135], ["cardiac muscle", "ANATOMY", 316, 330], ["DMD", "DISEASE", 241, 244], ["cardiac muscle", "DISEASE", 316, 330], ["human", "ORGANISM", 85, 90], ["AO", "SIMPLE_CHEMICAL", 136, 138], ["AO", "SIMPLE_CHEMICAL", 187, 189], ["cardiac muscle", "TISSUE", 316, 330], ["human", "SPECIES", 85, 90], ["human", "SPECIES", 85, 90], ["this therapeutic approach", "TREATMENT", 23, 48], ["a similar local intramuscular AO-injection protocol", "TREATMENT", 106, 157], ["AO-mediated exon-skipping", "TREATMENT", 187, 212], ["an effective therapy", "TREATMENT", 216, 236], ["DMD", "PROBLEM", 241, 244], ["systemic correction", "TREATMENT", 258, 277], ["the molecular defect", "PROBLEM", 281, 301], ["molecular defect", "OBSERVATION", 285, 301], ["cardiac muscle", "ANATOMY", 316, 330]]], ["Given that cardiomyopathy is a significant cause of morbidity and death in DMD patients, restoration of dystrophin expression in heart is a critical requirement for successful exon skipping therapy (14, 15) .", [["heart", "ANATOMY", 129, 134], ["cardiomyopathy", "DISEASE", 11, 25], ["death", "DISEASE", 66, 71], ["DMD", "DISEASE", 75, 78], ["patients", "ORGANISM", 79, 87], ["dystrophin", "GENE_OR_GENE_PRODUCT", 104, 114], ["heart", "ORGAN", 129, 134], ["dystrophin", "PROTEIN", 104, 114], ["exon", "DNA", 176, 180], ["patients", "SPECIES", 79, 87], ["cardiomyopathy", "PROBLEM", 11, 25], ["morbidity", "PROBLEM", 52, 61], ["death", "PROBLEM", 66, 71], ["dystrophin expression in heart", "PROBLEM", 104, 134], ["a critical requirement", "PROBLEM", 138, 160], ["successful exon skipping therapy", "TREATMENT", 165, 197], ["cardiomyopathy", "OBSERVATION", 11, 25], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["morbidity", "OBSERVATION", 52, 61], ["dystrophin expression", "OBSERVATION", 104, 125], ["heart", "ANATOMY", 129, 134]]], ["Previous work has shown that alternative chemistry phosphorodiamidate morpholino oligomers (PMO) are capable of restoring dystrophin expression in multiple muscle groups following systemic intravenous delivery in mdx mice, but this required a high-dose multi-injection protocol and molecular correction in cardiac muscle was not observed (4).INTRODUCTIONShort, positively charged arginine-rich peptides have been shown to function as cell penetrating peptides, enhancing the cell uptake of a variety of cargoes including oligonucleotides (16) .", [["muscle", "ANATOMY", 156, 162], ["intravenous", "ANATOMY", 189, 200], ["cardiac muscle", "ANATOMY", 306, 320], ["cell", "ANATOMY", 434, 438], ["cell", "ANATOMY", 475, 479], ["phosphorodiamidate", "CHEMICAL", 51, 69], ["PMO", "CHEMICAL", 92, 95], ["arginine", "CHEMICAL", 380, 388], ["phosphorodiamidate", "CHEMICAL", 51, 69], ["arginine", "CHEMICAL", 380, 388], ["phosphorodiamidate morpholino oligomers", "SIMPLE_CHEMICAL", 51, 90], ["PMO", "SIMPLE_CHEMICAL", 92, 95], ["dystrophin", "GENE_OR_GENE_PRODUCT", 122, 132], ["muscle", "ORGAN", 156, 162], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 189, 200], ["mdx mice", "ORGANISM", 213, 221], ["cardiac muscle", "TISSUE", 306, 320], ["arginine", "AMINO_ACID", 380, 388], ["cell", "CELL", 434, 438], ["cell", "CELL", 475, 479], ["dystrophin", "PROTEIN", 122, 132], ["mice", "SPECIES", 217, 221], ["mice", "SPECIES", 217, 221], ["alternative chemistry phosphorodiamidate morpholino oligomers", "TREATMENT", 29, 90], ["restoring dystrophin expression", "PROBLEM", 112, 143], ["systemic intravenous delivery in mdx mice", "TREATMENT", 180, 221], ["a high-dose multi-injection protocol", "TREATMENT", 241, 277], ["cell penetrating peptides", "TEST", 434, 459], ["oligonucleotides", "TEST", 521, 537], ["dystrophin expression", "OBSERVATION", 122, 143], ["muscle", "ANATOMY", 156, 162], ["cardiac muscle", "ANATOMY", 306, 320], ["cell uptake", "OBSERVATION", 475, 486]]], ["Such peptide -oligonucleotide conjugates have been previously demonstrated to effect splice correction of mutant dystrophin transcripts in cell culture and also in neonatal mdx mice via intraperitoneal injection, demonstrating their potential for enhancing the delivery and exon-skipping efficacy of AOs (17, 18) .", [["cell culture", "ANATOMY", 139, 151], ["intraperitoneal", "ANATOMY", 186, 201], ["dystrophin", "GENE_OR_GENE_PRODUCT", 113, 123], ["cell culture", "CELL", 139, 151], ["mdx mice", "ORGANISM", 173, 181], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 186, 201], ["AOs", "SIMPLE_CHEMICAL", 300, 303], ["mutant dystrophin transcripts", "RNA", 106, 135], ["mice", "SPECIES", 177, 181], ["mice", "SPECIES", 177, 181], ["Such peptide -oligonucleotide conjugates", "PROBLEM", 0, 40], ["mutant dystrophin transcripts", "PROBLEM", 106, 135], ["cell culture", "TEST", 139, 151], ["intraperitoneal injection", "TREATMENT", 186, 211], ["enhancing the delivery", "TREATMENT", 247, 269], ["AOs", "TEST", 300, 303], ["dystrophin transcripts", "OBSERVATION", 113, 135], ["intraperitoneal", "ANATOMY", 186, 201]]], ["Here we evaluate two arginine-rich peptide-PMO conjugates in adult mdx mice by systemic intravenous injection and demonstrate highly effective and widespread dystrophin correction in multiple peripheral skeletal muscles and in cardiac muscle, at low systemic AO doses.RESULTSTo test whether improved systemic AO delivery and cardiac dystrophin correction could be obtained in mdx dystrophic mice, we investigated a previously described arginine-rich peptide-PMO conjugate, P007-PMO, and a novel conjugate B-PMO (see Table 1 for AO and peptide sequence information).", [["intravenous", "ANATOMY", 88, 99], ["peripheral skeletal muscles", "ANATOMY", 192, 219], ["cardiac muscle", "ANATOMY", 227, 241], ["cardiac", "ANATOMY", 325, 332], ["arginine", "CHEMICAL", 21, 29], ["arginine", "CHEMICAL", 436, 444], ["P007-PMO", "CHEMICAL", 473, 481], ["arginine", "CHEMICAL", 21, 29], ["arginine", "CHEMICAL", 436, 444], ["arginine-rich peptide", "SIMPLE_CHEMICAL", 21, 42], ["mdx mice", "ORGANISM", 67, 75], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 88, 99], ["dystrophin", "GENE_OR_GENE_PRODUCT", 158, 168], ["skeletal muscles", "TISSUE", 203, 219], ["cardiac muscle", "TISSUE", 227, 241], ["AO", "SIMPLE_CHEMICAL", 309, 311], ["cardiac", "ORGAN", 325, 332], ["dystrophin", "GENE_OR_GENE_PRODUCT", 333, 343], ["mdx dystrophic mice", "ORGANISM", 376, 395], ["arginine-rich peptide", "SIMPLE_CHEMICAL", 436, 457], ["PMO", "SIMPLE_CHEMICAL", 458, 461], ["P007-PMO", "SIMPLE_CHEMICAL", 473, 481], ["B-PMO", "SIMPLE_CHEMICAL", 505, 510], ["AO", "SIMPLE_CHEMICAL", 528, 530], ["dystrophin", "PROTEIN", 158, 168], ["dystrophin", "PROTEIN", 333, 343], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 391, 395], ["mice", "SPECIES", 71, 75], ["mice", "SPECIES", 391, 395], ["arginine-rich peptide", "TREATMENT", 21, 42], ["PMO conjugates", "TREATMENT", 43, 57], ["systemic intravenous injection", "TREATMENT", 79, 109], ["widespread dystrophin correction in multiple peripheral skeletal muscles", "PROBLEM", 147, 219], ["RESULTSTo test", "TEST", 268, 282], ["systemic AO delivery", "TREATMENT", 300, 320], ["cardiac dystrophin correction", "TREATMENT", 325, 354], ["arginine-rich peptide", "TREATMENT", 436, 457], ["widespread", "OBSERVATION_MODIFIER", 147, 157], ["dystrophin correction", "OBSERVATION", 158, 179], ["multiple", "ANATOMY_MODIFIER", 183, 191], ["peripheral", "ANATOMY_MODIFIER", 192, 202], ["skeletal muscles", "ANATOMY", 203, 219], ["cardiac muscle", "ANATOMY", 227, 241], ["cardiac", "ANATOMY", 325, 332], ["dystrophin", "OBSERVATION", 333, 343]]], ["Peptides were conjugated to PMO AOs targeting the murine dystrophin exon 23 5 0 splice donor site, using an established 25mer target sequence.", [["PMO AOs", "SIMPLE_CHEMICAL", 28, 35], ["murine", "ORGANISM", 50, 56], ["dystrophin", "GENE_OR_GENE_PRODUCT", 57, 67], ["murine dystrophin exon 23 5 0 splice donor site", "DNA", 50, 97], ["25mer target sequence", "DNA", 120, 141], ["murine", "SPECIES", 50, 56], ["Peptides", "TREATMENT", 0, 8], ["the murine dystrophin exon", "TREATMENT", 46, 72]]], ["Conjugates were evaluated initially by intramuscular delivery into adult 6 -8-week-old mdx tibialis anterior (TA) muscles and demonstrated to promote high levels of dystrophin protein restoration as shown by the widespread dystrophin-positive muscle fibres throughout muscle cross-sections by immunostaining (Supplementary Material, Fig. S1 ) and western blot (data not shown).", [["intramuscular", "ANATOMY", 39, 52], ["mdx tibialis anterior (TA) muscles", "ANATOMY", 87, 121], ["muscle fibres", "ANATOMY", 243, 256], ["muscle cross-sections", "ANATOMY", 268, 289], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 39, 52], ["mdx", "TISSUE", 87, 90], ["tibialis anterior", "TISSUE", 91, 108], ["TA) muscles", "TISSUE", 110, 121], ["dystrophin", "GENE_OR_GENE_PRODUCT", 165, 175], ["dystrophin", "GENE_OR_GENE_PRODUCT", 223, 233], ["muscle fibres", "TISSUE", 243, 256], ["muscle cross-sections", "MULTI-TISSUE_STRUCTURE", 268, 289], ["dystrophin", "PROTEIN", 165, 175], ["dystrophin", "PROTEIN", 223, 233], ["S1", "PROTEIN", 338, 340], ["dystrophin protein restoration", "TREATMENT", 165, 195], ["the widespread dystrophin-positive muscle fibres", "PROBLEM", 208, 256], ["western blot", "TEST", 347, 359], ["mdx tibialis", "ANATOMY", 87, 99], ["anterior", "ANATOMY_MODIFIER", 100, 108], ["muscles", "ANATOMY", 114, 121], ["dystrophin protein restoration", "OBSERVATION", 165, 195], ["widespread", "OBSERVATION_MODIFIER", 212, 222], ["dystrophin", "OBSERVATION", 223, 233], ["positive muscle fibres", "OBSERVATION", 234, 256], ["muscle", "ANATOMY", 268, 274]]], ["We then went on to evaluate these compounds by systemic intravenous delivery in adult mdx mice.RESULTSSingle low-dose PMO-peptide conjugates restore dystrophin expression in muscle and cardiac tissue Given the high-level intramuscular correction obtained with the two PMO-peptide conjugates, we therefore investigated whether single intravenous injections of these PMO conjugates could restore dystrophin expression systemically.", [["intravenous", "ANATOMY", 56, 67], ["muscle", "ANATOMY", 174, 180], ["cardiac tissue", "ANATOMY", 185, 199], ["intravenous", "ANATOMY", 333, 344], ["PMO", "CHEMICAL", 365, 368], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 56, 67], ["mdx mice", "ORGANISM", 86, 94], ["PMO-peptide conjugates", "SIMPLE_CHEMICAL", 118, 140], ["dystrophin", "GENE_OR_GENE_PRODUCT", 149, 159], ["muscle", "ORGAN", 174, 180], ["cardiac tissue", "TISSUE", 185, 199], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 221, 234], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 333, 344], ["PMO conjugates", "SIMPLE_CHEMICAL", 365, 379], ["dystrophin", "GENE_OR_GENE_PRODUCT", 394, 404], ["dystrophin", "PROTEIN", 149, 159], ["dystrophin", "PROTEIN", 394, 404], ["mice", "SPECIES", 90, 94], ["mice", "SPECIES", 90, 94], ["systemic intravenous delivery in adult mdx mice", "TREATMENT", 47, 94], ["RESULTSSingle low-dose PMO", "TREATMENT", 95, 121], ["peptide conjugates", "TREATMENT", 122, 140], ["dystrophin expression in muscle and cardiac tissue", "PROBLEM", 149, 199], ["the high-level intramuscular correction", "TREATMENT", 206, 245], ["the two PMO-peptide conjugates", "TREATMENT", 260, 290], ["single intravenous injections", "TREATMENT", 326, 355], ["these PMO conjugates", "TREATMENT", 359, 379], ["dystrophin expression systemically", "PROBLEM", 394, 428], ["dystrophin expression", "OBSERVATION", 149, 170], ["muscle", "ANATOMY", 174, 180], ["cardiac tissue", "ANATOMY", 185, 199]]], ["A 25 mg/kg single injection administration protocol was tested with the P007-PMO conjugate administered via the mouse tail vein.", [["tail vein", "ANATOMY", 118, 127], ["P007", "CHEMICAL", 72, 76], ["P007-PMO conjugate", "SIMPLE_CHEMICAL", 72, 90], ["mouse", "ORGANISM", 112, 117], ["tail vein", "MULTI-TISSUE_STRUCTURE", 118, 127], ["mouse", "SPECIES", 112, 117], ["mouse", "SPECIES", 112, 117], ["A 25 mg/kg single injection administration protocol", "TREATMENT", 0, 51], ["the P007-PMO conjugate", "TREATMENT", 68, 90], ["the mouse tail vein", "TREATMENT", 108, 127], ["tail vein", "ANATOMY", 118, 127]]], ["Three weeks following single injections, all skeletal muscle fibres immunostained positive for sarcolemmal dystrophin.", [["skeletal muscle fibres", "ANATOMY", 45, 67], ["sarcolemmal", "ANATOMY", 95, 106], ["skeletal muscle fibres", "TISSUE", 45, 67], ["sarcolemmal dystrophin", "GENE_OR_GENE_PRODUCT", 95, 117], ["sarcolemmal dystrophin", "PROTEIN", 95, 117], ["single injections", "TREATMENT", 22, 39], ["all skeletal muscle fibres", "TEST", 41, 67], ["sarcolemmal dystrophin", "PROBLEM", 95, 117], ["skeletal muscle", "ANATOMY", 45, 60], ["sarcolemmal dystrophin", "OBSERVATION", 95, 117]]], ["The intensity of dystrophin expression was near normal in most skeletal muscle groups analysed, although slightly lower in biceps as shown (Fig. 1A) .", [["skeletal muscle", "ANATOMY", 63, 78], ["biceps", "ANATOMY", 123, 129], ["dystrophin", "GENE_OR_GENE_PRODUCT", 17, 27], ["skeletal muscle", "ORGAN", 63, 78], ["biceps", "ORGANISM_SUBDIVISION", 123, 129], ["dystrophin", "PROTEIN", 17, 27], ["dystrophin expression", "PROBLEM", 17, 38], ["slightly lower in biceps", "PROBLEM", 105, 129], ["dystrophin expression", "OBSERVATION", 17, 38], ["skeletal muscle", "ANATOMY", 63, 78], ["slightly", "OBSERVATION_MODIFIER", 105, 113], ["lower", "OBSERVATION_MODIFIER", 114, 119], ["biceps", "ANATOMY", 123, 129]]], ["Widespread, uniform expression of dystrophin protein over multiple tissue sections within each muscle group was detected in hind limb, fore limb, abdominal wall and diaphragm muscles.", [["tissue sections", "ANATOMY", 67, 82], ["muscle", "ANATOMY", 95, 101], ["hind limb", "ANATOMY", 124, 133], ["fore limb", "ANATOMY", 135, 144], ["abdominal wall", "ANATOMY", 146, 160], ["diaphragm muscles", "ANATOMY", 165, 182], ["dystrophin", "GENE_OR_GENE_PRODUCT", 34, 44], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 67, 82], ["muscle", "ORGAN", 95, 101], ["hind limb", "ORGANISM_SUBDIVISION", 124, 133], ["fore limb", "ORGANISM_SUBDIVISION", 135, 144], ["abdominal wall", "MULTI-TISSUE_STRUCTURE", 146, 160], ["diaphragm muscles", "TISSUE", 165, 182], ["dystrophin protein", "PROTEIN", 34, 52], ["dystrophin protein over multiple tissue sections", "PROBLEM", 34, 82], ["uniform", "OBSERVATION_MODIFIER", 12, 19], ["expression", "OBSERVATION_MODIFIER", 20, 30], ["dystrophin protein", "OBSERVATION", 34, 52], ["multiple tissue", "OBSERVATION_MODIFIER", 58, 73], ["muscle", "ANATOMY", 95, 101], ["hind limb", "ANATOMY", 124, 133], ["fore limb", "ANATOMY", 135, 144], ["abdominal wall", "ANATOMY", 146, 160], ["diaphragm muscles", "ANATOMY", 165, 182]]], ["Surprisingly, no obvious area-toarea variation was found within individual muscle groups as previously reported with the systemic delivery of naked PMO AOs (4).", [["muscle", "ANATOMY", 75, 81], ["muscle", "ORGAN", 75, 81], ["obvious area-toarea variation", "PROBLEM", 17, 46], ["no", "UNCERTAINTY", 14, 16], ["obvious", "OBSERVATION_MODIFIER", 17, 24], ["area-toarea", "OBSERVATION", 25, 36]]], ["RT-PCR results revealed almost total exon skipping of the mutated transcript with highly effective skipping of mdx dystrophin exon 23 (Fig. 1B) in all skeletal muscles analysed including the diaphragm.", [["skeletal muscles", "ANATOMY", 151, 167], ["diaphragm", "ANATOMY", 191, 200], ["1B", "GENE_OR_GENE_PRODUCT", 140, 142], ["skeletal muscles", "ORGAN", 151, 167], ["diaphragm", "ORGAN", 191, 200], ["mdx dystrophin exon 23", "DNA", 111, 133], ["RT-PCR", "TEST", 0, 6], ["the mutated transcript", "PROBLEM", 54, 76], ["mdx dystrophin exon", "PROBLEM", 111, 130], ["all", "ANATOMY_MODIFIER", 147, 150], ["skeletal muscles", "ANATOMY", 151, 167], ["diaphragm", "ANATOMY", 191, 200]]], ["Less efficient molecular correction was observed in heart, where 50% of the mutated transcript was found to be exon skipped by RT-PCR.", [["heart", "ANATOMY", 52, 57], ["heart", "ORGAN", 52, 57], ["mutated transcript", "RNA", 76, 94], ["PCR", "TEST", 130, 133], ["molecular correction", "OBSERVATION", 15, 35], ["heart", "ANATOMY", 52, 57]]], ["A shorter band was also detected in the RT-PCR assay in many analysed tissues, which was likely to correspond to a skipped transcript lacking exons 22 and 23.", [["tissues", "ANATOMY", 70, 77], ["tissues", "TISSUE", 70, 77], ["exons 22 and 23", "DNA", 142, 157], ["A shorter band", "PROBLEM", 0, 14], ["the RT-PCR assay", "TEST", 36, 52], ["a skipped transcript lacking exons", "PROBLEM", 113, 147]]], ["Subsequent sequencing of this PCR fragment confirmed that the minor transcript product contained exon 22 and 23 deletions (data not shown).", [["PCR fragment", "DNA", 30, 42], ["exon 22", "DNA", 97, 104], ["this PCR fragment", "TEST", 25, 42], ["the minor transcript product", "PROBLEM", 58, 86], ["exon 22 and 23 deletions", "PROBLEM", 97, 121]]], ["To quantify the levels of dystrophin protein restored, western blot analysis was undertaken, using total protein extracted from all muscle groups including heart, and from normal C57 TA and heart muscle tissues as positive controls.", [["muscle", "ANATOMY", 132, 138], ["heart", "ANATOMY", 156, 161], ["C57 TA", "ANATOMY", 179, 185], ["heart muscle tissues", "ANATOMY", 190, 210], ["dystrophin", "GENE_OR_GENE_PRODUCT", 26, 36], ["muscle", "ORGAN", 132, 138], ["heart", "ORGAN", 156, 161], ["C57 TA", "TISSUE", 179, 185], ["heart muscle tissues", "TISSUE", 190, 210], ["dystrophin protein", "PROTEIN", 26, 44], ["dystrophin protein", "PROBLEM", 26, 44], ["western blot analysis", "TEST", 55, 76], ["total protein", "TREATMENT", 99, 112], ["heart", "ANATOMY", 156, 161], ["heart", "ANATOMY", 190, 195], ["muscle tissues", "ANATOMY", 196, 210], ["positive", "OBSERVATION", 214, 222]]], ["This indicated that between 25 and 100% of normal dystrophin protein levels had been restored in body-wide skeletal muscles following the single systemic AO injection.", [["body", "ANATOMY", 97, 101], ["skeletal muscles", "ANATOMY", 107, 123], ["dystrophin", "GENE_OR_GENE_PRODUCT", 50, 60], ["body", "ORGANISM_SUBDIVISION", 97, 101], ["skeletal muscles", "ORGAN", 107, 123], ["dystrophin protein", "PROTEIN", 50, 68], ["normal dystrophin protein levels", "TEST", 43, 75], ["the single systemic AO injection", "TREATMENT", 134, 166], ["wide", "OBSERVATION_MODIFIER", 102, 106], ["skeletal muscles", "ANATOMY", 107, 123]]], ["Of particular significance were the levels approaching 100% restoration of dystrophin protein that were detected in distal muscle groups, i.e. TA and biceps, while even in the diaphragm almost 25% of normal dystrophin protein was restored (Fig. 1C) .RESULTSCardiac tissue from treated mice was also analysed by immunostaining and this too demonstrated widely distributed dystrophin-positive fibres throughout the cardiac muscle (Fig. 1A) .", [["distal muscle", "ANATOMY", 116, 129], ["biceps", "ANATOMY", 150, 156], ["diaphragm", "ANATOMY", 176, 185], ["RESULTSCardiac tissue", "ANATOMY", 250, 271], ["fibres", "ANATOMY", 391, 397], ["cardiac muscle", "ANATOMY", 413, 427], ["dystrophin", "GENE_OR_GENE_PRODUCT", 75, 85], ["muscle", "ORGAN", 123, 129], ["TA", "GENE_OR_GENE_PRODUCT", 143, 145], ["biceps", "ORGANISM_SUBDIVISION", 150, 156], ["diaphragm", "ORGAN", 176, 185], ["dystrophin", "GENE_OR_GENE_PRODUCT", 207, 217], ["RESULTSCardiac tissue", "TISSUE", 250, 271], ["mice", "ORGANISM", 285, 289], ["dystrophin", "GENE_OR_GENE_PRODUCT", 371, 381], ["cardiac muscle", "TISSUE", 413, 427], ["dystrophin protein", "PROTEIN", 75, 93], ["dystrophin protein", "PROTEIN", 207, 225], ["dystrophin", "PROTEIN", 371, 381], ["mice", "SPECIES", 285, 289], ["mice", "SPECIES", 285, 289], ["dystrophin protein", "PROBLEM", 75, 93], ["RESULTSCardiac tissue", "PROBLEM", 250, 271], ["immunostaining", "TEST", 311, 325], ["dystrophin protein", "OBSERVATION", 75, 93], ["distal", "ANATOMY_MODIFIER", 116, 122], ["muscle", "ANATOMY", 123, 129], ["biceps", "ANATOMY", 150, 156], ["diaphragm", "ANATOMY", 176, 185], ["dystrophin protein", "OBSERVATION", 207, 225], ["dystrophin", "OBSERVATION", 371, 381], ["positive fibres", "OBSERVATION", 382, 397], ["cardiac muscle", "ANATOMY", 413, 427]]], ["Dystrophin protein restoration was not found to be as high in heart as for peripheral skeletal muscle groups but levels of between 10 and 20% of that found in normal mouse heart were typically seen by western analysis in all treated animals (Fig. 1D ).", [["heart", "ANATOMY", 62, 67], ["peripheral skeletal muscle", "ANATOMY", 75, 101], ["heart", "ANATOMY", 172, 177], ["Dystrophin", "GENE_OR_GENE_PRODUCT", 0, 10], ["heart", "ORGAN", 62, 67], ["skeletal muscle", "ORGAN", 86, 101], ["mouse", "ORGANISM", 166, 171], ["heart", "ORGAN", 172, 177], ["Dystrophin protein", "PROTEIN", 0, 18], ["mouse", "SPECIES", 166, 171], ["mouse", "SPECIES", 166, 171], ["Dystrophin protein restoration", "PROBLEM", 0, 30], ["peripheral skeletal muscle groups", "TEST", 75, 108], ["levels", "TEST", 113, 119], ["protein restoration", "OBSERVATION", 11, 30], ["heart", "ANATOMY", 62, 67], ["peripheral", "ANATOMY_MODIFIER", 75, 85], ["skeletal muscle", "ANATOMY", 86, 101], ["normal", "OBSERVATION", 159, 165], ["mouse heart", "ANATOMY", 166, 177]]], ["This is the first demonstration of widespread dystrophin protein correction in the mdx mouse heart with such low AO doses.RESULTSComparison of P007-PMO with other arginine-rich PMO peptide conjugates P007-PMO contains alternating arginine and non-natural 6 aminohexanoic acid amino acids in an (RXR) 4 sequence.", [["heart", "ANATOMY", 93, 98], ["P007", "CHEMICAL", 143, 147], ["arginine", "CHEMICAL", 163, 171], ["P007-PMO", "CHEMICAL", 200, 208], ["arginine", "CHEMICAL", 230, 238], ["6 aminohexanoic acid amino acids", "CHEMICAL", 255, 287], ["arginine", "CHEMICAL", 163, 171], ["arginine", "CHEMICAL", 230, 238], ["6 aminohexanoic acid amino acids", "CHEMICAL", 255, 287], ["dystrophin", "GENE_OR_GENE_PRODUCT", 46, 56], ["mouse", "ORGANISM", 87, 92], ["heart", "ORGAN", 93, 98], ["P007-PMO", "SIMPLE_CHEMICAL", 143, 151], ["arginine-rich PMO peptide", "SIMPLE_CHEMICAL", 163, 188], ["P007-PMO", "SIMPLE_CHEMICAL", 200, 208], ["arginine", "AMINO_ACID", 230, 238], ["non-natural 6 aminohexanoic acid", "SIMPLE_CHEMICAL", 243, 275], ["amino acids", "AMINO_ACID", 276, 287], ["dystrophin protein", "PROTEIN", 46, 64], ["RXR", "PROTEIN", 295, 298], ["mouse", "SPECIES", 87, 92], ["mouse", "SPECIES", 87, 92], ["widespread dystrophin protein correction", "TREATMENT", 35, 75], ["the mdx mouse heart", "TREATMENT", 79, 98], ["such low AO doses", "TREATMENT", 104, 121], ["P007", "TEST", 143, 147], ["other arginine-rich PMO peptide conjugates", "TEST", 157, 199], ["alternating arginine", "TREATMENT", 218, 238], ["non-natural 6 aminohexanoic acid amino acids", "TREATMENT", 243, 287], ["an (RXR)", "TREATMENT", 291, 299], ["widespread", "OBSERVATION_MODIFIER", 35, 45], ["dystrophin protein correction", "OBSERVATION", 46, 75], ["mdx mouse", "OBSERVATION", 83, 92], ["heart", "ANATOMY", 93, 98], ["low AO", "OBSERVATION_MODIFIER", 109, 115]]], ["To test the efficacy of further modified arginine-rich PMO-peptide conjugates, we directly compared a second conjugate (B-PMO) containing a transduction peptide in which two 6 aminohexanoic acid residues were substituted with b-alanine residues, a second non-natural amino acid (see peptide sequences in Table 1 ).", [["arginine", "CHEMICAL", 41, 49], ["B-PMO", "CHEMICAL", 120, 125], ["aminohexanoic acid", "CHEMICAL", 176, 194], ["b-alanine", "CHEMICAL", 226, 235], ["amino acid", "CHEMICAL", 267, 277], ["arginine", "CHEMICAL", 41, 49], ["aminohexanoic acid", "CHEMICAL", 176, 194], ["b-alanine", "CHEMICAL", 226, 235], ["amino acid", "CHEMICAL", 267, 277], ["arginine-rich PMO-peptide conjugates", "SIMPLE_CHEMICAL", 41, 77], ["B-PMO", "SIMPLE_CHEMICAL", 120, 125], ["aminohexanoic acid", "SIMPLE_CHEMICAL", 176, 194], ["b-alanine", "SIMPLE_CHEMICAL", 226, 235], ["amino acid", "AMINO_ACID", 267, 277], ["further modified arginine-rich PMO", "TREATMENT", 24, 58], ["a second conjugate (B-PMO)", "TREATMENT", 100, 126], ["a transduction peptide", "TREATMENT", 138, 160], ["two 6 aminohexanoic acid residues", "TREATMENT", 170, 203], ["b-alanine residues", "TREATMENT", 226, 244], ["a second non-natural amino acid", "TREATMENT", 246, 277]]], ["Taking the same approach, B-PMO delivered by intravenous delivery also demonstrated highly effective systemic dystrophin correction in skeletal muscle and cardiac tissue but with a lower efficiency than the P007-PMO AO at the same dose, as shown by western analysis (Supplementary Material, Fig. S2 ).Evaluation of a lower-dose intravenous P007-PMO dosing protocol to optimize dystrophin correctionOur RT-PCR data above showed almost complete exon skipping at the RNA level in the majority of skeletal muscles following treatment with a 25 mg/kg AO dose, suggesting the possibility that the AO dose had reached near saturation in these tissues.", [["intravenous", "ANATOMY", 45, 56], ["skeletal muscle", "ANATOMY", 135, 150], ["cardiac tissue", "ANATOMY", 155, 169], ["intravenous", "ANATOMY", 328, 339], ["skeletal muscles", "ANATOMY", 493, 509], ["tissues", "ANATOMY", 636, 643], ["B-PMO", "CHEMICAL", 26, 31], ["P007", "CHEMICAL", 340, 344], ["AO", "CHEMICAL", 546, 548], ["B-PMO", "SIMPLE_CHEMICAL", 26, 31], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 45, 56], ["dystrophin", "GENE_OR_GENE_PRODUCT", 110, 120], ["skeletal muscle", "TISSUE", 135, 150], ["cardiac tissue", "TISSUE", 155, 169], ["P007-PMO AO", "SIMPLE_CHEMICAL", 207, 218], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 328, 339], ["P007", "SIMPLE_CHEMICAL", 340, 344], ["dystrophin", "GENE_OR_GENE_PRODUCT", 377, 387], ["skeletal muscles", "ORGAN", 493, 509], ["AO", "SIMPLE_CHEMICAL", 546, 548], ["AO", "SIMPLE_CHEMICAL", 591, 593], ["tissues", "TISSUE", 636, 643], ["dystrophin", "PROTEIN", 110, 120], ["S2", "PROTEIN", 296, 298], ["dystrophin", "PROTEIN", 377, 387], ["B-PMO", "TREATMENT", 26, 31], ["intravenous delivery", "TREATMENT", 45, 65], ["highly effective systemic dystrophin correction in skeletal muscle", "PROBLEM", 84, 150], ["cardiac tissue", "PROBLEM", 155, 169], ["a lower efficiency", "PROBLEM", 179, 197], ["Evaluation", "TEST", 301, 311], ["a lower-dose intravenous P007-PMO dosing protocol", "TREATMENT", 315, 364], ["dystrophin correctionOur RT-PCR data", "TEST", 377, 413], ["almost complete exon skipping", "PROBLEM", 427, 456], ["dystrophin correction", "OBSERVATION", 110, 131], ["skeletal muscle", "ANATOMY", 135, 150], ["cardiac tissue", "ANATOMY", 155, 169], ["lower efficiency", "OBSERVATION_MODIFIER", 181, 197], ["exon skipping", "OBSERVATION", 443, 456], ["majority", "ANATOMY_MODIFIER", 481, 489], ["skeletal muscles", "ANATOMY", 493, 509], ["tissues", "ANATOMY", 636, 643]]], ["Given this finding and that the half-life of dystrophin protein in vivo has been estimated at up to 26 weeks in mdx mice (19) , we decided to test whether modifications to the AO delivery protocol to include multiple lower-dose injections could improve molecular dystrophin correction without AO dose saturation in skeletal muscles.", [["skeletal muscles", "ANATOMY", 315, 331], ["dystrophin", "GENE_OR_GENE_PRODUCT", 45, 55], ["mdx mice", "ORGANISM", 112, 120], ["dystrophin", "GENE_OR_GENE_PRODUCT", 263, 273], ["AO", "SIMPLE_CHEMICAL", 293, 295], ["skeletal muscles", "ORGAN", 315, 331], ["dystrophin protein", "PROTEIN", 45, 63], ["dystrophin", "PROTEIN", 263, 273], ["mice", "SPECIES", 116, 120], ["mice", "SPECIES", 116, 120], ["dystrophin protein", "PROBLEM", 45, 63], ["the AO delivery protocol", "TREATMENT", 172, 196], ["multiple lower-dose injections", "TREATMENT", 208, 238], ["molecular dystrophin correction", "TREATMENT", 253, 284], ["AO dose saturation", "TEST", 293, 311], ["skeletal muscles", "ANATOMY", 315, 331]]], ["A protocol of weekly injections of P007-PMO at 6 mg/kg for 3 weeks resulted in a lower total AO dose administered and significantly improved molecular correction compared with age-matched controls in body-wide muscles as shown by immunostaining ( Fig. 2A) .", [["body", "ANATOMY", 200, 204], ["muscles", "ANATOMY", 210, 217], ["P007-PMO", "CHEMICAL", 35, 43], ["AO", "CHEMICAL", 93, 95], ["P007-PMO", "SIMPLE_CHEMICAL", 35, 43], ["AO", "SIMPLE_CHEMICAL", 93, 95], ["body", "ORGANISM_SUBDIVISION", 200, 204], ["muscles", "ORGAN", 210, 217], ["A protocol of weekly injections", "TREATMENT", 0, 31], ["P007-PMO", "TREATMENT", 35, 43], ["a lower total AO dose", "TREATMENT", 79, 100], ["wide muscles", "ANATOMY", 205, 217]]], ["High levels of dystrophin expression were detected in TA, quadriceps and gastrocnemius muscles, comparable with that found following the 25 mg/kg dose.", [["TA", "ANATOMY", 54, 56], ["quadriceps", "ANATOMY", 58, 68], ["gastrocnemius muscles", "ANATOMY", 73, 94], ["dystrophin", "GENE_OR_GENE_PRODUCT", 15, 25], ["TA", "TISSUE", 54, 56], ["quadriceps", "ORGANISM_SUBDIVISION", 58, 68], ["gastrocnemius muscles", "ORGAN", 73, 94], ["dystrophin", "PROTEIN", 15, 25], ["High levels of dystrophin expression", "PROBLEM", 0, 36], ["dystrophin expression", "OBSERVATION", 15, 36], ["quadriceps", "ANATOMY", 58, 68], ["gastrocnemius muscles", "ANATOMY", 73, 94]]], ["The most striking differences were seen in the abdominal wall muscles, diaphragm and heart, where a lower level of dystrophin correction was found with the 6 mg/kg dose regime compared with the 25 mg/kg dose.", [["abdominal wall muscles", "ANATOMY", 47, 69], ["diaphragm", "ANATOMY", 71, 80], ["heart", "ANATOMY", 85, 90], ["abdominal wall muscles", "MULTI-TISSUE_STRUCTURE", 47, 69], ["diaphragm", "ORGAN", 71, 80], ["heart", "ORGAN", 85, 90], ["dystrophin", "GENE_OR_GENE_PRODUCT", 115, 125], ["dystrophin", "PROTEIN", 115, 125], ["a lower level of dystrophin correction", "PROBLEM", 98, 136], ["abdominal", "ANATOMY_MODIFIER", 47, 56], ["wall", "ANATOMY_MODIFIER", 57, 61], ["muscles", "ANATOMY", 62, 69], ["diaphragm", "ANATOMY", 71, 80], ["heart", "ANATOMY", 85, 90], ["lower", "OBSERVATION_MODIFIER", 100, 105], ["dystrophin correction", "OBSERVATION", 115, 136]]], ["RT-PCR results were consistent with the immunostaining data, again showing almost complete exon 23 skipping in TA, quadriceps and gastrocnemius muscles, but only 50% exon skipping efficiency in diaphragm and abdominal wall muscles, with even less dystrophin exon 23 skipping detectable in heart, although dystrophin-positive fibres were observed in the cardiac tissue by immunostaining (Fig. 2B) .", [["TA", "ANATOMY", 111, 113], ["quadriceps", "ANATOMY", 115, 125], ["gastrocnemius muscles", "ANATOMY", 130, 151], ["diaphragm", "ANATOMY", 194, 203], ["abdominal wall muscles", "ANATOMY", 208, 230], ["heart", "ANATOMY", 289, 294], ["dystrophin-positive fibres", "ANATOMY", 305, 331], ["cardiac tissue", "ANATOMY", 353, 367], ["quadriceps", "ORGANISM_SUBDIVISION", 115, 125], ["gastrocnemius muscles", "ORGAN", 130, 151], ["diaphragm", "ORGAN", 194, 203], ["abdominal wall muscles", "ORGAN", 208, 230], ["dystrophin", "GENE_OR_GENE_PRODUCT", 247, 257], ["heart", "ORGAN", 289, 294], ["dystrophin", "GENE_OR_GENE_PRODUCT", 305, 315], ["cardiac tissue", "TISSUE", 353, 367], ["exon 23", "DNA", 91, 98], ["dystrophin exon 23", "RNA", 247, 265], ["dystrophin", "PROTEIN", 305, 315], ["RT-PCR", "TEST", 0, 6], ["the immunostaining data", "TEST", 36, 59], ["almost complete exon 23 skipping in TA, quadriceps and gastrocnemius muscles", "PROBLEM", 75, 151], ["50% exon skipping efficiency in diaphragm and abdominal wall muscles", "PROBLEM", 162, 230], ["even less dystrophin exon", "PROBLEM", 237, 262], ["dystrophin-positive fibres", "PROBLEM", 305, 331], ["consistent with", "UNCERTAINTY", 20, 35], ["quadriceps", "ANATOMY", 115, 125], ["gastrocnemius muscles", "ANATOMY", 130, 151], ["skipping efficiency", "OBSERVATION", 171, 190], ["diaphragm", "ANATOMY", 194, 203], ["abdominal wall", "ANATOMY", 208, 222], ["muscles", "ANATOMY", 223, 230], ["heart", "ANATOMY", 289, 294], ["positive fibres", "OBSERVATION", 316, 331], ["cardiac tissue", "ANATOMY", 353, 367]]], ["The western blot data demonstrated a lower level of protein restoration in abdominal wall, diaphragm and heart tissues, compared with that seen following the 25 mg/kg treatment, consistent with the RT-PCR and immunostaining findings (Fig. 2C ).", [["abdominal wall", "ANATOMY", 75, 89], ["diaphragm", "ANATOMY", 91, 100], ["heart tissues", "ANATOMY", 105, 118], ["abdominal wall", "MULTI-TISSUE_STRUCTURE", 75, 89], ["diaphragm", "MULTI-TISSUE_STRUCTURE", 91, 100], ["heart tissues", "TISSUE", 105, 118], ["The western blot data", "TEST", 0, 21], ["a lower level of protein restoration in abdominal wall, diaphragm and heart tissues", "PROBLEM", 35, 118], ["the 25 mg/kg treatment", "TREATMENT", 154, 176], ["the RT-PCR", "TEST", 194, 204], ["immunostaining findings", "TEST", 209, 232], ["protein restoration", "OBSERVATION", 52, 71], ["abdominal wall", "ANATOMY", 75, 89], ["diaphragm", "ANATOMY", 91, 100], ["heart tissues", "ANATOMY", 105, 118], ["consistent with", "UNCERTAINTY", 178, 193]]], ["In this lower-dose study, we also compared the second peptide-PMO conjugate-B-PMO-using the same approach, with the results again confirming that the P007-PMO compound had superior activity to B-PMO as determined at both RNA (data not shown) and protein levels (Supplementary Material, Fig. S2C ).Evaluation of a lower-dose intravenous P007-PMO dosing protocol to optimize dystrophin correctionR, L-arginine; X, 6-aminohexanoic acid; B, b-alanine.", [["intravenous", "ANATOMY", 324, 335], ["B-PMO", "CHEMICAL", 76, 81], ["P007", "CHEMICAL", 150, 154], ["B-PMO", "CHEMICAL", 193, 198], ["P007", "CHEMICAL", 336, 340], ["L-arginine", "CHEMICAL", 397, 407], ["6-aminohexanoic acid", "CHEMICAL", 412, 432], ["b-alanine", "CHEMICAL", 437, 446], ["P007-PMO", "CHEMICAL", 150, 158], ["B-PMO", "CHEMICAL", 193, 198], ["L-arginine", "CHEMICAL", 397, 407], ["6-aminohexanoic acid", "CHEMICAL", 412, 432], ["B", "CHEMICAL", 434, 435], ["b-alanine", "CHEMICAL", 437, 446], ["PMO conjugate-B-PMO", "SIMPLE_CHEMICAL", 62, 81], ["P007-PMO", "SIMPLE_CHEMICAL", 150, 158], ["B-PMO", "SIMPLE_CHEMICAL", 193, 198], ["P007", "SIMPLE_CHEMICAL", 336, 340], ["dystrophin", "GENE_OR_GENE_PRODUCT", 373, 383], ["L-arginine; X, 6-aminohexanoic acid", "SIMPLE_CHEMICAL", 397, 432], ["B, b-alanine", "SIMPLE_CHEMICAL", 434, 446], ["dystrophin", "PROTEIN", 373, 383], ["the second peptide", "TEST", 43, 61], ["the P007", "TEST", 146, 154], ["PMO compound", "PROBLEM", 155, 167], ["B-PMO", "TREATMENT", 193, 198], ["protein levels", "TEST", 246, 260], ["Evaluation", "TEST", 297, 307], ["a lower-dose intravenous P007-PMO dosing protocol", "TREATMENT", 311, 360], ["dystrophin correctionR", "TREATMENT", 373, 395], ["L-arginine", "TREATMENT", 397, 407], ["aminohexanoic acid", "TREATMENT", 414, 432], ["b-alanine", "TREATMENT", 437, 446]]], ["RT-PCR to detect exon skipping efficiency at the RNA level demonstrated almost complete exon 23 skipping in the peripheral skeletal muscles indicated and 50% exon skipping in heart in treated mdx mice.", [["peripheral skeletal muscles", "ANATOMY", 112, 139], ["heart", "ANATOMY", 175, 180], ["skeletal muscles", "ORGAN", 123, 139], ["heart", "ORGAN", 175, 180], ["mdx mice", "ORGANISM", 192, 200], ["exon 23", "DNA", 88, 95], ["mice", "SPECIES", 196, 200], ["mice", "SPECIES", 196, 200], ["RT-PCR", "TEST", 0, 6], ["exon skipping efficiency", "PROBLEM", 17, 41], ["the RNA level", "TEST", 45, 58], ["complete exon 23 skipping in the peripheral skeletal muscles", "PROBLEM", 79, 139], ["peripheral", "ANATOMY_MODIFIER", 112, 122], ["skeletal muscles", "ANATOMY", 123, 139], ["heart", "ANATOMY", 175, 180]]], ["This is shown by shorter exon-skipped bands (indicated by the boxed numbered 22-24-for exon 23 skipping).", [["exon 23", "DNA", 87, 94], ["shorter exon-skipped bands", "PROBLEM", 17, 43]]], ["Truncated transcripts deleted for both exons 22 and 23 were also seen as indicated by the box 21-24.", [["exons 22 and 23", "DNA", 39, 54], ["box 21-24", "DNA", 90, 99], ["Truncated transcripts", "PROBLEM", 0, 21]]], ["(C) Western blot for dystrophin expression in peripheral skeletal muscles showed 100% dystrophin restoration in all skeletal muscles except the diaphragm and with P007-PMO conjugate treatment compared with levels found in normal C57BL6 mice.", [["peripheral skeletal muscles", "ANATOMY", 46, 73], ["skeletal muscles", "ANATOMY", 116, 132], ["diaphragm", "ANATOMY", 144, 153], ["P007-PMO conjugate", "CHEMICAL", 163, 181], ["dystrophin", "GENE_OR_GENE_PRODUCT", 21, 31], ["skeletal muscles", "ORGAN", 57, 73], ["dystrophin", "GENE_OR_GENE_PRODUCT", 86, 96], ["skeletal muscles", "ORGAN", 116, 132], ["diaphragm", "ORGAN", 144, 153], ["P007-PMO conjugate", "SIMPLE_CHEMICAL", 163, 181], ["C57BL6 mice", "ORGANISM", 229, 240], ["dystrophin", "PROTEIN", 21, 31], ["dystrophin", "PROTEIN", 86, 96], ["mice", "SPECIES", 236, 240], ["mice", "SPECIES", 236, 240], ["Western blot", "TEST", 4, 16], ["dystrophin expression in peripheral skeletal muscles", "PROBLEM", 21, 73], ["100% dystrophin restoration in all skeletal muscles", "PROBLEM", 81, 132], ["P007-PMO conjugate treatment", "TREATMENT", 163, 191], ["peripheral", "ANATOMY_MODIFIER", 46, 56], ["skeletal muscles", "ANATOMY", 57, 73], ["dystrophin restoration", "OBSERVATION", 86, 108], ["all", "ANATOMY_MODIFIER", 112, 115], ["skeletal muscles", "ANATOMY", 116, 132], ["diaphragm", "ANATOMY", 144, 153]]], ["Equal loading of 10 mg protein is shown for each sample with a-actinin expression detected as a loading control.", [["sample", "ANATOMY", 49, 55], ["a-actinin", "GENE_OR_GENE_PRODUCT", 61, 70], ["a-actinin", "PROTEIN", 61, 70], ["10 mg protein", "TREATMENT", 17, 30], ["a-actinin expression", "TREATMENT", 61, 81], ["a loading control", "TREATMENT", 94, 111]]], ["(D) Western blot to detect dystrophin expression in heart tissue from normal C57BL6 heart (20, 10 and 5% of normal levels shown), untreated mdx heart and P007-PMO treated heart.", [["heart tissue", "ANATOMY", 52, 64], ["C57BL6 heart", "ANATOMY", 77, 89], ["mdx heart", "ANATOMY", 140, 149], ["heart", "ANATOMY", 171, 176], ["dystrophin", "GENE_OR_GENE_PRODUCT", 27, 37], ["heart tissue", "TISSUE", 52, 64], ["C57BL6", "ORGANISM", 77, 83], ["heart", "ORGAN", 84, 89], ["mdx", "ORGANISM", 140, 143], ["heart", "ORGAN", 144, 149], ["heart", "ORGAN", 171, 176], ["dystrophin", "PROTEIN", 27, 37], ["dystrophin expression in heart tissue", "PROBLEM", 27, 64], ["untreated mdx heart and P007", "PROBLEM", 130, 158], ["heart", "ANATOMY", 52, 57], ["tissue", "ANATOMY_MODIFIER", 58, 64], ["normal", "OBSERVATION", 70, 76], ["C57BL6", "ANATOMY_MODIFIER", 77, 83], ["heart", "ANATOMY", 84, 89], ["mdx heart", "ANATOMY", 140, 149], ["heart", "ANATOMY", 171, 176]]], ["Data shows dystrophin protein restoration to 15% of normal levels in treated mdx heart tissue.Evaluation of a lower-dose intravenous P007-PMO dosing protocol to optimize dystrophin correctionFunctional correction in skeletal muscle following systemic delivery of the P007-PMO conjugateEvaluation of a lower-dose intravenous P007-PMO dosing protocol to optimize dystrophin correctionDystrophin plays a critical role in muscle by linking cytoplasmic actin to a sarcolemmal dystrophin-associated protein complex (DAPC) and via this to the extracellular matrix (20, 21) .", [["mdx heart tissue", "ANATOMY", 77, 93], ["intravenous", "ANATOMY", 121, 132], ["skeletal muscle", "ANATOMY", 216, 231], ["intravenous", "ANATOMY", 312, 323], ["muscle", "ANATOMY", 418, 424], ["cytoplasmic", "ANATOMY", 436, 447], ["sarcolemmal", "ANATOMY", 459, 470], ["extracellular matrix", "ANATOMY", 536, 556], ["P007", "CHEMICAL", 133, 137], ["skeletal muscle", "DISEASE", 216, 231], ["P007", "CHEMICAL", 324, 328], ["dystrophin", "GENE_OR_GENE_PRODUCT", 11, 21], ["mdx heart tissue", "TISSUE", 77, 93], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 121, 132], ["P007", "SIMPLE_CHEMICAL", 133, 137], ["dystrophin", "GENE_OR_GENE_PRODUCT", 170, 180], ["skeletal muscle", "ORGAN", 216, 231], ["P007", "GENE_OR_GENE_PRODUCT", 267, 271], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 312, 323], ["P007", "SIMPLE_CHEMICAL", 324, 328], ["dystrophin", "GENE_OR_GENE_PRODUCT", 361, 371], ["muscle", "ORGAN", 418, 424], ["cytoplasmic", "ORGANISM_SUBSTANCE", 436, 447], ["actin", "GENE_OR_GENE_PRODUCT", 448, 453], ["sarcolemmal", "CELLULAR_COMPONENT", 459, 470], ["dystrophin-associated protein complex", "GENE_OR_GENE_PRODUCT", 471, 508], ["DAPC", "GENE_OR_GENE_PRODUCT", 510, 514], ["extracellular matrix", "CELLULAR_COMPONENT", 536, 556], ["dystrophin", "PROTEIN", 11, 21], ["dystrophin", "PROTEIN", 170, 180], ["P007", "PROTEIN", 267, 271], ["PMO conjugate", "PROTEIN", 272, 285], ["dystrophin", "PROTEIN", 361, 371], ["correctionDystrophin", "PROTEIN", 372, 392], ["cytoplasmic actin", "PROTEIN", 436, 453], ["sarcolemmal dystrophin-associated protein complex", "PROTEIN", 459, 508], ["DAPC", "PROTEIN", 510, 514], ["dystrophin protein restoration", "PROBLEM", 11, 41], ["Evaluation", "TEST", 94, 104], ["a lower-dose intravenous P007-PMO dosing protocol", "TREATMENT", 108, 157], ["dystrophin correction", "TREATMENT", 170, 191], ["systemic delivery", "TREATMENT", 242, 259], ["Evaluation", "TEST", 285, 295], ["a lower-dose intravenous P007-PMO dosing protocol", "TREATMENT", 299, 348], ["dystrophin correctionDystrophin", "PROBLEM", 361, 392], ["a sarcolemmal dystrophin", "TEST", 457, 481], ["dystrophin", "OBSERVATION", 11, 21], ["protein restoration", "OBSERVATION", 22, 41], ["treated mdx", "OBSERVATION", 69, 80], ["heart tissue", "ANATOMY", 81, 93], ["skeletal muscle", "ANATOMY", 216, 231], ["muscle", "ANATOMY", 418, 424], ["extracellular matrix", "ANATOMY", 536, 556]]], ["The DAPC also has important signalling functions via nNOS and other components (22, 23) .", [["DAPC", "CHEMICAL", 4, 8], ["DAPC", "GENE_OR_GENE_PRODUCT", 4, 8], ["nNOS", "GENE_OR_GENE_PRODUCT", 53, 57], ["DAPC", "PROTEIN", 4, 8], ["nNOS", "PROTEIN", 53, 57], ["signalling functions", "OBSERVATION", 28, 48], ["components", "OBSERVATION_MODIFIER", 68, 78]]], ["In the absence of functional dystrophin the DAPC fails to localize accurately to the sarcolemma and its function is compromised.", [["sarcolemma", "ANATOMY", 85, 95], ["dystrophin", "GENE_OR_GENE_PRODUCT", 29, 39], ["DAPC", "GENE_OR_GENE_PRODUCT", 44, 48], ["sarcolemma", "CELLULAR_COMPONENT", 85, 95], ["dystrophin", "PROTEIN", 29, 39], ["DAPC", "PROTEIN", 44, 48], ["functional dystrophin", "OBSERVATION", 18, 39], ["sarcolemma", "ANATOMY", 85, 95]]], ["We therefore investigated whether restored dystrophin protein expression via systemic P007-PMO delivery resulted in the successful relocalization of DAPC protein constituents to the sarcolemma.", [["sarcolemma", "ANATOMY", 182, 192], ["dystrophin", "GENE_OR_GENE_PRODUCT", 43, 53], ["P007", "GENE_OR_GENE_PRODUCT", 86, 90], ["DAPC", "GENE_OR_GENE_PRODUCT", 149, 153], ["sarcolemma", "CELLULAR_COMPONENT", 182, 192], ["dystrophin protein", "PROTEIN", 43, 61], ["P007", "PROTEIN", 86, 90], ["DAPC protein", "PROTEIN", 149, 161], ["restored dystrophin protein expression", "PROBLEM", 34, 72], ["systemic P007-PMO delivery", "TREATMENT", 77, 103], ["DAPC protein constituents", "TREATMENT", 149, 174], ["the sarcolemma", "PROBLEM", 178, 192], ["sarcolemma", "ANATOMY", 182, 192]]], ["As expected, the expression of multiple DAPC component proteins including b-dystroglycan, a-sarcoglycan and b-sarcoglycan and nNOS, was detected in peripheral skeletal muscles with correct sarcolemmal localization and with staining intensities commensurate with that observed for dystrophin at the 25 mg/kg dose (Fig. 3A) .", [["peripheral skeletal muscles", "ANATOMY", 148, 175], ["sarcolemmal", "ANATOMY", 189, 200], ["DAPC", "GENE_OR_GENE_PRODUCT", 40, 44], ["b-dystroglycan", "GENE_OR_GENE_PRODUCT", 74, 88], ["a-sarcoglycan", "GENE_OR_GENE_PRODUCT", 90, 103], ["b-sarcoglycan", "GENE_OR_GENE_PRODUCT", 108, 121], ["nNOS", "GENE_OR_GENE_PRODUCT", 126, 130], ["peripheral skeletal muscles", "TISSUE", 148, 175], ["sarcolemmal", "MULTI-TISSUE_STRUCTURE", 189, 200], ["dystrophin", "GENE_OR_GENE_PRODUCT", 280, 290], ["DAPC component proteins", "PROTEIN", 40, 63], ["b-dystroglycan", "PROTEIN", 74, 88], ["a-sarcoglycan", "PROTEIN", 90, 103], ["b-sarcoglycan", "PROTEIN", 108, 121], ["nNOS", "PROTEIN", 126, 130], ["dystrophin", "PROTEIN", 280, 290], ["multiple DAPC component proteins", "PROBLEM", 31, 63], ["b-dystroglycan", "TREATMENT", 74, 88], ["a-sarcoglycan", "TEST", 90, 103], ["nNOS", "PROBLEM", 126, 130], ["staining intensities", "PROBLEM", 223, 243], ["dystrophin", "TREATMENT", 280, 290], ["peripheral", "ANATOMY_MODIFIER", 148, 158], ["skeletal muscles", "ANATOMY", 159, 175], ["sarcolemmal localization", "OBSERVATION", 189, 213]]], ["The restoration of DAPC components was also observed in the 6 mg/kg dose study although at a correspondingly lower level of expression (data not shown).", [["DAPC", "GENE_OR_GENE_PRODUCT", 19, 23], ["DAPC", "PROTEIN", 19, 23], ["DAPC components", "TREATMENT", 19, 34], ["dose study", "TEST", 68, 78]]], ["As a result of successfully restored dystrophin and DAPC expression we then wished to determine whether any evidence of improved muscle function could be detected.", [["muscle", "ANATOMY", 129, 135], ["dystrophin", "GENE_OR_GENE_PRODUCT", 37, 47], ["DAPC", "GENE_OR_GENE_PRODUCT", 52, 56], ["muscle", "ORGAN", 129, 135], ["dystrophin", "PROTEIN", 37, 47], ["DAPC", "PROTEIN", 52, 56], ["dystrophin and DAPC expression", "TREATMENT", 37, 67], ["improved muscle function", "PROBLEM", 120, 144]]], ["Using a functional test of grip force strength (24 -26) , evaluating predominantly but not exclusively forelimb muscle strength, mdx mice treated with P007-PMO AO were shown to have significantly improved grip strength to within the normal range following a 25 mg/kg dose, compared with untreated mdx control mice (Fig. 3B) .", [["forelimb muscle", "ANATOMY", 103, 118], ["forelimb muscle", "TISSUE", 103, 118], ["mdx mice", "ORGANISM", 129, 137], ["P007-PMO AO", "SIMPLE_CHEMICAL", 151, 162], ["mdx control mice", "ORGANISM", 297, 313], ["mice", "SPECIES", 133, 137], ["mice", "SPECIES", 309, 313], ["mice", "SPECIES", 133, 137], ["mice", "SPECIES", 309, 313], ["a functional test of grip force strength", "TEST", 6, 46], ["muscle", "ANATOMY", 112, 118]]], ["Some improvement was also detected in mdx mice treated with the 6 mg/kg P007-PMO dose but it was not as great as that seen following the 25 mg/kg treatment (data not shown).", [["P007-PMO", "CHEMICAL", 72, 80], ["mdx mice", "ORGANISM", 38, 46], ["P007-PMO", "SIMPLE_CHEMICAL", 72, 80], ["mice", "SPECIES", 42, 46], ["mice", "SPECIES", 42, 46], ["the 6 mg/kg P007-PMO dose", "TREATMENT", 60, 85], ["improvement", "OBSERVATION_MODIFIER", 5, 16]]], ["The percentage of muscle fibres with centrally located nuclei is an index of ongoing degeneration/regeneration cycles (27, 28) .", [["muscle fibres", "ANATOMY", 18, 31], ["nuclei", "ANATOMY", 55, 61], ["muscle fibres", "TISSUE", 18, 31], ["nuclei", "CELLULAR_COMPONENT", 55, 61], ["centrally located nuclei", "PROBLEM", 37, 61], ["ongoing degeneration/regeneration cycles", "PROBLEM", 77, 117], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["muscle fibres", "ANATOMY", 18, 31], ["centrally", "OBSERVATION_MODIFIER", 37, 46], ["index", "OBSERVATION_MODIFIER", 68, 73], ["ongoing", "OBSERVATION_MODIFIER", 77, 84], ["degeneration", "OBSERVATION", 85, 97], ["regeneration cycles", "OBSERVATION", 98, 117]]], ["Counts of centrally located nuclei within treated mdx muscle groups (TA, gastrocnemius and quadriceps) revealed a significant reduction in centrally nucleated myofibres compared with untreated control mdx mice, suggesting a reduced regenerative stimulus and restoration of normal myofibre architecture commensurate with improved function (Fig. 3C) .", [["nuclei", "ANATOMY", 28, 34], ["mdx muscle", "ANATOMY", 50, 60], ["TA", "ANATOMY", 69, 71], ["gastrocnemius", "ANATOMY", 73, 86], ["quadriceps", "ANATOMY", 91, 101], ["myofibres", "ANATOMY", 159, 168], ["myofibre", "ANATOMY", 280, 288], ["nuclei", "CELLULAR_COMPONENT", 28, 34], ["mdx muscle", "TISSUE", 50, 60], ["TA", "MULTI-TISSUE_STRUCTURE", 69, 71], ["gastrocnemius", "MULTI-TISSUE_STRUCTURE", 73, 86], ["quadriceps", "ORGANISM_SUBDIVISION", 91, 101], ["myofibres", "CELL", 159, 168], ["mdx mice", "ORGANISM", 201, 209], ["centrally nucleated myofibres", "CELL_TYPE", 139, 168], ["mice", "SPECIES", 205, 209], ["mice", "SPECIES", 205, 209], ["a significant reduction in centrally nucleated myofibres", "PROBLEM", 112, 168], ["a reduced regenerative stimulus", "PROBLEM", 222, 253], ["centrally", "ANATOMY_MODIFIER", 10, 19], ["mdx muscle", "ANATOMY", 50, 60], ["gastrocnemius", "ANATOMY", 73, 86], ["quadriceps", "ANATOMY", 91, 101], ["significant", "OBSERVATION_MODIFIER", 114, 125], ["reduction", "OBSERVATION", 126, 135], ["centrally nucleated myofibres", "OBSERVATION", 139, 168], ["reduced", "OBSERVATION_MODIFIER", 224, 231], ["regenerative stimulus", "OBSERVATION", 232, 253], ["normal", "OBSERVATION", 273, 279], ["myofibre architecture", "OBSERVATION", 280, 301]]], ["There was also a significant fall in the number of centrally nucleated fibres in TA and gastrocnemius muscles at the 6 mg/kg dose (data not shown).", [["nucleated fibres", "ANATOMY", 61, 77], ["TA", "ANATOMY", 81, 83], ["gastrocnemius muscles", "ANATOMY", 88, 109], ["nucleated fibres", "TISSUE", 61, 77], ["TA", "TISSUE", 81, 83], ["gastrocnemius muscles", "TISSUE", 88, 109], ["centrally nucleated fibres", "CELL_TYPE", 51, 77], ["a significant fall", "PROBLEM", 15, 33], ["significant", "OBSERVATION_MODIFIER", 17, 28], ["fall", "OBSERVATION", 29, 33], ["nucleated fibres", "OBSERVATION", 61, 77], ["gastrocnemius muscles", "ANATOMY", 88, 109]]], ["Serum creatine kinase (CK) levels are elevated in mdx mice and are indicative of ongoing muscle pathology and membrane instability (29) .", [["Serum", "ANATOMY", 0, 5], ["muscle", "ANATOMY", 89, 95], ["membrane", "ANATOMY", 110, 118], ["creatine", "CHEMICAL", 6, 14], ["creatine", "CHEMICAL", 6, 14], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 6, 21], ["CK", "GENE_OR_GENE_PRODUCT", 23, 25], ["mdx mice", "ORGANISM", 50, 58], ["muscle", "ORGAN", 89, 95], ["membrane", "CELLULAR_COMPONENT", 110, 118], ["Serum creatine kinase", "PROTEIN", 0, 21], ["CK", "PROTEIN", 23, 25], ["mice", "SPECIES", 54, 58], ["mice", "SPECIES", 54, 58], ["Serum creatine kinase", "TEST", 0, 21], ["CK) levels", "TEST", 23, 33], ["elevated in mdx mice", "PROBLEM", 38, 58], ["ongoing muscle pathology", "PROBLEM", 81, 105], ["membrane instability", "PROBLEM", 110, 130], ["elevated", "OBSERVATION_MODIFIER", 38, 46], ["indicative of", "UNCERTAINTY", 67, 80], ["muscle", "ANATOMY", 89, 95], ["pathology", "OBSERVATION", 96, 105], ["membrane instability", "OBSERVATION", 110, 130]]], ["The significantly lower levels of serum CK found in P007-PMO treated mdx mice compared with untreated controls indicated the widespread protection effect of restored dystrophin expression on myofibre integrity (Fig. 3D) .Investigation of toxicity following treatment with the P007-PMO conjugatesMdx mice treated with the peptide-PMO conjugates demonstrated no obvious outward signs of ill health.", [["serum", "ANATOMY", 34, 39], ["myofibre", "ANATOMY", 191, 199], ["toxicity", "DISEASE", 238, 246], ["P007", "CHEMICAL", 276, 280], ["serum", "ORGANISM_SUBSTANCE", 34, 39], ["CK", "GENE_OR_GENE_PRODUCT", 40, 42], ["P007-PMO", "SIMPLE_CHEMICAL", 52, 60], ["mdx mice", "ORGANISM", 69, 77], ["dystrophin", "GENE_OR_GENE_PRODUCT", 166, 176], ["myofibre", "MULTI-TISSUE_STRUCTURE", 191, 199], ["P007", "SIMPLE_CHEMICAL", 276, 280], ["Mdx", "ORGANISM", 295, 298], ["mice", "ORGANISM", 299, 303], ["serum CK", "PROTEIN", 34, 42], ["dystrophin", "PROTEIN", 166, 176], ["mice", "SPECIES", 73, 77], ["mice", "SPECIES", 299, 303], ["mice", "SPECIES", 73, 77], ["mice", "SPECIES", 299, 303], ["serum CK", "TEST", 34, 42], ["P007", "TEST", 52, 56], ["mdx mice", "TREATMENT", 69, 77], ["restored dystrophin expression", "PROBLEM", 157, 187], ["toxicity", "PROBLEM", 238, 246], ["treatment", "TREATMENT", 257, 266], ["the P007-PMO conjugates", "TREATMENT", 272, 295], ["the peptide-PMO conjugates", "TEST", 317, 343], ["obvious outward signs of ill health", "PROBLEM", 360, 395], ["significantly", "OBSERVATION_MODIFIER", 4, 17], ["lower", "OBSERVATION_MODIFIER", 18, 23], ["dystrophin expression", "OBSERVATION", 166, 187], ["no obvious", "UNCERTAINTY", 357, 367]]], ["In order to further monitor any potential systemic cytotoxicity induced by the PMO and/or conjugated peptides, we undertook histological study of liver and kidney tissues and analysed a series of serum markers commonly used as indices of liver and kidney dysfunction.", [["liver", "ANATOMY", 146, 151], ["kidney tissues", "ANATOMY", 156, 170], ["serum", "ANATOMY", 196, 201], ["liver", "ANATOMY", 238, 243], ["kidney", "ANATOMY", 248, 254], ["PMO", "CHEMICAL", 79, 82], ["liver and kidney dysfunction", "DISEASE", 238, 266], ["PMO", "SIMPLE_CHEMICAL", 79, 82], ["liver", "ORGAN", 146, 151], ["kidney tissues", "TISSUE", 156, 170], ["serum", "ORGANISM_SUBSTANCE", 196, 201], ["liver", "ORGAN", 238, 243], ["kidney", "ORGAN", 248, 254], ["serum markers", "PROTEIN", 196, 209], ["systemic cytotoxicity", "PROBLEM", 42, 63], ["the PMO and/or conjugated peptides", "PROBLEM", 75, 109], ["histological study", "TEST", 124, 142], ["a series of serum markers", "TEST", 184, 209], ["liver and kidney dysfunction", "PROBLEM", 238, 266], ["liver", "ANATOMY", 146, 151], ["kidney tissues", "ANATOMY", 156, 170], ["liver", "ANATOMY", 238, 243], ["kidney", "ANATOMY", 248, 254], ["dysfunction", "OBSERVATION", 255, 266]]], ["Haematoxylin and eosin staining of liver and kidney tissue sections did not reveal overt signs of tissue damage in mdx mice treated with P007-PMO conjugate, with no deleterious changes detectable in tissue morphology or increase in the numbers of infiltrating cells compared with untreated mdx control mice.", [["liver", "ANATOMY", 35, 40], ["kidney tissue sections", "ANATOMY", 45, 67], ["tissue", "ANATOMY", 98, 104], ["tissue", "ANATOMY", 199, 205], ["infiltrating cells", "ANATOMY", 247, 265], ["tissue damage", "DISEASE", 98, 111], ["P007-PMO", "CHEMICAL", 137, 145], ["Haematoxylin", "CHEMICAL", 0, 12], ["eosin", "CHEMICAL", 17, 22], ["Haematoxylin", "SIMPLE_CHEMICAL", 0, 12], ["eosin", "GENE_OR_GENE_PRODUCT", 17, 22], ["liver", "ORGAN", 35, 40], ["kidney tissue sections", "MULTI-TISSUE_STRUCTURE", 45, 67], ["tissue", "TISSUE", 98, 104], ["mdx mice", "ORGANISM", 115, 123], ["P007-PMO conjugate", "SIMPLE_CHEMICAL", 137, 155], ["tissue", "TISSUE", 199, 205], ["cells", "CELL", 260, 265], ["mdx control mice", "ORGANISM", 290, 306], ["infiltrating cells", "CELL_TYPE", 247, 265], ["mice", "SPECIES", 119, 123], ["mice", "SPECIES", 302, 306], ["mice", "SPECIES", 119, 123], ["mice", "SPECIES", 302, 306], ["Haematoxylin", "TEST", 0, 12], ["eosin staining", "TEST", 17, 31], ["liver and kidney tissue sections", "TEST", 35, 67], ["tissue damage", "PROBLEM", 98, 111], ["P007-PMO conjugate", "TEST", 137, 155], ["deleterious changes", "PROBLEM", 165, 184], ["infiltrating cells", "PROBLEM", 247, 265], ["untreated mdx control mice", "TREATMENT", 280, 306], ["liver", "ANATOMY", 35, 40], ["kidney", "ANATOMY", 45, 51], ["tissue", "ANATOMY", 98, 104], ["damage", "OBSERVATION", 105, 111], ["tissue morphology", "OBSERVATION_MODIFIER", 199, 216], ["increase", "OBSERVATION_MODIFIER", 220, 228], ["numbers", "OBSERVATION_MODIFIER", 236, 243], ["infiltrating cells", "OBSERVATION", 247, 265]]], ["Of particular interest was the liver histology where not only was no evidence of toxicity found following treatment, but a reversal of the typical swollen hepatic cell pathology (30) found in untreated mdx mice was seen (Fig. 4A) .", [["liver", "ANATOMY", 31, 36], ["hepatic cell", "ANATOMY", 155, 167], ["toxicity", "DISEASE", 81, 89], ["liver", "ORGAN", 31, 36], ["hepatic cell", "CELL", 155, 167], ["mdx mice", "ORGANISM", 202, 210], ["mice", "SPECIES", 206, 210], ["mice", "SPECIES", 206, 210], ["the liver histology", "TEST", 27, 46], ["toxicity", "PROBLEM", 81, 89], ["treatment", "TREATMENT", 106, 115], ["the typical swollen hepatic cell pathology", "PROBLEM", 135, 177], ["liver", "ANATOMY", 31, 36], ["no evidence of", "UNCERTAINTY", 66, 80], ["toxicity", "OBSERVATION", 81, 89], ["typical", "OBSERVATION_MODIFIER", 139, 146], ["swollen", "OBSERVATION_MODIFIER", 147, 154], ["hepatic", "ANATOMY", 155, 162], ["cell pathology", "OBSERVATION", 163, 177], ["mdx mice", "OBSERVATION", 202, 210]]], ["Serum was collected from treated mdx mice and control mice, and this showed a significant decrease in the levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) liver enzymes in the treated mice, with levels of these enzymes returned to within the normal range compared with untreated mdx mice and normal age-matched untreated control mice (Fig. 4B) .", [["Serum", "ANATOMY", 0, 5], ["liver", "ANATOMY", 184, 189], ["aspartate", "CHEMICAL", 116, 125], ["alanine", "CHEMICAL", 153, 160], ["aspartate", "CHEMICAL", 116, 125], ["alanine", "CHEMICAL", 153, 160], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["mdx mice", "ORGANISM", 33, 41], ["mice", "ORGANISM", 54, 58], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 116, 142], ["AST", "SIMPLE_CHEMICAL", 144, 147], ["alanine aminotransferase", "GENE_OR_GENE_PRODUCT", 153, 177], ["ALT", "SIMPLE_CHEMICAL", 179, 182], ["liver", "ORGAN", 184, 189], ["mice", "ORGANISM", 213, 217], ["mdx mice", "ORGANISM", 308, 316], ["mice", "ORGANISM", 358, 362], ["aspartate aminotransferase", "PROTEIN", 116, 142], ["AST", "PROTEIN", 144, 147], ["alanine aminotransferase (ALT) liver enzymes", "PROTEIN", 153, 197], ["enzymes", "PROTEIN", 240, 247], ["mice", "SPECIES", 37, 41], ["mice", "SPECIES", 54, 58], ["mice", "SPECIES", 213, 217], ["mice", "SPECIES", 312, 316], ["mice", "SPECIES", 358, 362], ["mice", "SPECIES", 37, 41], ["mice", "SPECIES", 54, 58], ["mice", "SPECIES", 213, 217], ["mice", "SPECIES", 312, 316], ["mice", "SPECIES", 358, 362], ["Serum", "TEST", 0, 5], ["a significant decrease", "PROBLEM", 76, 98], ["aspartate aminotransferase", "TEST", 116, 142], ["AST", "TEST", 144, 147], ["alanine aminotransferase", "TEST", 153, 177], ["ALT", "TEST", 179, 182], ["liver enzymes", "TEST", 184, 197], ["levels", "TEST", 224, 230], ["these enzymes", "TEST", 234, 247], ["significant", "OBSERVATION_MODIFIER", 78, 89], ["decrease", "OBSERVATION", 90, 98], ["liver", "ANATOMY", 184, 189]]], ["No change was found in the serum levels of urea and creatinine with P007-PMO treatment compared with untreated mdx controls and normal mice (data not shown) suggesting no adverse effects of the P007-PMO treatment on renal function at the doses studied.", [["serum", "ANATOMY", 27, 32], ["renal", "ANATOMY", 216, 221], ["urea", "CHEMICAL", 43, 47], ["creatinine", "CHEMICAL", 52, 62], ["P007-PMO", "CHEMICAL", 68, 76], ["P007-PMO", "CHEMICAL", 194, 202], ["urea", "CHEMICAL", 43, 47], ["creatinine", "CHEMICAL", 52, 62], ["P007-PMO", "CHEMICAL", 68, 76], ["serum", "ORGANISM_SUBSTANCE", 27, 32], ["urea", "SIMPLE_CHEMICAL", 43, 47], ["creatinine", "SIMPLE_CHEMICAL", 52, 62], ["P007-PMO", "SIMPLE_CHEMICAL", 68, 76], ["mdx controls", "ORGANISM", 111, 123], ["mice", "ORGANISM", 135, 139], ["P007-PMO", "SIMPLE_CHEMICAL", 194, 202], ["renal", "ORGAN", 216, 221], ["mice", "SPECIES", 135, 139], ["mice", "SPECIES", 135, 139], ["the serum levels", "TEST", 23, 39], ["urea", "TEST", 43, 47], ["creatinine", "TEST", 52, 62], ["P007-PMO treatment", "TREATMENT", 68, 86], ["the P007-PMO treatment", "TREATMENT", 190, 212], ["renal function", "TREATMENT", 216, 230], ["change", "OBSERVATION", 3, 9], ["renal", "ANATOMY", 216, 221]]], ["Overall these results indicated that over the course of the experiment, the P007-PMO conjugate did not induce any overt hepatic or renal toxicity at the systemic dose of 25 mg/kg in mdx mice.", [["hepatic", "ANATOMY", 120, 127], ["renal", "ANATOMY", 131, 136], ["P007", "CHEMICAL", 76, 80], ["hepatic or renal toxicity", "DISEASE", 120, 145], ["P007-PMO", "CHEMICAL", 76, 84], ["P007", "SIMPLE_CHEMICAL", 76, 80], ["hepatic", "ORGAN", 120, 127], ["renal", "ORGAN", 131, 136], ["mdx mice", "ORGANISM", 182, 190], ["mice", "SPECIES", 186, 190], ["mice", "SPECIES", 186, 190], ["the P007-PMO conjugate", "TEST", 72, 94], ["renal toxicity", "PROBLEM", 131, 145], ["hepatic", "ANATOMY", 120, 127], ["renal", "ANATOMY", 131, 136], ["toxicity", "OBSERVATION", 137, 145]]], ["No signs of toxicity were observed with 6 mg/kg dose regime (data not shown).DISCUSSIONIn this report we demonstrate effective systemic dystrophin correction in adult mdx dystrophic mice in both peripheral Figure 1 .", [["toxicity", "DISEASE", 12, 20], ["dystrophin", "GENE_OR_GENE_PRODUCT", 136, 146], ["mdx dystrophic mice", "ORGANISM", 167, 186], ["dystrophin", "PROTEIN", 136, 146], ["mice", "SPECIES", 182, 186], ["mice", "SPECIES", 182, 186], ["toxicity", "PROBLEM", 12, 20], ["effective systemic dystrophin correction", "TREATMENT", 117, 157], ["signs of", "UNCERTAINTY", 3, 11], ["toxicity", "OBSERVATION", 12, 20], ["peripheral Figure", "OBSERVATION", 195, 212]]], ["Continued skeletal muscle and cardiac tissue using PMO AOs conjugated to arginine-rich peptides, administered at low systemic doses.", [["skeletal muscle", "ANATOMY", 10, 25], ["cardiac tissue", "ANATOMY", 30, 44], ["arginine", "CHEMICAL", 73, 81], ["arginine", "CHEMICAL", 73, 81], ["skeletal muscle", "TISSUE", 10, 25], ["cardiac tissue", "TISSUE", 30, 44], ["PMO", "SIMPLE_CHEMICAL", 51, 54], ["AOs", "SIMPLE_CHEMICAL", 55, 58], ["arginine-rich peptides", "SIMPLE_CHEMICAL", 73, 95], ["PMO AOs", "TREATMENT", 51, 58], ["arginine-rich peptides", "TREATMENT", 73, 95], ["low systemic doses", "TREATMENT", 113, 131], ["skeletal muscle", "ANATOMY", 10, 25], ["cardiac tissue", "ANATOMY", 30, 44]]], ["A single 25 mg/kg intravenous dose of PMO-peptide conjugate was sufficient to rescue high levels of sarcolemmal dystrophin protein, DAPC component re-localization and histological and functional correction, with the P007-PMO conjugate demonstrating the greater efficacy.", [["intravenous", "ANATOMY", 18, 29], ["sarcolemmal", "ANATOMY", 100, 111], ["PMO-peptide", "CHEMICAL", 38, 49], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 18, 29], ["PMO-peptide conjugate", "SIMPLE_CHEMICAL", 38, 59], ["sarcolemmal dystrophin", "GENE_OR_GENE_PRODUCT", 100, 122], ["DAPC", "SIMPLE_CHEMICAL", 132, 136], ["P007", "SIMPLE_CHEMICAL", 216, 220], ["sarcolemmal dystrophin protein", "PROTEIN", 100, 130], ["DAPC", "PROTEIN", 132, 136], ["P007", "PROTEIN", 216, 220], ["A single 25 mg/kg intravenous dose of PMO-peptide conjugate", "TREATMENT", 0, 59], ["sarcolemmal dystrophin protein", "TREATMENT", 100, 130], ["DAPC component re-localization", "TREATMENT", 132, 162], ["the P007", "TEST", 212, 220], ["greater", "OBSERVATION_MODIFIER", 253, 260]]], ["This highlights the potential of PMO-peptide conjugates as compounds with therapeutic value for body-wide and cardiac dystrophin correction and is corroborated in a recent report of a related conjugate (31) .", [["body", "ANATOMY", 96, 100], ["cardiac", "ANATOMY", 110, 117], ["PMO-peptide conjugates", "SIMPLE_CHEMICAL", 33, 55], ["body", "ORGANISM_SUBDIVISION", 96, 100], ["cardiac", "ORGAN", 110, 117], ["dystrophin", "GENE_OR_GENE_PRODUCT", 118, 128], ["dystrophin", "PROTEIN", 118, 128], ["PMO-peptide conjugates", "TREATMENT", 33, 55], ["body-wide and cardiac dystrophin correction", "TREATMENT", 96, 139], ["cardiac", "ANATOMY", 110, 117], ["dystrophin", "OBSERVATION", 118, 128]]], ["Clinical studies to evaluate AO exon skipping in DMD patients are in progress in both The Netherlands (11) and the UK, using 2 0 O-methyl phosphorothioate and PMO AO compounds, respectively.", [["DMD", "DISEASE", 49, 52], ["phosphorothioate", "CHEMICAL", 138, 154], ["O-methyl phosphorothioate", "CHEMICAL", 129, 154], ["PMO AO", "CHEMICAL", 159, 165], ["patients", "ORGANISM", 53, 61], ["2 0 O-methyl phosphorothioate", "SIMPLE_CHEMICAL", 125, 154], ["PMO AO compounds", "SIMPLE_CHEMICAL", 159, 175], ["AO exon", "DNA", 29, 36], ["patients", "SPECIES", 53, 61], ["Clinical studies", "TEST", 0, 16], ["AO exon skipping in DMD", "PROBLEM", 29, 52], ["2 0 O-methyl phosphorothioate", "TREATMENT", 125, 154]]], ["AO-peptide conjugates therefore offer the possibility of efficient systemic and cardiac dystrophin correction at significantly lower doses than previously used for unconjugated AOs in mdx mice (4), reducing possible concerns regarding potential toxicity of high dose 2 0 O-methyl phosphorothioate and PMO AOs in human subjects and the cost of AOs.", [["cardiac", "ANATOMY", 80, 87], ["toxicity", "DISEASE", 245, 253], ["2 0 O-methyl phosphorothioate", "CHEMICAL", 267, 296], ["PMO AOs", "CHEMICAL", 301, 308], ["2 0 O-methyl phosphorothioate", "CHEMICAL", 267, 296], ["PMO", "CHEMICAL", 301, 304], ["AO", "SIMPLE_CHEMICAL", 0, 2], ["dystrophin", "GENE_OR_GENE_PRODUCT", 88, 98], ["AOs", "SIMPLE_CHEMICAL", 177, 180], ["mdx mice", "ORGANISM", 184, 192], ["2 0 O-methyl phosphorothioate", "SIMPLE_CHEMICAL", 267, 296], ["PMO AOs", "SIMPLE_CHEMICAL", 301, 308], ["human", "ORGANISM", 312, 317], ["AOs", "SIMPLE_CHEMICAL", 343, 346], ["dystrophin", "PROTEIN", 88, 98], ["mice", "SPECIES", 188, 192], ["human", "SPECIES", 312, 317], ["mice", "SPECIES", 188, 192], ["human", "SPECIES", 312, 317], ["AO-peptide conjugates", "TREATMENT", 0, 21], ["efficient systemic and cardiac dystrophin correction", "TREATMENT", 57, 109], ["unconjugated AOs", "PROBLEM", 164, 180], ["potential toxicity", "PROBLEM", 235, 253], ["methyl phosphorothioate", "TREATMENT", 273, 296], ["cardiac", "ANATOMY", 80, 87], ["dystrophin", "OBSERVATION", 88, 98]]], ["While further studies are warranted to fully investigate the toxicological profile of the transduction peptides used in this report, we found no evidence of systemic toxicity in treated mdx mice over the course of the experiments.DISCUSSIONPrevious work investigating PMO-based exon skipping in adult mdx mice failed to find evidence of cardiac dystrophin correction even at a very high multiple doses of 100 mg/kg (4, 18) .", [["cardiac", "ANATOMY", 337, 344], ["toxicity", "DISEASE", 166, 174], ["mdx mice", "ORGANISM", 186, 194], ["PMO", "SIMPLE_CHEMICAL", 268, 271], ["mdx mice", "ORGANISM", 301, 309], ["cardiac", "ORGAN", 337, 344], ["dystrophin", "GENE_OR_GENE_PRODUCT", 345, 355], ["dystrophin", "PROTEIN", 345, 355], ["mice", "SPECIES", 190, 194], ["mice", "SPECIES", 305, 309], ["mice", "SPECIES", 190, 194], ["mice", "SPECIES", 305, 309], ["further studies", "TEST", 6, 21], ["systemic toxicity", "PROBLEM", 157, 174], ["based exon skipping", "PROBLEM", 272, 291], ["cardiac dystrophin correction", "PROBLEM", 337, 366], ["no evidence of", "UNCERTAINTY", 142, 156], ["systemic", "OBSERVATION_MODIFIER", 157, 165], ["toxicity", "OBSERVATION", 166, 174], ["cardiac", "ANATOMY", 337, 344], ["dystrophin", "OBSERVATION", 345, 355]]], ["Our data demonstrating widespread dystrophin correction in heart, with protein levels restored up to 20% of normal at 3 weeks following single intravenous AO injections, shows that there is no intrinsic barrier to cardiac dystrophin correction in mdx mice using AO therapeutic agents (indeed high efficiency AO-mediated exon skipping can be achieved in primary mdx cardiomyocytes; Walker, Wood and Yin, unpublished data).", [["heart", "ANATOMY", 59, 64], ["intravenous", "ANATOMY", 143, 154], ["cardiac", "ANATOMY", 214, 221], ["mdx cardiomyocytes", "ANATOMY", 361, 379], ["AO", "CHEMICAL", 155, 157], ["dystrophin", "GENE_OR_GENE_PRODUCT", 34, 44], ["heart", "ORGAN", 59, 64], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 143, 154], ["AO", "SIMPLE_CHEMICAL", 155, 157], ["cardiac", "ORGAN", 214, 221], ["dystrophin", "GENE_OR_GENE_PRODUCT", 222, 232], ["mdx mice", "ORGANISM", 247, 255], ["mdx cardiomyocytes", "CELL", 361, 379], ["dystrophin", "PROTEIN", 34, 44], ["dystrophin", "PROTEIN", 222, 232], ["primary mdx cardiomyocytes", "CELL_TYPE", 353, 379], ["mice", "SPECIES", 251, 255], ["mice", "SPECIES", 251, 255], ["Our data", "TEST", 0, 8], ["widespread dystrophin correction in heart", "PROBLEM", 23, 64], ["protein levels", "TEST", 71, 85], ["single intravenous AO injections", "TREATMENT", 136, 168], ["cardiac dystrophin correction", "TREATMENT", 214, 243], ["mdx mice", "TREATMENT", 247, 255], ["AO therapeutic agents", "TREATMENT", 262, 283], ["AO-mediated exon skipping", "TREATMENT", 308, 333], ["widespread", "OBSERVATION_MODIFIER", 23, 33], ["dystrophin correction", "OBSERVATION", 34, 55], ["heart", "ANATOMY", 59, 64], ["no", "UNCERTAINTY", 190, 192], ["cardiac", "ANATOMY", 214, 221], ["dystrophin", "OBSERVATION", 222, 232]]], ["Given that correction of the cardiac defect due to loss of dystrophin protein is an essential component of a successful DMD therapy (14, 15) and that therapies restoring dystrophin in skeletal muscles but not in cardiac muscle may exacerbate the underlying cardiac pathology (32), PMOpeptide conjugates have significant potential for systemic correction of the DMD phenotype.", [["cardiac", "ANATOMY", 29, 36], ["skeletal muscles", "ANATOMY", 184, 200], ["cardiac muscle", "ANATOMY", 212, 226], ["cardiac", "ANATOMY", 257, 264], ["cardiac defect", "DISEASE", 29, 43], ["DMD", "DISEASE", 120, 123], ["cardiac muscle", "DISEASE", 212, 226], ["DMD", "DISEASE", 361, 364], ["PMOpeptide", "CHEMICAL", 281, 291], ["cardiac", "ORGAN", 29, 36], ["dystrophin", "GENE_OR_GENE_PRODUCT", 59, 69], ["dystrophin", "GENE_OR_GENE_PRODUCT", 170, 180], ["skeletal muscles", "ORGAN", 184, 200], ["cardiac muscle", "TISSUE", 212, 226], ["cardiac", "PATHOLOGICAL_FORMATION", 257, 264], ["PMOpeptide conjugates", "SIMPLE_CHEMICAL", 281, 302], ["dystrophin protein", "PROTEIN", 59, 77], ["dystrophin", "PROTEIN", 170, 180], ["the cardiac defect", "PROBLEM", 25, 43], ["loss of dystrophin protein", "PROBLEM", 51, 77], ["a successful DMD therapy", "TREATMENT", 107, 131], ["dystrophin in skeletal muscles", "PROBLEM", 170, 200], ["the underlying cardiac pathology", "PROBLEM", 242, 274], ["PMOpeptide conjugates", "TREATMENT", 281, 302], ["systemic correction", "TREATMENT", 334, 353], ["the DMD phenotype", "PROBLEM", 357, 374], ["cardiac", "ANATOMY", 29, 36], ["defect", "OBSERVATION", 37, 43], ["dystrophin protein", "OBSERVATION", 59, 77], ["essential", "OBSERVATION_MODIFIER", 84, 93], ["component", "OBSERVATION_MODIFIER", 94, 103], ["successful", "OBSERVATION_MODIFIER", 109, 119], ["DMD", "OBSERVATION", 120, 123], ["dystrophin", "OBSERVATION", 170, 180], ["skeletal muscles", "ANATOMY", 184, 200], ["cardiac muscle", "ANATOMY", 212, 226], ["cardiac", "ANATOMY", 257, 264], ["pathology", "OBSERVATION", 265, 274], ["DMD phenotype", "OBSERVATION", 361, 374]]], ["The mechanism by which the arginine-rich (RXR) 4 transduction peptide facilitates cardiac AO delivery and efficacy within that tissue remains unclear.", [["cardiac", "ANATOMY", 82, 89], ["tissue", "ANATOMY", 127, 133], ["arginine", "CHEMICAL", 27, 35], ["arginine", "CHEMICAL", 27, 35], ["arginine-rich (RXR) 4", "GENE_OR_GENE_PRODUCT", 27, 48], ["cardiac AO", "MULTI-TISSUE_STRUCTURE", 82, 92], ["tissue", "TISSUE", 127, 133], ["the arginine-rich (RXR)", "TREATMENT", 23, 46], ["transduction peptide", "TREATMENT", 49, 69], ["cardiac AO delivery", "TREATMENT", 82, 101]]], ["Such cationic peptides are thought to bind to cell-associated glycosaminoglycans to be subsequently internalized by endocytosis (16) , thus the mechanism by which such biochemical events may lead to enhanced transvascular AO delivery to Figure 1A .", [["cell", "ANATOMY", 46, 50], ["transvascular", "ANATOMY", 208, 221], ["cell", "CELL", 46, 50], ["glycosaminoglycans", "SIMPLE_CHEMICAL", 62, 80], ["Such cationic peptides", "PROBLEM", 0, 22], ["associated glycosaminoglycans", "PROBLEM", 51, 80], ["such biochemical events", "PROBLEM", 163, 186], ["enhanced transvascular AO delivery", "TREATMENT", 199, 233], ["glycosaminoglycans", "OBSERVATION", 62, 80]]], ["Muscle tissues analysed were from tibialis anterior (TA), gastrocnemius, quadriceps, biceps, abdominal wall, diaphragm and heart muscles (scale bar \u00bc 200 mm).", [["Muscle tissues", "ANATOMY", 0, 14], ["tibialis anterior", "ANATOMY", 34, 51], ["TA", "ANATOMY", 53, 55], ["gastrocnemius", "ANATOMY", 58, 71], ["quadriceps", "ANATOMY", 73, 83], ["biceps", "ANATOMY", 85, 91], ["abdominal wall", "ANATOMY", 93, 107], ["diaphragm", "ANATOMY", 109, 118], ["heart muscles", "ANATOMY", 123, 136], ["Muscle tissues", "TISSUE", 0, 14], ["tibialis anterior", "TISSUE", 34, 51], ["TA", "MULTI-TISSUE_STRUCTURE", 53, 55], ["gastrocnemius", "MULTI-TISSUE_STRUCTURE", 58, 71], ["quadriceps", "TISSUE", 73, 83], ["biceps", "TISSUE", 85, 91], ["abdominal wall", "TISSUE", 93, 107], ["diaphragm", "MULTI-TISSUE_STRUCTURE", 109, 118], ["heart muscles", "TISSUE", 123, 136], ["Muscle tissues", "TEST", 0, 14], ["tibialis", "ANATOMY", 34, 42], ["anterior", "ANATOMY_MODIFIER", 43, 51], ["gastrocnemius", "ANATOMY", 58, 71], ["quadriceps", "ANATOMY", 73, 83], ["biceps", "ANATOMY", 85, 91], ["abdominal wall", "ANATOMY", 93, 107], ["diaphragm", "ANATOMY", 109, 118], ["heart muscles", "ANATOMY", 123, 136]]], ["High numbers of dystrophin-positive fibres are detected in crosssections within the skeletal muscles but not in heart.", [["dystrophin-positive fibres", "ANATOMY", 16, 42], ["skeletal muscles", "ANATOMY", 84, 100], ["heart", "ANATOMY", 112, 117], ["dystrophin", "GENE_OR_GENE_PRODUCT", 16, 26], ["crosssections", "CANCER", 59, 72], ["skeletal muscles", "ORGAN", 84, 100], ["heart", "ORGAN", 112, 117], ["dystrophin", "PROTEIN", 16, 26], ["dystrophin-positive fibres", "PROBLEM", 16, 42], ["numbers", "OBSERVATION_MODIFIER", 5, 12], ["dystrophin", "OBSERVATION", 16, 26], ["positive fibres", "OBSERVATION", 27, 42], ["skeletal muscles", "ANATOMY", 84, 100], ["heart", "ANATOMY", 112, 117]]], ["(B) RT-PCR to detect the dystrophin exon skipping products in various treated mdx muscle groups as shown; unskipped or deleted for exon 23 or exon 22 and 23 as indicated in the boxes.", [["mdx muscle", "ANATOMY", 78, 88], ["dystrophin", "GENE_OR_GENE_PRODUCT", 25, 35], ["mdx muscle", "ORGAN", 78, 88], ["dystrophin exon skipping products", "PROTEIN", 25, 58], ["exon 23", "DNA", 131, 138], ["exon 22", "DNA", 142, 149], ["RT-PCR", "TEST", 4, 10], ["the dystrophin exon skipping products", "TREATMENT", 21, 58], ["various treated mdx muscle groups", "TREATMENT", 62, 95], ["dystrophin", "OBSERVATION", 25, 35], ["exon skipping", "OBSERVATION", 36, 49], ["mdx muscle", "ANATOMY", 78, 88]]], ["Results show almost no full-length dystrophin transcript is detectable in TA, quadriceps and gastrocnemius (indicated by boxed number [22] [23] [24] , with 50% exon 23 skipping in abdominal muscle and diaphragm and less in heart.", [["TA", "ANATOMY", 74, 76], ["quadriceps", "ANATOMY", 78, 88], ["gastrocnemius", "ANATOMY", 93, 106], ["abdominal muscle", "ANATOMY", 180, 196], ["diaphragm", "ANATOMY", 201, 210], ["heart", "ANATOMY", 223, 228], ["dystrophin", "GENE_OR_GENE_PRODUCT", 35, 45], ["TA", "TISSUE", 74, 76], ["quadriceps", "ORGANISM_SUBDIVISION", 78, 88], ["gastrocnemius", "ORGAN", 93, 106], ["abdominal muscle", "ORGAN", 180, 196], ["diaphragm", "ORGAN", 201, 210], ["heart", "ORGAN", 223, 228], ["dystrophin transcript", "RNA", 35, 56], ["exon 23", "DNA", 160, 167], ["full-length dystrophin transcript", "PROBLEM", 23, 56], ["50% exon 23 skipping in abdominal muscle and diaphragm", "PROBLEM", 156, 210], ["quadriceps", "ANATOMY", 78, 88], ["gastrocnemius", "ANATOMY", 93, 106], ["abdominal muscle", "ANATOMY", 180, 196], ["diaphragm", "ANATOMY", 201, 210], ["less", "OBSERVATION_MODIFIER", 215, 219], ["heart", "ANATOMY", 223, 228]]], ["(C) Western blot to detect dystrophin protein in the indicated muscle groups from treated mdx mice compared with C57BL6 and untreated mdx control mice.", [["muscle", "ANATOMY", 63, 69], ["dystrophin", "GENE_OR_GENE_PRODUCT", 27, 37], ["muscle", "ORGAN", 63, 69], ["mdx mice", "ORGANISM", 90, 98], ["C57BL6", "ORGANISM", 113, 119], ["mdx control mice", "ORGANISM", 134, 150], ["dystrophin protein", "PROTEIN", 27, 45], ["mice", "SPECIES", 94, 98], ["mice", "SPECIES", 146, 150], ["mice", "SPECIES", 94, 98], ["mice", "SPECIES", 146, 150], ["Western blot", "TEST", 4, 16], ["dystrophin protein", "TEST", 27, 45], ["C57BL6 and untreated mdx control mice", "TREATMENT", 113, 150], ["muscle", "ANATOMY", 63, 69]]], ["Data shows up to 30% dystrophin expression in quadriceps and gastrocnemius, but lower levels in diaphragm and less in heart.", [["quadriceps", "ANATOMY", 46, 56], ["gastrocnemius", "ANATOMY", 61, 74], ["diaphragm", "ANATOMY", 96, 105], ["heart", "ANATOMY", 118, 123], ["dystrophin", "GENE_OR_GENE_PRODUCT", 21, 31], ["quadriceps", "ORGANISM_SUBDIVISION", 46, 56], ["gastrocnemius", "ORGAN", 61, 74], ["diaphragm", "ORGAN", 96, 105], ["heart", "ORGAN", 118, 123], ["dystrophin", "PROTEIN", 21, 31], ["Data", "TEST", 0, 4], ["30% dystrophin expression in quadriceps and gastrocnemius", "PROBLEM", 17, 74], ["quadriceps", "ANATOMY", 46, 56], ["gastrocnemius", "ANATOMY", 61, 74], ["lower", "ANATOMY_MODIFIER", 80, 85], ["diaphragm", "ANATOMY", 96, 105], ["less", "OBSERVATION_MODIFIER", 110, 114], ["heart", "ANATOMY", 118, 123]]], ["Equal loading of 50 mg protein is shown for each sample except for C57BL6 control lane where 5 mg of protein was loaded. a-actinin expression was detected as a loading control. cardiac and muscle tissue is not understood.", [["sample", "ANATOMY", 49, 55], ["cardiac", "ANATOMY", 177, 184], ["muscle tissue", "ANATOMY", 189, 202], ["a-actinin", "GENE_OR_GENE_PRODUCT", 121, 130], ["cardiac", "TISSUE", 177, 184], ["muscle tissue", "TISSUE", 189, 202], ["a-actinin", "PROTEIN", 121, 130], ["C57BL6 control lane", "TREATMENT", 67, 86], ["protein", "TREATMENT", 101, 108], ["a loading control", "TREATMENT", 158, 175], ["muscle tissue", "ANATOMY", 189, 202]]], ["Nevertheless, highly efficient cardiac and muscle gene delivery can be achieved using AAV vectors (33, 34) , including the delivery of splice correcting DNA constructs (35) , and therefore it seems plausible that arginine-rich transduction peptides permit efficient transvascular AO tissue entry to these tissues via similar mechanisms.", [["cardiac", "ANATOMY", 31, 38], ["muscle", "ANATOMY", 43, 49], ["transvascular AO tissue", "ANATOMY", 266, 289], ["tissues", "ANATOMY", 305, 312], ["arginine", "CHEMICAL", 213, 221], ["arginine", "CHEMICAL", 213, 221], ["cardiac", "MULTI-TISSUE_STRUCTURE", 31, 38], ["muscle", "ORGAN", 43, 49], ["AAV", "ORGANISM", 86, 89], ["DNA", "CELLULAR_COMPONENT", 153, 156], ["arginine", "SIMPLE_CHEMICAL", 213, 221], ["transvascular AO tissue", "TISSUE", 266, 289], ["tissues", "TISSUE", 305, 312], ["splice correcting DNA constructs", "DNA", 135, 167], ["muscle gene delivery", "TREATMENT", 43, 63], ["AAV vectors", "TREATMENT", 86, 97], ["the delivery of splice correcting DNA constructs", "TREATMENT", 119, 167], ["arginine-rich transduction peptides", "TREATMENT", 213, 248], ["muscle", "ANATOMY", 43, 49], ["AO tissue", "OBSERVATION", 280, 289]]], ["While re-administration of peptide-PMO AOs will be required, our data suggests that similar levels of cardiac dystrophin correction may be achievable compared with that found using the AAV antisense strategy, without the potential disadvantages of toxic or immunological effects attributable to the vector.", [["cardiac", "ANATOMY", 102, 109], ["peptide-PMO AOs", "SIMPLE_CHEMICAL", 27, 42], ["cardiac", "ORGAN", 102, 109], ["dystrophin", "GENE_OR_GENE_PRODUCT", 110, 120], ["AAV", "ORGANISM", 185, 188], ["dystrophin", "PROTEIN", 110, 120], ["peptide-PMO AOs", "TREATMENT", 27, 42], ["our data", "TEST", 61, 69], ["cardiac dystrophin correction", "TREATMENT", 102, 131], ["the AAV antisense strategy", "TREATMENT", 181, 207], ["toxic or immunological effects", "PROBLEM", 248, 278], ["cardiac", "ANATOMY", 102, 109], ["dystrophin", "OBSERVATION", 110, 120]]], ["Mechanistic insight and further structure-activity studies are likely to identify improved peptides for transvascular cardiac AO transduction.", [["cardiac", "ANATOMY", 118, 125], ["activity studies", "TEST", 42, 58], ["transvascular cardiac AO transduction", "TREATMENT", 104, 141]]], ["Whether restoration of cardiac dystrophin protein to 20% of normal levels is likely to be adequate to regain or maintain normal cardiac function is unknown and further studies will be required, particularly in DMD animal models manifesting a significant cardiac phenotype, e.g. dystrophin and utrophin deficient DKO mice (36) or the golden retriever dog model.", [["cardiac", "ANATOMY", 23, 30], ["cardiac", "ANATOMY", 128, 135], ["cardiac", "ANATOMY", 254, 261], ["DMD", "DISEASE", 210, 213], ["cardiac", "ORGAN", 23, 30], ["dystrophin", "GENE_OR_GENE_PRODUCT", 31, 41], ["cardiac", "ORGAN", 128, 135], ["cardiac", "ORGAN", 254, 261], ["dystrophin", "GENE_OR_GENE_PRODUCT", 278, 288], ["utrophin", "GENE_OR_GENE_PRODUCT", 293, 301], ["golden retriever dog", "ORGANISM", 333, 353], ["cardiac dystrophin protein", "PROTEIN", 23, 49], ["dystrophin", "PROTEIN", 278, 288], ["utrophin", "PROTEIN", 293, 301], ["mice", "SPECIES", 316, 320], ["golden retriever dog", "SPECIES", 333, 353], ["cardiac dystrophin protein", "TEST", 23, 49], ["further studies", "TEST", 160, 175], ["DMD animal models", "PROBLEM", 210, 227], ["a significant cardiac phenotype", "PROBLEM", 240, 271], ["dystrophin and utrophin deficient DKO mice", "PROBLEM", 278, 320], ["cardiac", "ANATOMY", 23, 30], ["dystrophin", "OBSERVATION", 31, 41], ["cardiac", "ANATOMY", 128, 135], ["significant", "OBSERVATION_MODIFIER", 242, 253], ["cardiac", "ANATOMY", 254, 261], ["phenotype", "OBSERVATION", 262, 271]]], ["However in DMD patients, the degree to which cardiac function is regained or maintained will depend not only on the level of dystrophin protein restored but also on the particular BMD-like dystrophin isoform restored by exon skipping in each case, given that the BMD cardiac phenotype is highly heterogeneous (14, 37) .DISCUSSIONOur data showed widespread, uniform, high-level dystrophin protein expression in all mdx peripheral muscle groups studied, including central abdominal wall and diaphragm muscles, 3 weeks following treatment with a single 25 mg/ kg PMO-peptide dose.", [["cardiac", "ANATOMY", 45, 52], ["cardiac", "ANATOMY", 267, 274], ["mdx peripheral muscle", "ANATOMY", 414, 435], ["abdominal wall", "ANATOMY", 470, 484], ["diaphragm muscles", "ANATOMY", 489, 506], ["DMD", "DISEASE", 11, 14], ["PMO-peptide", "CHEMICAL", 560, 571], ["patients", "ORGANISM", 15, 23], ["cardiac", "ORGAN", 45, 52], ["dystrophin", "GENE_OR_GENE_PRODUCT", 125, 135], ["dystrophin", "GENE_OR_GENE_PRODUCT", 189, 199], ["dystrophin", "GENE_OR_GENE_PRODUCT", 377, 387], ["mdx peripheral muscle", "TISSUE", 414, 435], ["abdominal wall", "MULTI-TISSUE_STRUCTURE", 470, 484], ["diaphragm muscles", "TISSUE", 489, 506], ["PMO-peptide", "SIMPLE_CHEMICAL", 560, 571], ["dystrophin protein", "PROTEIN", 125, 143], ["BMD-like dystrophin isoform", "PROTEIN", 180, 207], ["dystrophin protein", "PROTEIN", 377, 395], ["patients", "SPECIES", 15, 23], ["dystrophin protein", "PROBLEM", 125, 143], ["dystrophin isoform", "TREATMENT", 189, 207], ["the BMD cardiac phenotype", "TEST", 259, 284], ["DISCUSSIONOur data", "TEST", 319, 337], ["widespread, uniform, high-level dystrophin protein expression", "PROBLEM", 345, 406], ["treatment", "TREATMENT", 526, 535], ["a single 25 mg/ kg PMO-peptide dose", "TREATMENT", 541, 576], ["cardiac", "ANATOMY", 267, 274], ["phenotype", "OBSERVATION", 275, 284], ["highly", "OBSERVATION_MODIFIER", 288, 294], ["heterogeneous", "OBSERVATION_MODIFIER", 295, 308], ["widespread", "OBSERVATION_MODIFIER", 345, 355], ["uniform", "OBSERVATION_MODIFIER", 357, 364], ["high", "OBSERVATION_MODIFIER", 366, 370], ["dystrophin protein expression", "OBSERVATION", 377, 406], ["all", "ANATOMY_MODIFIER", 410, 413], ["mdx", "ANATOMY", 414, 417], ["peripheral", "ANATOMY_MODIFIER", 418, 428], ["muscle", "ANATOMY", 429, 435], ["central", "ANATOMY_MODIFIER", 462, 469], ["abdominal", "ANATOMY_MODIFIER", 470, 479], ["wall", "ANATOMY_MODIFIER", 480, 484], ["diaphragm muscles", "ANATOMY", 489, 506]]], ["Many muscle groups demonstrated dystrophin protein restored to levels in excess of 50% of normal, significantly higher than that reported previously using naked PMO compounds (4) or estimated in the first Figure 3 .", [["muscle", "ANATOMY", 5, 11], ["muscle", "ORGAN", 5, 11], ["dystrophin", "GENE_OR_GENE_PRODUCT", 32, 42], ["dystrophin protein", "PROTEIN", 32, 50], ["dystrophin protein", "TEST", 32, 50], ["levels in excess", "TEST", 63, 79], ["muscle", "ANATOMY", 5, 11], ["dystrophin", "OBSERVATION", 32, 42], ["normal", "OBSERVATION", 90, 96]]], ["Functional evaluation of mdx skeletal muscles following treatment with the P007-PMO conjugate.", [["mdx skeletal muscles", "ANATOMY", 25, 45], ["mdx skeletal muscles", "TISSUE", 25, 45], ["P007", "GENE_OR_GENE_PRODUCT", 75, 79], ["P007", "PROTEIN", 75, 79], ["Functional evaluation", "TEST", 0, 21], ["treatment", "TREATMENT", 56, 65], ["skeletal muscles", "ANATOMY", 29, 45]]], ["(A) Restoration of the dystrophin-associated protein complex (DAPC) in mdx mice treated with P007-PMO at 25 mg/kg was studied to assess dystrophin function and recovery of normal myoarchitecture.", [["P007-PMO", "CHEMICAL", 93, 101], ["dystrophin-associated protein complex", "GENE_OR_GENE_PRODUCT", 23, 60], ["DAPC", "GENE_OR_GENE_PRODUCT", 62, 66], ["mdx mice", "ORGANISM", 71, 79], ["P007-PMO", "SIMPLE_CHEMICAL", 93, 101], ["dystrophin", "GENE_OR_GENE_PRODUCT", 136, 146], ["dystrophin-associated protein complex", "PROTEIN", 23, 60], ["DAPC", "PROTEIN", 62, 66], ["dystrophin", "PROTEIN", 136, 146], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 75, 79], ["the dystrophin", "PROBLEM", 19, 33], ["associated protein complex (DAPC)", "TREATMENT", 34, 67], ["P007-PMO", "TREATMENT", 93, 101], ["dystrophin function", "TEST", 136, 155], ["dystrophin", "OBSERVATION", 23, 33], ["protein complex", "OBSERVATION", 45, 60], ["normal myoarchitecture", "OBSERVATION", 172, 194]]], ["DAPC protein components b-dystroglycan, a and b-sarcoglycan and nNOS were detected by immunostaining in tissue cross-sections of TA muscles from treated mdx mice compared with C57BL6 normal mice and untreated mdx control mice.", [["tissue cross-sections", "ANATOMY", 104, 125], ["TA muscles", "ANATOMY", 129, 139], ["DAPC", "GENE_OR_GENE_PRODUCT", 0, 4], ["b-dystroglycan", "GENE_OR_GENE_PRODUCT", 24, 38], ["b-sarcoglycan", "GENE_OR_GENE_PRODUCT", 46, 59], ["nNOS", "GENE_OR_GENE_PRODUCT", 64, 68], ["tissue cross-sections", "MULTI-TISSUE_STRUCTURE", 104, 125], ["TA muscles", "TISSUE", 129, 139], ["mdx mice", "ORGANISM", 153, 161], ["C57BL6 normal mice", "ORGANISM", 176, 194], ["mdx control mice", "ORGANISM", 209, 225], ["DAPC protein components", "PROTEIN", 0, 23], ["b-dystroglycan", "PROTEIN", 24, 38], ["b-sarcoglycan", "PROTEIN", 46, 59], ["nNOS", "PROTEIN", 64, 68], ["mice", "SPECIES", 157, 161], ["mice", "SPECIES", 190, 194], ["mice", "SPECIES", 221, 225], ["mice", "SPECIES", 157, 161], ["C57BL6", "SPECIES", 176, 182], ["mice", "SPECIES", 190, 194], ["mice", "SPECIES", 221, 225], ["nNOS", "PROBLEM", 64, 68], ["muscles", "ANATOMY", 132, 139]]], ["All detected DAPC components are found to be successfully re-localized to the mdx muscle sarcolemma after treatment.", [["DAPC components", "ANATOMY", 13, 28], ["mdx muscle sarcolemma", "ANATOMY", 78, 99], ["DAPC", "GENE_OR_GENE_PRODUCT", 13, 17], ["mdx muscle sarcolemma", "TISSUE", 78, 99], ["DAPC components", "PROTEIN", 13, 28], ["treatment", "TREATMENT", 106, 115], ["mdx", "ANATOMY", 78, 81], ["muscle sarcolemma", "ANATOMY", 82, 99]]], ["(B) Muscle function was assessed using a functional grip strength test to determine the physical improvement of P007-PMO treated mdx mice compared with C57BL6 and untreated mdx mice.", [["Muscle", "ANATOMY", 4, 10], ["Muscle", "ORGAN", 4, 10], ["P007-PMO", "SIMPLE_CHEMICAL", 112, 120], ["mdx mice", "ORGANISM", 129, 137], ["C57BL6", "ORGANISM", 152, 158], ["mdx mice", "ORGANISM", 173, 181], ["mice", "SPECIES", 133, 137], ["mice", "SPECIES", 177, 181], ["mice", "SPECIES", 133, 137], ["mice", "SPECIES", 177, 181], ["a functional grip strength test", "TEST", 39, 70], ["C57BL6 and untreated mdx mice", "TREATMENT", 152, 181], ["Muscle", "ANATOMY", 4, 10]]], ["Data shows significant functional improvement in treated mdx mice with functional recovery observed into the normal range seen in untreated age-matched control mice (P , 0.005).", [["mdx mice", "ORGANISM", 57, 65], ["mice", "ORGANISM", 160, 164], ["mice", "SPECIES", 61, 65], ["mice", "SPECIES", 160, 164], ["mice", "SPECIES", 61, 65], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["functional", "OBSERVATION_MODIFIER", 23, 33], ["improvement", "OBSERVATION_MODIFIER", 34, 45]]], ["(C) Evaluation of the numbers of centrally nucleated myofibres in TA, gastrocnemius and quadriceps muscles following a P007-PMO treatment compared with the corresponding untreated mdx muscles.", [["myofibres", "ANATOMY", 53, 62], ["TA", "ANATOMY", 66, 68], ["gastrocnemius", "ANATOMY", 70, 83], ["quadriceps muscles", "ANATOMY", 88, 106], ["mdx muscles", "ANATOMY", 180, 191], ["P007-PMO", "CHEMICAL", 119, 127], ["myofibres", "TISSUE", 53, 62], ["TA", "MULTI-TISSUE_STRUCTURE", 66, 68], ["gastrocnemius", "MULTI-TISSUE_STRUCTURE", 70, 83], ["quadriceps muscles", "TISSUE", 88, 106], ["P007-PMO", "SIMPLE_CHEMICAL", 119, 127], ["mdx muscles", "TISSUE", 180, 191], ["centrally nucleated myofibres", "CELL_TYPE", 33, 62], ["Evaluation", "TEST", 4, 14], ["a P007-PMO treatment", "TREATMENT", 117, 137], ["myofibres", "OBSERVATION", 53, 62], ["gastrocnemius", "ANATOMY", 70, 83], ["quadriceps muscles", "ANATOMY", 88, 106], ["mdx muscles", "ANATOMY", 180, 191]]], ["Data shows a significant decrease in the number of centrally nucleated myofibres in treated mdx muscles compared with controls (P , 0.005).", [["myofibres", "ANATOMY", 71, 80], ["mdx muscles", "ANATOMY", 92, 103], ["myofibres", "TISSUE", 71, 80], ["mdx muscles", "ORGAN", 92, 103], ["centrally nucleated myofibres", "CELL_TYPE", 51, 80], ["a significant decrease", "PROBLEM", 11, 33], ["centrally nucleated myofibres in treated mdx muscles", "PROBLEM", 51, 103], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["decrease", "OBSERVATION_MODIFIER", 25, 33], ["centrally", "OBSERVATION_MODIFIER", 51, 60], ["nucleated myofibres", "OBSERVATION", 61, 80], ["mdx muscles", "ANATOMY", 92, 103]]], ["(D) Measurement of serum creatine kinase (CK) levels as an index of ongoing muscle membrane instability in treated mdx mice compared with normal and mdx control mice.", [["serum", "ANATOMY", 19, 24], ["muscle membrane", "ANATOMY", 76, 91], ["creatine", "CHEMICAL", 25, 33], ["creatine", "CHEMICAL", 25, 33], ["serum", "ORGANISM_SUBSTANCE", 19, 24], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 25, 40], ["CK", "GENE_OR_GENE_PRODUCT", 42, 44], ["muscle membrane", "MULTI-TISSUE_STRUCTURE", 76, 91], ["mdx mice", "ORGANISM", 115, 123], ["mdx control mice", "ORGANISM", 149, 165], ["serum creatine kinase", "PROTEIN", 19, 40], ["CK", "PROTEIN", 42, 44], ["mice", "SPECIES", 119, 123], ["mice", "SPECIES", 161, 165], ["mice", "SPECIES", 119, 123], ["mice", "SPECIES", 161, 165], ["Measurement of serum creatine kinase", "TEST", 4, 40], ["CK) levels", "TEST", 42, 52], ["an index", "TEST", 56, 64], ["ongoing muscle membrane instability", "PROBLEM", 68, 103], ["muscle", "ANATOMY", 76, 82], ["membrane instability", "OBSERVATION", 83, 103]]], ["Data show a significant fall in the serum CK levels in mdx mice treated with P007-PMO compared with untreated age-matched mdx controls (n \u00bc 6 for treated group and n \u00bc 4 for control, P , 0.05).DISCUSSIONhuman clinical study with direct intramuscular delivery of 2 0 O-methyl phosphorothioate AOs (11) .", [["serum", "ANATOMY", 36, 41], ["intramuscular", "ANATOMY", 236, 249], ["P007-PMO", "CHEMICAL", 77, 85], ["2 0 O-methyl phosphorothioate", "CHEMICAL", 262, 291], ["2 0 O-methyl phosphorothioate AOs", "CHEMICAL", 262, 295], ["serum", "ORGANISM_SUBSTANCE", 36, 41], ["CK", "GENE_OR_GENE_PRODUCT", 42, 44], ["mdx mice", "ORGANISM", 55, 63], ["P007-PMO", "SIMPLE_CHEMICAL", 77, 85], ["mdx", "ORGANISM", 122, 125], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 236, 249], ["2 0 O-methyl phosphorothioate AOs", "SIMPLE_CHEMICAL", 262, 295], ["CK", "PROTEIN", 42, 44], ["mice", "SPECIES", 59, 63], ["mice", "SPECIES", 59, 63], ["a significant fall", "PROBLEM", 10, 28], ["the serum CK levels", "TEST", 32, 51], ["P007-PMO", "TREATMENT", 77, 85], ["clinical study", "TEST", 209, 223], ["direct intramuscular delivery", "TREATMENT", 229, 258], ["O-methyl phosphorothioate AOs", "TEST", 266, 295], ["significant", "OBSERVATION_MODIFIER", 12, 23], ["fall", "OBSERVATION", 24, 28]]], ["As a consequence we found that DAPC protein components were efficiently re-localized, muscle histology appeared normal and muscle grip strength was restored to within the normal range.", [["muscle", "ANATOMY", 86, 92], ["muscle", "ANATOMY", 123, 129], ["DAPC", "GENE_OR_GENE_PRODUCT", 31, 35], ["muscle", "ORGAN", 86, 92], ["muscle grip", "TISSUE", 123, 134], ["DAPC protein components", "PROTEIN", 31, 54], ["DAPC protein components", "PROBLEM", 31, 54], ["muscle histology", "TEST", 86, 102], ["muscle grip strength", "TEST", 123, 143], ["muscle", "ANATOMY", 86, 92], ["normal", "OBSERVATION", 112, 118], ["muscle", "ANATOMY", 123, 129]]], ["RT-PCR analysis using a nested reaction at 25 cycles revealed that for all tissues except the heart, virtually all mutant transcripts had been successfully skipped suggesting the possibility of AO-target saturation.", [["tissues", "ANATOMY", 75, 82], ["heart", "ANATOMY", 94, 99], ["tissues", "TISSUE", 75, 82], ["heart", "ORGAN", 94, 99], ["AO", "SIMPLE_CHEMICAL", 194, 196], ["mutant transcripts", "RNA", 115, 133], ["RT-PCR analysis", "TEST", 0, 15], ["a nested reaction", "PROBLEM", 22, 39], ["heart", "ANATOMY", 94, 99], ["suggesting the possibility", "UNCERTAINTY", 164, 190]]], ["We therefore tested whether or not a lower dose of PMO-peptide conjugate could effectively restore dystrophin expression.", [["PMO-peptide", "CHEMICAL", 51, 62], ["PMO-peptide conjugate", "SIMPLE_CHEMICAL", 51, 72], ["dystrophin", "GENE_OR_GENE_PRODUCT", 99, 109], ["dystrophin", "PROTEIN", 99, 109], ["a lower dose of PMO-peptide conjugate", "TREATMENT", 35, 72], ["dystrophin expression", "PROBLEM", 99, 120]]], ["While near normal levels of dystrophin protein were restored in peripheral muscles with this lower dose, central muscles including diaphragm and heart were less well corrected at dystrophin and DAPC protein levels.", [["peripheral muscles", "ANATOMY", 64, 82], ["central muscles", "ANATOMY", 105, 120], ["diaphragm", "ANATOMY", 131, 140], ["heart", "ANATOMY", 145, 150], ["dystrophin", "GENE_OR_GENE_PRODUCT", 28, 38], ["peripheral muscles", "ORGAN", 64, 82], ["central muscles", "ORGAN", 105, 120], ["diaphragm", "ORGAN", 131, 140], ["heart", "ORGAN", 145, 150], ["dystrophin", "GENE_OR_GENE_PRODUCT", 179, 189], ["DAPC", "GENE_OR_GENE_PRODUCT", 194, 198], ["dystrophin protein", "PROTEIN", 28, 46], ["dystrophin", "PROTEIN", 179, 189], ["DAPC", "PROTEIN", 194, 198], ["dystrophin protein", "PROBLEM", 28, 46], ["dystrophin and DAPC protein levels", "TEST", 179, 213], ["dystrophin protein", "OBSERVATION", 28, 46], ["peripheral", "ANATOMY_MODIFIER", 64, 74], ["muscles", "ANATOMY", 75, 82], ["central", "ANATOMY_MODIFIER", 105, 112], ["muscles", "ANATOMY", 113, 120], ["diaphragm", "ANATOMY", 131, 140], ["heart", "ANATOMY", 145, 150]]], ["The question therefore arises as to the optimal dosing regime of PMO-peptide AOs.", [["PMO-peptide AOs", "CHEMICAL", 65, 80], ["PMO-peptide AOs", "SIMPLE_CHEMICAL", 65, 80], ["the optimal dosing regime of PMO", "TREATMENT", 36, 68]]], ["Given our data at the high 25 mg/kg dose, that the estimated half-life of dystrophin protein approaches 26 weeks in mdx mice (18, 19) and that peptide conjugates are known to increase PMO tissue uptake and retention (38, 39) , a single higher PMO-peptide threshold dose followed by lower maintenance doses at 4 -8 week intervals may be optimal.", [["tissue", "ANATOMY", 188, 194], ["dystrophin", "GENE_OR_GENE_PRODUCT", 74, 84], ["mdx mice", "ORGANISM", 116, 124], ["peptide conjugates", "SIMPLE_CHEMICAL", 143, 161], ["PMO tissue", "TISSUE", 184, 194], ["dystrophin protein", "PROTEIN", 74, 92], ["mice", "SPECIES", 120, 124], ["mice", "SPECIES", 120, 124], ["dystrophin protein approaches", "TREATMENT", 74, 103], ["peptide conjugates", "PROBLEM", 143, 161], ["increase PMO tissue uptake", "PROBLEM", 175, 201], ["a single higher PMO-peptide threshold dose", "TREATMENT", 227, 269], ["lower maintenance doses", "TREATMENT", 282, 305], ["retention", "OBSERVATION_MODIFIER", 206, 215]]], ["Further studies will be required to determine this and to evaluate the longer-term functional and physiological effects of this treatment.AnimalsSix-to-eight-week old mdx mice were used in all experiments (six mice in the test and four in control groups).", [["mdx", "ORGANISM", 167, 170], ["mice", "ORGANISM", 171, 175], ["mice", "ORGANISM", 210, 214], ["mice", "SPECIES", 171, 175], ["mice", "SPECIES", 210, 214], ["mice", "SPECIES", 171, 175], ["Further studies", "TEST", 0, 15], ["this treatment", "TREATMENT", 123, 137], ["AnimalsSix", "TEST", 138, 148], ["mdx mice", "TREATMENT", 167, 175], ["the test", "TEST", 218, 226]]], ["Mice were killed by CO 2 inhalation or cervical dislocation at desired time points, and muscles and other tissues were snap-frozen in liquid nitrogen-cooled isopentane and stored at 2808C.PMO and PMO-peptide conjugatesDetails of PMO and PMO-peptide conjugates are shown in Table 1 .", [["cervical", "ANATOMY", 39, 47], ["muscles", "ANATOMY", 88, 95], ["tissues", "ANATOMY", 106, 113], ["cervical dislocation", "DISEASE", 39, 59], ["nitrogen", "CHEMICAL", 141, 149], ["PMO", "CHEMICAL", 188, 191], ["PMO-peptide conjugates", "CHEMICAL", 196, 218], ["CO 2", "CHEMICAL", 20, 24], ["nitrogen", "CHEMICAL", 141, 149], ["isopentane", "CHEMICAL", 157, 167], ["Mice", "ORGANISM", 0, 4], ["cervical", "ORGAN", 39, 47], ["muscles", "ORGANISM_SUBDIVISION", 88, 95], ["tissues", "TISSUE", 106, 113], ["isopentane", "SIMPLE_CHEMICAL", 157, 167], ["PMO", "SIMPLE_CHEMICAL", 188, 191], ["PMO-peptide", "SIMPLE_CHEMICAL", 196, 207], ["PMO", "SIMPLE_CHEMICAL", 229, 232], ["PMO-peptide conjugates", "SIMPLE_CHEMICAL", 237, 259], ["Mice", "SPECIES", 0, 4], ["cervical dislocation", "PROBLEM", 39, 59], ["snap", "TEST", 119, 123], ["liquid nitrogen", "TREATMENT", 134, 149], ["PMO and PMO-peptide conjugates", "TREATMENT", 188, 218], ["PMO and PMO-peptide conjugates", "TREATMENT", 229, 259], ["cervical", "ANATOMY", 39, 47], ["dislocation", "OBSERVATION", 48, 59], ["muscles", "ANATOMY", 88, 95], ["tissues", "ANATOMY", 106, 113]]], ["Conjugations of peptide with PMO were synthesized by a stable amide linker as described elsewhere (40) .", [["PMO", "CHEMICAL", 29, 32], ["PMO", "CHEMICAL", 29, 32], ["amide", "CHEMICAL", 62, 67], ["PMO", "SIMPLE_CHEMICAL", 29, 32], ["Conjugations of peptide with PMO", "TREATMENT", 0, 32], ["a stable amide linker", "TREATMENT", 53, 74], ["stable", "OBSERVATION_MODIFIER", 55, 61]]], ["The PMO AO sequence against the boundary sequences of exon and intron 23 of the dystrophin gene was 5 0 -ggccaaacctcggcttacctgaaat-3 0 , and designated as 25mer PMO (M23D).RNA extraction and nested RT-PCR analysisTotal RNA was extracted from skeletal muscle and heart tissue with Trizol (Invitrogen, UK) and 200 ng of RNA template was used for 20 ml RT-PCR with OneStep RT-PCR kit (Qiagen, UK).", [["skeletal muscle", "ANATOMY", 242, 257], ["heart tissue", "ANATOMY", 262, 274], ["intron 23", "CELLULAR_COMPONENT", 63, 72], ["dystrophin", "GENE_OR_GENE_PRODUCT", 80, 90], ["skeletal muscle", "TISSUE", 242, 257], ["heart tissue", "TISSUE", 262, 274], ["UK", "GENE_OR_GENE_PRODUCT", 300, 302], ["PMO AO sequence", "DNA", 4, 19], ["boundary sequences", "DNA", 32, 50], ["exon", "DNA", 54, 58], ["intron 23", "DNA", 63, 72], ["dystrophin gene", "DNA", 80, 95], ["5 0 -ggccaaacctcggcttacctgaaat-3 0", "DNA", 100, 134], ["25mer PMO", "DNA", 155, 164], ["M23D", "DNA", 166, 170], ["The PMO AO sequence", "TEST", 0, 19], ["exon and intron", "TREATMENT", 54, 69], ["the dystrophin gene", "TEST", 76, 95], ["RNA extraction", "TREATMENT", 172, 186], ["nested RT-PCR analysisTotal RNA", "TEST", 191, 222], ["Trizol (Invitrogen", "TREATMENT", 280, 298], ["RNA template", "TREATMENT", 318, 330], ["PCR", "TEST", 353, 356], ["OneStep RT", "TREATMENT", 362, 372], ["skeletal muscle", "ANATOMY", 242, 257], ["heart tissue", "ANATOMY", 262, 274]]], ["The primer sequences for the initial RT-PCR were Exon20Fo 5 0 -CAGAATTCTGCCAATTGCTGAG-3 0 and Ex26Ro 5 0 -TTCTTCAGCTTGTGTCATCC-3 0 for amplification of messenger RNA from exons 20 to 26.", [["primer sequences", "DNA", 4, 20], ["Exon20Fo 5 0", "DNA", 49, 61], ["Ex26Ro 5 0", "DNA", 94, 104], ["TTCTTCAGCTTGTGTCATCC-3 0", "DNA", 106, 130], ["messenger RNA", "RNA", 152, 165], ["exons 20 to 26", "DNA", 171, 185], ["The primer sequences", "TEST", 0, 20], ["the initial RT-PCR", "TEST", 25, 43], ["Exon20Fo", "TEST", 49, 57], ["CAGAATTCTGCCAATTGCTGAG", "TEST", 63, 85], ["Ex26Ro", "TEST", 94, 100], ["TTCTTCAGCTTGTGTCATCC", "TEST", 106, 126]]], ["The cycle conditions were 958C for 30 s, 558C for 1 min and 728C for 2 min for 25 cycles.", [["958C", "CHEMICAL", 26, 30], ["The cycle conditions", "TEST", 0, 20]]], ["RT-PCR product (1 ml) was then used as the template for secondary PCR performed in 25 ml with 0.5U Taq DNA polymerase (Invitrogen, UK).", [["DNA", "CELLULAR_COMPONENT", 103, 106], ["UK", "GENE_OR_GENE_PRODUCT", 131, 133], ["0.5U Taq DNA polymerase", "PROTEIN", 94, 117], ["RT-PCR product", "TREATMENT", 0, 14], ["secondary PCR", "TEST", 56, 69], ["0.5U Taq DNA polymerase", "TREATMENT", 94, 117]]], ["The primer sequences for the second round were Ex20Fi CCCAGTCTACCACCCTATCAG AGC-3 0 and Ex24Ri 5 0 -CAGCCATCCATTTCTGTAAGG -3.", [["primer sequences", "DNA", 4, 20], ["Ex24Ri 5 0", "DNA", 88, 98], ["CAGCCATCCATTTCTGTAAGG -3", "DNA", 100, 124], ["The primer sequences", "TEST", 0, 20], ["CCCAGTCTACCACCCTATCAG", "TEST", 54, 75], ["AGC", "TEST", 76, 79], ["Ex24Ri", "TEST", 88, 94]]], ["The cycle conditions were 958C for 1 min, 578C for 1 min and 728C for 2 min for 25 cycles.", [["958C", "CHEMICAL", 26, 30], ["The cycle conditions", "TEST", 0, 20]]], ["The products were examined by electrophoresis on a 2% agarose gel.Intramuscular and systemic injection of PMO-peptide conjugatesFor intramuscular studies the TA muscle of each experimental mdx mouse was injected with a 40 ml dose of PMO -peptide conjugates with saline at a final concentration of 125 mg/ml, and the contralateral muscle was injected with saline.", [["Intramuscular", "ANATOMY", 66, 79], ["TA muscle", "ANATOMY", 158, 167], ["muscle", "ANATOMY", 330, 336], ["PMO-peptide conjugates", "CHEMICAL", 106, 128], ["PMO -peptide", "CHEMICAL", 233, 245], ["agarose", "SIMPLE_CHEMICAL", 54, 61], ["Intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 66, 79], ["PMO-peptide", "SIMPLE_CHEMICAL", 106, 117], ["TA muscle", "TISSUE", 158, 167], ["mdx", "ORGANISM", 189, 192], ["mouse", "ORGANISM", 193, 198], ["PMO -peptide conjugates", "SIMPLE_CHEMICAL", 233, 256], ["saline", "SIMPLE_CHEMICAL", 262, 268], ["muscle", "ORGAN", 330, 336], ["saline", "SIMPLE_CHEMICAL", 355, 361], ["mouse", "SPECIES", 193, 198], ["mouse", "SPECIES", 193, 198], ["a 2% agarose gel", "TREATMENT", 49, 65], ["Intramuscular", "TREATMENT", 66, 79], ["systemic injection of PMO", "TREATMENT", 84, 109], ["peptide conjugates", "TREATMENT", 110, 128], ["intramuscular studies", "TEST", 132, 153], ["a 40 ml dose of PMO -peptide conjugates", "TREATMENT", 217, 256], ["saline", "TREATMENT", 262, 268], ["saline", "TREATMENT", 355, 361], ["contralateral muscle", "ANATOMY", 316, 336]]], ["For systemic intravenous injections, 500 mg PMO-peptide conjugates in 80 ml saline buffer were injected into tail vein of mdx mice at the final dose of 25 mg/kg and 6 mg/kg, respectively.", [["intravenous", "ANATOMY", 13, 24], ["tail vein", "ANATOMY", 109, 118], ["PMO-peptide", "CHEMICAL", 44, 55], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 13, 24], ["PMO-peptide conjugates", "SIMPLE_CHEMICAL", 44, 66], ["tail vein", "MULTI-TISSUE_STRUCTURE", 109, 118], ["mdx mice", "ORGANISM", 122, 130], ["mice", "SPECIES", 126, 130], ["mice", "SPECIES", 126, 130], ["systemic intravenous injections", "TREATMENT", 4, 35], ["500 mg PMO-peptide conjugates", "TREATMENT", 37, 66], ["saline buffer", "TREATMENT", 76, 89], ["tail vein", "ANATOMY", 109, 118]]], ["The animals were killed at various time points after injection by CO 2 inhalation and tissues were removed and snap-frozen in liquid nitrogen-cooled isopentane and stored at 2808C.Immunohistochemistry and histologySections of 8 mm were cut from at least two-thirds of the muscle length of TA, quadriceps, gastrocnemius, biceps, abdominal wall and diaphragm muscles and cardiac muscle at 100 mm intervals.", [["tissues", "ANATOMY", 86, 93], ["muscle", "ANATOMY", 272, 278], ["TA", "ANATOMY", 289, 291], ["quadriceps", "ANATOMY", 293, 303], ["gastrocnemius", "ANATOMY", 305, 318], ["biceps", "ANATOMY", 320, 326], ["abdominal wall", "ANATOMY", 328, 342], ["diaphragm muscles", "ANATOMY", 347, 364], ["cardiac muscle", "ANATOMY", 369, 383], ["nitrogen", "CHEMICAL", 133, 141], ["CO 2", "CHEMICAL", 66, 70], ["nitrogen", "CHEMICAL", 133, 141], ["isopentane", "CHEMICAL", 149, 159], ["animals", "ORGANISM", 4, 11], ["tissues", "TISSUE", 86, 93], ["nitrogen", "SIMPLE_CHEMICAL", 133, 141], ["isopentane", "SIMPLE_CHEMICAL", 149, 159], ["muscle", "ORGAN", 272, 278], ["TA", "MULTI-TISSUE_STRUCTURE", 289, 291], ["quadriceps", "ORGANISM_SUBDIVISION", 293, 303], ["gastrocnemius", "MULTI-TISSUE_STRUCTURE", 305, 318], ["biceps", "TISSUE", 320, 326], ["abdominal wall", "TISSUE", 328, 342], ["diaphragm muscles", "TISSUE", 347, 364], ["cardiac muscle", "TISSUE", 369, 383], ["snap", "TEST", 111, 115], ["liquid nitrogen", "TREATMENT", 126, 141], ["Immunohistochemistry", "TEST", 180, 200], ["histologySections", "TEST", 205, 222], ["tissues", "ANATOMY", 86, 93], ["8 mm", "OBSERVATION_MODIFIER", 226, 230], ["thirds", "ANATOMY_MODIFIER", 258, 264], ["muscle", "ANATOMY", 272, 278], ["length", "ANATOMY_MODIFIER", 279, 285], ["TA", "ANATOMY", 289, 291], ["quadriceps", "ANATOMY", 293, 303], ["gastrocnemius", "ANATOMY", 305, 318], ["biceps", "ANATOMY", 320, 326], ["abdominal wall", "ANATOMY", 328, 342], ["diaphragm muscles", "ANATOMY", 347, 364], ["cardiac muscle", "ANATOMY", 369, 383]]], ["The sections were then examined for dystrophin expression with a polyclonal antibody 2166 against the dystrophin C-terminal region (the antibody was kindly provided by Professor Kay Davies).", [["sections", "ANATOMY", 4, 12], ["C", "CHEMICAL", 113, 114], ["sections", "CANCER", 4, 12], ["dystrophin", "GENE_OR_GENE_PRODUCT", 36, 46], ["dystrophin", "GENE_OR_GENE_PRODUCT", 102, 112], ["dystrophin", "PROTEIN", 36, 46], ["polyclonal antibody 2166", "PROTEIN", 65, 89], ["dystrophin C-terminal region", "PROTEIN", 102, 130], ["The sections", "TEST", 0, 12], ["dystrophin expression", "PROBLEM", 36, 57], ["a polyclonal antibody", "TEST", 63, 84], ["terminal", "ANATOMY_MODIFIER", 115, 123], ["region", "ANATOMY_MODIFIER", 124, 130]]], ["The maximum number of dystrophinpositive fibres in one section was counted using the Zeiss AxioVision fluorescence microscope.", [["dystrophinpositive fibres", "ANATOMY", 22, 47], ["section", "ANATOMY", 55, 62], ["dystrophinpositive fibres", "TISSUE", 22, 47], ["maximum", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18], ["dystrophinpositive fibres", "OBSERVATION", 22, 47], ["one section", "OBSERVATION_MODIFIER", 51, 62]]], ["The intervening muscle sections were collected either for RT-PCR analysis and western blot or as serial sections for immunohistochemistry.", [["muscle sections", "ANATOMY", 16, 31], ["sections", "ANATOMY", 104, 112], ["muscle sections", "MULTI-TISSUE_STRUCTURE", 16, 31], ["The intervening muscle sections", "TEST", 0, 31], ["RT-PCR analysis", "TEST", 58, 73], ["serial sections", "TEST", 97, 112], ["immunohistochemistry", "TEST", 117, 137], ["muscle", "ANATOMY", 16, 22]]], ["Polyclonal antibodies were detected by goat-anti-rabbit IgGs Alexa Fluro 594 (Molecular Probe, UK).", [["Fluro 594", "CHEMICAL", 67, 76], ["Alexa Fluro 594", "SIMPLE_CHEMICAL", 61, 76], ["Polyclonal antibodies", "PROTEIN", 0, 21], ["goat-anti-rabbit IgGs Alexa Fluro 594", "PROTEIN", 39, 76], ["goat", "SPECIES", 39, 43], ["anti-rabbit", "SPECIES", 44, 55], ["goat", "SPECIES", 39, 43], ["Alexa Fluro 594", "SPECIES", 61, 76], ["Polyclonal antibodies", "TEST", 0, 21], ["anti-rabbit IgGs Alexa Fluro", "TREATMENT", 44, 72]]], ["Routine haematoxylin and eosin staining was used to examine overall muscle morphology and assess the level of infiltrating mononuclear cells.", [["muscle", "ANATOMY", 68, 74], ["infiltrating mononuclear cells", "ANATOMY", 110, 140], ["haematoxylin", "CHEMICAL", 8, 20], ["eosin", "CHEMICAL", 25, 30], ["haematoxylin", "SIMPLE_CHEMICAL", 8, 20], ["muscle", "ORGAN", 68, 74], ["infiltrating mononuclear cells", "CELL", 110, 140], ["infiltrating mononuclear cells", "CELL_TYPE", 110, 140], ["Routine haematoxylin", "TREATMENT", 0, 20], ["eosin staining", "TEST", 25, 39], ["infiltrating mononuclear cells", "PROBLEM", 110, 140], ["infiltrating mononuclear cells", "OBSERVATION", 110, 140]]], ["The serial sections were also stained with a panel of polyclonal and monoclonal antibodies for the detection of DAPC protein components.", [["sections", "ANATOMY", 11, 19], ["DAPC", "GENE_OR_GENE_PRODUCT", 112, 116], ["polyclonal and monoclonal antibodies", "PROTEIN", 54, 90], ["DAPC protein components", "PROTEIN", 112, 135], ["The serial sections", "TEST", 0, 19], ["a panel", "TEST", 43, 50], ["polyclonal", "TEST", 54, 64], ["monoclonal antibodies", "TEST", 69, 90], ["DAPC protein components", "PROBLEM", 112, 135]]], ["Rabbit polyclonal antibody to neuronal nitric oxide synthase (nNOS) and mouse monoclonal antibodies to b dystroglycan, a-sarcoglycan and b-sarcoglycan were used according to manufacturer's instructions (Novocastra, UK).", [["nitric oxide", "CHEMICAL", 39, 51], ["nitric oxide", "CHEMICAL", 39, 51], ["Rabbit", "ORGANISM", 0, 6], ["neuronal nitric oxide synthase", "GENE_OR_GENE_PRODUCT", 30, 60], ["NOS", "GENE_OR_GENE_PRODUCT", 63, 66], ["mouse", "ORGANISM", 72, 77], ["monoclonal antibodies to b dystroglycan", "GENE_OR_GENE_PRODUCT", 78, 117], ["a-sarcoglycan", "GENE_OR_GENE_PRODUCT", 119, 132], ["b-sarcoglycan", "SIMPLE_CHEMICAL", 137, 150], ["UK", "GENE_OR_GENE_PRODUCT", 215, 217], ["Rabbit polyclonal antibody", "PROTEIN", 0, 26], ["neuronal nitric oxide synthase", "PROTEIN", 30, 60], ["NOS", "PROTEIN", 63, 66], ["mouse monoclonal antibodies", "PROTEIN", 72, 99], ["b dystroglycan", "PROTEIN", 103, 117], ["a-sarcoglycan", "PROTEIN", 119, 132], ["b-sarcoglycan", "PROTEIN", 137, 150], ["Rabbit", "SPECIES", 0, 6], ["mouse", "SPECIES", 72, 77], ["Rabbit", "SPECIES", 0, 6], ["mouse", "SPECIES", 72, 77], ["Rabbit polyclonal antibody", "TREATMENT", 0, 26], ["neuronal nitric oxide synthase", "TREATMENT", 30, 60], ["mouse monoclonal antibodies", "TREATMENT", 72, 99], ["a-sarcoglycan", "TREATMENT", 119, 132], ["b-sarcoglycan", "TREATMENT", 137, 150]]], ["Centrally nucleated fibre counts TA, quadriceps and gastrocnemius muscles from mdx mice treated with PMO-peptide conjugates were examined.", [["nucleated fibre", "ANATOMY", 10, 25], ["quadriceps", "ANATOMY", 37, 47], ["gastrocnemius muscles", "ANATOMY", 52, 73], ["PMO-peptide", "CHEMICAL", 101, 112], ["fibre", "TISSUE", 20, 25], ["quadriceps", "ORGANISM_SUBDIVISION", 37, 47], ["gastrocnemius muscles", "TISSUE", 52, 73], ["mdx mice", "ORGANISM", 79, 87], ["PMO-peptide conjugates", "SIMPLE_CHEMICAL", 101, 123], ["mice", "SPECIES", 83, 87], ["mice", "SPECIES", 83, 87], ["Centrally nucleated fibre counts TA", "TEST", 0, 35], ["mdx mice", "TREATMENT", 79, 87], ["PMO-peptide conjugates", "TREATMENT", 101, 123], ["nucleated", "OBSERVATION_MODIFIER", 10, 19], ["fibre counts", "OBSERVATION", 20, 32], ["quadriceps", "ANATOMY", 37, 47], ["gastrocnemius muscles", "ANATOMY", 52, 73], ["mdx", "ANATOMY", 79, 82]]], ["To ascertain the number of centrally nucleated muscle fibres, sections were stained for dystrophin with rabbit polyclonal antibody 2166 and counter-stained with DAPI for cell nuclei (Sigma, UK).", [["muscle fibres", "ANATOMY", 47, 60], ["sections", "ANATOMY", 62, 70], ["cell nuclei", "ANATOMY", 170, 181], ["DAPI", "CHEMICAL", 161, 165], ["muscle fibres", "TISSUE", 47, 60], ["sections", "MULTI-TISSUE_STRUCTURE", 62, 70], ["dystrophin", "GENE_OR_GENE_PRODUCT", 88, 98], ["rabbit", "ORGANISM", 104, 110], ["DAPI", "SIMPLE_CHEMICAL", 161, 165], ["cell nuclei", "CELL", 170, 181], ["UK", "GENE_OR_GENE_PRODUCT", 190, 192], ["dystrophin", "PROTEIN", 88, 98], ["rabbit polyclonal antibody 2166", "PROTEIN", 104, 135], ["rabbit", "SPECIES", 104, 110], ["rabbit", "SPECIES", 104, 110], ["dystrophin", "TEST", 88, 98], ["rabbit polyclonal antibody", "TEST", 104, 130], ["muscle fibres", "ANATOMY", 47, 60], ["cell nuclei", "OBSERVATION", 170, 181]]], ["About 500 dystrophin positive fibres for each tissue sample were counted and assessed for the presence of central nuclei using a Zeiss AxioVision fluorescence microscope.", [["fibres", "ANATOMY", 30, 36], ["tissue sample", "ANATOMY", 46, 59], ["nuclei", "ANATOMY", 114, 120], ["dystrophin", "GENE_OR_GENE_PRODUCT", 10, 20], ["tissue sample", "CANCER", 46, 59], ["nuclei", "CELLULAR_COMPONENT", 114, 120], ["dystrophin", "PROTEIN", 10, 20], ["500 dystrophin positive fibres", "PROBLEM", 6, 36], ["each tissue sample", "TEST", 41, 59], ["central nuclei", "PROBLEM", 106, 120], ["central nuclei", "ANATOMY", 106, 120]]], ["Fibres were judged centrally nucleated if one or more nuclei were not located at the periphery of the fibre.", [["nuclei", "ANATOMY", 54, 60], ["fibre", "ANATOMY", 102, 107], ["nuclei", "CELLULAR_COMPONENT", 54, 60], ["fibre", "CELLULAR_COMPONENT", 102, 107], ["periphery", "ANATOMY_MODIFIER", 85, 94], ["fibre", "OBSERVATION_MODIFIER", 102, 107]]], ["Untreated age-matched mdx mice were used as controls.Protein extraction and western blotThe collected sections were placed in a 1.5 ml polypropylene eppendorf tube (Anachem, UK) on dry ice.", [["sections", "ANATOMY", 102, 110], ["polypropylene", "CHEMICAL", 135, 148], ["mdx", "ORGANISM", 22, 25], ["mice", "ORGANISM", 26, 30], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 26, 30], ["Untreated age-matched mdx mice", "TREATMENT", 0, 30], ["Protein extraction", "TREATMENT", 53, 71], ["The collected sections", "TREATMENT", 88, 110], ["a 1.5 ml polypropylene eppendorf tube", "TREATMENT", 126, 163], ["dry ice", "TREATMENT", 181, 188]]], ["The tissue sections were lysed with 150 ml protein extraction buffer containing 125 mmol/l Tris-HCl (pH \u00bc 6.8), 10% sodium dodecyl sulphate, 2 mol/l urea, 20% glycerol and 5% 2-mercaptoethanol.", [["tissue sections", "ANATOMY", 4, 19], ["Tris-HCl", "CHEMICAL", 91, 99], ["sodium dodecyl sulphate", "CHEMICAL", 116, 139], ["mol/l urea", "CHEMICAL", 143, 153], ["glycerol", "CHEMICAL", 159, 167], ["2-mercaptoethanol", "CHEMICAL", 175, 192], ["Tris-HCl", "CHEMICAL", 91, 99], ["sodium dodecyl sulphate", "CHEMICAL", 116, 139], ["urea", "CHEMICAL", 149, 153], ["glycerol", "CHEMICAL", 159, 167], ["2-mercaptoethanol", "CHEMICAL", 175, 192], ["tissue sections", "CANCER", 4, 19], ["Tris-HCl", "SIMPLE_CHEMICAL", 91, 99], ["sodium dodecyl sulphate", "SIMPLE_CHEMICAL", 116, 139], ["2 mol/l urea", "SIMPLE_CHEMICAL", 141, 153], ["glycerol", "SIMPLE_CHEMICAL", 159, 167], ["2-mercaptoethanol", "SIMPLE_CHEMICAL", 175, 192], ["The tissue sections", "TREATMENT", 0, 19], ["protein extraction buffer", "TREATMENT", 43, 68], ["Tris", "TEST", 91, 95], ["pH", "TEST", 101, 103], ["sodium dodecyl sulphate", "TEST", 116, 139], ["urea", "TEST", 149, 153], ["glycerol", "TREATMENT", 159, 167], ["mercaptoethanol", "TREATMENT", 177, 192]]], ["The supernatant was collected and the protein concentration was quantified by Bradford assay (Sigma, UK).", [["supernatant", "ANATOMY", 4, 15], ["The supernatant", "TREATMENT", 0, 15], ["the protein concentration", "TEST", 34, 59]]], ["Various amounts of protein from normal C57BL6 mice as a positive control and corresponding amounts of protein from muscles of treated or untreated mdx mice were loaded onto sodium dodecyl sulphate polyacrylamide gel electrophoresis gels (4% stacking, 6% resolving).", [["muscles", "ANATOMY", 115, 122], ["sodium dodecyl sulphate", "CHEMICAL", 173, 196], ["sodium dodecyl sulphate polyacrylamide", "CHEMICAL", 173, 211], ["C57BL6 mice", "ORGANISM", 39, 50], ["muscles", "ORGANISM_SUBDIVISION", 115, 122], ["mdx mice", "ORGANISM", 147, 155], ["sodium dodecyl sulphate polyacrylamide", "SIMPLE_CHEMICAL", 173, 211], ["mice", "SPECIES", 46, 50], ["mice", "SPECIES", 151, 155], ["mice", "SPECIES", 46, 50], ["mice", "SPECIES", 151, 155], ["protein", "TEST", 19, 26], ["sodium dodecyl sulphate polyacrylamide gel electrophoresis gels", "TREATMENT", 173, 236], ["4% stacking", "TREATMENT", 238, 249], ["amounts", "OBSERVATION_MODIFIER", 8, 15]]], ["Samples were electrophoresed for 4 h at 80 mA and transferred to nitrocellulose overnight at 50 V at 48C.", [["Samples", "ANATOMY", 0, 7], ["nitrocellulose", "CHEMICAL", 65, 79], ["Samples", "TEST", 0, 7]]], ["The membrane was then washed and blocked with 5% skimmed milk and probed overnight with DYS1 (monoclonal antibody against dystrophin R8 repeat, 1:200, NovoCastra, UK) for the detection of dytstrophin protein and a-actinin (monoclonal antibody, 1:5000, Sigma, UK) as a loading control.", [["membrane", "ANATOMY", 4, 12], ["milk", "ANATOMY", 57, 61], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["milk", "ORGANISM_SUBSTANCE", 57, 61], ["DYS1", "SIMPLE_CHEMICAL", 88, 92], ["dystrophin", "GENE_OR_GENE_PRODUCT", 122, 132], ["UK", "GENE_OR_GENE_PRODUCT", 163, 165], ["dytstrophin", "GENE_OR_GENE_PRODUCT", 188, 199], ["a-actinin", "GENE_OR_GENE_PRODUCT", 212, 221], ["UK", "GENE_OR_GENE_PRODUCT", 259, 261], ["DYS1", "PROTEIN", 88, 92], ["monoclonal antibody", "PROTEIN", 94, 113], ["dystrophin R8 repeat", "PROTEIN", 122, 142], ["dytstrophin protein", "PROTEIN", 188, 207], ["a-actinin", "PROTEIN", 212, 221], ["monoclonal antibody", "PROTEIN", 223, 242], ["5% skimmed milk", "TREATMENT", 46, 61], ["DYS1", "TREATMENT", 88, 92], ["monoclonal antibody", "TEST", 94, 113], ["dystrophin R8 repeat", "TEST", 122, 142], ["the detection", "TEST", 171, 184], ["dytstrophin protein", "TEST", 188, 207], ["monoclonal antibody", "TEST", 223, 242], ["a loading control", "TREATMENT", 266, 283]]], ["The bound primary antibody was detected by horseradish peroxidiseconjugated rabbit anti-mouse IgGs and the ECL Western Blotting Analysis system (Amersham Pharmacia Biosciences, UK).", [["horseradish", "SIMPLE_CHEMICAL", 43, 54], ["rabbit", "ORGANISM", 76, 82], ["primary antibody", "PROTEIN", 10, 26], ["horseradish peroxidiseconjugated rabbit anti-mouse IgGs", "PROTEIN", 43, 98], ["horseradish", "SPECIES", 43, 54], ["rabbit", "SPECIES", 76, 82], ["anti-mouse", "SPECIES", 83, 93], ["rabbit", "SPECIES", 76, 82], ["The bound primary antibody", "TEST", 0, 26]]], ["The intensity of the bands obtained from treated mdx muscles was measured by Image J software; the quantification is based on band intensity and area, and is compared with that from normal muscles of C57BL6 mice.Functional grip strength analysisTreated mice and control mice were tested using a commercial grip strength monitor (Chatillon, UK).", [["mdx muscles", "ANATOMY", 49, 60], ["muscles", "ANATOMY", 189, 196], ["mdx muscles", "TISSUE", 49, 60], ["muscles", "ORGANISM_SUBDIVISION", 189, 196], ["C57BL6 mice", "ORGANISM", 200, 211], ["mice", "ORGANISM", 253, 257], ["mice", "ORGANISM", 270, 274], ["mice", "SPECIES", 207, 211], ["mice", "SPECIES", 253, 257], ["mice", "SPECIES", 270, 274], ["mice", "SPECIES", 207, 211], ["mice", "SPECIES", 253, 257], ["mice", "SPECIES", 270, 274], ["the bands", "PROBLEM", 17, 26], ["Image J software", "TEST", 77, 93], ["band intensity", "TEST", 126, 140], ["Functional grip strength analysis", "TEST", 212, 245], ["a commercial grip strength monitor", "TEST", 293, 327], ["intensity", "OBSERVATION_MODIFIER", 4, 13], ["mdx muscles", "ANATOMY", 49, 60], ["band intensity", "OBSERVATION_MODIFIER", 126, 140], ["muscles", "ANATOMY", 189, 196]]], ["Each mouse was held 2 cm from the base of the tail, allowed to grip a protruding metal triangle bar attached to the apparatus with their forepaws, and pulled gently until they released their grip.", [["tail", "ANATOMY", 46, 50], ["forepaws", "ANATOMY", 137, 145], ["mouse", "ORGANISM", 5, 10], ["tail", "ORGANISM_SUBDIVISION", 46, 50], ["mouse", "SPECIES", 5, 10], ["mouse", "SPECIES", 5, 10], ["a protruding metal triangle bar", "TREATMENT", 68, 99], ["their forepaws", "TREATMENT", 131, 145], ["base", "ANATOMY_MODIFIER", 34, 38], ["tail", "ANATOMY", 46, 50]]], ["The force exerted was recorded and five sequential tests were carried out for each mouse, averaged at 30 s apart.Serum creatinine kinase measurements and other biochemical testsSerum and plasma were taken from the mouse jugular vein immediately after the killing with CO 2 inhalation.", [["Serum", "ANATOMY", 113, 118], ["plasma", "ANATOMY", 187, 193], ["jugular vein", "ANATOMY", 220, 232], ["creatinine", "CHEMICAL", 119, 129], ["creatinine", "CHEMICAL", 119, 129], ["CO 2", "CHEMICAL", 268, 272], ["mouse", "ORGANISM", 83, 88], ["Serum", "ORGANISM_SUBSTANCE", 113, 118], ["creatinine", "SIMPLE_CHEMICAL", 119, 129], ["plasma", "ORGANISM_SUBSTANCE", 187, 193], ["mouse", "ORGANISM", 214, 219], ["jugular vein", "MULTI-TISSUE_STRUCTURE", 220, 232], ["Serum creatinine kinase", "PROTEIN", 113, 136], ["mouse", "SPECIES", 83, 88], ["mouse", "SPECIES", 214, 219], ["mouse", "SPECIES", 83, 88], ["mouse", "SPECIES", 214, 219], ["five sequential tests", "TEST", 35, 56], ["Serum creatinine kinase measurements", "TEST", 113, 149], ["other biochemical testsSerum", "TEST", 154, 182], ["plasma", "TEST", 187, 193], ["CO 2 inhalation", "TREATMENT", 268, 283], ["jugular vein", "ANATOMY", 220, 232]]], ["Analysis of serum CK, AST, ALT, urea and creatinine levels was performed by the clinical pathology laboratory (Mary Lyon Centre, Medical Research Council, Harwell, Oxfordshire, UK).Statistical analysisAll data are reported as mean values +SEM.", [["serum", "ANATOMY", 12, 17], ["urea", "CHEMICAL", 32, 36], ["creatinine", "CHEMICAL", 41, 51], ["urea", "CHEMICAL", 32, 36], ["creatinine", "CHEMICAL", 41, 51], ["serum", "ORGANISM_SUBSTANCE", 12, 17], ["CK", "GENE_OR_GENE_PRODUCT", 18, 20], ["AST", "SIMPLE_CHEMICAL", 22, 25], ["ALT", "SIMPLE_CHEMICAL", 27, 30], ["urea", "SIMPLE_CHEMICAL", 32, 36], ["creatinine", "SIMPLE_CHEMICAL", 41, 51], ["serum CK", "PROTEIN", 12, 20], ["AST", "PROTEIN", 22, 25], ["ALT", "PROTEIN", 27, 30], ["Analysis", "TEST", 0, 8], ["serum CK", "TEST", 12, 20], ["AST", "TEST", 22, 25], ["ALT", "TEST", 27, 30], ["urea", "TEST", 32, 36], ["creatinine levels", "TEST", 41, 58], ["Statistical analysis", "TEST", 181, 201], ["All data", "TEST", 201, 209]]], ["Statistical differences between treatment groups and control groups were evaluated by SigmaStat (Systat Software, UK) and onetailed t-test was applied.SUPPLEMENTARY MATERIALSupplementary Material is available at HMG Online.FUNDINGThis work was supported by UK Department of Health and the UK Muscular Dystrophy Campaign.", [["SUPPLEMENTARY", "DISEASE", 151, 164], ["Muscular Dystrophy", "DISEASE", 292, 310], ["HMG", "CHEMICAL", 212, 215], ["HMG", "PROTEIN", 212, 215], ["treatment groups", "TREATMENT", 32, 48], ["control groups", "TREATMENT", 53, 67], ["onetailed t-test", "TEST", 122, 138], ["SUPPLEMENTARY MATERIALSupplementary Material", "TREATMENT", 151, 195], ["Muscular Dystrophy", "PROBLEM", 292, 310], ["Muscular", "ANATOMY", 292, 300], ["Dystrophy", "OBSERVATION", 301, 310]]]], "4657dad21dad40261c5b00314e1b622102264eec": [["The coronavirus disease 2019 (COVID- 19) pandemic has had significant impact upon the provision of medical and dental care globally.", [["coronavirus disease", "DISEASE", 4, 23], ["COVID- 19", "CHEMICAL", 30, 39], ["coronavirus", "ORGANISM", 4, 15], ["COVID- 19", "ORGANISM", 30, 39], ["coronavirus disease 2019 (COVID- 19", "SPECIES", 4, 39], ["The coronavirus disease", "PROBLEM", 0, 23], ["COVID", "TEST", 30, 35], ["medical and dental care", "TREATMENT", 99, 122], ["coronavirus disease", "OBSERVATION", 4, 23]]], ["In the United Kingdom, routine dental treatment was suspended in late March 2020 [1] [2] [3] [4] , with care instead being provided through a network of urgent dental care centres 5 .", [["routine dental treatment", "TREATMENT", 23, 47], ["urgent dental care centres", "TREATMENT", 153, 179]]], ["During this period, it was advised that aerosol generating procedures (AGPs) were avoided unless absolutely necessary, leading to altered treatment planning and a negative impact on patient care 6 .", [["patient", "ORGANISM", 182, 189], ["patient", "SPECIES", 182, 189], ["aerosol generating procedures (AGPs)", "TREATMENT", 40, 76], ["altered treatment planning", "TREATMENT", 130, 156]]], ["As more routine dental services start to resume worldwide, the guidance in the UK and elsewhere is still to avoid or defer AGPs where possible [7] [8] [9] [10] [11] [12] [13] .", [["[7] [8] [9] [10] [11] [12] [13]", "CHEMICAL", 143, 174], ["[7] [8] [9] [10] [11] [12] [13]", "SIMPLE_CHEMICAL", 143, 174]]], ["This will have an effect both on patients attending for urgent and emergency care, as well as those requiring routine dental treatment for oral rehabilitation.", [["oral", "ANATOMY", 139, 143], ["patients", "ORGANISM", 33, 41], ["oral", "ORGANISM_SUBDIVISION", 139, 143], ["patients", "SPECIES", 33, 41], ["urgent and emergency care", "TREATMENT", 56, 81], ["routine dental treatment", "TREATMENT", 110, 134], ["oral rehabilitation", "TREATMENT", 139, 158]]], ["Standard operating procedures (SOPs) have been published by a number of organisations to inform practice, however many of these acknowledge a limited evidence base [14] [15] [16] [17] [18] .", [["[14] [15] [16] [17] [18]", "CHEMICAL", 164, 188], ["[14] [15] [16] [17] [18]", "SIMPLE_CHEMICAL", 164, 188]]]], "4600273935786871df51c3644a39d86c3ad2cc8e": [["INTRODUCTIONHuman and animal populations are continuously confronted with emerging viral infections (Delwart, 2007; Lipkin, 2010; Smits and Osterhaus, 2013) .", [["viral infections", "DISEASE", 83, 99], ["INTRODUCTIONHuman", "TREATMENT", 0, 17], ["emerging viral infections", "PROBLEM", 74, 99]]], ["In a proportion of patients and animals suffering from disease, no pathogens can be detected using a range of sensitive diagnostic assays, suggesting the presence of unidentified viruses in human and animal populations (Bloch and Glaser, 2007; Denno et al., 2012) .", [["patients", "ORGANISM", 19, 27], ["human", "ORGANISM", 190, 195], ["patients", "SPECIES", 19, 27], ["human", "SPECIES", 190, 195], ["human", "SPECIES", 190, 195], ["disease", "PROBLEM", 55, 62], ["pathogens", "PROBLEM", 67, 76], ["diagnostic assays", "TEST", 120, 137], ["unidentified viruses in human", "PROBLEM", 166, 195], ["disease", "OBSERVATION", 55, 62], ["viruses", "OBSERVATION", 179, 186]]], ["Classically, new viruses were identified by standard molecular detection methods, virus replication in tissue culture or animal experiments.", [["tissue culture", "ANATOMY", 103, 117], ["tissue", "TISSUE", 103, 109], ["new viruses", "PROBLEM", 13, 24], ["standard molecular detection methods", "TEST", 44, 80], ["virus replication", "TREATMENT", 82, 99], ["tissue culture", "TEST", 103, 117], ["new", "OBSERVATION_MODIFIER", 13, 16], ["viruses", "OBSERVATION", 17, 24]]], ["Nowadays, in order to discover and characterize new or (re-) emerging viruses, metagenome sequencing is increasingly being used to identify viral pathogens.", [["emerging viruses", "PROBLEM", 61, 77], ["metagenome sequencing", "TEST", 79, 100], ["viral pathogens", "PROBLEM", 140, 155], ["new", "OBSERVATION_MODIFIER", 48, 51]]], ["In addition, these techniques are more and more often being used to generate complete genomes of uncultivated viruses, but also other organisms (Delwart, 2007; Lipkin, 2010; Iverson et al., 2012; Albertsen et al., 2013; Smits and Osterhaus, 2013; Handley et al., 2014) .INTRODUCTIONMetagenomic strategies to virus discovery rely on sequenceindependent amplification of nucleic acids combined with next generation sequencing platforms instead of targeting specific genomic loci, thereby generating DNA sequences (i.e., reads) that align to various genomic locations for the numerous genomes present in the sample, including non-microbes (Sharpton, 2014) .", [["sample", "ANATOMY", 605, 611], ["nucleic acids", "CHEMICAL", 369, 382], ["nucleic acids", "SIMPLE_CHEMICAL", 369, 382], ["DNA", "CELLULAR_COMPONENT", 497, 500], ["genomic loci", "DNA", 464, 476], ["DNA sequences", "DNA", 497, 510], ["uncultivated viruses", "PROBLEM", 97, 117], ["nucleic acids", "TREATMENT", 369, 382], ["next generation sequencing platforms", "TREATMENT", 397, 433], ["targeting specific genomic loci", "PROBLEM", 445, 476], ["generating DNA sequences", "TEST", 486, 510], ["the numerous genomes", "PROBLEM", 569, 589], ["viruses", "OBSERVATION", 110, 117], ["numerous", "OBSERVATION_MODIFIER", 573, 581], ["genomes", "OBSERVATION", 582, 589]]], ["Common random amplification methods are multiple displacement amplification (MDA) or sequence-independent singleprimer amplification (SISPA) (Hutchison et al., 2005; Spits et al., 2006; Delwart, 2007; Djikeng et al., 2008; Lipkin, 2010; Smits and Osterhaus, 2013) .", [["Common random amplification methods", "TREATMENT", 0, 35], ["multiple displacement amplification", "PROBLEM", 40, 75], ["multiple", "OBSERVATION_MODIFIER", 40, 48], ["displacement", "OBSERVATION_MODIFIER", 49, 61]]], ["The advantages of sequence-independent amplification are simplicity and relative speed and the ability to identify and sequence hundreds of viruses simultaneously thereby allowing detection of new or previously unrecognized viruses that are highly divergent from already described ones (Bodewes et al., 2014a,c) .", [["sequence-independent amplification", "TREATMENT", 18, 52], ["viruses", "PROBLEM", 140, 147], ["new or previously unrecognized viruses", "PROBLEM", 193, 231], ["new", "OBSERVATION_MODIFIER", 193, 196], ["viruses", "OBSERVATION", 224, 231]]], ["Inherent to the approach is that a large fraction of the metagenome consists of sequences of other organisms than the viral targets, including host sequences, archaea, bacteria, and bacteriophages, despite physical enrichment strategies for virus particles that are often applied (Van Leeuwen et al., 2010; Kostic et al., 2012; Van Den Brand et al., 2012; Wylie et al., 2012; Bodewes et al., 2013; Schurch et al., 2014) .INTRODUCTIONMetagenomic sequence data analysis with the aim to identify viral sequences presents several challenges.", [["a large fraction of the metagenome", "PROBLEM", 33, 67], ["other organisms", "PROBLEM", 93, 108], ["the viral targets", "TEST", 114, 131], ["host sequences", "TEST", 143, 157], ["archaea", "PROBLEM", 159, 166], ["bacteria", "PROBLEM", 168, 176], ["bacteriophages", "PROBLEM", 182, 196], ["physical enrichment strategies", "TREATMENT", 206, 236], ["virus particles", "PROBLEM", 241, 256], ["sequence data analysis", "TEST", 445, 467], ["viral sequences", "TEST", 493, 508], ["large", "OBSERVATION_MODIFIER", 35, 40], ["fraction", "OBSERVATION", 41, 49]]], ["Datasets are relatively complex and large.", [["relatively", "OBSERVATION_MODIFIER", 13, 23], ["complex", "OBSERVATION_MODIFIER", 24, 31], ["large", "OBSERVATION_MODIFIER", 36, 41]]], ["In addition, the obtained viral reads in metagenomes can either originate from taxonomically informative genomic regions and even provide insight in the biological function of the encoded protein or originate from less conserved genomic regions for which biological functions are difficult to assign.", [["viral reads", "DNA", 26, 37], ["encoded protein", "PROTEIN", 180, 195], ["genomic regions", "DNA", 229, 244], ["the obtained viral reads in metagenomes", "PROBLEM", 13, 52]]], ["Current strategies rely mostly on filtering steps to remove host nucleic acid from metagenomes either before or after sequencing and analysis of the data, including assembly and homology searches against annotated sequences in public databases (Woyke et al., 2006; Chew and Holmes, 2009; Schmieder and Edwards, 2012; Garcia-Garcera et al., 2013; Prachayangprecha et al., 2014; Schurch et al., 2014) .", [["nucleic acid", "CHEMICAL", 65, 77], ["Current strategies", "TREATMENT", 0, 18], ["the data", "TEST", 145, 153]]], ["Untargeted metagenomic approaches have enabled the identification of numerous newly emerging or previously unidentified viral pathogens in recent years.", [["previously unidentified viral pathogens", "PROBLEM", 96, 135], ["numerous", "OBSERVATION_MODIFIER", 69, 77], ["newly", "OBSERVATION_MODIFIER", 78, 83], ["viral pathogens", "OBSERVATION", 120, 135]]], ["However, obtaining full-length viral genomes from metagenomic datasets remains challenging.INTRODUCTIONThe number of reads obtained from a specific virus in metagenome samples is correlated to the viral load in the sample under study (De Vries et al., 2012; Prachayangprecha et al., 2014) .", [["samples", "ANATOMY", 168, 175], ["viral genomes", "DNA", 31, 44], ["metagenomic datasets", "PROBLEM", 50, 70], ["a specific virus", "PROBLEM", 137, 153], ["the viral load", "TEST", 193, 207]]], ["However, direct assembly of complete viral and bacterial genomes from metagenomic data can involve a large amount of manual curation (Handley et al., 2014; Sharpton, 2014) as most pathogen genomes are not completely represented by reads and most viral communities are highly diverse (Mavromatis et al., 2007; Mende et al., 2012) .", [["viral and bacterial genomes", "DNA", 37, 64], ["complete viral and bacterial genomes", "PROBLEM", 28, 64], ["metagenomic data", "TEST", 70, 86], ["bacterial genomes", "OBSERVATION", 47, 64], ["large", "OBSERVATION_MODIFIER", 101, 106], ["amount", "OBSERVATION_MODIFIER", 107, 113]]], ["Currently, fulllength viral genomes are often obtained with additional experimental approaches based on PCR amplification with specific primers designed on obtained reads or contigs and/or 5 and 3 RACE PCR in combination with a Sanger sequencing approach (Van Leeuwen et al., 2010; Siegers et al., 2014) .", [["fulllength viral genomes", "DNA", 11, 35], ["fulllength viral genomes", "PROBLEM", 11, 35], ["experimental approaches", "TREATMENT", 71, 94], ["PCR amplification", "TEST", 104, 121], ["specific primers", "TEST", 127, 143], ["RACE PCR", "TEST", 197, 205], ["a Sanger sequencing approach", "TREATMENT", 226, 254], ["viral genomes", "OBSERVATION", 22, 35]]], ["However, by optimally mining sequences in metagenomes, the likelihood and speed of identifying viral reads and the level of viral genome completeness can be increased and the need for laboratory followup minimized.", [["viral reads", "TEST", 95, 106], ["viral genome completeness", "PROBLEM", 124, 149], ["laboratory followup", "TEST", 184, 203], ["viral genome", "OBSERVATION", 124, 136]]], ["In the present study, we describe and compare methods to obtain viral target genomes from metagenomes using a retrospective approach on 454-sequencing datasets containing three recently described viruses from the families Rhabdo-and Coronaviridae.DATASETSThe first metagenome dataset was obtained from a cell culture supernatant (CCS) containing a rhabdovirus-like virus isolated from tissue collected from a stranded white-beaked dolphin (Lagenorhynchus albirostris) (Osterhaus et al., 1993; Siegers et al., 2014) .", [["cell culture supernatant", "ANATOMY", 304, 328], ["tissue", "ANATOMY", 385, 391], ["cell", "CELL", 304, 308], ["rhabdovirus-like virus", "ORGANISM", 348, 370], ["tissue", "TISSUE", 385, 391], ["dolphin", "ORGANISM", 431, 438], ["Lagenorhynchus albirostris", "ORGANISM", 440, 466], ["viral target genomes", "DNA", 64, 84], ["Lagenorhynchus albirostris", "SPECIES", 440, 466], ["white-beaked dolphin", "SPECIES", 418, 438], ["Lagenorhynchus albirostris", "SPECIES", 440, 466], ["the present study", "TEST", 3, 20], ["viral target genomes", "PROBLEM", 64, 84], ["a retrospective approach", "TREATMENT", 108, 132], ["the families Rhabdo", "TREATMENT", 209, 228], ["Coronaviridae", "TREATMENT", 233, 246], ["a cell culture supernatant", "TEST", 302, 328], ["a rhabdovirus-like virus", "PROBLEM", 346, 370], ["a stranded white-beaked dolphin", "PROBLEM", 407, 438], ["viruses", "OBSERVATION", 196, 203], ["rhabdovirus", "OBSERVATION", 348, 359], ["stranded", "OBSERVATION_MODIFIER", 409, 417]]], ["Genetic and phylogenetic characterization of the dolphin rhabdovirus (DRV) revealed that it was closely related to rhabdoviruses of the genera Perhabdovirus and Vesiculovirus found in fish (Siegers et al., 2014) .", [["dolphin rhabdovirus", "ORGANISM", 49, 68], ["DRV", "CANCER", 70, 73], ["Perhabdovirus", "GENE_OR_GENE_PRODUCT", 143, 156], ["Vesiculovirus", "GENE_OR_GENE_PRODUCT", 161, 174], ["fish", "ORGANISM", 184, 188], ["DRV", "SPECIES", 70, 73], ["phylogenetic characterization", "TEST", 12, 41], ["the dolphin rhabdovirus (DRV)", "TEST", 45, 74], ["rhabdoviruses", "PROBLEM", 115, 128], ["the genera Perhabdovirus", "PROBLEM", 132, 156], ["Vesiculovirus", "PROBLEM", 161, 174], ["genera Perhabdovirus", "OBSERVATION", 136, 156]]], ["In the second case, a highly divergent rhabdovirus, called red fox fecal rhabdovirus (RFFRV) was identified during a metagenomic survey of feces of red foxes from Spain (Vulpes vulpes) (Bodewes et al., 2014c) .", [["rhabdovirus", "ORGANISM", 39, 50], ["red fox fecal rhabdovirus", "ORGANISM", 59, 84], ["RFFRV", "ORGANISM", 86, 91], ["feces", "ORGANISM_SUBDIVISION", 139, 144], ["fox fecal rhabdovirus", "SPECIES", 63, 84], ["Vulpes vulpes", "SPECIES", 170, 183], ["red fox fecal rhabdovirus", "SPECIES", 59, 84], ["RFFRV", "SPECIES", 86, 91], ["red foxes", "SPECIES", 148, 157], ["Vulpes vulpes", "SPECIES", 170, 183], ["a highly divergent rhabdovirus", "PROBLEM", 20, 50], ["red fox fecal rhabdovirus", "PROBLEM", 59, 84], ["red foxes", "PROBLEM", 148, 157], ["divergent", "OBSERVATION_MODIFIER", 29, 38], ["rhabdovirus", "OBSERVATION", 39, 50], ["fecal rhabdovirus", "ANATOMY", 67, 84], ["red foxes", "OBSERVATION", 148, 157]]], ["The last metagenome dataset was from lung tissue of a dead Indian python (Python molurus) with pneumonia, in which a novel nidovirus belonging to the family Coronaviridae within the order Nidovirales was identified.", [["lung tissue", "ANATOMY", 37, 48], ["pneumonia", "DISEASE", 95, 104], ["lung tissue", "TISSUE", 37, 48], ["Python molurus", "ORGANISM", 74, 88], ["nidovirus", "CANCER", 123, 132], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 157, 170], ["Nidovirales", "GENE_OR_GENE_PRODUCT", 188, 199], ["Python molurus", "SPECIES", 74, 88], ["Indian python", "SPECIES", 59, 72], ["Python molurus", "SPECIES", 74, 88], ["lung tissue", "PROBLEM", 37, 48], ["a dead Indian python", "PROBLEM", 52, 72], ["pneumonia", "PROBLEM", 95, 104], ["a novel nidovirus", "TREATMENT", 115, 132], ["lung", "ANATOMY", 37, 41], ["pneumonia", "OBSERVATION", 95, 104]]], ["It was the first description of a reptile nidovirus (python nidovirus, PNV) and phylogenetic analysis placed this virus in the subfamily Torovirinae (Bodewes et al., 2014a) .", [["python nidovirus", "ORGANISM", 53, 69], ["a reptile nidovirus", "PROBLEM", 32, 51], ["python nidovirus", "TREATMENT", 53, 69], ["PNV", "TREATMENT", 71, 74], ["phylogenetic analysis", "TEST", 80, 101]]], ["These datasets were acquired using a random sequence amplification and deep sequencing approach on a 454 GS Junior instrument (Roche) as previously described by Van Leeuwen et al. (2010) , Bodewes et al. (2013 Bodewes et al. ( , 2014a .", [["a random sequence amplification", "TREATMENT", 35, 66], ["deep sequencing approach", "TEST", 71, 95]]], ["At present full-length genomes (DRV) or expected complete coding sequences (PNV, RFFRV) are available.ASSEMBLY METHODSFour different assembly methods, exhaustive iterative assembly , CLC Genomics Workbench 6.0.4 assembler (CLC bio, Aarhus, Denmark), Genovo version 0.4 (Laserson et al., 2011) , and Newbler 2.5 (Roche), were compared in their efficiency of detecting viral reads in the three metagenome datasets.", [["full-length genomes", "DNA", 11, 30], ["DRV", "DNA", 32, 35], ["coding sequences", "DNA", 58, 74], ["PNV", "DNA", 76, 79], ["RFFRV", "DNA", 81, 86], ["viral reads", "OBSERVATION", 367, 378]]], ["The resulting singletons and contigs were iteratively assembled by CAP3 until no new contigs were formed.ASSEMBLY METHODSSubsequently, the trimmed reads were mapped back to the identified taxonomic units with Newbler (454 GSMapper version 2.7, Roche) with standard parameters .", [["CAP3", "DNA", 67, 71], ["trimmed reads", "DNA", 139, 152], ["The resulting singletons", "PROBLEM", 0, 24], ["CAP3", "TREATMENT", 67, 71], ["new contigs", "PROBLEM", 81, 92]]], ["CLC Genomics Workbench 6.0.4 assembler (CLC bio, Aarhus, Denmark) was run with the previously trimmed reads with automatic bubble and word size.", [["automatic bubble", "OBSERVATION", 113, 129], ["size", "OBSERVATION_MODIFIER", 139, 143]]], ["Genovo version 0.4 was run with 40 iterations and otherwise default values (Laserson et al., 2011) .", [["Genovo version", "TREATMENT", 0, 14]]], ["Newbler 2.5 (Roche) was run with default values.DETERMINATION OF TAXONOMIC CONTENTContigs and singletons of the iterative assembly approach that were longer than 75 bases were filtered with Dustmasker which is part of the NCBI-BLAST+ 2.2.25 suite of tools for sequences that contain more than 60% low complexity sequences (Camacho et al., 2009) .", [["TAXONOMIC CONTENTContigs", "TREATMENT", 65, 89], ["the iterative assembly approach", "TREATMENT", 108, 139], ["sequences", "TEST", 260, 269], ["TAXONOMIC CONTENTContigs", "OBSERVATION", 65, 89]]], ["After filtering of low complexity sequences, the remaining taxonomic units were subjected to a BLASTN search against a database that contained only nucleotide sequences from birds (Aves, taxonomic identifier 8782), carnivores (Carnivora, taxID 33554), primates (Primates, taxID 9443), rodents (Rodentia, taxID 9989), and ruminants (Ruminantia, taxID 9845) with an e-value cut-off of 0.001 for subtraction of potential host sequences.", [["nucleotide", "CHEMICAL", 148, 158], ["nucleotide", "CHEMICAL", 148, 158], ["primates", "ORGANISM", 252, 260], ["nucleotide sequences", "DNA", 148, 168], ["potential host sequences", "DNA", 408, 432], ["ruminants", "SPECIES", 321, 330], ["a database", "TEST", 117, 127], ["nucleotide sequences", "TEST", 148, 168], ["low complexity", "OBSERVATION_MODIFIER", 19, 33]]], ["Sequences without hits in the host-BLAST were then subjected to a BLASTN search against the entire nt database with an e-value cut-off of 0.001.", [["host-BLAST", "DNA", 30, 40], ["a BLASTN search", "TEST", 64, 79], ["the entire nt database", "TEST", 88, 110], ["an e-value cut-off", "TEST", 116, 134]]], ["All sequences without hits were then subjected to a BLASTX search against protein sequences present in the nr database.", [["All sequences", "TEST", 0, 13], ["a BLASTX search", "TEST", 50, 65], ["protein sequences", "TEST", 74, 91]]], ["BLAST hits were categorized by assigning a taxonomic category.DETERMINATION OF TAXONOMIC CONTENTThe percentage of viral reads in the sequence datasets and read coverage of the target genome using different assembly methods were determined by mapping trimmed reads to reference genomes with GSMapper Version 2.7 (Roche) with a minimum overlap identity of 80%.REMOTE HOMOLOGY SEARCHAll contigs were translated in six frames.", [["target genome", "DNA", 176, 189], ["SEARCHAll contigs", "DNA", 374, 391], ["BLAST hits", "TEST", 0, 10], ["TAXONOMIC CONTENT", "PROBLEM", 79, 96], ["the sequence datasets", "TEST", 129, 150], ["GSMapper Version", "TEST", 290, 306], ["TAXONOMIC CONTENT", "OBSERVATION", 79, 96], ["viral reads", "OBSERVATION", 114, 125]]], ["Hidden Markov Models (HMMs) of PFAM families associated with Rhabdoviridae (pfam14314, pfam00945, pfam02484, pfam03216, pfam03342, pfam03012, pfam03397, pfam04785, pfam05554, pfam00922, pfam00974, pfam06326) were used to search the translated contigs of the metagenome datasets with rhabdoviruses with HMMER3.1 (Punta et al., 2012) .", [["pfam03342", "CHEMICAL", 120, 129], ["pfam03012", "CHEMICAL", 131, 140], ["pfam03397", "CHEMICAL", 142, 151], ["pfam04785", "CHEMICAL", 153, 162], ["pfam05554", "CHEMICAL", 164, 173], ["pfam00922", "CHEMICAL", 175, 184], ["pfam00974", "CHEMICAL", 186, 195], ["pfam06326", "CHEMICAL", 197, 206], ["pfam00945", "GENE_OR_GENE_PRODUCT", 87, 96], ["pfam02484", "GENE_OR_GENE_PRODUCT", 98, 107], ["pfam03216", "GENE_OR_GENE_PRODUCT", 109, 118], ["pfam03342", "GENE_OR_GENE_PRODUCT", 120, 129], ["pfam03012", "GENE_OR_GENE_PRODUCT", 131, 140], ["pfam03397", "GENE_OR_GENE_PRODUCT", 142, 151], ["PFAM families", "PROTEIN", 31, 44], ["pfam02484", "PROTEIN", 98, 107], ["pfam03216", "PROTEIN", 109, 118], ["pfam03342", "PROTEIN", 120, 129], ["pfam03012", "PROTEIN", 131, 140], ["pfam03397", "PROTEIN", 142, 151], ["pfam04785", "PROTEIN", 153, 162], ["pfam05554", "PROTEIN", 164, 173], ["pfam00922", "PROTEIN", 175, 184], ["pfam00974", "PROTEIN", 186, 195], ["pfam06326", "PROTEIN", 197, 206], ["Rhabdoviridae", "TREATMENT", 61, 74]]], ["Accordingly, HMMs of 45 PFAM families associated with Coronaviridae (pfam05213, pfam06460, pfam04694, pfam09408, pfam08717, pfam08716, pfam08715, pfam06478, pfam06471, pfam05409, pfam03262, pfam03053, pfam02723, pfam01601, pfam01600, pfam00937, pfam08779, pfam12383, pfam12379, pfam12133, pfam12124, pfam12093, pfam11963, pfam11633, pfam11501, pfam11395, pfam11289, pfam11030, pfam10943, pfam09401, pfam08710, pfam06336, pfam06145, pfam05528, pfam04753, pfam03905, pfam03622, pfam03620, pfam03617, pfam03187, pfam02398, pfam01635, pfam09399, pfam01831) were used to search the translated contigs of the PNV metagenome.MOTIF DISCOVERY AND MOTIF SEARCHMotif sequence patterns were discovered with MEME Version 4.9.1 (Bailey et al., 2009 ) by allowing any number of repetitions on the sequence.", [["pfam04694", "CHEMICAL", 91, 100], ["pfam09408", "CHEMICAL", 102, 111], ["pfam08717", "CHEMICAL", 113, 122], ["pfam08716", "CHEMICAL", 124, 133], ["pfam08715", "CHEMICAL", 135, 144], ["pfam06478", "CHEMICAL", 146, 155], ["pfam06471", "CHEMICAL", 157, 166], ["pfam05409", "CHEMICAL", 168, 177], ["pfam03262", "CHEMICAL", 179, 188], ["pfam03053", "CHEMICAL", 190, 199], ["pfam02723", "CHEMICAL", 201, 210], ["pfam01601", "CHEMICAL", 212, 221], ["pfam01600", "CHEMICAL", 223, 232], ["pfam00937", "CHEMICAL", 234, 243], ["pfam08779", "CHEMICAL", 245, 254], ["pfam12383", "CHEMICAL", 256, 265], ["pfam12379", "CHEMICAL", 267, 276], ["pfam12133", "CHEMICAL", 278, 287], ["pfam12124", "CHEMICAL", 289, 298], ["pfam12093", "CHEMICAL", 300, 309], ["pfam11963", "CHEMICAL", 311, 320], ["pfam11633", "CHEMICAL", 322, 331], ["pfam11501", "CHEMICAL", 333, 342], ["pfam11395", "CHEMICAL", 344, 353], ["pfam11289", "CHEMICAL", 355, 364], ["pfam11030", "CHEMICAL", 366, 375], ["pfam10943", "CHEMICAL", 377, 386], ["pfam09401", "CHEMICAL", 388, 397], ["pfam08710", "CHEMICAL", 399, 408], ["pfam06336", "CHEMICAL", 410, 419], ["pfam06145", "CHEMICAL", 421, 430], ["pfam05528", "CHEMICAL", 432, 441], ["pfam04753", "CHEMICAL", 443, 452], ["pfam03905", "CHEMICAL", 454, 463], ["pfam03622", "CHEMICAL", 465, 474], ["pfam03620", "CHEMICAL", 476, 485], ["pfam03617", "CHEMICAL", 487, 496], ["pfam03187", "CHEMICAL", 498, 507], ["pfam02398", "CHEMICAL", 509, 518], ["pfam01635", "CHEMICAL", 520, 529], ["pfam09399", "CHEMICAL", 531, 540], ["pfam01831", "CHEMICAL", 542, 551], ["pfam05213", "GENE_OR_GENE_PRODUCT", 69, 78], ["pfam06460", "GENE_OR_GENE_PRODUCT", 80, 89], ["pfam04694", "GENE_OR_GENE_PRODUCT", 91, 100], ["pfam09408", "GENE_OR_GENE_PRODUCT", 102, 111], ["pfam08717", "GENE_OR_GENE_PRODUCT", 113, 122], ["pfam08716", "GENE_OR_GENE_PRODUCT", 124, 133], ["pfam08715", "GENE_OR_GENE_PRODUCT", 135, 144], ["pfam06478", "GENE_OR_GENE_PRODUCT", 146, 155], ["pfam06471", "GENE_OR_GENE_PRODUCT", 157, 166], ["pfam05409", "GENE_OR_GENE_PRODUCT", 168, 177], ["pfam03262", "GENE_OR_GENE_PRODUCT", 179, 188], ["pfam03053", "GENE_OR_GENE_PRODUCT", 190, 199], ["pfam02723", "GENE_OR_GENE_PRODUCT", 201, 210], ["pfam01601", "GENE_OR_GENE_PRODUCT", 212, 221], ["pfam01600", "GENE_OR_GENE_PRODUCT", 223, 232], ["pfam00937", "GENE_OR_GENE_PRODUCT", 234, 243], ["pfam08779", "GENE_OR_GENE_PRODUCT", 245, 254], ["pfam12383", "GENE_OR_GENE_PRODUCT", 256, 265], ["pfam12379", "GENE_OR_GENE_PRODUCT", 267, 276], ["pfam12133", "GENE_OR_GENE_PRODUCT", 278, 287], ["pfam12124", "GENE_OR_GENE_PRODUCT", 289, 298], ["pfam12093", "GENE_OR_GENE_PRODUCT", 300, 309], ["pfam11963", "GENE_OR_GENE_PRODUCT", 311, 320], ["pfam11633", "GENE_OR_GENE_PRODUCT", 322, 331], ["pfam11501", "GENE_OR_GENE_PRODUCT", 333, 342], ["pfam11395", "GENE_OR_GENE_PRODUCT", 344, 353], ["pfam11289", "GENE_OR_GENE_PRODUCT", 355, 364], ["pfam11030", "GENE_OR_GENE_PRODUCT", 366, 375], ["pfam10943", "GENE_OR_GENE_PRODUCT", 377, 386], ["pfam09401", "GENE_OR_GENE_PRODUCT", 388, 397], ["pfam08710", "GENE_OR_GENE_PRODUCT", 399, 408], ["pfam06336", "GENE_OR_GENE_PRODUCT", 410, 419], ["pfam06145", "GENE_OR_GENE_PRODUCT", 421, 430], ["pfam05528", "GENE_OR_GENE_PRODUCT", 432, 441], ["pfam04753", "GENE_OR_GENE_PRODUCT", 443, 452], ["pfam03905", "GENE_OR_GENE_PRODUCT", 454, 463], ["pfam03622", "GENE_OR_GENE_PRODUCT", 465, 474], ["pfam03620", "GENE_OR_GENE_PRODUCT", 476, 485], ["pfam03617", "GENE_OR_GENE_PRODUCT", 487, 496], ["pfam03187", "GENE_OR_GENE_PRODUCT", 498, 507], ["pfam02398", "GENE_OR_GENE_PRODUCT", 509, 518], ["45 PFAM families", "PROTEIN", 21, 37], ["Coronaviridae (pfam05213, pfam06460, pfam04694, pfam09408, pfam08717, pfam08716, pfam08715", "DNA", 54, 144], ["pfam06478", "DNA", 146, 155], ["pfam06471", "DNA", 157, 166], ["pfam05409", "DNA", 168, 177], ["pfam03262", "DNA", 179, 188], ["pfam03053", "DNA", 190, 199], ["pfam02723", "DNA", 201, 210], ["pfam01601", "DNA", 212, 221], ["pfam01600", "DNA", 223, 232], ["pfam00937", "DNA", 234, 243], ["pfam08779", "DNA", 245, 254], ["pfam12383", "DNA", 256, 265], ["pfam12379", "DNA", 267, 276], ["pfam12133", "DNA", 278, 287], ["pfam12124", "DNA", 289, 298], ["pfam12093", "DNA", 300, 309], ["pfam11963", "DNA", 311, 320], ["pfam11633", "DNA", 322, 331], ["pfam11501", "DNA", 333, 342], ["pfam11395", "DNA", 344, 353], ["pfam11289", "DNA", 355, 364], ["pfam11030", "DNA", 366, 375], ["pfam10943", "DNA", 377, 386], ["pfam09401", "DNA", 388, 397], ["pfam08710", "DNA", 399, 408], ["pfam06336", "DNA", 410, 419], ["pfam06145", "DNA", 421, 430], ["pfam05528", "DNA", 432, 441], ["pfam04753", "DNA", 443, 452], ["pfam03905", "DNA", 454, 463], ["pfam03622", "DNA", 465, 474], ["pfam03620", "DNA", 476, 485], ["pfam03617", "DNA", 487, 496], ["pfam03187", "DNA", 498, 507], ["pfam02398", "DNA", 509, 518], ["pfam01635", "DNA", 520, 529], ["pfam09399", "DNA", 531, 540], ["pfam01831", "DNA", 542, 551], ["PNV metagenome", "DNA", 603, 617], ["HMMs", "TEST", 13, 17], ["Coronaviridae", "TREATMENT", 54, 67], ["the PNV metagenome", "TREATMENT", 599, 617], ["MOTIF SEARCHMotif sequence patterns", "TEST", 638, 673]]], ["The best scoring detected motif distributed over the seed contig was then used to search the motif in the collection of all contigs longer than 500 bases in all three datasets with MAST (Bailey et al., 2009) with an e-value lower than 0.1.COVERAGE PROFILE BINNINGThe average coverage of all contigs identified using exhaustive iterative assembly was calculated by dividing the number of reads covering the contigs by its length, as determined by the mapping procedure of the virus discovery pipeline.", [["seed contig", "DNA", 53, 64], ["the seed contig", "TREATMENT", 49, 64], ["an e-value", "TEST", 213, 223], ["all contigs", "TREATMENT", 287, 298], ["the mapping procedure", "TREATMENT", 446, 467]]], ["Frequency of binned coverage profiles was visualized in R statistical package version 3.1.K-mer FREQUENCY RANKINGK-mer frequency was determined with the Bioconductor package biostrings (Pages et al., in press) for 3mers to 8mers for contigs larger than 1 kb in R statistical package version 3.1 (Team, 2012) .", [["binned coverage profiles", "TREATMENT", 13, 37], ["RANKINGK", "TEST", 106, 114]]], ["Absolute differences between the k-mer frequencies of the seed contig and all other contigs were summed among different k-mer lengths and ranked, and visualized in relation to contig size.ACCESSION NUMBERSViral genome sequences used in this study were taken from Genbank, accession numbers KF958252 (DRV), KF823814 (RFFRV), and KJ935003 (PNV).EVALUATION OF DIFFERENT ASSEMBLY ALGORITHMSThe objective of this study was to test and evaluate methods to increase the likelihood and speed of identifying viral reads and the level of viral genome completeness from metagenomic datasets generated on the 454-sequencing platform.", [["seed contig", "ANATOMY", 58, 69], ["seed contig", "DNA", 58, 69], ["NUMBERSViral genome sequences", "DNA", 198, 227], ["viral genome", "DNA", 528, 540], ["Absolute differences", "PROBLEM", 0, 20], ["the seed contig", "TREATMENT", 54, 69], ["all other contigs", "TREATMENT", 74, 91], ["this study", "TEST", 236, 246], ["DRV", "TEST", 300, 303], ["KF823814", "TEST", 306, 314], ["RFFRV", "TEST", 316, 321], ["EVALUATION", "TEST", 343, 353], ["this study", "TEST", 403, 413], ["test", "TEST", 421, 425], ["viral reads", "TEST", 499, 510], ["viral genome completeness", "PROBLEM", 528, 553], ["metagenomic datasets", "TEST", 559, 579], ["size", "OBSERVATION_MODIFIER", 183, 187]]], ["The three 454-sequencing datasets obtained from a CCS, a red fox fecal (RFF) metagenome, and a tiger python lung tissue (TPLT) metagenome contained 69,358, 56,174, and 135,812 sequence reads, respectively (Table 1) .", [["lung tissue", "ANATOMY", 108, 119], ["fecal", "ORGANISM_SUBSTANCE", 65, 70], ["lung tissue", "TISSUE", 108, 119], ["CCS", "DNA", 50, 53], ["red fox fecal (RFF) metagenome", "DNA", 57, 87], ["tiger python lung tissue (TPLT) metagenome", "DNA", 95, 137], ["red fox", "SPECIES", 57, 64], ["tiger python", "SPECIES", 95, 107], ["sequencing datasets", "TEST", 14, 33], ["a CCS", "TEST", 48, 53], ["a red fox fecal (RFF) metagenome", "PROBLEM", 55, 87], ["a tiger python lung tissue", "TEST", 93, 119], ["metagenome", "TEST", 127, 137], ["lung tissue", "ANATOMY", 108, 119]]], ["These reads were analyzed with an automatic analysis pipeline that included stringent quality and length trimming, exhaustive iterative assembly, and low complexity filtering .", [["an automatic analysis pipeline", "TEST", 31, 61], ["length trimming", "TREATMENT", 98, 113], ["low complexity", "OBSERVATION_MODIFIER", 150, 164]]], ["A total of 28,207, 32,455 and 50,024 reads from the CCS and the RFF and TPLT metagenome, respectively were subjected to homology searches ( Table 2) .", [["CCS", "DNA", 52, 55], ["RFF", "DNA", 64, 67], ["TPLT metagenome", "DNA", 72, 87], ["the CCS", "TEST", 48, 55], ["the RFF", "TEST", 60, 67], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["The analysis showed a high variety among almost all taxonomic categories in the three different datasets ( Table 2 ).", [["The analysis", "TEST", 0, 12], ["a high variety", "PROBLEM", 20, 34], ["high", "OBSERVATION_MODIFIER", 22, 26], ["variety", "OBSERVATION_MODIFIER", 27, 34], ["taxonomic categories", "OBSERVATION", 52, 72]]], ["The overall viral content determined by homology search was relatively low (0.72%) in dataset 3 (TPLT metagenome), and high (30.21 and 68.05%) in datasets 1 and 2 (CCS and RFF metagenome, Table 2 ).EVALUATION OF DIFFERENT ASSEMBLY ALGORITHMSIterative exhaustive assembly resulted in assembled metagenomes containing between 40-60% of the original total amount of obtained reads ( Table 1 ) of which the virome has a large dynamic range of reads depending on the sample under analysis.", [["homology search", "TEST", 40, 55], ["TPLT metagenome", "TEST", 97, 112], ["datasets", "TEST", 146, 154], ["CCS", "TEST", 164, 167], ["RFF metagenome", "TEST", 172, 186], ["EVALUATION", "TEST", 198, 208], ["assembled metagenomes", "PROBLEM", 283, 304], ["the sample under analysis", "TEST", 458, 483], ["viral content", "OBSERVATION", 12, 25], ["high", "OBSERVATION_MODIFIER", 119, 123], ["large", "OBSERVATION_MODIFIER", 416, 421]]], ["Unsurprisingly, the CCS dataset from an assumingly relatively pure virus culture supernatant had a high viral content, consisting predominantly of DRV.", [["supernatant", "ANATOMY", 81, 92], ["DRV", "PROTEIN", 147, 150], ["the CCS dataset", "TEST", 16, 31], ["an assumingly relatively pure virus culture supernatant", "PROBLEM", 37, 92], ["a high viral content", "PROBLEM", 97, 117], ["high viral content", "OBSERVATION", 99, 117], ["DRV", "ANATOMY", 147, 150]]], ["The viromes of the RFF metagenome showed a much smaller percentage of the RFFRV indicating the presence of multiple different viruses (Tables 1, 2) .EVALUATION OF DIFFERENT ASSEMBLY ALGORITHMSGenomes of DRV, RFFRV, and PNV were not completely assembled by the exhaustive iterative assembly approach implemented in the automated analysis pipeline.", [["RFFRV", "GENE_OR_GENE_PRODUCT", 74, 79], ["RFF metagenome", "DNA", 19, 33], ["RFFRV", "PROTEIN", 74, 79], ["DRV, RFFRV, and PNV", "DNA", 203, 222], ["the RFF metagenome", "TEST", 15, 33], ["multiple different viruses", "PROBLEM", 107, 133], ["EVALUATION", "TEST", 149, 159], ["DRV", "TEST", 203, 206], ["RFFRV", "TREATMENT", 208, 213], ["PNV", "TREATMENT", 219, 222], ["smaller", "OBSERVATION_MODIFIER", 48, 55], ["multiple", "OBSERVATION_MODIFIER", 107, 115], ["different", "OBSERVATION_MODIFIER", 116, 125], ["viruses", "OBSERVATION", 126, 133], ["DRV", "ANATOMY", 203, 206]]], ["The largest contigs were 7291 bases (64.32% of DRV, DRV seed contig) and 7682 bases (47.9% of RFFRV), respectively, of an expected size of 11 to 15 kb for Rhabdoviridae and 24,734 bases (73.68% of PNV) of an expected 30 kb for Coronaviridae (Figures 1A-C) .", [["7291 bases", "DNA", 25, 35], ["DRV, DRV seed contig", "DNA", 47, 67], ["bases", "TEST", 30, 35], ["DRV", "TEST", 47, 50], ["bases", "TEST", 78, 83], ["RFFRV", "TEST", 94, 99], ["Rhabdoviridae", "TEST", 155, 168], ["bases", "TEST", 180, 185], ["PNV", "TEST", 197, 200], ["Coronaviridae", "TEST", 227, 240], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["bases", "ANATOMY_MODIFIER", 30, 35], ["bases", "ANATOMY_MODIFIER", 78, 83], ["size", "OBSERVATION_MODIFIER", 131, 135]]], ["Interestingly, retrospective mapping of reads to the viral target genomes showed that a large percentage of the sequences identified as \"unknowns\" by homology searches in the TPLT and RFF metagenome were actually derived from the target genome, most likely from parts of the target genomes without detectable similarity to any other viral protein in the BLAST database (Tables 1, 2) .EVALUATION OF DIFFERENT ASSEMBLY ALGORITHMSTo evaluate if other assembly algorithms would be able to directly assemble the complete target viral genomes from the deep sequencing data, we compared the contigs assembled from trimmed reads by iterative assembly, CLC Genomics Workbench assembler, Genovo and Newbler.", [["TPLT", "CANCER", 175, 179], ["viral target genomes", "DNA", 53, 73], ["TPLT and RFF metagenome", "DNA", 175, 198], ["target genome", "DNA", 230, 243], ["target genomes", "DNA", 275, 289], ["viral protein", "PROTEIN", 333, 346], ["viral genomes", "DNA", 523, 536], ["retrospective mapping", "TEST", 15, 36], ["the viral target genomes", "TEST", 49, 73], ["the TPLT and RFF metagenome", "PROBLEM", 171, 198], ["EVALUATION", "TEST", 384, 394], ["the deep sequencing data", "TEST", 542, 566], ["large", "OBSERVATION_MODIFIER", 88, 93], ["target genome", "OBSERVATION", 230, 243], ["most likely", "UNCERTAINTY", 245, 256]]], ["While Genovo and Newbler both produced many small contigs covering part of the target genomes (Figures 1A-C) , CLC Genomics Workbench assembler and the iterative assembly approach produced a similar number of contigs (two to five).", [["target genomes", "DNA", 79, 93], ["CLC Genomics Workbench assembler", "DNA", 111, 143], ["many small contigs", "PROBLEM", 39, 57], ["small", "OBSERVATION_MODIFIER", 44, 49], ["contigs", "OBSERVATION", 50, 57]]], ["However, large contigs (>1 kb) produced by iterative assembly covered the target genomes more completely than any other set of contigs obtained with other assembly algorithms.", [["target genomes", "DNA", 74, 88], ["large contigs", "PROBLEM", 9, 22], ["large", "OBSERVATION_MODIFIER", 9, 14]]], ["None of the assemblers tested here was able to completely assemble the viral genomes from the reads into a single contig (Figures 1A-C) .EVALUATION OF DIFFERENT ASSEMBLY ALGORITHMSThe contigs produced by iterative assembly and CLC Genomics Workbench for DRV were clearly overlapping ( Figure 1A ) and could be fused to a single assembly of a complete DRV genome by manual curation.", [["viral genomes", "DNA", 71, 84], ["DRV", "DNA", 254, 257], ["DRV genome", "DNA", 351, 361], ["the viral genomes", "PROBLEM", 67, 84], ["EVALUATION", "TEST", 137, 147], ["DRV", "TREATMENT", 254, 257], ["a complete DRV genome", "TREATMENT", 340, 361], ["DRV genome", "OBSERVATION", 351, 361]]], ["For RFFRV in dataset 2, contigs assembled by iterative assembly and Genovo overlapped.", [["RFFRV", "DNA", 4, 9], ["Genovo", "DNA", 68, 74], ["RFFRV", "PROBLEM", 4, 9]]], ["However, a very small overlap of only five nucleotides between position 4356 and 4361, probably due to the combination of a drop in coverage and a stretch of sequence with low complexity (Figure 1B) did not allow us to retrieve a complete viral genome.", [["nucleotides", "CHEMICAL", 43, 54], ["viral genome", "DNA", 239, 251], ["a very small overlap", "PROBLEM", 9, 29], ["a drop in coverage", "PROBLEM", 122, 140], ["a stretch of sequence", "TEST", 145, 166], ["a complete viral genome", "PROBLEM", 228, 251], ["very", "OBSERVATION_MODIFIER", 11, 15], ["small", "OBSERVATION_MODIFIER", 16, 21], ["overlap", "OBSERVATION", 22, 29], ["position", "OBSERVATION_MODIFIER", 63, 71], ["probably due to", "UNCERTAINTY", 87, 102], ["drop", "OBSERVATION", 124, 128], ["viral genome", "OBSERVATION", 239, 251]]], ["Moreover, with the exception of the largest contig (the RFFRV seed contig), no other RFFRV contigs had a homolog in the NCBI nucleotide or protein database.", [["nucleotide", "CHEMICAL", 125, 135], ["RFFRV", "GENE_OR_GENE_PRODUCT", 85, 90], ["RFFRV seed contig", "DNA", 56, 73], ["RFFRV contigs", "DNA", 85, 98], ["NCBI nucleotide", "DNA", 120, 135], ["the largest contig", "PROBLEM", 32, 50], ["the RFFRV seed contig", "TREATMENT", 52, 73], ["other RFFRV contigs", "PROBLEM", 79, 98], ["protein database", "TEST", 139, 155], ["largest", "OBSERVATION_MODIFIER", 36, 43]]], ["The minor overlap, in combination with absence of homology, prevented assembly of a complete RFFRV genome.", [["RFFRV", "GENE_OR_GENE_PRODUCT", 93, 98], ["RFFRV genome", "DNA", 93, 105], ["a complete RFFRV genome", "PROBLEM", 82, 105], ["minor", "OBSERVATION_MODIFIER", 4, 9], ["overlap", "OBSERVATION", 10, 17]]], ["Similarly, the overlaps between contigs of PNV obtained with different assembly algorithms, in combination with the absence of homology, were insufficient to conclusively obtain a full-length PNV genome.", [["PNV", "GENE_OR_GENE_PRODUCT", 43, 46], ["PNV", "GENE_OR_GENE_PRODUCT", 192, 195], ["PNV", "DNA", 43, 46], ["PNV genome", "DNA", 192, 202], ["PNV", "TREATMENT", 43, 46], ["a full-length PNV genome", "TREATMENT", 178, 202]]], ["In the TPLT metagenome, a 24.7 kb contig had a stretch with an average identity of 29% amino acid identity to the replicase polyprotein of Berne virus, subfamily Torovirinae ( Figure 1C) .", [["amino acid", "CHEMICAL", 87, 97], ["amino acid", "CHEMICAL", 87, 97], ["amino acid", "AMINO_ACID", 87, 97], ["Berne virus", "ORGANISM", 139, 150], ["TPLT metagenome", "DNA", 7, 22], ["24.7 kb contig", "DNA", 26, 40], ["replicase polyprotein", "PROTEIN", 114, 135], ["Berne virus", "SPECIES", 139, 150], ["amino acid identity", "TEST", 87, 106], ["Berne virus", "PROBLEM", 139, 150], ["replicase polyprotein", "OBSERVATION", 114, 135], ["Berne virus", "OBSERVATION", 139, 150]]], ["This contig was used as seed contig.", [["seed contig", "DNA", 24, 35], ["This contig", "TREATMENT", 0, 11]]], ["Overall, the data indicate that iterative exhaustive assembly seems to perform best in terms of production of large contigs and coverage of target genomes compared to other assemblers.", [["target genomes", "DNA", 140, 154], ["the data", "TEST", 9, 17], ["large contigs", "PROBLEM", 110, 123], ["target genomes", "PROBLEM", 140, 154], ["large", "OBSERVATION_MODIFIER", 110, 115]]], ["Thus, for further analysis we used the set of contigs produced by iterative assembly.", [["further analysis", "TEST", 10, 26]]], ["It is of note, however, that using a combination of different assembly algorithms may result in a higher level of completeness of target genomes if not complete genome assembly.REMOTE HOMOLOGY SEARCHIn absence of BLAST-detectable sequence homology to previously described viruses for some stretches of the target genomes we attempted to use methods that are able to detect remote homologs, i.e., profile hidden markov models (Figures 1A-C) .REMOTE HOMOLOGY SEARCHTo retrieve and link contigs of the viral target genomes we used profile HMMs of protein domains present in Rhabdoviridae and Coronaviridae, respectively.", [["target genomes", "DNA", 130, 144], ["target genomes", "DNA", 306, 320], ["viral target genomes", "DNA", 499, 519], ["protein domains", "PROTEIN", 544, 559], ["methods", "TREATMENT", 341, 348], ["the viral target genomes", "TREATMENT", 495, 519], ["protein domains", "TREATMENT", 544, 559], ["Rhabdoviridae", "TREATMENT", 571, 584], ["Coronaviridae", "TREATMENT", 589, 602]]], ["For Rhabdoviridae, 12 domains were present in PFAM, from nucleocapsid, spike and matrix proteins.", [["matrix", "CELLULAR_COMPONENT", 81, 87], ["PFAM", "PROTEIN", 46, 50], ["nucleocapsid, spike and matrix proteins", "PROTEIN", 57, 96], ["Rhabdoviridae", "TREATMENT", 4, 17], ["nucleocapsid", "PROBLEM", 57, 69], ["spike and matrix proteins", "PROBLEM", 71, 96]]], ["Searching the translated contigs of the CCS containing DRV identified three regions (Vesiculovirus matrix protein-PF06326.7, Rhabdovirus nucleocapsid protein-PF00945.13 and the Rhabdovirus spike protein-PF00974.13) covered by several contigs (Figure 1A , contigs smaller than 1 kb not shown).", [["Vesiculovirus matrix protein-PF06326.7", "GENE_OR_GENE_PRODUCT", 85, 123], ["Rhabdovirus nucleocapsid protein-PF00945.13", "GENE_OR_GENE_PRODUCT", 125, 168], ["CCS", "DNA", 40, 43], ["DRV", "DNA", 55, 58], ["Vesiculovirus matrix protein", "PROTEIN", 85, 113], ["PF06326.7", "PROTEIN", 114, 123], ["Rhabdovirus nucleocapsid protein", "PROTEIN", 125, 157], ["PF00945.13", "PROTEIN", 158, 168], ["Rhabdovirus spike protein", "PROTEIN", 177, 202], ["PF00974.13", "PROTEIN", 203, 213], ["Figure 1A", "DNA", 243, 252], ["Vesiculovirus matrix protein", "TEST", 85, 113], ["Rhabdovirus nucleocapsid protein", "TEST", 125, 157], ["the Rhabdovirus spike protein", "TEST", 173, 202], ["Figure 1A , contigs smaller than 1 kb", "TREATMENT", 243, 280], ["DRV", "ANATOMY", 55, 58]]], ["The RFF metagenome did not give any hits (Figure 1B) .", [["RFF metagenome", "DNA", 4, 18]]], ["For Coronaviridae in the TPLT metagenome, 44 HMMs were present in PFAM, again covering all proteins families.", [["TPLT metagenome", "DNA", 25, 40], ["PFAM", "PROTEIN", 66, 70], ["Coronaviridae", "TREATMENT", 4, 17]]], ["Three Coronaviridae-specific HMMs identified several contigs, the Coronavirus NSP13 (F06460.7), the RNA synthesis protein NSP10 (PF09401.5) and the Coronavirus RPol N-terminus (PF06478.8).", [["N", "CHEMICAL", 165, 166], ["NSP10", "GENE_OR_GENE_PRODUCT", 122, 127], ["Coronaviridae-specific HMMs", "DNA", 6, 33], ["Coronavirus NSP13", "DNA", 66, 83], ["F06460.7", "DNA", 85, 93], ["RNA synthesis protein", "PROTEIN", 100, 121], ["NSP10", "PROTEIN", 122, 127], ["PF09401.5", "PROTEIN", 129, 138], ["Coronavirus RPol N-terminus", "PROTEIN", 148, 175], ["PF06478.8", "PROTEIN", 177, 186], ["the Coronavirus NSP13", "TEST", 62, 83], ["the RNA synthesis protein NSP10", "TEST", 96, 127], ["the Coronavirus RPol", "TEST", 144, 164]]], ["However, in all three datasets, all identified domains were already identified in contigs with BLAST sequence homology to a closely related virus (Figures 1A-C) .", [["BLAST sequence homology", "TREATMENT", 95, 118]]], ["Identification of regions with remote homology to family-specific domains did therefore not result in acquisition of additional genomic regions that were not identified by the original iterative assembly method in combination with homology search by BLAST.MOTIF SEARCHA sequence motif is a DNA pattern that occurs repeatedly in a genome or in a group of related sequences.", [["DNA", "CELLULAR_COMPONENT", 290, 293], ["genomic regions", "DNA", 128, 143], ["MOTIF SEARCHA sequence motif", "DNA", 256, 284], ["MOTIF SEARCHA sequence motif", "TEST", 256, 284], ["a DNA pattern", "PROBLEM", 288, 301]]], ["Motif discovery was performed on the seed contigs that showed homology to viruses of either the Rhabdoviridae or Coronaviridae family of metagenome 1 and 3 and on two adjacent, clearly overlapping RFFRV contigs of metagenome 2, including the RFFRV seed contig (Figure 2B) .", [["3", "GENE_OR_GENE_PRODUCT", 154, 155], ["seed contigs", "DNA", 37, 49], ["Rhabdoviridae or Coronaviridae family of metagenome 1 and 3", "DNA", 96, 155], ["RFFRV contigs", "DNA", 197, 210], ["metagenome 2", "DNA", 214, 226], ["RFFRV seed contig", "DNA", 242, 259], ["the seed contigs", "TEST", 33, 49], ["the RFFRV seed contig", "TREATMENT", 238, 259]]], ["The highest scoring motif (Figures S1A-C) of each seed contig was then used to screen all available contigs of the deep sequencing datasets.", [["each seed contig", "TREATMENT", 45, 61]]], ["Four additional DRV-matching contigs smaller than 1 kb (not indicated in Figure 1A ) were identified in the CCS.", [["CCS", "DISEASE", 108, 111], ["DRV-matching contigs", "DNA", 16, 36], ["Four additional DRV-matching contigs", "TREATMENT", 0, 36], ["DRV", "OBSERVATION", 16, 19], ["smaller", "OBSERVATION_MODIFIER", 37, 44]]], ["In the RFF metagenome, four additional RFFRV contigs were identified and in the TLPT metagenome, one additional PNV contig exhibited the detected pattern (Figures 1B-C) .", [["RFF", "CANCER", 7, 10], ["RFFRV", "GENE_OR_GENE_PRODUCT", 39, 44], ["RFF metagenome", "DNA", 7, 21], ["RFFRV contigs", "DNA", 39, 52], ["TLPT metagenome", "DNA", 80, 95], ["PNV contig", "DNA", 112, 122], ["four additional RFFRV contigs", "TREATMENT", 23, 52], ["additional PNV contig", "TREATMENT", 101, 122]]], ["No false positive contigs were identified with this method.", [["false positive contigs", "DNA", 3, 25], ["false positive contigs", "PROBLEM", 3, 25], ["this method", "TREATMENT", 47, 58], ["false", "OBSERVATION", 3, 8], ["positive contigs", "OBSERVATION", 9, 25]]], ["Moreover, when the PNV motif was used to search all three viral genomes including the rhabdovirus genomes, it exhibited highest specificity for the PNV genome (e-value 4e-12), with e-values above 1 for RFFRV and DRV.", [["PNV motif", "DNA", 19, 28], ["viral genomes", "DNA", 58, 71], ["rhabdovirus genomes", "DNA", 86, 105], ["PNV genome", "DNA", 148, 158], ["RFFRV", "SPECIES", 202, 207], ["the PNV motif", "TREATMENT", 15, 28], ["the rhabdovirus genomes", "PROBLEM", 82, 105], ["the PNV genome", "TEST", 144, 158], ["e-values", "TEST", 181, 189], ["RFFRV", "TREATMENT", 202, 207], ["DRV", "TREATMENT", 212, 215], ["rhabdovirus genomes", "OBSERVATION", 86, 105], ["DRV", "ANATOMY", 212, 215]]], ["The DRV and the RFFRV motif were most specific for their originating genome, while the e-value for the respective other rhabdovirus genome was relatively low (0.62 and 0.015), suggesting those motifs might be conserved among both rhabdovirus genomes.", [["DRV", "CANCER", 4, 7], ["RFFRV", "GENE_OR_GENE_PRODUCT", 16, 21], ["rhabdovirus", "GENE_OR_GENE_PRODUCT", 120, 131], ["DRV", "DNA", 4, 7], ["RFFRV motif", "DNA", 16, 27], ["rhabdovirus genome", "DNA", 120, 138], ["rhabdovirus genomes", "DNA", 230, 249], ["The DRV", "TREATMENT", 0, 7], ["the RFFRV motif", "TREATMENT", 12, 27], ["the respective other rhabdovirus genome", "PROBLEM", 99, 138], ["DRV", "ANATOMY", 4, 7], ["rhabdovirus genome", "OBSERVATION", 120, 138], ["rhabdovirus genomes", "OBSERVATION", 230, 249]]], ["The high specificity of the motifs described here was also demonstrated when scanning all contigs of the three metagenomes: the motif discovered contigs of the respective viral genomes with a high specificity.", [["viral genomes", "DNA", 171, 184], ["the respective viral genomes", "PROBLEM", 156, 184], ["high", "OBSERVATION_MODIFIER", 4, 8], ["viral genomes", "OBSERVATION", 171, 184]]], ["The detection sensitivity however was restricted by the number of contigs that contained the motif.", [["The detection sensitivity", "TEST", 0, 25]]], ["For example, the eight occurrences of the motif in the RFFRV genome were, with one exception, all found in intergenic regions.", [["RFFRV", "GENE_OR_GENE_PRODUCT", 55, 60], ["RFFRV genome", "DNA", 55, 67], ["intergenic regions", "DNA", 107, 125], ["intergenic", "ANATOMY_MODIFIER", 107, 117], ["regions", "ANATOMY_MODIFIER", 118, 125]]], ["Contigs not containing intergenic regions could not be identified with this method.FIGURE 1 | ContinuedNewbler assembler.", [["intergenic regions", "DNA", 23, 41], ["intergenic regions", "PROBLEM", 23, 41], ["this method", "TREATMENT", 71, 82]]], ["Small black boxes at the bottom of the read coverage line mark stretches of low sequence complexity.", [["Small black boxes", "PROBLEM", 0, 17], ["black boxes", "OBSERVATION", 6, 17]]], ["\"ORF\" indicates the genome organization as described below.", [["ORF", "DNA", 1, 4], ["ORF", "PROBLEM", 1, 4], ["genome organization", "OBSERVATION", 20, 39]]], ["\"BLAST\" shows regions with sequence homology as determined by BLASTX.", [["BLASTX", "DNA", 62, 68]]], ["All occurrences of the detected motifs in the target genomes are indicated in Figures 1A-C.", [["target genomes", "DNA", 46, 60]]], ["For both RFFRV and PNV, motif detection was able to identify contigs from genomic regions lacking BLAST or HMM-detectable homology.", [["RFFRV", "DNA", 9, 14], ["PNV", "DNA", 19, 22], ["genomic regions", "DNA", 74, 89], ["both RFFRV", "TREATMENT", 4, 14], ["PNV", "TREATMENT", 19, 22], ["motif detection", "TEST", 24, 39]]], ["This information was sufficient to obtain the complete coding region of the RFFRV genome in combination with the iterative assembly approach.COVERAGE PROFILE BINNINGIn order to find additional contigs by coverage profile binning, the average coverage of every contig of the CCS and the two metagenomes was calculated by dividing the number of reads by the length of the contig.", [["RFFRV genome", "DNA", 76, 88], ["CCS", "DNA", 274, 277], ["the RFFRV genome", "TREATMENT", 72, 88], ["the iterative assembly approach", "TREATMENT", 109, 140], ["the CCS", "TREATMENT", 270, 277]]], ["In the CCS dataset, an average coverage of 1.20 reads per base was achieved for the DRV seed contig.", [["DRV seed contig", "DNA", 84, 99], ["an average coverage", "TREATMENT", 20, 39], ["the DRV seed contig", "TREATMENT", 80, 99]]], ["Accordingly, another contig that had a coverage of more than 1.1 read/base was obtained from the DRV genome (Figure 2A) .", [["DRV genome", "DNA", 97, 107], ["a coverage", "TEST", 37, 47], ["DRV genome", "ANATOMY", 97, 107]]], ["All other contigs in the CCS dataset showed a lower coverage profile.COVERAGE PROFILE BINNINGIn the RFF metagenome however, contigs with a similar coverage frequency as the seed contig of RFFRV (coverage of 0.42) were identified as putative plant genes, with a closest homolog to a hypothetical protein of Medicago truncatula (BLASTX e-value 6e-60, coverage of 0.45) or as part of the Vulpes vulpes mitochondrium (e-value 0.0, coverage of 0.58) ( Figure 2B ) and as two parts of a novel picobirnavirus, RFF picobirnavirus, isolate 40-2 (Bodewes et al., 2014b ) (e-value 0.0, coverage of 0.299 and 0.99).COVERAGE PROFILE BINNINGIn the TPLT metagenome, the seed contig of PNV was covered by 0.5 reads per base.", [["RFFRV", "GENE_OR_GENE_PRODUCT", 188, 193], ["Medicago truncatula", "ORGANISM", 306, 325], ["Vulpes vulpes", "ORGANISM", 385, 398], ["mitochondrium", "ORGANISM", 399, 412], ["RFF picobirnavirus", "CELL", 503, 521], ["PNV", "GENE_OR_GENE_PRODUCT", 670, 673], ["RFF metagenome", "DNA", 100, 114], ["seed contig", "DNA", 173, 184], ["RFFRV", "DNA", 188, 193], ["putative plant genes", "DNA", 232, 252], ["TPLT metagenome", "DNA", 634, 649], ["seed contig", "DNA", 655, 666], ["PNV", "DNA", 670, 673], ["Medicago truncatula", "SPECIES", 306, 325], ["Vulpes vulpes", "SPECIES", 385, 398], ["Medicago truncatula", "SPECIES", 306, 325], ["Vulpes vulpes", "SPECIES", 385, 398], ["a lower coverage profile", "PROBLEM", 44, 68], ["the RFF metagenome", "TREATMENT", 96, 114], ["a similar coverage frequency", "TREATMENT", 137, 165], ["the seed contig of RFFRV (coverage", "TREATMENT", 169, 203], ["BLASTX e-value", "TEST", 327, 341], ["e-value", "TEST", 414, 421], ["coverage", "TEST", 427, 435], ["a novel picobirnavirus", "TREATMENT", 479, 501], ["e-value", "TEST", 562, 569], ["coverage", "TEST", 575, 583], ["the TPLT metagenome", "TREATMENT", 630, 649], ["the seed contig of PNV", "TREATMENT", 651, 673], ["lower coverage", "OBSERVATION", 46, 60]]], ["Four of five contigs with a coverage profile of more than 0.2 were matching the PNV genome ( Figure 2C) , with the exception of one contig identified as hypothetical protein of Clostridium thermocellum (BLASTX e-value 4e-29).", [["Clostridium thermocellum", "ORGANISM", 177, 201], ["PNV genome", "DNA", 80, 90], ["Clostridium thermocellum", "SPECIES", 177, 201], ["Clostridium thermocellum", "SPECIES", 177, 201], ["a coverage profile", "TEST", 26, 44], ["hypothetical protein of Clostridium thermocellum", "PROBLEM", 153, 201], ["BLASTX e-value 4e", "TEST", 203, 220]]], ["In conclusion, coverage profile binning identified additional contigs in two of the datasets.K-mer FREQUENCIESAnother possible method to detect contigs that lack homology to known viruses but are part of the viral target genome is to determine k-mer frequencies.", [["K", "CHEMICAL", 93, 94], ["viral target genome", "DNA", 208, 227], ["coverage profile binning", "TREATMENT", 15, 39], ["K", "TEST", 93, 94], ["method", "PROBLEM", 127, 133], ["lack homology to known viruses", "PROBLEM", 157, 187], ["the viral target genome", "PROBLEM", 204, 227], ["viruses", "OBSERVATION", 180, 187]]], ["The frequency of every oligomer at length k was determined for k = 3, 4, 5, 6, 7 and 8 and ranked according to their absolute difference with the sum of the k-mer frequencies of the seed contig (Figure 3) .", [["seed contig", "DNA", 182, 193], ["length k", "TEST", 35, 43], ["k", "TEST", 63, 64]]], ["Low ranking contigs have a similar k-mer frequency profile as the seed contig, whereas high ranking contigs differ in their k-mer frequency profile.", [["seed contig", "DNA", 66, 77], ["Low ranking contigs", "PROBLEM", 0, 19]]], ["For the CCS dataset, one 7.5 kb contig had a closely matching, high ranking k-mer frequency profile and was indeed originating from DRV ( Figure 3A) .", [["CCS dataset", "DNA", 8, 19], ["7.5 kb contig", "DNA", 25, 38]]], ["Similarly, the two largest contigs (>3.5 kb) of RFFRV had the highest rank when compared to the frequency profile of the seed contig ( Figure 3B) .", [["RFFRV", "DNA", 48, 53], ["seed contig", "DNA", 121, 132], ["RFFRV", "TEST", 48, 53], ["two", "OBSERVATION_MODIFIER", 15, 18], ["largest", "OBSERVATION_MODIFIER", 19, 26]]], ["Two smaller contigs ranked at 14 and 24, suggesting that k-mer frequency profile clustering works better with long sequences.", [["long sequences", "DNA", 110, 124], ["Two smaller contigs", "PROBLEM", 0, 19], ["k-mer frequency profile clustering", "PROBLEM", 57, 91], ["smaller", "OBSERVATION_MODIFIER", 4, 11]]], ["However, for PNV, the highest ranking, largest contig was obtained from the python host genome and contained among others a sequence for cytochrome C oxidase subunit (BLASTX e-value 0).", [["cytochrome C oxidase subunit", "GENE_OR_GENE_PRODUCT", 137, 165], ["PNV", "DNA", 13, 16], ["python host genome", "DNA", 76, 94], ["cytochrome C oxidase subunit", "PROTEIN", 137, 165], ["BLASTX e-value 0", "PROTEIN", 167, 183], ["PNV", "TREATMENT", 13, 16], ["cytochrome C oxidase subunit", "TREATMENT", 137, 165]]], ["Two large contigs matching the PNV genome ranked at 22 and 47, and two small contigs that were obtained from the PNV genome had an even higher rank ( Figure 3C) .", [["PNV genome", "DNA", 31, 41], ["PNV genome", "DNA", 113, 123], ["PNV", "SPECIES", 113, 116], ["Two large contigs", "PROBLEM", 0, 17], ["the PNV genome", "TEST", 27, 41], ["two small contigs", "PROBLEM", 67, 84], ["the PNV genome", "TEST", 109, 123], ["large", "OBSERVATION_MODIFIER", 4, 9], ["contigs matching", "OBSERVATION", 10, 26]]], ["While k-mer frequency ranking identified an additional part of DRV, and two large RFFRV contigs, all highranking contigs (rank 10 or less) of dataset 3 were unrelated to PNV.DISCUSSIONWe tested and compared different strategies to assist in identifying viral contigs and increasing the level of viral genome completeness from metagenomes.", [["PNV", "DISEASE", 170, 173], ["DRV", "CANCER", 63, 66], ["DRV", "DNA", 63, 66], ["RFFRV contigs", "DNA", 82, 95], ["highranking contigs", "DNA", 101, 120], ["PNV", "DNA", 170, 173], ["viral contigs", "DNA", 253, 266], ["viral genome", "DNA", 295, 307], ["DRV", "TREATMENT", 63, 66], ["two large RFFRV contigs", "TREATMENT", 72, 95], ["all highranking contigs", "TREATMENT", 97, 120], ["viral contigs", "PROBLEM", 253, 266], ["viral genome", "OBSERVATION", 295, 307]]], ["The retrospective nature of this study allowed us to compare the success of the strategies in retrieving three novel viral genomes from 454 metagenomic data.", [["viral genomes", "DNA", 117, 130], ["this study", "TEST", 28, 38], ["the strategies", "TREATMENT", 76, 90], ["metagenomic data", "TEST", 140, 156]]], ["While different metagenome assembly strategies, especially for very large datasets of short read data, apply k-mer clustering or digital normalization and partitioning prior to assembly (Howe et al., 2014; Reddy et al., 2014) , we here concentrated on strategies to link contigs after assembly in silico.", [["k-mer clustering", "PROBLEM", 109, 125]]], ["A growing number of metagenome studies apply other next-generation sequencing techniques (e.g., Illumina), but 454 sequencing is still widely applied in viral metagenome studies, sometimes in combination with Illumina or PacBio sequences, because of the large read length (up to 800 bases) (De Vries et al., 2012; Grard et al., 2012; Philippe et al., 2013) .", [["Illumina or PacBio sequences", "DNA", 209, 237], ["metagenome studies", "TEST", 20, 38], ["viral metagenome studies", "TEST", 153, 177], ["PacBio sequences", "TEST", 221, 237], ["growing", "OBSERVATION_MODIFIER", 2, 9], ["large", "OBSERVATION_MODIFIER", 254, 259], ["length", "OBSERVATION_MODIFIER", 265, 271]]], ["In all three datasets presented here, the viral load of the samples was exceptionally high.", [["samples", "ANATOMY", 60, 67], ["the viral load", "TEST", 38, 52], ["the samples", "TEST", 56, 67]]], ["Despite the high number of reads obtained from the target virus, direct assembly of the full genomes was not possible.", [["not possible", "UNCERTAINTY", 105, 117]]], ["They assume even coverage and recognize high-coverage regions as repeats rather than a highly abundant species, or as an unevenly covered region introduced by amplification bias.", [["a highly abundant species", "PROBLEM", 85, 110], ["abundant", "OBSERVATION_MODIFIER", 94, 102], ["species", "OBSERVATION", 103, 110]]], ["Virus discovery relies heavily on low input material methods; therefore an amplification strategy is often necessary.", [["low input material methods", "TREATMENT", 34, 60], ["an amplification strategy", "TREATMENT", 72, 97]]], ["Common random amplification methods, such as MDA or sequence-independent SISPA (Dean et al., 2002; Hutchison et al., 2005; Spits et al., 2006) are known to produce strong amplification biases leading to highly uneven coverage depths (Karlsson et al., 2013; Rosseel et al., 2013) .", [["MDA", "CHEMICAL", 45, 48], ["MDA", "CHEMICAL", 45, 48], ["MDA", "SIMPLE_CHEMICAL", 45, 48], ["strong amplification biases", "PROBLEM", 164, 191]]], ["Nevertheless the need for amplification makes these two methods still the most widely used in virus discovery (Allander et al., 2005; Djikeng et al., 2008; Hall et al., 2014) .", [["amplification", "TREATMENT", 26, 39], ["these two methods", "TREATMENT", 46, 63]]], ["Introduction of amplification bias leads to stretches in the viral genome that are better covered than others.", [["viral genome", "DNA", 61, 73], ["Introduction of amplification bias", "TREATMENT", 0, 34], ["viral genome", "OBSERVATION", 61, 73]]], ["Accordingly, coverage binning was a successful strategy to link additional contigs for DRV and PNV, but not for RFFRV.", [["RFFRV", "PROTEIN", 112, 117], ["RFFRV", "SPECIES", 112, 117], ["coverage binning", "TREATMENT", 13, 29], ["DRV", "TREATMENT", 87, 90], ["PNV", "TREATMENT", 95, 98], ["RFFRV", "TREATMENT", 112, 117]]], ["Nevertheless, coverage profile binning was successfully applied to assemble viral genomes across a number of human gut metagenomes without the need of a reference (Nielsen et al., 2014) or to verify a cross-assembly of a novel bacteriophage in similar samples (Dutilh et al., 2014) .", [["samples", "ANATOMY", 252, 259], ["human", "ORGANISM", 109, 114], ["gut", "ORGANISM_SUBDIVISION", 115, 118], ["viral genomes", "DNA", 76, 89], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 109, 114], ["coverage profile binning", "TREATMENT", 14, 38], ["a novel bacteriophage", "PROBLEM", 219, 240], ["viral genomes", "OBSERVATION", 76, 89]]], ["Due to availability of a large amount of (fecal) sample for metagenome studies, amplification can often be avoided, which makes the application of coverage profile binning more straight-forward.", [["fecal", "ORGANISM_SUBDIVISION", 42, 47], ["a large amount of (fecal) sample", "TREATMENT", 23, 55], ["metagenome studies", "TEST", 60, 78], ["coverage profile binning", "TREATMENT", 147, 171]]], ["An additional issue in the case of viral metagenomes is the presence of distinct quasispecies sequences which can hamper direct assembly, especially at low sequencing depths.", [["quasispecies sequences", "DNA", 81, 103], ["viral metagenomes", "PROBLEM", 35, 52], ["distinct quasispecies sequences", "PROBLEM", 72, 103], ["viral metagenomes", "OBSERVATION", 35, 52], ["distinct", "OBSERVATION_MODIFIER", 72, 80], ["quasispecies", "OBSERVATION", 81, 93]]], ["Using stringent assembly parameters that are necessary to avoid chimeras can lead to highly similar singletons or small contigs that are too diverse for assembly into a population sequence.", [["stringent assembly parameters", "TREATMENT", 6, 35], ["chimeras", "PROBLEM", 64, 72], ["highly similar singletons", "PROBLEM", 85, 110], ["small contigs", "PROBLEM", 114, 127], ["a population sequence", "TEST", 167, 188], ["small contigs", "OBSERVATION", 114, 127]]], ["However, this is currently not possible for divergent viruses which lack a reference genome.", [["reference genome", "DNA", 75, 91], ["divergent viruses", "PROBLEM", 44, 61], ["not possible", "UNCERTAINTY", 27, 39], ["viruses", "OBSERVATION", 54, 61]]], ["While many metagenome assemblers to date were designed to handle short-read data, only very few assemblers are dedicated to assembly of longer (i.e., 454) reads without any further information such as paired-end or mate-pair information.", [["paired-end", "DNA", 201, 211]]], ["For this study, we used different assemblers, including an overlaplayout consensus algorithm (Newbler), an assembler that uses a generative probabilistic model (Genovo; Laserson et al., 2011) , a de Bruijn graph algorithm (CLC Genomics Workbench), and an assembly strategy applying the combination of an OLC and a greedy algorithm (iterative assembly; Schurch et al., 2014) .", [["overlaplayout consensus algorithm", "DNA", 59, 92], ["this study", "TEST", 4, 14], ["an OLC", "TREATMENT", 301, 307], ["a greedy algorithm", "TREATMENT", 312, 330]]], ["None of these strategies lead to a full reconstruction of the genomes of the novel viruses, but produced fragmented contigs.", [["a full reconstruction", "TREATMENT", 33, 54], ["the novel viruses", "PROBLEM", 73, 90], ["fragmented contigs", "PROBLEM", 105, 123], ["viruses", "OBSERVATION", 83, 90], ["fragmented contigs", "OBSERVATION", 105, 123]]], ["Overlaps between the contigs were often not recognized because of misassembled contig ends (not indicated in Figures 1A-C) .", [["misassembled contig ends", "DNA", 66, 90], ["misassembled contig ends", "PROBLEM", 66, 90]]], ["These misassembled ends could represent chimeric contigs, i.e., assembled from reads from different species, but also chimeric reads due to chimera formation during PCR.", [["chimeric contigs", "DNA", 40, 56], ["chimeric contigs", "PROBLEM", 40, 56], ["different species", "PROBLEM", 90, 107], ["chimera formation during PCR", "PROBLEM", 140, 168], ["could represent", "UNCERTAINTY", 24, 39], ["chimeric contigs", "OBSERVATION", 40, 56]]], ["Taxonomic \"misclassification\" of reads in the analysis described here, however, was rather due to the large number of taxonomic units without a homolog in the sequence databases.", [["the analysis", "TEST", 42, 54], ["taxonomic units", "TREATMENT", 118, 133]]], ["Another challenge for recovery of viral genomes from metagenomes poses the segmented genomes of some viruses, with up to 12 segments for some viruses in the family Reoviridae, for example the Colorado tick fever virus (Attoui et al., 2000) .", [["tick fever", "DISEASE", 201, 211], ["Reoviridae", "GENE_OR_GENE_PRODUCT", 164, 174], ["Colorado", "ORGANISM", 192, 200], ["tick fever virus", "ORGANISM", 201, 217], ["viral genomes", "DNA", 34, 47], ["tick fever virus", "SPECIES", 201, 217], ["Colorado tick fever virus", "SPECIES", 192, 217], ["Another challenge", "TREATMENT", 0, 17], ["viral genomes", "PROBLEM", 34, 47], ["some viruses", "PROBLEM", 96, 108], ["some viruses", "PROBLEM", 137, 149], ["Reoviridae", "TREATMENT", 164, 174], ["the Colorado tick fever virus", "PROBLEM", 188, 217], ["viral genomes", "OBSERVATION", 34, 47], ["some", "OBSERVATION_MODIFIER", 96, 100], ["viruses", "OBSERVATION", 101, 108], ["viruses", "OBSERVATION", 142, 149]]], ["The strategies described in this study can aid in identification of missing segments or contigs.DISCUSSIONThe strategy with the highest specificity was de novo motif discovery in the seed contig, and subsequent motif search in all contigs of the assembled metagenome.", [["seed contig", "ANATOMY", 183, 194], ["seed contig", "DNA", 183, 194], ["this study", "TEST", 28, 38], ["missing segments or contigs", "PROBLEM", 68, 95]]], ["The (A/U)CU7 motif detected between open reading frames of RFFRV could serve as a transcription termination/polyadenylation sequence similar to other rhabdoviruses (Whelan et al., 2004) .DISCUSSIONAdjacent to this termination signal was a stretch of conserved nucleotides which might function as a transcription initiation signal.", [["nucleotides", "CHEMICAL", 260, 271], ["RFFRV", "GENE_OR_GENE_PRODUCT", 59, 64], ["CU7 motif", "DNA", 9, 18], ["open reading frames", "DNA", 36, 55], ["RFFRV", "DNA", 59, 64], ["transcription termination/polyadenylation sequence", "DNA", 82, 132], ["A/U)CU7 motif", "TEST", 5, 18], ["a transcription termination", "TREATMENT", 80, 107], ["polyadenylation sequence", "PROBLEM", 108, 132], ["a stretch of conserved nucleotides", "PROBLEM", 237, 271]]], ["For the other detected motifs in DRV and PNV no obvious functions can be envisaged.", [["DRV", "CANCER", 33, 36], ["DRV", "TREATMENT", 33, 36], ["PNV", "TREATMENT", 41, 44], ["obvious functions", "PROBLEM", 48, 65], ["DRV", "ANATOMY", 33, 36]]], ["However, their power to detect additional contigs matching the target genomes was only limited by the number of occurrences of the motif in the genome.DISCUSSIONK-mer profile ranking detected large viral contigs with a similar profile as the seed contig in the CCS dataset and the RFF metagenome.", [["genome", "CELLULAR_COMPONENT", 144, 150], ["target genomes", "DNA", 63, 77], ["viral contigs", "DNA", 198, 211], ["seed contig", "DNA", 242, 253], ["CCS dataset", "DNA", 261, 272], ["RFF metagenome", "DNA", 281, 295], ["additional contigs matching the target genomes", "PROBLEM", 31, 77], ["large viral contigs", "PROBLEM", 192, 211]]], ["In both cases, further manual curation or a laboratory follow-up would have been necessary to confirm the predictions made by this technique.DISCUSSIONAssembly, in combination with motif discovery enabled retrieval of the complete RFFRV genome, with good results in k-mer frequency clustering.", [["RFFRV", "GENE_OR_GENE_PRODUCT", 231, 236], ["RFFRV genome", "DNA", 231, 243], ["further manual curation", "TEST", 15, 38], ["this technique", "TEST", 126, 140], ["the complete RFFRV genome", "TREATMENT", 218, 243]]], ["Two additional contigs of the PNV genome were identified by motif search, but linking of the remaining PNV contigs was only possible with frequency methods.", [["PNV", "GENE_OR_GENE_PRODUCT", 30, 33], ["PNV", "GENE_OR_GENE_PRODUCT", 103, 106], ["PNV genome", "DNA", 30, 40], ["PNV contigs", "DNA", 103, 114], ["the PNV genome", "TREATMENT", 26, 40], ["motif search", "TEST", 60, 72], ["the remaining PNV contigs", "PROBLEM", 89, 114]]], ["Surprisingly, all methods applied here showed good results in retrieval of the full genome of DRV from the CCS dataset.", [["DRV", "CANCER", 94, 97], ["DRV", "DNA", 94, 97], ["all methods", "TEST", 14, 25]]], ["This is most likely due to the high viral load which allowed assembly of the whole genome into two very long contigs in the first place.", [["whole genome", "DNA", 77, 89], ["the high viral load", "PROBLEM", 27, 46], ["most likely due to", "UNCERTAINTY", 8, 26], ["viral load", "OBSERVATION", 36, 46]]], ["Therefore, we feel that the development of more efficient and dedicated metagenome assemblers, taking into account the specific characteristics of viral genomes, will lead to improved retrieval of viral pathogen genomes from metagenome sequences.DISCUSSIONIn conclusion, iterative exhaustive assembly, although highly stringent and thus excluding a large amount of data, is actually performing rather well compared to other assembly algorithms in that it covered the target genomes more completely than any other set of contigs obtained with other assembly algorithms.", [["viral genomes", "DNA", 147, 160], ["viral pathogen genomes", "DNA", 197, 219], ["metagenome sequences", "DNA", 225, 245], ["target genomes", "DNA", 467, 481], ["viral genomes", "PROBLEM", 147, 160], ["viral pathogen genomes", "PROBLEM", 197, 219], ["metagenome sequences", "TEST", 225, 245], ["viral genomes", "OBSERVATION", 147, 160], ["viral pathogen genomes", "OBSERVATION", 197, 219], ["large", "OBSERVATION_MODIFIER", 349, 354], ["amount", "OBSERVATION_MODIFIER", 355, 361]]], ["Nevertheless, the number of identified target virus reads and the level of viral genome completeness can be increased by combining data generated with different assembly algorithms.", [["viral genome", "DNA", 75, 87], ["target virus reads", "PROBLEM", 39, 57], ["viral genome completeness", "PROBLEM", 75, 100], ["virus reads", "OBSERVATION", 46, 57], ["viral genome", "OBSERVATION", 75, 87]]], ["In addition, various methods can be applied to obtain additional genome fragments although a success rate cannot be predicted beforehand based on our analyses and probably depend largely on the dataset under study.", [["genome fragments", "DNA", 65, 81], ["various methods", "TREATMENT", 13, 28], ["additional genome fragments", "PROBLEM", 54, 81], ["our analyses", "TEST", 146, 158], ["the dataset under study", "TEST", 190, 213]]], ["These results indicate that a combination of these methods can be of great value to rapidly obtain additional genome information of a previously unknown virus.", [["a previously unknown virus", "PROBLEM", 132, 158]]]], "PMC7295607": [["This special issue includes pearls from recognized specialists in sports cardiology aimed to improve the skills of the reader with up-to-date, state-of-the-art reviews on the cardiovascular management of athlete in some of these specific scenarios.", [["cardiovascular", "ANATOMY", 175, 189], ["cardiovascular", "ANATOMICAL_SYSTEM", 175, 189], ["the cardiovascular management", "TREATMENT", 171, 200]]]], "PMC7158942": [["IntroductionQuarantine is the separation and restriction of movement of people who have potentially been exposed to a contagious disease to ascertain if they become unwell, so reducing the risk of them infecting others.1 This definition differs from isolation, which is the separation of people who have been diagnosed with a contagious disease from people who are not sick; however, the two terms are often used interchangeably, especially in communication with the public.2 The word quarantine was first used in Venice, Italy in 1127 with regards to leprosy and was widely used in response to the Black Death, although it was not until 300 years later that the UK properly began to impose quarantine in response to plague.3 Most recently, quarantine has been used in the coronavirus disease 2019 (COVID-19) outbreak.", [["IntroductionQuarantine", "CHEMICAL", 0, 22], ["leprosy", "DISEASE", 552, 559], ["Death", "DISEASE", 605, 610], ["plague", "DISEASE", 717, 723], ["coronavirus disease", "DISEASE", 773, 792], ["people", "ORGANISM", 72, 78], ["people", "ORGANISM", 288, 294], ["people", "ORGANISM", 350, 356], ["coronavirus", "ORGANISM", 773, 784], ["people", "SPECIES", 72, 78], ["people", "SPECIES", 288, 294], ["people", "SPECIES", 350, 356], ["coronavirus disease 2019 (COVID-19", "SPECIES", 773, 807], ["IntroductionQuarantine", "TREATMENT", 0, 22], ["the separation", "TREATMENT", 26, 40], ["a contagious disease", "PROBLEM", 116, 136], ["unwell", "PROBLEM", 165, 171], ["a contagious disease", "PROBLEM", 324, 344], ["leprosy", "PROBLEM", 552, 559], ["the Black Death", "PROBLEM", 595, 610], ["quarantine", "TREATMENT", 741, 751], ["the coronavirus disease", "PROBLEM", 769, 792], ["contagious", "OBSERVATION_MODIFIER", 326, 336], ["leprosy", "OBSERVATION", 552, 559], ["coronavirus", "ANATOMY", 773, 784]]], ["This outbreak has seen entire cities in China effectively placed under mass quarantine, while many thousands of foreign nationals returning home from China have been asked to self-isolate at home or in state-run facilities.4 There are precedents for such measures.", [["such measures", "TREATMENT", 250, 263], ["entire", "OBSERVATION_MODIFIER", 23, 29], ["cities", "OBSERVATION_MODIFIER", 30, 36], ["mass", "OBSERVATION", 71, 75]]], ["Citywide quarantines were also imposed in areas of China and Canada during the 2003 outbreak of severe acute respiratory syndrome (SARS), whereas entire villages in many west African countries were quarantined during the 2014 Ebola outbreak.Introduction", [["acute respiratory syndrome", "DISEASE", 103, 129], ["SARS", "DISEASE", 131, 135], ["Ebola", "DISEASE", 226, 231], ["Citywide quarantines", "TREATMENT", 0, 20], ["severe acute respiratory syndrome", "PROBLEM", 96, 129], ["SARS", "PROBLEM", 131, 135], ["severe", "OBSERVATION_MODIFIER", 96, 102], ["acute", "OBSERVATION_MODIFIER", 103, 108], ["respiratory syndrome", "OBSERVATION", 109, 129]]]], "e774a3c1f13059c7d0f17756af7b6f9feb5170fb": [["Endogenous monoamine oxidase (MAO) inhibitory component was first discovered in normal human urine by Glover et al. (1980) and the compound responsible for the MAO activity was subsequently given the name ''tribulin'' (Sandler, 1982) .", [["urine", "ANATOMY", 93, 98], ["MAO", "CHEMICAL", 160, 163], ["monoamine", "CHEMICAL", 11, 20], ["monoamine oxidase", "GENE_OR_GENE_PRODUCT", 11, 28], ["MAO", "GENE_OR_GENE_PRODUCT", 30, 33], ["human", "ORGANISM", 87, 92], ["urine", "ORGANISM_SUBSTANCE", 93, 98], ["MAO", "GENE_OR_GENE_PRODUCT", 160, 163], ["monoamine oxidase", "PROTEIN", 11, 28], ["MAO", "PROTEIN", 30, 33], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 87, 92], ["Endogenous monoamine oxidase (MAO) inhibitory component", "TREATMENT", 0, 55], ["monoamine oxidase", "OBSERVATION", 11, 28]]], ["In 1988, isatin was identified as a major constituent of tribulin (Glover et al., 1988) .", [["isatin", "CHEMICAL", 9, 15], ["tribulin", "CHEMICAL", 57, 65], ["isatin", "CHEMICAL", 9, 15], ["tribulin", "CHEMICAL", 57, 65], ["isatin", "SIMPLE_CHEMICAL", 9, 15], ["tribulin", "SIMPLE_CHEMICAL", 57, 65]]], ["We also identified isatin as one of the extracts in the urine of stroke-prone spontaneously hypertensive rats (SHRSP) (Hamaue et al., 1992) and in SHRSP brains (Hamaue et al., 1994) using gaschromatography-mass spectrometry (GC-MS).", [["extracts", "ANATOMY", 40, 48], ["urine", "ANATOMY", 56, 61], ["brains", "ANATOMY", 153, 159], ["isatin", "CHEMICAL", 19, 25], ["stroke", "DISEASE", 65, 71], ["hypertensive", "DISEASE", 92, 104], ["isatin", "CHEMICAL", 19, 25], ["isatin", "SIMPLE_CHEMICAL", 19, 25], ["extracts", "ORGANISM_SUBSTANCE", 40, 48], ["urine", "ORGANISM_SUBSTANCE", 56, 61], ["rats", "ORGANISM", 105, 109], ["SHRSP", "MULTI-TISSUE_STRUCTURE", 111, 116], ["SHRSP brains", "ORGANISM", 147, 159], ["rats", "SPECIES", 105, 109], ["SHRSP", "SPECIES", 111, 116], ["SHRSP", "SPECIES", 147, 152], ["isatin", "TREATMENT", 19, 25], ["the urine", "TEST", 52, 61], ["stroke", "PROBLEM", 65, 71], ["prone spontaneously hypertensive rats", "PROBLEM", 72, 109], ["gaschromatography", "TEST", 188, 205], ["mass spectrometry", "TEST", 206, 223], ["stroke", "OBSERVATION", 65, 71]]], ["Tribulin may be responsible for the metabolites of isatin-related compounds (McIntyre and Norman, 1990) .", [["Tribulin", "CHEMICAL", 0, 8], ["isatin", "CHEMICAL", 51, 57], ["Tribulin", "CHEMICAL", 0, 8], ["isatin", "CHEMICAL", 51, 57], ["Tribulin", "SIMPLE_CHEMICAL", 0, 8], ["isatin", "SIMPLE_CHEMICAL", 51, 57], ["Tribulin", "TREATMENT", 0, 8], ["the metabolites of isatin", "PROBLEM", 32, 57], ["may be responsible for", "UNCERTAINTY", 9, 31]]], ["MAO inhibitory drugs such as selegiline have been widely used in clinical practice, originally for depressive illness, anxiety and for Parkinson's disease.", [["MAO", "CHEMICAL", 0, 3], ["selegiline", "CHEMICAL", 29, 39], ["depressive illness", "DISEASE", 99, 117], ["anxiety", "DISEASE", 119, 126], ["Parkinson's disease", "DISEASE", 135, 154], ["selegiline", "CHEMICAL", 29, 39], ["MAO", "GENE_OR_GENE_PRODUCT", 0, 3], ["selegiline", "SIMPLE_CHEMICAL", 29, 39], ["MAO inhibitory drugs", "TREATMENT", 0, 20], ["selegiline", "TREATMENT", 29, 39], ["depressive illness", "PROBLEM", 99, 117], ["anxiety", "PROBLEM", 119, 126], ["Parkinson's disease", "PROBLEM", 135, 154]]], ["There is, however, virtually no information regarding the detailed central nervous system (CNS) function of isatin.", [["central nervous system", "ANATOMY", 67, 89], ["CNS", "ANATOMY", 91, 94], ["isatin", "CHEMICAL", 108, 114], ["isatin", "CHEMICAL", 108, 114], ["central nervous system", "ANATOMICAL_SYSTEM", 67, 89], ["CNS", "ANATOMICAL_SYSTEM", 91, 94], ["isatin", "SIMPLE_CHEMICAL", 108, 114], ["central", "ANATOMY_MODIFIER", 67, 74], ["nervous system", "ANATOMY", 75, 89]]], ["Some experiments suggested that isatin can serve as a marker of stress and anxiety Tozawa et al., 1998) .", [["isatin", "CHEMICAL", 32, 38], ["anxiety", "DISEASE", 75, 82], ["isatin", "CHEMICAL", 32, 38], ["isatin", "SIMPLE_CHEMICAL", 32, 38], ["anxiety", "PROBLEM", 75, 82]]], ["We previously reported that exogenously administered isatin increased dopamine (DA) levels in the rat striatum (Hamaue et al., 1999a) and recently demonstrated that a significant increase in urinary isatin excretion was present in patients with Parkinson's disease (Yahr' s classifications III, IV, V) (Hamaue et al., 2000) .", [["striatum", "ANATOMY", 102, 110], ["urinary", "ANATOMY", 191, 198], ["isatin", "CHEMICAL", 53, 59], ["dopamine", "CHEMICAL", 70, 78], ["DA", "CHEMICAL", 80, 82], ["isatin", "CHEMICAL", 199, 205], ["Parkinson's disease", "DISEASE", 245, 264], ["isatin", "CHEMICAL", 53, 59], ["dopamine", "CHEMICAL", 70, 78], ["isatin", "CHEMICAL", 199, 205], ["isatin", "SIMPLE_CHEMICAL", 53, 59], ["dopamine", "SIMPLE_CHEMICAL", 70, 78], ["DA", "SIMPLE_CHEMICAL", 80, 82], ["rat", "ORGANISM", 98, 101], ["striatum", "MULTI-TISSUE_STRUCTURE", 102, 110], ["urinary", "ORGANISM_SUBSTANCE", 191, 198], ["isatin", "SIMPLE_CHEMICAL", 199, 205], ["patients", "ORGANISM", 231, 239], ["rat", "SPECIES", 98, 101], ["patients", "SPECIES", 231, 239], ["isatin increased dopamine", "TREATMENT", 53, 78], ["a significant increase in urinary isatin excretion", "PROBLEM", 165, 215], ["Parkinson's disease", "PROBLEM", 245, 264], ["significant", "OBSERVATION_MODIFIER", 167, 178], ["increase", "OBSERVATION_MODIFIER", 179, 187], ["urinary", "ANATOMY", 191, 198], ["isatin excretion", "OBSERVATION", 199, 215]]], ["These results suggest that isatin may be associated with the pathogenic process in Parkinson's disease.", [["isatin", "CHEMICAL", 27, 33], ["Parkinson's disease", "DISEASE", 83, 102], ["isatin", "CHEMICAL", 27, 33], ["isatin", "SIMPLE_CHEMICAL", 27, 33], ["Parkinson's disease", "CANCER", 83, 102], ["isatin", "PROBLEM", 27, 33], ["the pathogenic process", "PROBLEM", 57, 79], ["Parkinson's disease", "PROBLEM", 83, 102], ["may be associated with", "UNCERTAINTY", 34, 56], ["pathogenic", "OBSERVATION_MODIFIER", 61, 71], ["Parkinson's disease", "OBSERVATION", 83, 102]]], ["In this study, we analyzed neurochemical and pathological changes in our rat model of Parkinson's disease induced by the Japanese encephalitis virus (JEV).", [["Parkinson's disease", "DISEASE", 86, 105], ["Japanese encephalitis", "DISEASE", 121, 142], ["JEV", "DISEASE", 150, 153], ["rat", "ORGANISM", 73, 76], ["Japanese encephalitis virus", "ORGANISM", 121, 148], ["JEV", "ORGANISM", 150, 153], ["rat", "SPECIES", 73, 76], ["Japanese encephalitis virus", "SPECIES", 121, 148], ["Japanese encephalitis virus", "SPECIES", 121, 148], ["JEV", "SPECIES", 150, 153], ["this study", "TEST", 3, 13], ["pathological changes", "PROBLEM", 45, 65], ["Parkinson's disease", "PROBLEM", 86, 105], ["the Japanese encephalitis virus", "PROBLEM", 117, 148]]], ["By analyzing the DA levels together with movement problems, we evaluated the potential treatment of JEV-induced parkinsonism by endogenous MAO inhibitor isatin and synthesized MAO-B inhibitor selegiline.", [["DA", "CHEMICAL", 17, 19], ["JEV", "DISEASE", 100, 103], ["parkinsonism", "DISEASE", 112, 124], ["isatin", "CHEMICAL", 153, 159], ["MAO-B", "CHEMICAL", 176, 181], ["selegiline", "CHEMICAL", 192, 202], ["isatin", "CHEMICAL", 153, 159], ["selegiline", "CHEMICAL", 192, 202], ["DA", "SIMPLE_CHEMICAL", 17, 19], ["JEV", "ORGANISM", 100, 103], ["MAO", "GENE_OR_GENE_PRODUCT", 139, 142], ["isatin", "SIMPLE_CHEMICAL", 153, 159], ["MAO-B", "GENE_OR_GENE_PRODUCT", 176, 181], ["selegiline", "SIMPLE_CHEMICAL", 192, 202], ["JEV", "SPECIES", 100, 103], ["movement problems", "PROBLEM", 41, 58], ["JEV", "PROBLEM", 100, 103], ["parkinsonism", "PROBLEM", 112, 124], ["endogenous MAO inhibitor isatin", "TREATMENT", 128, 159], ["synthesized MAO", "TREATMENT", 164, 179], ["B inhibitor selegiline", "TREATMENT", 180, 202]]], ["Furthermore, we analyzed and evaluated the MAO-inhibitor effects on neurochemical and pathological changes in our rat model of Parkinson's disease induced by JEV. with the serotonergic system (Oxenkrug and McIntyre, 1985) .", [["Parkinson's disease", "DISEASE", 127, 146], ["JEV", "DISEASE", 158, 161], ["MAO", "GENE_OR_GENE_PRODUCT", 43, 46], ["rat", "ORGANISM", 114, 117], ["JEV", "ORGANISM", 158, 161], ["rat", "SPECIES", 114, 117], ["JEV", "SPECIES", 158, 161], ["the MAO-inhibitor effects", "TREATMENT", 39, 64], ["neurochemical and pathological changes", "PROBLEM", 68, 106], ["Parkinson's disease", "PROBLEM", 127, 146], ["Parkinson", "OBSERVATION", 127, 136]]], ["Cold-restraint stress increases the tribulin content in the rat heart and kidney (Armando et al., 1988) .", [["heart", "ANATOMY", 64, 69], ["kidney", "ANATOMY", 74, 80], ["tribulin", "CHEMICAL", 36, 44], ["tribulin", "CHEMICAL", 36, 44], ["tribulin", "SIMPLE_CHEMICAL", 36, 44], ["rat", "ORGANISM", 60, 63], ["heart", "ORGAN", 64, 69], ["kidney", "ORGAN", 74, 80], ["rat", "SPECIES", 60, 63], ["rat", "SPECIES", 60, 63], ["Cold-restraint stress", "TREATMENT", 0, 21], ["rat", "ANATOMY_MODIFIER", 60, 63], ["heart", "ANATOMY", 64, 69], ["kidney", "ANATOMY", 74, 80]]]], "PMC7440000": [["Author contributionsIL: idea, data collection, assembly and interpretation, statistical analysis, manuscript writing; EU: statistical expertise, advice and analysis, manuscript writing; EB: idea, manuscript correction and approval; MMS: idea, analysis and interpretation of data, manuscript writing, correction and approval.Author contributionsIL and MMS take the responsibility for the paper as a whole.Conflicts of interestThe authors declare no conflicts of interest.", [["IL", "GENE_OR_GENE_PRODUCT", 20, 22]]]], "24f9da4c3c24195bc4946bd4524032829f5fc8ca": [["IntroductionThe world is in the midst of a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).", [["acute respiratory syndrome coronavirus", "DISEASE", 69, 107], ["SARS-CoV-2", "ORGANISM", 111, 121], ["severe acute respiratory syndrome coronavirus", "SPECIES", 62, 107], ["SARS-CoV-2", "SPECIES", 111, 121], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 62, 107], ["CoV", "TEST", 116, 119], ["severe", "OBSERVATION_MODIFIER", 62, 68], ["acute", "OBSERVATION_MODIFIER", 69, 74], ["respiratory syndrome", "OBSERVATION", 75, 95]]], ["More than 15 million individuals from 200 countries have been infected with this virus, which resulted in over 600,000 deaths (https ://www.world omete rs.info/coron aviru s).", [["deaths", "DISEASE", 119, 125], ["individuals", "ORGANISM", 21, 32], ["this virus", "PROBLEM", 76, 86]]], ["One of the ways to reduce disease propagation is early diagnosis and isolating people infected with the virus.", [["people", "ORGANISM", 79, 85], ["people", "SPECIES", 79, 85], ["disease propagation", "PROBLEM", 26, 45], ["the virus", "PROBLEM", 100, 109], ["disease", "OBSERVATION", 26, 33]]], ["For this, mass testing is the need of the hour.", [["this, mass testing", "TEST", 4, 22], ["mass", "OBSERVATION", 10, 14]]], ["At such a scale, it is critical to innovatively leverage existing infrastructure to build surge capacity and investigate low cost, high throughput methods.IntroductionAmong the various methods available or developed recently, for diagnosis of SARS-CoV-2, RT-PCR is still the gold standard.", [["SARS", "DISEASE", 243, 247], ["SARS-CoV", "SPECIES", 243, 251], ["low cost", "PROBLEM", 121, 129], ["SARS", "PROBLEM", 243, 247], ["CoV", "TEST", 248, 251], ["RT-PCR", "TEST", 255, 261], ["low cost", "OBSERVATION_MODIFIER", 121, 129]]], ["Despite RT-PCR being well established and widely available, many problems have emerged in actual performance, ranging from sub-optimal sensitivity, especially as the virus mutates, to low throughput due to many intermediate steps and long reaction times (Tahamtan and Ardebili 2020) .", [["RT-PCR", "TEST", 8, 14], ["the virus mutates", "PROBLEM", 162, 179], ["long reaction", "PROBLEM", 234, 247]]], ["Additionally, specialized reagents are necessary for RT-PCR, which increases the cost of the test.", [["RT-PCR", "TEST", 53, 59], ["the test", "TEST", 89, 97]]], ["Apart from this, rapid antigen tests are also being extensively used in various countries for preliminary screening.", [["rapid antigen tests", "TEST", 17, 36], ["preliminary screening", "TEST", 94, 115]]], ["These tests are based on the detection of antigens from the nasopharyngeal swab using antibodies.", [["nasopharyngeal swab", "ANATOMY", 60, 79], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 60, 79], ["antigens", "PROTEIN", 42, 50], ["antibodies", "PROTEIN", 86, 96], ["These tests", "TEST", 0, 11], ["antigens", "PROBLEM", 42, 50], ["the nasopharyngeal swab", "TEST", 56, 79], ["nasopharyngeal swab", "ANATOMY", 60, 79]]], ["A positive test confirms the presence of the virus, but a negative test is inconclusive since the sensitivity of the antigen test is between 34 and 80% (Bruning et al. 2017 ).", [["A positive test", "TEST", 0, 15], ["the virus", "PROBLEM", 41, 50], ["the antigen test", "TEST", 113, 129], ["virus", "OBSERVATION", 45, 50]]], ["Thus, a highly sensitive method is required to directly detect the virus from the nasopharyngeal swab to facilitate rapid screening.", [["nasopharyngeal swab", "ANATOMY", 82, 101], ["nasopharyngeal swab", "ORGAN", 82, 101], ["a highly sensitive method", "PROBLEM", 6, 31], ["the virus", "PROBLEM", 63, 72], ["the nasopharyngeal swab", "TEST", 78, 101], ["rapid screening", "TEST", 116, 131], ["nasopharyngeal", "ANATOMY", 82, 96]]], ["Mass spectrometer with high accuracy and sensitivity can be an ideal platform to identify viral peptides with medium to high throughput.IntroductionMass spectrometry (MS) based viral peptide detection has earlier been used for detection of viral proteins (Majchrzykiewicz-Koehorst et al. 2015; Foster et al. 2015; Santana et al. 2014) .", [["viral proteins", "PROTEIN", 240, 254], ["Mass spectrometer", "PROBLEM", 0, 17], ["viral peptides", "PROBLEM", 90, 104], ["IntroductionMass spectrometry", "TEST", 136, 165], ["based viral peptide detection", "TEST", 171, 200], ["viral proteins", "PROBLEM", 240, 254]]], ["Identification of SARS-CoV-2 specific peptides have also been reported recently (Gouveia et al. 2020; IIhling et al. 2020) . infected cell lysate to identify peptides and validated these peptides in nasopharyngeal swab (Gouveia et al. 2020) .", [["cell lysate", "ANATOMY", 134, 145], ["nasopharyngeal swab", "ANATOMY", 199, 218], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 18, 28], ["cell lysate", "CELL", 134, 145], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 199, 218], ["SARS-CoV", "SPECIES", 18, 26], ["SARS", "PROBLEM", 18, 22], ["CoV", "TEST", 23, 26], ["infected cell lysate", "TREATMENT", 125, 145], ["these peptides", "TEST", 181, 195], ["nasopharyngeal swab", "TEST", 199, 218], ["SARS", "OBSERVATION", 18, 22], ["cell lysate", "OBSERVATION", 134, 145], ["nasopharyngeal swab", "ANATOMY", 199, 218]]], ["They also shortlisted several peptides for targeted mass spectrometric studies (Gouveia et al. 2020) .", [["targeted mass spectrometric studies", "PROBLEM", 43, 78]]], ["Ihling et al. used a gargle solution of 3 infected patients and report the identification of 1 peptide from nucleoprotein using a 180 min gradient (IIhling et al. 2020) .IntroductionIn this study, we report a simple and rapid method that could detect two peptides, QIAPGQTGK and AIVS-TIQRKYK, from structural spike glycoprotein and replicase polyprotein 1ab respectively in 2.3 min gradient with a sensitivity of 90% and specificity of 100%.", [["patients", "ORGANISM", 51, 59], ["AIVS-TIQRKYK", "GENE_OR_GENE_PRODUCT", 279, 291], ["TIQRKYK", "PROTEIN", 284, 291], ["structural spike glycoprotein", "PROTEIN", 298, 327], ["patients", "SPECIES", 51, 59], ["a gargle solution", "TREATMENT", 19, 36], ["a 180 min gradient", "TREATMENT", 128, 146], ["this study", "TEST", 185, 195], ["a simple and rapid method", "PROBLEM", 207, 232], ["QIAPGQTGK", "TEST", 265, 274], ["AIVS", "TEST", 279, 283], ["TIQRKYK", "TEST", 284, 291], ["structural spike glycoprotein", "PROBLEM", 298, 327], ["replicase polyprotein", "TREATMENT", 332, 353], ["a sensitivity", "TEST", 396, 409], ["specificity", "TEST", 421, 432]]], ["Using follow up samples of patients who have symptomatically recovered and also tested negative for RT-PCR analyses, we show that these peptides are present in these samples indicating the potential of asymptomatic diagnosis of COVID-19 in patients.Clinical sample collectionUpper respiratory tract sample (nasopharyngeal swab and oropharyngeal swab) were collected in virus transport medium and samples were analyzed using COBAS 6800 automated system (Roche, Basel)according to the manufacturers guidelines (Corman et al. 2020) .", [["samples", "ANATOMY", 16, 23], ["samples", "ANATOMY", 166, 173], ["respiratory tract sample", "ANATOMY", 281, 305], ["nasopharyngeal swab", "ANATOMY", 307, 326], ["oropharyngeal swab", "ANATOMY", 331, 349], ["samples", "ANATOMY", 396, 403], ["patients", "ORGANISM", 27, 35], ["samples", "CANCER", 166, 173], ["patients", "ORGANISM", 240, 248], ["respiratory tract", "ORGANISM_SUBDIVISION", 281, 298], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 307, 326], ["oropharyngeal swab", "ORGAN", 331, 349], ["patients", "SPECIES", 27, 35], ["patients", "SPECIES", 240, 248], ["follow up samples", "TEST", 6, 23], ["RT-PCR analyses", "TEST", 100, 115], ["these peptides", "PROBLEM", 130, 144], ["COVID", "TEST", 228, 233], ["Clinical sample collectionUpper respiratory tract sample", "PROBLEM", 249, 305], ["nasopharyngeal swab", "TEST", 307, 326], ["oropharyngeal swab", "TEST", 331, 349], ["COBAS", "TEST", 424, 429], ["respiratory tract", "ANATOMY", 281, 298], ["oropharyngeal", "ANATOMY", 331, 344]]], ["This study was approved by institutional ethics committees of National Centre for Disease Control, New Delhi and CSIR-Institute of Genomics and Integrative Biology, Delhi.Sample preparationNaso and oropharyngeal swab collected in viral transport media (VTM) were inactivated by incubation of samples with lysis buffer (25% guanidinium thiocyanate and 5% SDS) for 20 min at room temperature (Pastorino et al. 2020) .", [["oropharyngeal swab", "ANATOMY", 198, 216], ["samples", "ANATOMY", 292, 299], ["Naso", "CHEMICAL", 189, 193], ["guanidinium thiocyanate", "CHEMICAL", 323, 346], ["guanidinium thiocyanate", "CHEMICAL", 323, 346], ["Naso", "SIMPLE_CHEMICAL", 189, 193], ["oropharyngeal swab", "ORGANISM_SUBSTANCE", 198, 216], ["guanidinium thiocyanate", "SIMPLE_CHEMICAL", 323, 346], ["This study", "TEST", 0, 10], ["Disease Control", "TREATMENT", 82, 97], ["Sample preparation", "TEST", 171, 189], ["Naso", "TEST", 189, 193], ["oropharyngeal swab", "TEST", 198, 216], ["viral transport media", "TREATMENT", 230, 251], ["lysis buffer", "TREATMENT", 305, 317], ["25% guanidinium thiocyanate", "TREATMENT", 319, 346], ["5% SDS", "TREATMENT", 351, 357], ["oropharyngeal", "ANATOMY", 198, 211]]], ["To this, 100 \u00b5l sodium deoxycholate (0.15% w/v) per ml of sample was added and was incubated for 10 min at room temperature followed by addition of 20% (w/v) trichloroacetic acid (TCA) for protein precipitation.", [["sample", "ANATOMY", 58, 64], ["sodium deoxycholate", "CHEMICAL", 16, 35], ["trichloroacetic acid", "CHEMICAL", 158, 178], ["TCA", "CHEMICAL", 180, 183], ["sodium deoxycholate", "CHEMICAL", 16, 35], ["trichloroacetic acid", "CHEMICAL", 158, 178], ["TCA", "CHEMICAL", 180, 183], ["\u00b5l sodium deoxycholate", "SIMPLE_CHEMICAL", 13, 35], ["/v) trichloroacetic acid", "SIMPLE_CHEMICAL", 154, 178], ["TCA", "SIMPLE_CHEMICAL", 180, 183], ["100 \u00b5l sodium deoxycholate", "TREATMENT", 9, 35], ["trichloroacetic acid (TCA", "TREATMENT", 158, 183], ["protein precipitation", "PROBLEM", 189, 210]]], ["The samples were then centrifuged at 15,000 g for 15 min at 4 \u00b0C. Pellets were washed three times with pre-chilled acetone and protein pellets were resuspended in 100 mM Tris-HCl with 8 M urea (pH-8.5).Identification of SARS-CoV-2 proteins using high-resolution mass spectrometryProteins extracted from the nasopharyngeal swab of eight RT-PCR confirmed COVID-19 patients were pooled and 300 \u00b5g of protein was reduced with 25 mM dithiothreitol for 25 min at 56 \u00b0C, followed by alkylation using 55 mM iodoacetamide (IAA) at room temperature for 20 min in dark.", [["samples", "ANATOMY", 4, 11], ["Pellets", "ANATOMY", 66, 73], ["nasopharyngeal swab", "ANATOMY", 307, 326], ["acetone", "CHEMICAL", 115, 122], ["Tris-HCl", "CHEMICAL", 170, 178], ["urea", "CHEMICAL", 188, 192], ["dithiothreitol", "CHEMICAL", 428, 442], ["iodoacetamide", "CHEMICAL", 499, 512], ["IAA", "CHEMICAL", 514, 517], ["acetone", "CHEMICAL", 115, 122], ["Tris-HCl", "CHEMICAL", 170, 178], ["urea", "CHEMICAL", 188, 192], ["dithiothreitol", "CHEMICAL", 428, 442], ["iodoacetamide", "CHEMICAL", 499, 512], ["IAA", "CHEMICAL", 514, 517], ["acetone", "SIMPLE_CHEMICAL", 115, 122], ["Tris-HCl", "SIMPLE_CHEMICAL", 170, 178], ["urea", "SIMPLE_CHEMICAL", 188, 192], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 220, 230], ["nasopharyngeal swab", "MULTI-TISSUE_STRUCTURE", 307, 326], ["patients", "ORGANISM", 362, 370], ["dithiothreitol", "SIMPLE_CHEMICAL", 428, 442], ["iodoacetamide", "SIMPLE_CHEMICAL", 499, 512], ["IAA", "SIMPLE_CHEMICAL", 514, 517], ["SARS-CoV-2 proteins", "PROTEIN", 220, 239], ["patients", "SPECIES", 362, 370], ["SARS-CoV", "SPECIES", 220, 228], ["Pellets", "TREATMENT", 66, 73], ["pre-chilled acetone and protein pellets", "TREATMENT", 103, 142], ["pH", "TEST", 194, 196], ["SARS", "PROBLEM", 220, 224], ["CoV", "TEST", 225, 228], ["high-resolution mass spectrometry", "PROBLEM", 246, 279], ["Proteins", "TEST", 279, 287], ["the nasopharyngeal swab", "TEST", 303, 326], ["PCR", "TEST", 339, 342], ["COVID", "TEST", 353, 358], ["protein", "TEST", 397, 404], ["25 mM dithiothreitol", "TREATMENT", 422, 442], ["alkylation", "TREATMENT", 476, 486], ["55 mM iodoacetamide", "TREATMENT", 493, 512], ["SARS", "OBSERVATION", 220, 224], ["nasopharyngeal", "ANATOMY", 307, 321]]], ["This sample was subjected to trypsin digestion (sequencing grade, Promega) using an enzyme-substrate ratio of 1:10 for 18 h at 37 \u00b0C and dried under vacuum.", [["sample", "ANATOMY", 5, 11], ["trypsin", "PROTEIN", 29, 36], ["This sample", "TEST", 0, 11], ["trypsin digestion", "PROBLEM", 29, 46], ["an enzyme-substrate ratio", "TEST", 81, 106], ["vacuum", "OBSERVATION", 149, 155]]], ["The digested peptides were then fractionated into 8 fractions using cation exchange chromatography using a SCX Cartridge (5 micron, 300 \u00c5 bead from AB Sciex, USA).A step-gradient of increasing concentration of ammonium formate buffer (35 mM, 50 mM, 75 mM, 100 mM, 125 mM, 150 mM, 250 mM and 350 mM ammonium formate, 30% v/v acetonitrile and 0.1% formic acid; pH = 2.9) was used to elute the peptides.LC-MS/MS data acquisitionThe fractionated peptides were analyzed on a quadrupole-TOF hybrid mass spectrometer (TripleTOF 6600, Sciex, USA) coupled to a nano-LC system (Eksigent NanoLC-425) in data-dependent acquisition (DDA) mode.", [["ammonium formate", "CHEMICAL", 210, 226], ["ammonium formate", "CHEMICAL", 298, 314], ["formic acid", "CHEMICAL", 346, 357], ["Eksigent NanoLC-425", "CHEMICAL", 568, 587], ["ammonium formate", "CHEMICAL", 210, 226], ["ammonium formate", "CHEMICAL", 298, 314], ["acetonitrile", "CHEMICAL", 324, 336], ["formic acid", "CHEMICAL", 346, 357], ["cation", "SIMPLE_CHEMICAL", 68, 74], ["ammonium formate", "SIMPLE_CHEMICAL", 210, 226], ["ammonium formate", "SIMPLE_CHEMICAL", 298, 314], ["v/v acetonitrile", "SIMPLE_CHEMICAL", 320, 336], ["formic acid", "SIMPLE_CHEMICAL", 346, 357], ["The digested peptides", "TREATMENT", 0, 21], ["cation exchange chromatography", "TREATMENT", 68, 98], ["a SCX Cartridge", "TREATMENT", 105, 120], ["increasing concentration of ammonium formate buffer", "TREATMENT", 182, 233], ["ammonium formate", "TEST", 298, 314], ["30% v/v acetonitrile", "TREATMENT", 316, 336], ["formic acid", "TEST", 346, 357], ["pH", "TEST", 359, 361], ["data acquisition", "TEST", 409, 425], ["The fractionated peptides", "TREATMENT", 425, 450], ["NanoLC", "TEST", 577, 583], ["gradient", "OBSERVATION_MODIFIER", 170, 178], ["increasing", "OBSERVATION_MODIFIER", 182, 192], ["concentration", "OBSERVATION_MODIFIER", 193, 206]]], ["Peptides from each fractions were cleaned using C18 Ziptip (Merck, USA) and 4 \u00b5g of these peptides were loaded on a trap-column (ChromXP C18CL 5 \u00b5m 120 \u00c5, Eksigent) where desalting was performed with a flow rate of 10 \u00b5l per minutes for 10 min.", [["C18 Ziptip", "TREATMENT", 48, 58], ["these peptides", "TREATMENT", 84, 98], ["a trap-column (ChromXP C18CL", "TREATMENT", 114, 142], ["a flow rate", "TEST", 200, 211]]], ["Peptides were separated on a reverse-phase C18 analytical column (ChromXP C18, 3 \u00b5m 120 \u00c5, Eksigent) at a flow rate of 5 \u00b5l/minute using buffer A (water with 0.1% formic acid) and buffer B (acetonitrile with 0.1% formic acid) with following gradient: buffer B was increased gradually from 3 to 25% in first 38 min.", [["ChromXP C18", "CHEMICAL", 66, 77], ["formic acid", "CHEMICAL", 163, 174], ["buffer B", "CHEMICAL", 180, 188], ["acetonitrile", "CHEMICAL", 190, 202], ["formic acid", "CHEMICAL", 213, 224], ["formic acid", "CHEMICAL", 163, 174], ["acetonitrile", "CHEMICAL", 190, 202], ["formic acid", "CHEMICAL", 213, 224], ["formic acid", "SIMPLE_CHEMICAL", 163, 174], ["buffer B", "SIMPLE_CHEMICAL", 180, 188], ["acetonitrile", "SIMPLE_CHEMICAL", 190, 202], ["formic acid", "SIMPLE_CHEMICAL", 213, 224], ["Peptides", "TEST", 0, 8], ["ChromXP C18", "TEST", 66, 77], ["a flow rate", "TEST", 104, 115], ["buffer A (water with 0.1% formic acid)", "TREATMENT", 137, 175], ["buffer B (acetonitrile", "TREATMENT", 180, 202], ["0.1% formic acid", "TREATMENT", 208, 224], ["buffer B", "TREATMENT", 251, 259]]], ["It was increased to 32% solvent B in the next 5 min, in the next 2 min buffer B was ramped up to 80% and 90% in further 0.5 min.", [["increased", "OBSERVATION_MODIFIER", 7, 16]]], ["Buffer B was brought to the initial 3% concentration in the next 1 min and column was reconditioned for 8 min before next run.LC-MS/MS data acquisitionIon source parameters were set to 5.5 kV for the ion spray voltage, 25 psi for the curtain gas, 15 psi for the nebulizer gas and 250 \u00b0C as temperature.", [["LC", "TEST", 126, 128], ["MS data", "TEST", 132, 139], ["source parameters", "TEST", 155, 172], ["the ion spray voltage", "TEST", 196, 217], ["the curtain gas", "TEST", 230, 245], ["the nebulizer gas", "TEST", 258, 275]]], ["For DDA, a 1.8 s instrument cycle was repeated in high sensitivity mode throughout the whole gradient, consisting of a full scan MS spectrum (400-1250 m/z) with an accumulation time of 0.25 s, followed by 30 MS/MS experiments (100-1500 m/z) with 0.050 s accumulation time each, on MS precursors with charge state 2 + to 5 + exceeding a 150 cps threshold.", [["DDA", "CHEMICAL", 4, 7], ["DDA", "CHEMICAL", 4, 7], ["DDA", "SIMPLE_CHEMICAL", 4, 7], ["DDA", "PROBLEM", 4, 7], ["a full scan MS spectrum", "TEST", 117, 140]]], ["Rolling collision energy was used and former target ions were excluded for 15 s.Database searchFor viral protein identification, a merged search for 8 DDA runs was performed in Protein Pilot software v5.0.1 (Sciex, USA) with paragon algorithm.", [["Database searchFor viral protein identification", "TEST", 80, 127], ["8 DDA runs", "TEST", 149, 159], ["paragon algorithm", "TEST", 225, 242]]], ["The parameters used were as follows: Cysteine alkylation-IAA, digestion-trypsin and 2 missed cleavages were allowed.", [["Cysteine", "CHEMICAL", 37, 45], ["IAA", "CHEMICAL", 57, 60], ["Cysteine", "CHEMICAL", 37, 45], ["IAA", "CHEMICAL", 57, 60], ["Cysteine alkylation-IAA", "SIMPLE_CHEMICAL", 37, 60], ["trypsin", "PROTEIN", 72, 79], ["Cysteine alkylation", "TREATMENT", 37, 56], ["IAA", "PROBLEM", 57, 60], ["digestion", "PROBLEM", 62, 71], ["trypsin", "TREATMENT", 72, 79], ["2 missed cleavages", "TREATMENT", 84, 102]]], ["Proteins identified with 1% global FDR were considered.", [["Proteins", "TEST", 0, 8], ["1% global FDR", "PROBLEM", 25, 38]]], ["The search was carried out against a UniProt database containing thirteen SARS-CoV-2 proteins.Protein BLAST searchProtein BLAST search was performed for each of the identified peptide with non-redundant protein sequences (nr) database using NCBI blastp suite using default parameters for short sequence search.Peptide variability analysisTo check whether the identified peptides fall in the invariable region of proteins in SARS-CoV-2, their sequence homology was checked with protein sequences of around 54,000 SARS-CoV-2 strains submitted in the Global Initiative on Sharing All Influenza Data (GISAID) in FASTA format (version 01July2020).", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 74, 84], ["SARS-CoV-2", "ORGANISM", 424, 434], ["SARS-CoV-2 proteins", "PROTEIN", 74, 93], ["non-redundant protein sequences", "DNA", 189, 220], ["SARS-CoV", "SPECIES", 424, 432], ["a UniProt database", "TEST", 35, 53], ["thirteen SARS", "TEST", 65, 78], ["Protein BLAST searchProtein BLAST search", "TEST", 94, 134], ["non-redundant protein sequences", "TEST", 189, 220], ["default parameters", "TEST", 265, 283], ["short sequence search", "TEST", 288, 309], ["Peptide variability analysis", "TEST", 310, 338], ["the identified peptides fall", "PROBLEM", 355, 383], ["SARS", "PROBLEM", 424, 428], ["CoV", "TEST", 429, 432], ["their sequence homology", "TEST", 436, 459], ["protein sequences", "TEST", 477, 494], ["SARS", "TEST", 512, 516], ["CoV", "TEST", 517, 520], ["strains", "PROBLEM", 523, 530]]], ["Different protein sequences were segregated and aligned, to observe the variability of the identified peptides amongst different strains.", [["Different protein sequences", "TEST", 0, 27], ["different strains", "PROBLEM", 119, 136]]], ["JalView tool was used for viewing the consensus of peptides over all the strains (Waterhouse et al. 2009 ).Method standardizationA short scheduled multiple reaction monitoring (sMRM) method, with a retention time window of 20 s was developed with the unique viral peptides identified in DDA runs, with multiple transitions for each of the peptides.", [["DDA", "CHEMICAL", 287, 290], ["DDA", "CHEMICAL", 287, 290], ["DDA", "SIMPLE_CHEMICAL", 287, 290], ["Method standardizationA short scheduled multiple reaction monitoring", "TREATMENT", 107, 175], ["the unique viral peptides", "PROBLEM", 247, 272], ["DDA runs", "PROBLEM", 287, 295], ["the peptides", "TREATMENT", 335, 347]]], ["Sample preparation was performed as described above and data acquisition was performed using a triple quadrupole hybrid ion trap mass spectrometer (QTrap 6500 + , Sciex) coupled with a Sciex ExionLC UHPLC system.", [["Sample preparation", "TEST", 0, 18], ["data acquisition", "TEST", 56, 72], ["a triple quadrupole hybrid ion trap mass spectrometer", "TREATMENT", 93, 146], ["a Sciex ExionLC UHPLC system", "TREATMENT", 183, 211]]], ["Tryptic peptides were loaded on an Acquity CSH C18 column (1.7 \u00b5m 2.1 \u00d7 100 mm, Waters) and separated using a binary gradient with buffer A (0.1% formic acid in water) and buffer B (0.1% formic acid in acetonitrile).", [["formic acid", "CHEMICAL", 146, 157], ["formic acid", "CHEMICAL", 187, 198], ["acetonitrile", "CHEMICAL", 202, 214], ["formic acid", "CHEMICAL", 146, 157], ["formic acid", "CHEMICAL", 187, 198], ["acetonitrile", "CHEMICAL", 202, 214], ["formic acid", "SIMPLE_CHEMICAL", 146, 157], ["water", "SIMPLE_CHEMICAL", 161, 166], ["buffer B", "SIMPLE_CHEMICAL", 172, 180], ["formic acid", "SIMPLE_CHEMICAL", 187, 198], ["acetonitrile", "SIMPLE_CHEMICAL", 202, 214], ["Tryptic peptides", "PROBLEM", 0, 16], ["an Acquity CSH C18 column", "TEST", 32, 57], ["a binary gradient", "TREATMENT", 108, 125], ["buffer A (0.1% formic acid in water)", "TREATMENT", 131, 167], ["buffer B", "TREATMENT", 172, 180], ["formic acid in acetonitrile", "TREATMENT", 187, 214]]], ["Peptides were loaded on column with a flow-rate of 600 \u00b5L per minute and 98% buffer A. Buffer B concentration was increased from an initial 2-10% in 0.2 min and 50% in 1.1minutes.", [["Buffer B", "SIMPLE_CHEMICAL", 87, 95], ["a flow", "TEST", 36, 42], ["Buffer B concentration", "TREATMENT", 87, 109]]], ["Buffer B concentration was ramped-up to 90% in another 0.2 min and held at the same gradient for 0.1 min and then brought to initial 2% in the next 0.1minute and held at the same concentration for 0.6.", [["Buffer B", "SIMPLE_CHEMICAL", 0, 8], ["Buffer B concentration", "TREATMENT", 0, 22]]], ["The total gradient was for 2.3 min.", [["The total gradient", "TEST", 0, 18], ["total", "OBSERVATION_MODIFIER", 4, 9], ["gradient", "OBSERVATION_MODIFIER", 10, 18]]], ["Peak review was performed using MultiQuant 3.0 (Sciex).Serology test for detection of antibody against SARS-CoV-2To check if the individuals had developed antibodies against SARS-CoV-2, we collected blood samples (5 ml) in vacutainer tubes from individuals and separated the plasma by centrifugation.", [["blood samples", "ANATOMY", 199, 212], ["plasma", "ANATOMY", 275, 281], ["SARS", "DISEASE", 174, 178], ["SARS-CoV-2To", "ORGANISM", 103, 115], ["individuals", "ORGANISM", 129, 140], ["SARS-CoV-2", "ORGANISM", 174, 184], ["blood samples", "ORGANISM_SUBSTANCE", 199, 212], ["vacutainer tubes", "ORGANISM_SUBSTANCE", 223, 239], ["plasma", "ORGANISM_SUBSTANCE", 275, 281], ["antibodies", "PROTEIN", 155, 165], ["SARS-CoV-2To", "SPECIES", 103, 115], ["SARS-CoV", "SPECIES", 174, 182], ["Peak review", "TEST", 0, 11], ["MultiQuant 3.0 (Sciex)", "TREATMENT", 32, 54], ["Serology test", "TEST", 55, 68], ["antibody", "TEST", 86, 94], ["SARS", "TEST", 103, 107], ["CoV", "TEST", 108, 111], ["the individuals", "TEST", 125, 140], ["antibodies", "TEST", 155, 165], ["SARS", "PROBLEM", 174, 178], ["CoV", "TEST", 179, 182], ["blood samples", "TEST", 199, 212], ["vacutainer tubes", "TREATMENT", 223, 239]]], ["Presence of antibodies was detected using Elecsys anti-SARS-CoV-2 on Cobas e411, Roche.Identification of SARS-CoV-2 proteins using high-resolution mass spectrometryWe initially performed a data-dependent acquisition of a pool of eight symptomatic RT-PCR confirmed patients using high-resolution mass spectrometer as mentioned in the methods section.", [["Roche", "ORGANISM_SUBSTANCE", 81, 86], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 105, 115], ["patients", "ORGANISM", 264, 272], ["antibodies", "PROTEIN", 12, 22], ["SARS-CoV-2 proteins", "PROTEIN", 105, 124], ["patients", "SPECIES", 264, 272], ["SARS-CoV", "SPECIES", 105, 113], ["antibodies", "TEST", 12, 22], ["Elecsys", "TEST", 42, 49], ["anti-SARS", "TEST", 50, 59], ["CoV", "TEST", 60, 63], ["Cobas", "TEST", 69, 74], ["SARS", "PROBLEM", 105, 109], ["CoV", "TEST", 110, 113], ["high-resolution mass spectrometry", "PROBLEM", 131, 164], ["a data", "TEST", 187, 193], ["eight symptomatic RT-PCR", "TEST", 229, 253], ["high-resolution mass spectrometer", "TREATMENT", 279, 312], ["SARS", "OBSERVATION", 105, 109]]], ["We identified 22 peptides from 4 proteins of SARS-CoV-2with 1% False discovery rate (FDR).", [["SARS-CoV", "SPECIES", 45, 53], ["SARS", "TEST", 45, 49], ["CoV", "TEST", 50, 53], ["22 peptides", "OBSERVATION_MODIFIER", 14, 25]]], ["We identified three structural proteins-spike glycoprotein (spike), nucleoprotein (NP) and envelope small membrane protein (ENV) and a protein Replicase polyprotein 1ab (Rep) from non-structural part (Supplementary Table 1 )-Among these, eight peptides from 3 proteins (Rep, Spike and NP), that were unique and un-modified was selected for generation of an in-house sMRM method for SARS-CoV-2 specific protein detection in patients (Table 1) .Protein BLAST searchWe also performed Protein BLAST searches with non-redundant protein sequences (nr) database using NCBI blast suite.", [["nucleoprotein (NP) and envelope small membrane protein", "GENE_OR_GENE_PRODUCT", 68, 122], ["ENV", "GENE_OR_GENE_PRODUCT", 124, 127], ["Rep", "GENE_OR_GENE_PRODUCT", 270, 273], ["Spike", "GENE_OR_GENE_PRODUCT", 275, 280], ["NP", "GENE_OR_GENE_PRODUCT", 285, 287], ["CoV-2", "GENE_OR_GENE_PRODUCT", 387, 392], ["patients", "ORGANISM", 423, 431], ["structural proteins", "PROTEIN", 20, 39], ["spike glycoprotein", "PROTEIN", 40, 58], ["spike", "PROTEIN", 60, 65], ["nucleoprotein", "PROTEIN", 68, 81], ["NP", "PROTEIN", 83, 85], ["envelope small membrane protein", "PROTEIN", 91, 122], ["ENV", "PROTEIN", 124, 127], ["protein Replicase polyprotein 1ab", "PROTEIN", 135, 168], ["Rep", "PROTEIN", 170, 173], ["Rep", "PROTEIN", 270, 273], ["Spike", "PROTEIN", 275, 280], ["NP", "PROTEIN", 285, 287], ["non-redundant protein sequences", "DNA", 509, 540], ["patients", "SPECIES", 423, 431], ["SARS-CoV", "SPECIES", 382, 390], ["three structural proteins", "PROBLEM", 14, 39], ["spike glycoprotein", "PROBLEM", 40, 58], ["nucleoprotein (NP)", "TREATMENT", 68, 86], ["envelope small membrane protein (ENV", "TREATMENT", 91, 127], ["a protein Replicase polyprotein", "TREATMENT", 133, 164], ["SARS", "PROBLEM", 382, 386], ["CoV", "TEST", 387, 390], ["Protein BLAST searchWe", "TEST", 443, 465], ["Protein BLAST searches", "TEST", 481, 503], ["non-redundant protein sequences", "TEST", 509, 540], ["BLAST searchWe", "OBSERVATION", 451, 465]]], ["The search revealed that seven of the eight peptides were unique to SARS-CoV-2.", [["SARS", "DISEASE", 68, 72], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 68, 78], ["SARS-CoV", "SPECIES", 68, 76], ["The search", "TEST", 0, 10], ["SARS", "TEST", 68, 72], ["CoV", "TEST", 73, 76]]], ["They were AIVSTIQRKYK and MDGSIIQFPN of Rep, QIAPGQTGK, LIANQFNSAIGK, AHFPREGVFVSNGTHWFVTQR and STNLVKNK of Spike and ADETQALPQR of NP.Peptides in conserved regionsSequences for more than 54,000 strains of SARS-CoV-2 have been documented in GISAID up to July 1, 2020.", [["SARS", "DISEASE", 206, 210], ["SARS-CoV-2", "ORGANISM", 206, 216], ["Rep", "PROTEIN", 40, 43], ["STNLVKNK", "PROTEIN", 96, 104], ["Spike", "PROTEIN", 108, 113], ["ADETQALPQR", "PROTEIN", 118, 128], ["SARS-CoV", "SPECIES", 206, 214], ["Spike", "PROBLEM", 108, 113], ["ADETQALPQR of NP", "TREATMENT", 118, 134], ["Peptides in conserved regionsSequences", "PROBLEM", 135, 173], ["SARS", "PROBLEM", 206, 210], ["CoV", "TEST", 211, 214]]], ["This gave us an opportunity to check if the peptides selected were in the invariant region.", [["the peptides", "TEST", 40, 52]]], ["Screening through protein sequences of all these strains we found these peptides to be completely conserved among different SARS-CoV2 strains and showed no variability in the peptide sequences ( Supplementary Fig. 1 ).", [["Screening through protein sequences", "TEST", 0, 35], ["all these strains", "TEST", 39, 56], ["these peptides", "TEST", 66, 80], ["CoV2 strains", "TEST", 129, 141], ["variability in the peptide sequences", "PROBLEM", 156, 192]]], ["Few strain sequences in the GISAID database show gaps and variations, probably due to low sequence quality or host editing.Detection of SARS-CoV-2 specific proteinsFor diagnostic purposes, it is important to obtain the desired results in the shortest possible time.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 136, 146], ["GISAID database", "DNA", 28, 43], ["SARS-CoV-2 specific proteins", "PROTEIN", 136, 164], ["SARS-CoV", "SPECIES", 136, 144], ["Few strain sequences", "TEST", 0, 20], ["the GISAID database", "TEST", 24, 43], ["low sequence quality", "PROBLEM", 86, 106], ["host editing", "PROBLEM", 110, 122], ["SARS", "PROBLEM", 136, 140], ["CoV", "TEST", 141, 144], ["diagnostic purposes", "TEST", 168, 187], ["gaps", "OBSERVATION", 49, 53], ["probably due to", "UNCERTAINTY", 70, 85], ["host editing", "OBSERVATION", 110, 122]]], ["Keeping this in mind, we developed a short scheduled multiple reaction monitoring (sMRM) method of 2.3 min with multiple transitions for each of the identified peptides.", [["a short scheduled multiple reaction monitoring", "TREATMENT", 35, 81]]], ["Based on the consistency and quality of the peaks in the ion chromatogram we included two peptides-AIVSTIQRKYK from Rep and QIAPGQTGK from spike in the sMRM method (Fig. 1) .", [["Rep", "GENE_OR_GENE_PRODUCT", 116, 119], ["Rep", "PROTEIN", 116, 119], ["QIAPGQTGK", "PROTEIN", 124, 133], ["the ion chromatogram", "TEST", 53, 73], ["two peptides", "TEST", 86, 98], ["Rep and QIAPGQTGK", "TREATMENT", 116, 133], ["spike", "PROBLEM", 139, 144]]], ["Apart from that, we also included an additional peptide of serum albumin as an internal control for protein amount (Fig. 1) .", [["serum", "ANATOMY", 59, 64], ["serum", "ORGANISM_SUBSTANCE", 59, 64], ["albumin", "GENE_OR_GENE_PRODUCT", 65, 72], ["serum albumin", "PROTEIN", 59, 72], ["serum albumin", "TEST", 59, 72]]], ["The optimized parameters used for the MRM method, to detect SARS-CoV-2 proteins in patient samples are provided in Supplementary Table 2 .", [["samples", "ANATOMY", 91, 98], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 60, 70], ["patient", "ORGANISM", 83, 90], ["SARS-CoV-2 proteins", "PROTEIN", 60, 79], ["patient", "SPECIES", 83, 90], ["SARS-CoV", "SPECIES", 60, 68], ["the MRM method", "TEST", 34, 48], ["SARS", "TEST", 60, 64], ["CoV", "TEST", 65, 68]]], ["We considered a sample to be positive for SARS-CoV-2 if overlapping transitions were present with an intensity of greater than 1.5 \u00d7 10 3 and a signal to noise ratio of greater than 10for either of the two selected peptides.Detection of SARS-CoV-2 in naso-oropharyngeal swab samplesWe analyzed 103samples using the sMRM method developed in two different sample sets.", [["naso-oropharyngeal swab samples", "ANATOMY", 251, 282], ["SARS", "DISEASE", 42, 46], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 237, 247], ["oropharyngeal swab samples", "ORGANISM_SUBSTANCE", 256, 282], ["SARS-CoV", "SPECIES", 42, 50], ["SARS-CoV", "SPECIES", 237, 245], ["a sample", "TEST", 14, 22], ["SARS", "PROBLEM", 42, 46], ["CoV", "TEST", 47, 50], ["overlapping transitions", "PROBLEM", 56, 79], ["a signal to noise ratio", "TEST", 142, 165], ["SARS", "TEST", 237, 241], ["CoV", "TEST", 242, 245], ["naso", "TEST", 251, 255], ["oropharyngeal swab samples", "TEST", 256, 282], ["the sMRM method", "TREATMENT", 311, 326], ["oropharyngeal", "ANATOMY", 256, 269]]], ["The first set consisted of 20 samples (including follow up) from 14 patients for whom we had to follow-up RT-PCR data ( Table 2) .", [["samples", "ANATOMY", 30, 37], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["PCR data", "TEST", 109, 117]]], ["Interestingly, although most of the patients had recovered as was evident from their being RT-PCR negative and being free of symptoms, we found that they continue to retain the peptides even after 14 days (Sample 5, 6, 7, 8, 10 in Table 2 ) of initial infection.", [["infection", "DISEASE", 252, 261], ["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["RT-PCR", "TEST", 91, 97], ["symptoms", "PROBLEM", 125, 133], ["Sample", "TEST", 206, 212], ["initial infection", "PROBLEM", 244, 261], ["infection", "OBSERVATION", 252, 261]]], ["In 2 of the patients (sample 1 and 14), RT-PCR was found to be negative while the patients had symptoms.", [["patients", "ORGANISM", 12, 20], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 82, 90], ["sample", "TEST", 22, 28], ["RT-PCR", "TEST", 40, 46], ["symptoms", "PROBLEM", 95, 103], ["negative", "OBSERVATION", 63, 71]]], ["One of these patients (sample 14) was found to be negative on the 1 st day but was found positive on the second day while we found peptide peaks to be present on both the days, clearly indicating the sensitivity of the sMRM method.Detection of SARS-CoV-2 in naso-oropharyngeal swab samplesIn the second set, we analyzed 82 case control samples.", [["naso-oropharyngeal swab samples", "ANATOMY", 258, 289], ["samples", "ANATOMY", 336, 343], ["patients", "ORGANISM", 13, 21], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 244, 254], ["oropharyngeal swab samples", "ORGANISM_SUBSTANCE", 263, 289], ["patients", "SPECIES", 13, 21], ["SARS-CoV", "SPECIES", 244, 252], ["peptide peaks", "PROBLEM", 131, 144], ["SARS", "TEST", 244, 248], ["CoV", "TEST", 249, 252], ["naso", "TEST", 258, 262], ["oropharyngeal swab samples", "TEST", 263, 289], ["negative", "OBSERVATION", 50, 58], ["positive", "OBSERVATION", 89, 97], ["peaks", "OBSERVATION", 139, 144], ["oropharyngeal", "ANATOMY", 263, 276]]], ["Among these 63 were RT-PCR positive and considered as patients.", [["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["RT-PCR", "TEST", 20, 26]]], ["For controls, we considered 20 individuals who had negative RT-PCR and did not have any antibodies as evident from negative serology test indicating the absence of IgM and IgG against SARS-CoV-2.", [["IgM", "GENE_OR_GENE_PRODUCT", 164, 167], ["IgG", "GENE_OR_GENE_PRODUCT", 172, 175], ["SARS-CoV-2", "ORGANISM", 184, 194], ["antibodies", "PROTEIN", 88, 98], ["IgM", "PROTEIN", 164, 167], ["IgG", "PROTEIN", 172, 175], ["SARS-CoV", "SPECIES", 184, 192], ["RT-PCR", "TEST", 60, 66], ["any antibodies", "PROBLEM", 84, 98], ["serology test", "TEST", 124, 137], ["IgM", "TEST", 164, 167], ["IgG", "TEST", 172, 175], ["SARS", "TEST", 184, 188], ["CoV", "TEST", 189, 192]]], ["Mass spectrometric analysis revealed that in all the 20 negative samples, peptides were not detected.", [["samples", "ANATOMY", 65, 72], ["Mass spectrometric analysis", "TEST", 0, 27], ["peptides", "TEST", 74, 82]]], ["Of the 63 positive samples, 57 were found to be positive using our method.", [["samples", "ANATOMY", 19, 26], ["samples", "CANCER", 19, 26], ["our method", "TEST", 63, 73], ["positive", "OBSERVATION", 48, 56]]], ["Thus, our method has a sensitivity of 90.4% and specificity of 100% with respect to RT-PCR positive samples and true controls (serologically negative, RT-PCR negative).DiscussionThe objective of the study was to develop a simple and rapid targeted mass spectrometric method (sMRM) to identify peptides specific to SARS-CoV-2.", [["samples", "ANATOMY", 100, 107], ["SARS", "DISEASE", 314, 318], ["SARS-CoV-2", "ORGANISM", 314, 324], ["SARS-CoV", "SPECIES", 314, 322], ["a sensitivity", "TEST", 21, 34], ["specificity", "TEST", 48, 59], ["RT", "TEST", 84, 86], ["PCR", "TEST", 87, 90], ["true controls", "TEST", 112, 125], ["serologically", "TEST", 127, 140], ["RT-PCR", "TEST", 151, 157], ["the study", "TEST", 195, 204], ["a simple and rapid targeted mass spectrometric method", "PROBLEM", 220, 273], ["SARS", "TEST", 314, 318], ["CoV", "TEST", 319, 322]]], ["For this, we initially analyzed samples in high-resolution mass spectrometer and identified eight unique and unmodified peptides from three proteins of SARS-CoV-2.", [["samples", "ANATOMY", 32, 39], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 152, 162], ["SARS-CoV", "SPECIES", 152, 160], ["high-resolution mass spectrometer", "TREATMENT", 43, 76], ["SARS", "TEST", 152, 156], ["CoV", "TEST", 157, 160]]], ["These peptides were unique to SARS-CoV-2 and most importantly lay in the invariant region as revealed by analysis of more than 54,000 SARS-CoV-2 strains sequences submitted in GSAID up to 1st July 2020.", [["SARS", "DISEASE", 30, 34], ["SARS-CoV-2", "ORGANISM", 30, 40], ["SARS-CoV-2 strains sequences", "DNA", 134, 162], ["SARS-CoV", "SPECIES", 30, 38], ["SARS", "TEST", 30, 34], ["CoV", "TEST", 35, 38], ["SARS", "TEST", 134, 138], ["CoV-2 strains sequences", "TEST", 139, 162]]], ["This indicates that even if there are mutations in the virus, it should not affect the sequence of the peptides chosen.", [["mutations in the virus", "PROBLEM", 38, 60]]], ["Using these peptides, we developed a short, 2.3 min, the gradient for the sMRM method and selected two peptides AIVSTIQRKYK from Replicase and QIAPGQTGK from Spike protein of SARS CoV-2 based on the consistency and quality of the spectra.", [["Replicase", "PROTEIN", 129, 138], ["QIAPGQTGK", "PROTEIN", 143, 152], ["Spike protein", "PROTEIN", 158, 171], ["SARS CoV", "SPECIES", 175, 183], ["the gradient", "TEST", 53, 65], ["the sMRM method", "TREATMENT", 70, 85], ["Replicase", "TEST", 129, 138], ["QIAPGQTGK", "TEST", 143, 152], ["Spike protein", "TEST", 158, 171], ["SARS CoV", "TEST", 175, 183]]], ["Apart from these two peptides, we also included one peptide of human serum albumin AEFAEVSK as a control for protein amount.", [["serum", "ANATOMY", 69, 74], ["human", "ORGANISM", 63, 68], ["serum", "ORGANISM_SUBSTANCE", 69, 74], ["albumin", "GENE_OR_GENE_PRODUCT", 75, 82], ["human serum albumin AEFAEVSK", "PROTEIN", 63, 91], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 63, 68], ["human serum albumin AEFAEVSK", "TREATMENT", 63, 91]]], ["This was important since in a few samples we found that the intensities of albumin transitions were very low indicating low protein concentration and if the viral load is low in such samples it could result in false-negative results.", [["samples", "ANATOMY", 183, 190], ["albumin", "GENE_OR_GENE_PRODUCT", 75, 82], ["albumin transitions", "PROBLEM", 75, 94], ["low protein concentration", "PROBLEM", 120, 145], ["the viral load", "TEST", 153, 167], ["low protein", "OBSERVATION_MODIFIER", 120, 131], ["viral load", "OBSERVATION", 157, 167]]], ["These samples were thus not considered.", [["samples", "ANATOMY", 6, 13], ["These samples", "TEST", 0, 13], ["not considered", "UNCERTAINTY", 24, 38]]], ["Using this method we analyzed 103 naso-oropharyngeal samples in two sets.", [["naso-oropharyngeal samples", "ANATOMY", 34, 60], ["oropharyngeal samples", "CANCER", 39, 60], ["this method", "TREATMENT", 6, 17]]], ["In the first set, we included 20 samples from 14 patients for which RT-PCR data of two or more time points was available.", [["samples", "ANATOMY", 33, 40], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["RT-PCR data", "TEST", 68, 79]]], ["Interestingly, peptide peaks were detected in patients who recovered from the symptoms and were RT-PCR negative for SARS-CoV-2.", [["patients", "ORGANISM", 46, 54], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 116, 126], ["patients", "SPECIES", 46, 54], ["SARS-CoV", "SPECIES", 116, 124], ["the symptoms", "PROBLEM", 74, 86], ["RT-PCR", "TEST", 96, 102], ["SARS", "PROBLEM", 116, 120], ["CoV", "TEST", 121, 124], ["peaks", "OBSERVATION_MODIFIER", 23, 28]]], ["Interestingly, peptide peaks were observed in two symptomatic patients who tested negative with RT-PCR of which one was tested positive in subsequent RT-PCR indicating false negative RT-PCR in the first instance.", [["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["peptide peaks", "PROBLEM", 15, 28], ["RT-PCR", "TEST", 96, 102], ["PCR", "TEST", 153, 156], ["false negative RT-PCR", "PROBLEM", 168, 189], ["peaks", "OBSERVATION_MODIFIER", 23, 28], ["symptomatic", "OBSERVATION_MODIFIER", 50, 61], ["false negative", "OBSERVATION", 168, 182]]], ["Thus, the data indicates high sensitivity of the current method and can be used for initial diagnosis including diagnosis of asymptomatic cases.DiscussionIn the second set, we analyzed case-control samples.", [["the data", "TEST", 6, 14], ["asymptomatic cases", "PROBLEM", 125, 143]]], ["As discussed previously, patients who have recovered, and were RT-PCR negative also show peptide peaks.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["RT-PCR", "TEST", 63, 69], ["peptide peaks", "PROBLEM", 89, 102], ["peptide peaks", "OBSERVATION", 89, 102]]], ["For this, we considered healthy individuals with no exposure to SARS-CoV-2 virus as revealed by serology tests for antibodies against SARS-CoV-2and RT-PCR.", [["SARS", "DISEASE", 64, 68], ["SARS-CoV-2 virus", "ORGANISM", 64, 80], ["CoV-2 virus", "SPECIES", 69, 80], ["SARS-CoV-2 virus", "SPECIES", 64, 80], ["SARS-CoV", "SPECIES", 134, 142], ["healthy individuals", "PROBLEM", 24, 43], ["SARS", "PROBLEM", 64, 68], ["CoV", "TEST", 69, 72], ["virus", "PROBLEM", 75, 80], ["serology tests", "TEST", 96, 110], ["antibodies", "TEST", 115, 125], ["SARS", "TEST", 134, 138], ["CoV", "TEST", 139, 142], ["RT", "TEST", 148, 150], ["PCR", "TEST", 151, 154]]], ["These are the true controls since they neither have any active infection nor had been infected by the virus, previously.", [["infection", "DISEASE", 63, 72], ["any active infection", "PROBLEM", 52, 72], ["active", "OBSERVATION_MODIFIER", 56, 62], ["infection", "OBSERVATION", 63, 72], ["infected", "OBSERVATION", 86, 94]]], ["We considered a sample to be positive for SARS-CoV-2 if overlapping transitions were present with an intensity of greater than 1.5 \u00d7 10 3 and a signal to noise ratio of greater than 10 for either of the two selected peptides.", [["SARS", "DISEASE", 42, 46], ["SARS-CoV", "SPECIES", 42, 50], ["a sample", "TEST", 14, 22], ["SARS", "PROBLEM", 42, 46], ["CoV", "TEST", 47, 50], ["overlapping transitions", "PROBLEM", 56, 79], ["a signal to noise ratio", "TEST", 142, 165]]], ["This value was chosen since there will be residual peaks from carry-over of the previous sample and it was observed that the median values of the peaks in blank due to carry over were 2 \u00d7 10 2 -4.5 \u00d7 10 2 depending on the transition with a maximum intensity.", [["This value", "TEST", 0, 10], ["residual peaks", "PROBLEM", 42, 56], ["the median values", "TEST", 121, 138]]], ["Using this criterion; we could distinguish SARS-CoV-2 virus-infected individuals from uninfected ones with high specificity (100%) and sensitivity (90.4%) when compared with the RT-PCR.", [["SARS-CoV-2 virus", "ORGANISM", 43, 59], ["individuals", "ORGANISM", 69, 80], ["CoV-2 virus", "SPECIES", 48, 59], ["SARS-CoV-2 virus", "SPECIES", 43, 59], ["this criterion", "TEST", 6, 20], ["SARS", "PROBLEM", 43, 47], ["CoV", "TEST", 48, 51], ["2 virus", "PROBLEM", 52, 59], ["infected individuals", "PROBLEM", 60, 80], ["sensitivity", "TEST", 135, 146], ["the RT-PCR", "TEST", 174, 184]]], ["Out of the 63 RT-PCR positive samples, we reported 57 to be positive.", [["samples", "ANATOMY", 30, 37], ["positive", "OBSERVATION", 60, 68]]], ["Of the six samples that we did not confirm positive, three satisfied the criteria of at least three transitions in one peptide to be overlapping and having an intensity of greater than 1.5 \u00d7 103.", [["the six samples", "TEST", 3, 18], ["an intensity", "TEST", 156, 168], ["intensity", "OBSERVATION_MODIFIER", 159, 168]]], ["However, the signal to noise ratio for one of the three transitions was not above 10.", [["noise ratio", "TEST", 23, 34]]], ["In one sample although the signal to noise ratio in three transitions were more than 10, the intensity of one of the transition was 1.42 \u00d7 103 which fell marginally short of our criteria.", [["noise ratio", "TEST", 37, 48]]], ["In the remaining two samples, more than one transition did not meet our criteria.", [["samples", "ANATOMY", 21, 28]]], ["It should be noted that the results of RT PCR could also be falsely positive in these cases.DiscussionThere are several advantages of using mass spectrometer for the diagnosis of SARS-CoV-2.", [["SARS", "DISEASE", 179, 183], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 179, 189], ["SARS-CoV", "SPECIES", 179, 187], ["RT PCR", "TEST", 39, 45], ["mass spectrometer", "TREATMENT", 140, 157], ["SARS", "PROBLEM", 179, 183], ["CoV", "TEST", 184, 187]]], ["The swab samples can be directly collected in vials containing inactivation buffer ensuring safe transport and handling of the samples.", [["swab samples", "ANATOMY", 4, 16], ["samples", "ANATOMY", 127, 134], ["swab samples", "ORGANISM_SUBSTANCE", 4, 16], ["The swab samples", "TEST", 0, 16], ["inactivation buffer", "TREATMENT", 63, 82], ["the samples", "TEST", 123, 134]]], ["The major advantage of our method is its short run time with a 2.3 min gradient which is the fastest reported till date for detection of SARS-CoV-2 peptides.", [["SARS", "DISEASE", 137, 141], ["SARS-CoV-2 peptides", "GENE_OR_GENE_PRODUCT", 137, 156], ["a 2.3 min gradient", "TREATMENT", 61, 79], ["SARS", "PROBLEM", 137, 141], ["CoV", "TEST", 142, 145]]], ["Cardozo et al. (2020) reported a MRM with a gradient of 10.5 min that could detect SARS-CoV-2 peptides with a sensitivity of 83%.", [["a MRM", "TEST", 31, 36], ["a gradient", "TEST", 42, 52], ["SARS", "TEST", 83, 87], ["CoV", "TEST", 88, 91], ["a sensitivity", "TEST", 108, 121]]], ["Interestingly, they used fully automated sample preparation protocol using robotic liquid handler and turbulent flow chromatography, multiplexed for online sample clean-up and UPLC separation that enabled them to run 4 samples within the 10.5 min run.", [["sample", "ANATOMY", 41, 47], ["fully automated sample preparation protocol", "TREATMENT", 25, 68], ["robotic liquid handler", "TREATMENT", 75, 97], ["turbulent flow chromatography", "TEST", 102, 131], ["online sample clean", "TREATMENT", 149, 168], ["UPLC separation", "TREATMENT", 176, 191]]], ["In contrast, our method can be used in any laboratory equipped with a triple quadrupole mass spectrometer.DiscussionOne of the perceived disadvantages of using mass spectrometry-based diagnostics is the cost of the equipment, however, the per-sample assay cost (less than $3 per sample) is considerably lower when compared to other methods like RT-PCR.", [["a triple quadrupole mass spectrometer", "TREATMENT", 68, 105], ["mass spectrometry", "TEST", 160, 177], ["RT-PCR", "TEST", 345, 351]]], ["We thus, propose that targeted mass spectrometry should currently be explored for screening and diagnostic purpose, which can augment the number of tests that are currently being carried out to detect SARS-CoV-2 and complement traditional RT-PCR based assays or act as an alternate and accurate diagnostic tool with high specificity and sensitivity.", [["CoV-2", "ORGANISM", 206, 211], ["SARS-CoV", "SPECIES", 201, 209], ["targeted mass spectrometry", "PROBLEM", 22, 48], ["screening", "TEST", 82, 91], ["diagnostic purpose", "TEST", 96, 114], ["tests", "TEST", 148, 153], ["SARS", "TEST", 201, 205], ["CoV", "TEST", 206, 209], ["PCR based assays", "TEST", 242, 258]]]], "3660a0a14f82558378797b8a86fb7d0854bd1ab4": [["BackgroundPorcine epidemic diarrhea virus (PEDV) is an enveloped, single-stranded, positive-sense RNA virus in the family Coronaviridae [1] .", [["BackgroundPorcine epidemic diarrhea", "DISEASE", 0, 35], ["BackgroundPorcine epidemic diarrhea virus", "ORGANISM", 0, 41], ["BackgroundPorcine epidemic diarrhea virus", "SPECIES", 0, 41], ["BackgroundPorcine epidemic diarrhea virus", "SPECIES", 0, 41], ["PEDV", "SPECIES", 43, 47], ["BackgroundPorcine epidemic diarrhea virus (PEDV", "PROBLEM", 0, 47]]], ["In susceptible herds, PEDV is characterized by the rapid onset of watery diarrhea and vomiting in pigs of all ages, with mortality approaching 100 % in suckling piglets.", [["PEDV", "CHEMICAL", 22, 26], ["watery diarrhea", "DISEASE", 66, 81], ["vomiting", "DISEASE", 86, 94], ["pigs", "ORGANISM", 98, 102], ["piglets", "ORGANISM", 161, 168], ["pigs", "SPECIES", 98, 102], ["piglets", "SPECIES", 161, 168], ["PEDV", "SPECIES", 22, 26], ["pigs", "SPECIES", 98, 102], ["PEDV", "PROBLEM", 22, 26], ["watery diarrhea", "PROBLEM", 66, 81], ["vomiting", "PROBLEM", 86, 94], ["susceptible", "OBSERVATION_MODIFIER", 3, 14], ["herds", "OBSERVATION", 15, 20], ["rapid", "OBSERVATION_MODIFIER", 51, 56], ["onset", "OBSERVATION_MODIFIER", 57, 62], ["watery", "OBSERVATION_MODIFIER", 66, 72], ["diarrhea", "OBSERVATION", 73, 81]]], ["First identified in 1978, PEDV was not considered a serious threat to swine health until devastating outbreaks of PEDV were reported in China in 2006 in association with previously unrecognized genetic variants [2] .", [["PEDV", "CHEMICAL", 26, 30], ["PEDV", "CHEMICAL", 114, 118], ["PEDV", "SPECIES", 26, 30], ["swine", "SPECIES", 70, 75], ["PEDV", "SPECIES", 114, 118], ["PEDV", "PROBLEM", 26, 30], ["PEDV", "PROBLEM", 114, 118]]], ["Thereafter, pathogenic strains producing clinical PED outbreaks were reported in Japan, Korea, Thailand, the Philippines, the Western hemisphere and subsequently Portugal and Germany [3] [4] [5] .", [["PED outbreaks", "DISEASE", 50, 63], ["pathogenic strains", "PROBLEM", 12, 30], ["clinical PED outbreaks", "PROBLEM", 41, 63]]], ["Thus, in a relatively short time, pathogenic PEDV has become pandemic.BackgroundSince there is little possibility that PEDV will soon be eradicated, it is important to identify the means to prevent and/or control its effects: PEDV management will necessitate monitoring PEDV in swine populations.", [["PEDV", "CHEMICAL", 45, 49], ["PEDV", "CHEMICAL", 119, 123], ["PEDV", "CHEMICAL", 270, 274], ["PEDV", "CANCER", 45, 49], ["PEDV", "SIMPLE_CHEMICAL", 119, 123], ["swine", "SPECIES", 278, 283], ["PEDV", "SPECIES", 45, 49], ["PEDV", "SPECIES", 119, 123], ["PEDV", "SPECIES", 226, 230], ["PEDV", "SPECIES", 270, 274], ["swine", "SPECIES", 278, 283], ["pathogenic PEDV", "PROBLEM", 34, 49], ["pandemic", "PROBLEM", 61, 69], ["PEDV", "PROBLEM", 119, 123], ["PEDV management", "TREATMENT", 226, 241], ["PEDV", "OBSERVATION", 45, 49], ["pandemic", "OBSERVATION_MODIFIER", 61, 69], ["little possibility", "UNCERTAINTY", 95, 113]]], ["Therefore, the purpose of this study was to (1) describe the patterns of PEDV shedding and detection in growing pigs as shown by PEDV real-time reverse transcription polymerase chain reaction (rRT-PCR) testing of individual pig rectal swabs, pen fecal samples, and pen oral fluids; (2) describe PEDV antibody kinetics as shown by enzyme-linked immunosorbent assay (ELISA) detection of IgA and IgG in individual pig serum and pen oral fluid samples; and (3) estimate the cutoffs and performance of the PEDV \"whole virus\" IgA and IgG ELISAs (WV IgA or IgG ELISA).Experimental designIndividual pig samples (rectal swabs and/or serum) and pen samples (fecal and/or oral fluid specimens) were collected longitudinally from one PEDV-positive commercial wean-to-finish (WTF) barn in Missouri USA (Site One) and one PEDV-negative commercial WTF barn in Iowa USA (Site Two).", [["rectal swabs", "ANATOMY", 228, 240], ["fecal samples", "ANATOMY", 246, 259], ["oral fluids", "ANATOMY", 269, 280], ["serum", "ANATOMY", 415, 420], ["oral fluid samples", "ANATOMY", 429, 447], ["samples", "ANATOMY", 595, 602], ["rectal swabs", "ANATOMY", 604, 616], ["serum", "ANATOMY", 624, 629], ["pen samples", "ANATOMY", 635, 646], ["fecal", "ANATOMY", 648, 653], ["oral fluid specimens", "ANATOMY", 661, 681], ["PEDV", "CHEMICAL", 73, 77], ["PEDV", "ORGANISM", 73, 77], ["pigs", "ORGANISM", 112, 116], ["pig", "ORGANISM", 224, 227], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 228, 240], ["oral", "ORGANISM_SUBDIVISION", 269, 273], ["IgA", "GENE_OR_GENE_PRODUCT", 385, 388], ["IgG", "GENE_OR_GENE_PRODUCT", 393, 396], ["pig", "ORGANISM", 411, 414], ["serum", "ORGANISM_SUBSTANCE", 415, 420], ["oral fluid samples", "ORGANISM_SUBSTANCE", 429, 447], ["IgA", "GENE_OR_GENE_PRODUCT", 520, 523], ["IgA", "GENE_OR_GENE_PRODUCT", 543, 546], ["pig", "ORGANISM", 591, 594], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 604, 616], ["serum", "ORGANISM_SUBSTANCE", 624, 629], ["pen samples", "ORGANISM_SUBSTANCE", 635, 646], ["fecal", "ORGANISM_SUBSTANCE", 648, 653], ["oral fluid specimens", "ORGANISM_SUBSTANCE", 661, 681], ["PEDV antibody", "PROTEIN", 295, 308], ["IgA", "PROTEIN", 385, 388], ["IgG", "PROTEIN", 393, 396], ["PEDV", "PROTEIN", 501, 505], ["IgA", "PROTEIN", 520, 523], ["IgG ELISAs", "PROTEIN", 528, 538], ["WV IgA", "PROTEIN", 540, 546], ["IgG ELISA", "PROTEIN", 550, 559], ["pigs", "SPECIES", 112, 116], ["pig", "SPECIES", 224, 227], ["pig", "SPECIES", 411, 414], ["pig", "SPECIES", 591, 594], ["PEDV", "SPECIES", 73, 77], ["pigs", "SPECIES", 112, 116], ["pig", "SPECIES", 224, 227], ["PEDV", "SPECIES", 295, 299], ["pig", "SPECIES", 411, 414], ["PEDV", "SPECIES", 501, 505], ["pig", "SPECIES", 591, 594], ["this study", "TEST", 26, 36], ["PEDV shedding", "PROBLEM", 73, 86], ["reverse transcription polymerase chain reaction", "PROBLEM", 144, 191], ["rRT-PCR", "TEST", 193, 200], ["testing", "TEST", 202, 209], ["individual pig rectal swabs", "TEST", 213, 240], ["pen fecal samples", "TEST", 242, 259], ["pen oral fluids", "TREATMENT", 265, 280], ["PEDV antibody kinetics", "TEST", 295, 317], ["enzyme", "TEST", 330, 336], ["immunosorbent assay", "TEST", 344, 363], ["ELISA", "TEST", 365, 370], ["IgA", "TEST", 385, 388], ["IgG", "TEST", 393, 396], ["individual pig serum", "TEST", 400, 420], ["pen oral fluid samples", "TEST", 425, 447], ["the cutoffs", "TEST", 466, 477], ["the PEDV", "TEST", 497, 505], ["whole virus", "TEST", 507, 518], ["IgA", "TEST", 520, 523], ["IgG ELISAs", "TEST", 528, 538], ["WV IgA", "TEST", 540, 546], ["IgG ELISA", "TEST", 550, 559], ["Experimental designIndividual pig samples", "PROBLEM", 561, 602], ["rectal swabs and/or serum)", "TEST", 604, 630], ["pen samples", "TEST", 635, 646], ["fecal and/or oral fluid specimens", "TEST", 648, 681], ["PEDV", "OBSERVATION", 73, 77], ["fecal", "ANATOMY", 648, 653]]], ["Fecal samples and oral fluids were tested by PEDV real-time reverse-transcriptase polymerase chain reaction (rRT-PCR).", [["Fecal samples", "ANATOMY", 0, 13], ["oral fluids", "ANATOMY", 18, 29], ["Fecal samples", "ORGANISM_SUBSTANCE", 0, 13], ["oral fluids", "ORGANISM_SUBSTANCE", 18, 29], ["Fecal samples", "TEST", 0, 13], ["oral fluids", "TREATMENT", 18, 29], ["transcriptase polymerase chain reaction", "PROBLEM", 68, 107]]], ["Serum and oral fluid specimens were tested by two PEDV antibody WV ELISAs (IgA, IgG).", [["Serum", "ANATOMY", 0, 5], ["oral fluid specimens", "ANATOMY", 10, 30], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["oral fluid specimens", "ORGANISM_SUBSTANCE", 10, 30], ["IgA", "GENE_OR_GENE_PRODUCT", 75, 78], ["IgG", "GENE_OR_GENE_PRODUCT", 80, 83], ["PEDV antibody", "PROTEIN", 50, 63], ["WV", "PROTEIN", 64, 66], ["IgA", "PROTEIN", 75, 78], ["IgG", "PROTEIN", 80, 83], ["PEDV", "SPECIES", 50, 54], ["Serum and oral fluid specimens", "TEST", 0, 30], ["two PEDV antibody WV ELISAs", "TEST", 46, 73], ["IgA", "TEST", 75, 78], ["IgG", "TEST", 80, 83]]], ["Testing results were used to describe PEDV shedding, establish the performance parameters of two PEDV WV ELISAs (IgA, IgG), and characterize antibody kinetics in a commercial pig production system.", [["IgA", "GENE_OR_GENE_PRODUCT", 113, 116], ["IgG", "GENE_OR_GENE_PRODUCT", 118, 121], ["pig", "ORGANISM", 175, 178], ["PEDV", "PROTEIN", 97, 101], ["IgA", "PROTEIN", 113, 116], ["IgG", "PROTEIN", 118, 121], ["pig", "SPECIES", 175, 178], ["PEDV", "SPECIES", 38, 42], ["PEDV", "SPECIES", 97, 101], ["pig", "SPECIES", 175, 178], ["PEDV shedding", "PROBLEM", 38, 51], ["the performance parameters", "TEST", 63, 89], ["two PEDV WV ELISAs", "TEST", 93, 111], ["IgA", "TEST", 113, 116], ["antibody kinetics", "PROBLEM", 141, 158], ["a commercial pig production system", "TREATMENT", 162, 196], ["antibody kinetics", "OBSERVATION", 141, 158]]], ["This project was approved in writing both by an agent representing the livestock producer and the Iowa State University Office for Responsible Research.Site descriptionsSite One was a 52-pen WTF barn stocked with~800 pigs.", [["pigs", "ORGANISM", 217, 221], ["pigs", "SPECIES", 217, 221]]], ["Pens were separated by metal gates, with 26 pens on each side of the walk way.", [["Pens", "TREATMENT", 0, 4]]], ["Pens were equipped with automatic feeders, bowl drinkers, and fully slatted floors.", [["Pens", "TREATMENT", 0, 4]]], ["The facility was designed with negative pressure tunnel ventilation and a deep pit (2.4 m) manure handling system.", [["negative pressure tunnel ventilation", "TREATMENT", 31, 67], ["a deep pit (2.4 m) manure handling system", "TREATMENT", 72, 113], ["tunnel ventilation", "OBSERVATION", 49, 67], ["deep", "ANATOMY_MODIFIER", 74, 78]]], ["Pigs were placed in the facility at the time of weaning (~3 weeks of age).", [["Pigs", "ORGANISM", 0, 4], ["Pigs", "SPECIES", 0, 4], ["Pigs", "TREATMENT", 0, 4]]], ["Pen samples (feces and oral fluids) and pig samples (rectal swabs and serum) were collected from the same 6 pens and a convenience sample of 5 pigs in each of the 6 pens at each sampling point.", [["samples", "ANATOMY", 4, 11], ["feces", "ANATOMY", 13, 18], ["oral fluids", "ANATOMY", 23, 34], ["samples", "ANATOMY", 44, 51], ["rectal swabs", "ANATOMY", 53, 65], ["serum", "ANATOMY", 70, 75], ["Pen samples", "TISSUE", 0, 11], ["feces", "ORGANISM_SUBDIVISION", 13, 18], ["oral", "ORGANISM_SUBDIVISION", 23, 27], ["fluids", "ORGANISM_SUBSTANCE", 28, 34], ["pig", "ORGANISM", 40, 43], ["samples", "ORGANISM_SUBSTANCE", 44, 51], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 53, 65], ["serum", "ORGANISM_SUBSTANCE", 70, 75], ["pigs", "ORGANISM", 143, 147], ["pig", "SPECIES", 40, 43], ["pigs", "SPECIES", 143, 147], ["pig", "SPECIES", 40, 43], ["pigs", "SPECIES", 143, 147], ["Pen samples", "TEST", 0, 11], ["oral fluids)", "TREATMENT", 23, 35], ["pig samples", "TEST", 40, 51], ["rectal swabs and serum)", "TEST", 53, 76], ["a convenience sample", "TEST", 117, 137], ["rectal", "ANATOMY", 53, 59]]], ["Sampling began when the pigs were~3 weeks of age and continued at~2-week intervals for 27 weeks.", [["pigs", "ORGANISM", 24, 28], ["pigs", "SPECIES", 24, 28], ["pigs", "SPECIES", 24, 28]]], ["At 10 weeks post-placement, i.e., when pigs were approximately 13 weeks of age, the producer exposed the pigs (replacement gilts) to PEDV by mixing PEDV-positive fecal material with water and spraying feed and the pigs' oral-nasal area with the mixture using a hand-held sprayer.Site descriptionsSite Two consisted of 3 identical 40-pen WTF barns, each stocked with~900 pigs.", [["oral", "ANATOMY", 220, 224], ["nasal area", "ANATOMY", 225, 235], ["hand", "ANATOMY", 261, 265], ["PEDV", "CHEMICAL", 133, 137], ["PEDV", "CHEMICAL", 148, 152], ["pigs", "ORGANISM", 39, 43], ["pigs", "ORGANISM", 105, 109], ["gilts", "ORGANISM_SUBDIVISION", 123, 128], ["PEDV", "SIMPLE_CHEMICAL", 133, 137], ["PEDV", "SIMPLE_CHEMICAL", 148, 152], ["pigs", "ORGANISM", 214, 218], ["oral", "ORGANISM_SUBDIVISION", 220, 224], ["-nasal area", "MULTI-TISSUE_STRUCTURE", 224, 235], ["pigs", "ORGANISM", 370, 374], ["pigs", "SPECIES", 39, 43], ["pigs", "SPECIES", 105, 109], ["pigs", "SPECIES", 214, 218], ["pigs", "SPECIES", 370, 374], ["pigs", "SPECIES", 39, 43], ["pigs", "SPECIES", 105, 109], ["PEDV", "SPECIES", 133, 137], ["PEDV", "SPECIES", 148, 152], ["pigs", "SPECIES", 214, 218], ["placement", "TREATMENT", 17, 26], ["the pigs (replacement gilts)", "TREATMENT", 101, 129], ["PEDV", "PROBLEM", 133, 137], ["spraying feed", "TREATMENT", 192, 205], ["the pigs' oral-nasal area", "TREATMENT", 210, 235], ["a hand-held sprayer", "TREATMENT", 259, 278], ["positive fecal material", "OBSERVATION", 153, 176], ["nasal area", "ANATOMY", 225, 235]]], ["Pens were separated by solid walls, with 20 pens on each side of the walk way.", [["solid walls", "ANATOMY", 23, 34], ["solid walls", "MULTI-TISSUE_STRUCTURE", 23, 34], ["Pens", "TREATMENT", 0, 4], ["solid", "OBSERVATION_MODIFIER", 23, 28], ["walls", "OBSERVATION_MODIFIER", 29, 34]]], ["Pens were equipped with automatic feeders, bowl drinkers, and half-slatted floors.", [["Pens", "TREATMENT", 0, 4]]], ["The barns were constructed with natural ventilation and deep pit (2.4 m) manure handling systems.", [["natural ventilation", "TREATMENT", 32, 51], ["deep pit", "TREATMENT", 56, 64], ["natural ventilation", "OBSERVATION", 32, 51], ["deep", "ANATOMY_MODIFIER", 56, 60]]], ["Pigs were placed in the facility at the time of weaning (~3 weeks of age).", [["Pigs", "ORGANISM", 0, 4], ["Pigs", "SPECIES", 0, 4], ["Pigs", "TREATMENT", 0, 4]]], ["Pen oral fluid samples were collected from 36 pens (4 pens were not stocked) in each of the 3 barns and serum samples were collected from a convenience sample of 20 pigs in 2 pens (10 pigs per pen) in each barn.", [["oral fluid samples", "ANATOMY", 4, 22], ["serum samples", "ANATOMY", 104, 117], ["oral fluid samples", "ORGANISM_SUBSTANCE", 4, 22], ["serum samples", "ORGANISM_SUBSTANCE", 104, 117], ["pigs", "ORGANISM", 165, 169], ["pigs", "ORGANISM", 184, 188], ["pigs", "SPECIES", 165, 169], ["pigs", "SPECIES", 184, 188], ["pigs", "SPECIES", 165, 169], ["Pen oral fluid samples", "TEST", 0, 22], ["serum samples", "TEST", 104, 117]]], ["Sampling began at two weeks post placement (pigs were~5 weeks of age) and continued weekly for a total of 9 samplings.", [["pigs", "ORGANISM", 44, 48], ["pigs", "SPECIES", 44, 48], ["Sampling", "TEST", 0, 8], ["placement (pigs", "TREATMENT", 33, 48]]], ["Individual pig rectal swabs and pen fecal specimens were not collected on Site Two.Sample collectionIndividual pigs were restrained and bled using 12.5 mL vacutainer tubes (Covidien, Minneapolis, MN USA) and 20 gauge x 3.81 cm (1 \u00bd in.) needles (Smiths Medical, Dublin, OH USA).", [["rectal swabs", "ANATOMY", 15, 27], ["fecal specimens", "ANATOMY", 36, 51], ["pig", "ORGANISM", 11, 14], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 15, 27], ["fecal specimens", "ORGANISM_SUBSTANCE", 36, 51], ["pigs", "ORGANISM", 111, 115], ["pig", "SPECIES", 11, 14], ["pigs", "SPECIES", 111, 115], ["pig", "SPECIES", 11, 14], ["pigs", "SPECIES", 111, 115], ["Individual pig rectal swabs", "TREATMENT", 0, 27], ["pen fecal specimens", "TEST", 32, 51], ["Sample collectionIndividual pigs", "TREATMENT", 83, 115], ["12.5 mL vacutainer tubes", "TREATMENT", 147, 171], ["Minneapolis, MN USA)", "TREATMENT", 183, 203], ["rectal", "ANATOMY", 15, 21], ["swabs", "OBSERVATION", 22, 27]]], ["Blood samples were centrifuged at the laboratory, aliquoted, and stored at \u221220\u00b0C.Sample collectionFecal swabs were collected from individual pigs using a commercial collection and transport system (StarswabII\u00ae, Starplex\u00ae Scientific Inc., Cleveland, TN USA) and stored at \u221220\u00b0C. Prior to testing, swabs were suspended in 1 mL of PBS (1X pH 7.4, Invitrogen Corporation, Carlsbad, CA USA), vortexed, and the liquid submitted for testing by PEDV rRT-PCR.Sample collectionEach pen-level fecal sample consisted of a convenience sample of 3-to-5 fresh semi-solid feces from throughout the pen.", [["Blood samples", "ANATOMY", 0, 13], ["collectionFecal swabs", "ANATOMY", 88, 109], ["swabs", "ANATOMY", 296, 301], ["fecal sample", "ANATOMY", 482, 494], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["collectionFecal swabs", "ORGANISM_SUBSTANCE", 88, 109], ["pigs", "ORGANISM", 141, 145], ["feces", "ORGANISM_SUBDIVISION", 556, 561], ["pigs", "SPECIES", 141, 145], ["pigs", "SPECIES", 141, 145], ["PEDV", "SPECIES", 437, 441], ["Blood samples", "TEST", 0, 13], ["Sample collectionFecal swabs", "TEST", 81, 109], ["testing", "TEST", 287, 294], ["swabs", "TEST", 296, 301], ["PBS", "TEST", 328, 331], ["pH", "TEST", 336, 338], ["testing", "TEST", 426, 433], ["Sample collection", "TEST", 450, 467], ["Each pen-level fecal sample", "TEST", 467, 494], ["a convenience sample", "TEST", 508, 528], ["semi-solid feces", "OBSERVATION", 545, 561]]], ["Approximately equal portions of pen feces were placed in one 50 mL tube (Thermo Fisher Scientific, Waltham, MA USA) and stored at \u221220\u00b0C. Prior to testing, samples were homogenized (stirred),~1.0 g placed in 1 mL of PBS (1X pH 7.4, Invitrogen Corporation) and submitted for PEDV rRT-PCR testing.Sample collectionPen-based oral fluids were collected as described elsewhere [6] .", [["feces", "ANATOMY", 36, 41], ["samples", "ANATOMY", 155, 162], ["oral", "ANATOMY", 321, 325], ["Pen", "CHEMICAL", 311, 314], ["feces", "ORGANISM_SUBSTANCE", 36, 41], ["tube", "TISSUE", 67, 71], ["Pen", "GENE_OR_GENE_PRODUCT", 311, 314], ["oral", "ORGANISM_SUBDIVISION", 321, 325], ["PEDV", "SPECIES", 273, 277], ["pen feces", "TREATMENT", 32, 41], ["testing", "TEST", 146, 153], ["samples", "TEST", 155, 162], ["PBS", "TREATMENT", 215, 218], ["pH", "TEST", 223, 225], ["PEDV rRT", "TEST", 273, 281], ["PCR testing", "TEST", 282, 293], ["Sample collection", "TEST", 294, 311], ["Pen-based oral fluids", "TREATMENT", 311, 332], ["equal", "OBSERVATION_MODIFIER", 14, 19], ["portions", "OBSERVATION_MODIFIER", 20, 28], ["collection", "OBSERVATION", 301, 311]]], ["In brief, 3-strand, 100 % cotton rope was cut with the free end at shoulder height to the animals and suspended in the pen for 20 to 30 min.", [["shoulder", "ANATOMY", 67, 75], ["shoulder", "ORGANISM_SUBDIVISION", 67, 75], ["100 % cotton rope", "TREATMENT", 20, 37], ["shoulder", "ANATOMY", 67, 75]]], ["Pigs actively sought out and chewed the rope, leaving the strands moistened with oral fluids.", [["oral", "ANATOMY", 81, 85], ["Pigs", "ORGANISM", 0, 4], ["oral", "ORGANISM_SUBDIVISION", 81, 85], ["Pigs", "SPECIES", 0, 4], ["Pigs", "SPECIES", 0, 4], ["oral fluids", "TREATMENT", 81, 92]]], ["The rope was then removed from the pen and the wet portion placed in a single-use plastic bag.", [["The rope", "TREATMENT", 0, 8], ["the pen", "TREATMENT", 31, 38], ["the wet portion", "TREATMENT", 43, 58], ["a single-use plastic bag", "TREATMENT", 69, 93], ["wet", "OBSERVATION", 47, 50], ["plastic bag", "OBSERVATION", 82, 93]]], ["Oral fluids were extracted by either manual or mechanical compression (wringer) of the wet rope, after which the fluid was decanted into 50 mL centrifuge tubes (Fisher Scientific) and stored at \u221220\u00b0C.Sample collectionFor each site, all samples were completely randomized (random.org) within specimen type and submitted for testing at the end of the collection period.Sample collectionDiagnostic testing PEDV RNA extraction and real-time reverse transcriptase PCR (rRT-PCR)Sample collectionIn brief, 90 \u03bcl of viral RNA was eluted from rectal swabs, fecal samples and oral fluid specimens using the Ambion\u00ae MagMAX\u2122 viral RNA isolation kit (Life Technologies, Carlsbad CA USA) and a KingFisher\u00ae 96 magnetic particle processor (Thermo-Fisher Scientific) following the procedures provided by the manufacturers.", [["Oral", "ANATOMY", 0, 4], ["fluid", "ANATOMY", 113, 118], ["samples", "ANATOMY", 236, 243], ["rectal swabs", "ANATOMY", 534, 546], ["fecal samples", "ANATOMY", 548, 561], ["oral fluid specimens", "ANATOMY", 566, 586], ["rectal swabs", "ORGANISM_SUBSTANCE", 534, 546], ["fecal samples", "ORGANISM_SUBSTANCE", 548, 561], ["oral fluid specimens", "ORGANISM_SUBSTANCE", 566, 586], ["PEDV RNA", "RNA", 403, 411], ["reverse transcriptase", "PROTEIN", 437, 458], ["viral RNA", "RNA", 508, 517], ["Oral fluids", "TREATMENT", 0, 11], ["manual or mechanical compression (wringer)", "TREATMENT", 37, 79], ["the wet rope", "TREATMENT", 83, 95], ["Sample collection", "TEST", 200, 217], ["all samples", "TEST", 232, 243], ["specimen type", "TEST", 291, 304], ["testing", "TEST", 323, 330], ["Sample collectionDiagnostic testing", "TEST", 367, 402], ["PEDV RNA extraction", "TREATMENT", 403, 422], ["transcriptase PCR", "TEST", 445, 462], ["rRT", "TEST", 464, 467], ["Sample collection", "TEST", 472, 489], ["viral RNA", "PROBLEM", 508, 517], ["rectal swabs", "TEST", 534, 546], ["fecal samples", "TEST", 548, 561], ["oral fluid specimens", "TEST", 566, 586], ["the Ambion\u00ae MagMAX", "TREATMENT", 593, 611], ["the procedures", "TREATMENT", 760, 774], ["fluids", "OBSERVATION", 5, 11], ["mechanical compression", "OBSERVATION", 47, 69], ["fluid", "OBSERVATION", 113, 118], ["rectal", "ANATOMY", 534, 540], ["fecal", "ANATOMY", 548, 553]]], ["Samples were tested for PEDV using a PEDV N gene-based rRT-PCR described in Madson et al. [7] and performed routinely at the Iowa State University-Veterinary Diagnostic Laboratory (ISU-VDL SOP 9.5263).", [["Samples", "ANATOMY", 0, 7], ["PEDV", "SIMPLE_CHEMICAL", 24, 28], ["PEDV N gene", "DNA", 37, 48], ["rRT", "DNA", 55, 58], ["PEDV", "SPECIES", 24, 28], ["PEDV", "SPECIES", 37, 41], ["Samples", "TEST", 0, 7], ["PEDV", "PROBLEM", 24, 28], ["a PEDV N gene", "TREATMENT", 35, 48]]], ["The forward primer sequence was 5\u2032-CGCAAAGACTGAACCCACTAACCT-3\u2032, the reverse primer sequence was 5\u2032-TTGCCTCTGTTGTTACTTG GAGAT-3\u2032, and probe sequence was 5\u2032-FAM-TGTTG CCAT/ZEN/TACCACGACTCCTGC-Iowa Black-3\u2032.", [["5\u2032-FAM", "SIMPLE_CHEMICAL", 152, 158], ["forward primer sequence", "DNA", 4, 27], ["reverse primer sequence", "DNA", 68, 91], ["Iowa Black-3\u2032", "DNA", 190, 203], ["The forward primer sequence", "TEST", 0, 27], ["CGCAAAGACTGAACCCACTAACCT", "TEST", 35, 59], ["GAGAT", "TEST", 119, 124], ["probe sequence", "TEST", 133, 147], ["FAM", "TEST", 155, 158], ["CCAT", "TEST", 165, 169]]], ["The eluted RNA, primers, and probe were mixed with commercial reagents TaqMan\u00ae Fast Virus 1-Step Master Mix (Life Technologies) and the rRT-PCR reactions were conducted on an ABI 7500 Fast instrument (Life Technologies) in fast mode as follows: 1 cycle at 50\u00b0C for 5 min, 1 cycle at 95\u00b0C for 20 s, 40 cycles at 95\u00b0C for 3 s, and 60\u00b0C for 30 s.", [["The eluted RNA", "TREATMENT", 0, 14], ["primers", "TEST", 16, 23], ["commercial reagents", "TREATMENT", 51, 70], ["Fast Virus", "TREATMENT", 79, 89], ["the rRT", "TREATMENT", 132, 139], ["PCR reactions", "PROBLEM", 140, 153], ["an ABI", "TEST", 172, 178], ["eluted RNA", "OBSERVATION", 4, 14]]], ["Quantification cycle (Cq) values < 35 were considered positive for the corresponding coronavirus.", [["coronavirus", "DISEASE", 85, 96], ["coronavirus", "ORGANISM", 85, 96], ["Quantification cycle (Cq) values", "TEST", 0, 32], ["the corresponding coronavirus", "PROBLEM", 67, 96], ["coronavirus", "OBSERVATION", 85, 96]]], ["Data were reported as 'adjusted Cqs':PEDV whole virus (WV) antibody ELISAA U.S. prototype PEDV isolate (USA/NC35140/2013, [8] ) was used in the PEDV WV antibody ELISA.", [["PEDV whole virus", "ORGANISM", 37, 53], ["PEDV whole virus", "SPECIES", 37, 53], ["PEDV", "SPECIES", 144, 148], ["PEDV whole virus", "TEST", 37, 53]]], ["Each batch of approximately 1000 mL of PEDV was propagated on Vero cells (ATCC CCL-81).", [["Vero cells", "ANATOMY", 62, 72], ["ATCC CCL-81", "ANATOMY", 74, 85], ["PEDV", "CHEMICAL", 39, 43], ["PEDV", "SIMPLE_CHEMICAL", 39, 43], ["Vero cells", "CELL", 62, 72], ["ATCC CCL-81", "CELL", 74, 85], ["Vero cells", "CELL_LINE", 62, 72], ["ATCC CCL-81", "CELL_LINE", 74, 85], ["PEDV", "SPECIES", 39, 43], ["ATCC CCL-81", "SPECIES", 74, 85], ["PEDV", "PROBLEM", 39, 43], ["Vero cells", "TREATMENT", 62, 72], ["ATCC CCL", "TEST", 74, 82]]], ["Briefly, one 75 cm 2 flask (Thermo Fisher Scientific) of confluent Vero cells was inoculated with 3 mL of PEDV stock (1x10 5 TCID 50 per mL) followed by the addition of 50 mL of cell culture medium composed of MEM 1X (Minimum Essential Medium, Life Technologies) supplemented with 0.3 % tryptose phosphate broth, 0.02 % yeast extract, 5 ug per mL Trypsin 250 (Sigma-Aldrich, St. Louis, MO USA), plus penicillin/streptomycin (10 U per mL), gentamicin (0.05 mg per mL) and amphotericin (0.25 \u03bcg per mL) as antibiotics.", [["Vero cells", "ANATOMY", 67, 77], ["cell", "ANATOMY", 178, 182], ["extract", "ANATOMY", 326, 333], ["1x10 5 TCID", "CHEMICAL", 118, 129], ["tryptose phosphate", "CHEMICAL", 287, 305], ["penicillin", "CHEMICAL", 400, 410], ["streptomycin", "CHEMICAL", 411, 423], ["gentamicin", "CHEMICAL", 439, 449], ["amphotericin", "CHEMICAL", 471, 483], ["tryptose phosphate", "CHEMICAL", 287, 305], ["penicillin", "CHEMICAL", 400, 410], ["streptomycin", "CHEMICAL", 411, 423], ["gentamicin", "CHEMICAL", 439, 449], ["amphotericin", "CHEMICAL", 471, 483], ["Vero cells", "CELL", 67, 77], ["cell", "CELL", 178, 182], ["tryptose phosphate broth", "SIMPLE_CHEMICAL", 287, 311], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 360, 373], ["St. Louis", "ORGANISM", 375, 384], ["MO USA", "ORGANISM", 386, 392], ["penicillin", "SIMPLE_CHEMICAL", 400, 410], ["streptomycin", "SIMPLE_CHEMICAL", 411, 423], ["gentamicin", "SIMPLE_CHEMICAL", 439, 449], ["amphotericin", "SIMPLE_CHEMICAL", 471, 483], ["confluent Vero cells", "CELL_LINE", 57, 77], ["yeast", "SPECIES", 320, 325], ["PEDV", "SPECIES", 106, 110], ["yeast", "SPECIES", 320, 325], ["confluent Vero cells", "PROBLEM", 57, 77], ["PEDV stock", "TREATMENT", 106, 116], ["cell culture medium", "TREATMENT", 178, 197], ["Essential Medium, Life Technologies", "TREATMENT", 226, 261], ["0.3 % tryptose phosphate broth", "TREATMENT", 281, 311], ["penicillin", "TREATMENT", 400, 410], ["streptomycin", "TREATMENT", 411, 423], ["gentamicin", "TREATMENT", 439, 449], ["amphotericin", "TREATMENT", 471, 483], ["antibiotics", "TREATMENT", 504, 515], ["75 cm", "OBSERVATION_MODIFIER", 13, 18], ["confluent", "OBSERVATION_MODIFIER", 57, 66], ["Vero cells", "OBSERVATION", 67, 77]]], ["After 3 to 4 days at 37\u00b0C in a 5 % CO 2 incubator and when cytopathic effects were apparent, the contents of the flask (53 mL) were used to further expand the virus by inoculating each of 4 875 cm 2 flasks (BD Falcon, San Jose, CA) containing confluent Vero cell monolayers with 13 mL of the harvested PEDV plus 240 mL of culture medium.", [["Vero cell monolayers", "ANATOMY", 253, 273], ["PEDV", "CHEMICAL", 302, 306], ["CO 2", "CHEMICAL", 35, 39], ["Vero cell monolayers", "CELL", 253, 273], ["confluent Vero cell monolayers", "CELL_LINE", 243, 273], ["PEDV", "SPECIES", 302, 306], ["a 5 % CO 2 incubator", "TREATMENT", 29, 49], ["cytopathic effects", "PROBLEM", 59, 77], ["the virus", "PROBLEM", 155, 164], ["San Jose, CA)", "TREATMENT", 218, 231], ["confluent Vero cell monolayers", "TREATMENT", 243, 273], ["the harvested PEDV", "TREATMENT", 288, 306], ["culture medium", "TEST", 322, 336], ["confluent", "OBSERVATION_MODIFIER", 243, 252], ["Vero cell monolayers", "OBSERVATION", 253, 273], ["harvested PEDV", "OBSERVATION", 292, 306]]], ["After 3 to 4 days of incubation and when cytopathic effects were apparent, the fluid was frozen (\u221280\u00b0C), thawed, poured off, and then centrifuged at 4,000 x g for 15 min to remove cell debris.", [["fluid", "ANATOMY", 79, 84], ["cell", "ANATOMY", 180, 184], ["fluid", "ORGANISM_SUBSTANCE", 79, 84], ["cell", "CELL", 180, 184], ["incubation", "TREATMENT", 21, 31], ["cytopathic effects", "PROBLEM", 41, 59], ["cell debris", "PROBLEM", 180, 191], ["fluid", "OBSERVATION", 79, 84], ["cell debris", "OBSERVATION", 180, 191]]], ["The virus was pelleted by ultracentrifugation at 140,992 x g for 3 h, after which the pellet was washed twice with sterile PBS (1X pH 7.4) to remove culture medium components.", [["The virus", "PROBLEM", 0, 9], ["sterile PBS", "TREATMENT", 115, 126], ["pH", "TEST", 131, 133], ["culture medium components", "TEST", 149, 174], ["virus", "OBSERVATION", 4, 9]]], ["The purified virus was re-suspended in 100\u00b5l PBS (1X pH 7.4) at a 1:100 dilution of the original supernatant volume and stored at \u221280\u00b0C. Following titration and optimal dilution (PBS pH 7.4), polystyrene 96-well microtitration plates (Nalge Nunc, Rochester, NY USA) were manually coated (100 \u03bcl per well) with the viral antigen solution and incubated at 4\u00b0C overnight.", [["supernatant", "ANATOMY", 97, 108], ["polystyrene", "CHEMICAL", 192, 203], ["polystyrene", "CHEMICAL", 192, 203], ["The purified virus", "PROBLEM", 0, 18], ["pH", "TEST", 53, 55], ["titration", "TEST", 147, 156], ["optimal dilution", "TEST", 161, 177], ["PBS pH", "TEST", 179, 185], ["polystyrene", "TEST", 192, 203], ["the viral antigen solution", "TREATMENT", 310, 336], ["virus", "OBSERVATION", 13, 18], ["supernatant volume", "OBSERVATION", 97, 115]]], ["After incubation, plates were washed 5 times, blocked with 300 \u03bcl per well of a solution containing 1 % bovine serum albumin (Jackson ImmunoResearch Inc., West Grove, PA USA), and incubated at 25\u00b0C for 2 h.", [["serum", "ANATOMY", 111, 116], ["bovine", "ORGANISM", 104, 110], ["serum", "ORGANISM_SUBSTANCE", 111, 116], ["albumin", "ORGANISM_SUBSTANCE", 117, 124], ["bovine", "SPECIES", 104, 110], ["bovine", "SPECIES", 104, 110], ["ImmunoResearch", "SPECIES", 134, 148], ["plates", "TREATMENT", 18, 24], ["a solution", "TREATMENT", 78, 88], ["1 % bovine serum albumin", "TREATMENT", 100, 124]]], ["Plates were then dried at 37\u00b0C for 4 h and stored at 4\u00b0C in a sealed bag with desiccant packs.", [["a sealed bag", "TREATMENT", 60, 72], ["desiccant packs", "TREATMENT", 78, 93], ["bag", "OBSERVATION", 69, 72], ["desiccant packs", "OBSERVATION", 78, 93]]], ["The performance of each lot of plates was standardized using a panel of reference PEDV negatives and positives.", [["a panel", "TEST", 61, 68]]], ["ELISA conditions for the detection of anti-PEDV IgA and IgG antibodies in serum and oral fluid specimens, including coating and blocking conditions, reagent concentrations, incubation times, and buffers, were identical.", [["serum", "ANATOMY", 74, 79], ["oral fluid specimens", "ANATOMY", 84, 104], ["anti-PEDV IgA", "GENE_OR_GENE_PRODUCT", 38, 51], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 56, 70], ["serum", "ORGANISM_SUBSTANCE", 74, 79], ["oral fluid specimens", "ORGANISM_SUBSTANCE", 84, 104], ["anti-PEDV IgA", "PROTEIN", 38, 51], ["IgG antibodies", "PROTEIN", 56, 70], ["anti-PEDV", "SPECIES", 38, 47], ["ELISA conditions", "TEST", 0, 16], ["the detection", "TEST", 21, 34], ["anti-PEDV IgA", "TEST", 38, 51], ["IgG antibodies", "TEST", 56, 70], ["serum and oral fluid specimens", "TEST", 74, 104], ["coating and blocking conditions", "PROBLEM", 116, 147]]], ["Serum samples were diluted 1:50 and oral fluid samples were diluted 1:2, after which plates were loaded with 100 \u03bcl of the diluted sample per well.", [["Serum samples", "ANATOMY", 0, 13], ["oral fluid samples", "ANATOMY", 36, 54], ["sample", "ANATOMY", 131, 137], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["oral fluid samples", "ORGANISM_SUBSTANCE", 36, 54], ["Serum samples", "TEST", 0, 13], ["oral fluid samples", "TEST", 36, 54], ["the diluted sample", "TREATMENT", 119, 137]]], ["Plates were incubated at 25\u00b0C (serum) or 37\u00b0C (oral fluid) for 1 h and then washed 5 times with PBS (1X pH 7.4).", [["serum", "ANATOMY", 31, 36], ["oral fluid", "ANATOMY", 47, 57], ["serum", "ORGANISM_SUBSTANCE", 31, 36], ["oral", "ORGANISM_SUBDIVISION", 47, 51], ["fluid", "ORGANISM_SUBSTANCE", 52, 57], ["Plates", "TEST", 0, 6], ["serum", "TEST", 31, 36], ["PBS", "TEST", 96, 99], ["pH", "TEST", 104, 106]]], ["Positive and negative plate controls, i.e., antibody-positive and -negative experimental serum samples, were run in duplicate on each ELISA plate.PEDV whole virus (WV) antibody ELISATo perform the assay, 100 \u03bcl of peroxidase-conjugated goat anti-pig IgG (Fc) antibody (Bethyl Laboratories Inc., Montgomery, TX USA) diluted 1:20,000 for serum and 1:3,000 for oral fluid samples or goat anti-pig IgA (Bethyl Laboratories Inc.) diluted 1:7,000 for serum and 1:3,000 for oral fluid samples was added to each well and the plates incubated at 25\u00b0C (serum) or 37\u00b0C (oral fluid) for 1 h.", [["serum samples", "ANATOMY", 89, 102], ["serum", "ANATOMY", 336, 341], ["oral fluid samples", "ANATOMY", 358, 376], ["serum", "ANATOMY", 445, 450], ["oral fluid samples", "ANATOMY", 467, 485], ["serum", "ANATOMY", 543, 548], ["oral", "ANATOMY", 559, 563], ["serum", "ORGANISM", 89, 94], ["PEDV whole virus", "ORGANISM", 146, 162], ["peroxidase", "GENE_OR_GENE_PRODUCT", 214, 224], ["serum", "ORGANISM_SUBSTANCE", 336, 341], ["oral fluid samples", "ORGANISM_SUBSTANCE", 358, 376], ["goat", "ORGANISM", 380, 384], ["IgA", "GENE_OR_GENE_PRODUCT", 394, 397], ["Bethyl", "GENE_OR_GENE_PRODUCT", 399, 405], ["serum", "ORGANISM_SUBSTANCE", 445, 450], ["oral fluid samples", "ORGANISM_SUBSTANCE", 467, 485], ["serum", "ORGANISM_SUBSTANCE", 543, 548], ["oral", "ORGANISM_SUBDIVISION", 559, 563], ["fluid", "ORGANISM_SUBSTANCE", 564, 569], ["PEDV whole virus (WV) antibody ELISATo", "PROTEIN", 146, 184], ["peroxidase", "PROTEIN", 214, 224], ["conjugated goat anti-pig IgG (Fc) antibody", "PROTEIN", 225, 267], ["goat anti-pig IgA", "PROTEIN", 380, 397], ["goat", "SPECIES", 236, 240], ["goat", "SPECIES", 380, 384], ["PEDV whole virus", "SPECIES", 146, 162], ["goat", "SPECIES", 236, 240], ["goat", "SPECIES", 380, 384], ["antibody", "TEST", 44, 52], ["experimental serum samples", "TEST", 76, 102], ["PEDV whole virus", "TEST", 146, 162], ["the assay", "TEST", 193, 202], ["peroxidase", "TEST", 214, 224], ["conjugated goat anti-pig IgG", "TEST", 225, 253], ["antibody", "TEST", 259, 267], ["serum", "TEST", 336, 341], ["oral fluid samples", "TEST", 358, 376], ["goat anti-pig IgA", "TEST", 380, 397], ["serum", "TEST", 445, 450], ["oral fluid samples", "TEST", 467, 485], ["the plates", "TEST", 513, 523], ["serum", "TEST", 543, 548], ["negative plate controls", "OBSERVATION", 13, 36]]], ["After a washing step, the reaction was visualized by adding 100 \u03bcl of tetramethylbenzidine-hydrogen peroxide (Dako North America, Inc., Carpinteria, CA USA) substrate solution to each well.", [["tetramethylbenzidine-hydrogen peroxide", "CHEMICAL", 70, 108], ["tetramethylbenzidine", "CHEMICAL", 70, 90], ["hydrogen peroxide", "CHEMICAL", 91, 108], ["tetramethylbenzidine-hydrogen peroxide", "SIMPLE_CHEMICAL", 70, 108], ["a washing step", "TREATMENT", 6, 20], ["the reaction", "PROBLEM", 22, 34], ["tetramethylbenzidine", "TREATMENT", 70, 90], ["hydrogen peroxide", "TREATMENT", 91, 108], ["Carpinteria, CA USA) substrate solution", "TREATMENT", 136, 175]]], ["After 5 min incubation at room temperature, the reaction was stopped by the addition of 50 \u03bcl of stop solution (1 M sulfuric acid) to each well.", [["sulfuric acid", "CHEMICAL", 116, 129], ["sulfuric acid", "CHEMICAL", 116, 129], ["sulfuric acid", "SIMPLE_CHEMICAL", 116, 129], ["stop solution (1 M sulfuric acid)", "TREATMENT", 97, 130]]], ["Reactions were measured as optical density (OD) at 450 nm using an ELISA plate reader (Biotek \u00ae Instruments Inc., Winooski, VT USA) operated with commercial software (GEN5\u2122, Biotek \u00ae Instruments Inc.).", [["an ELISA plate reader (Biotek \u00ae Instruments", "TREATMENT", 64, 107]]], ["The antibody response in serum and oral fluid samples was represented as sample-to-positive (S/P) ratios calculated as:Data analysisStatistical analyses were performed using commercial statistical software (SAS\u00ae Version 9.4, SAS\u00ae Institute, Inc., Cary, NC) using test results on serum (Site One, n = 330; Site Two, n = 540), oral fluid (Site One, n = 66; Site 2, n = 972), rectal swabs (Site One, n = 330), and pen feces (Site One, n = 66).", [["serum", "ANATOMY", 25, 30], ["oral fluid samples", "ANATOMY", 35, 53], ["sample", "ANATOMY", 73, 79], ["serum", "ANATOMY", 279, 284], ["oral", "ANATOMY", 325, 329], ["rectal swabs", "ANATOMY", 373, 385], ["serum", "ORGANISM_SUBSTANCE", 25, 30], ["oral fluid samples", "ORGANISM_SUBSTANCE", 35, 53], ["serum", "ORGANISM_SUBSTANCE", 279, 284], ["oral", "ORGANISM_SUBDIVISION", 325, 329], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 373, 385], ["The antibody response", "TEST", 0, 21], ["serum", "TEST", 25, 30], ["oral fluid samples", "TEST", 35, 53], ["sample", "TEST", 73, 79], ["ratios", "TEST", 98, 104], ["Data analysisStatistical analyses", "TEST", 119, 152], ["Version", "TEST", 212, 219], ["serum", "TEST", 279, 284], ["Site", "TEST", 305, 309], ["oral fluid", "TEST", 325, 335], ["Site", "TEST", 355, 359], ["rectal swabs", "TEST", 373, 385], ["antibody response", "OBSERVATION", 4, 21], ["oral", "ANATOMY", 325, 329], ["fluid", "OBSERVATION", 330, 335], ["rectal", "ANATOMY", 373, 379]]], ["A mixed-effects repeated measures model (Proc GLIMMIX) was used to analyze the association between the detection of PEDV by rRT-PCR and the variables of interest, i.e., sample specimen (oral fluids, rectal swab, pen feces, serum) and day post exposure (DPE) using pen as a random effect.", [["sample specimen", "ANATOMY", 169, 184], ["oral", "ANATOMY", 186, 190], ["rectal swab", "ANATOMY", 199, 210], ["feces", "ANATOMY", 216, 221], ["serum", "ANATOMY", 223, 228], ["oral", "ORGANISM_SUBDIVISION", 186, 190], ["rectal swab", "MULTI-TISSUE_STRUCTURE", 199, 210], ["feces", "ORGANISM_SUBDIVISION", 216, 221], ["serum", "ORGANISM_SUBSTANCE", 223, 228], ["rRT", "PROTEIN", 124, 127], ["PEDV", "SPECIES", 116, 120], ["A mixed-effects repeated measures model (Proc GLIMMIX)", "TREATMENT", 0, 54], ["PEDV", "PROBLEM", 116, 120], ["rRT", "TEST", 124, 127], ["PCR", "TEST", 128, 131], ["sample specimen", "TEST", 169, 184], ["oral fluids", "TEST", 186, 197], ["rectal swab, pen feces, serum", "TEST", 199, 228], ["mixed", "OBSERVATION_MODIFIER", 2, 7]]], ["Fixed effects were considered significant at \u03b1 = 0.05.", [["Fixed effects", "PROBLEM", 0, 13]]], ["Differences in the proportion of PEDV rRT-PCR positive oral fluid, rectal swab, and pen feces was compared using the Fisher Exact Test.", [["oral fluid", "ANATOMY", 55, 65], ["rectal swab", "ANATOMY", 67, 78], ["oral fluid", "MULTI-TISSUE_STRUCTURE", 55, 65], ["rectal swab", "MULTI-TISSUE_STRUCTURE", 67, 78], ["feces", "ORGANISM_SUBSTANCE", 88, 93], ["PEDV", "SPECIES", 33, 37], ["PEDV rRT", "TEST", 33, 41], ["PCR", "TEST", 42, 45], ["oral fluid", "TEST", 55, 65], ["rectal swab", "TEST", 67, 78], ["the Fisher Exact Test", "TEST", 113, 134], ["rectal", "ANATOMY", 67, 73]]], ["Point and interval estimates of the sensitivity and specificity of the PEDV WV IgG and IgA ELISAs for serum and oral fluid samples were calculated using the exact Binomial formula and confidence intervals.PEDV rRT-PCROn Site Two, all oral fluid samples (n = 972) collected during the monitoring period were PEDV rRT-PCRnegative.", [["serum", "ANATOMY", 102, 107], ["oral fluid samples", "ANATOMY", 112, 130], ["oral fluid samples", "ANATOMY", 234, 252], ["IgG", "GENE_OR_GENE_PRODUCT", 79, 82], ["IgA", "GENE_OR_GENE_PRODUCT", 87, 90], ["serum", "ORGANISM_SUBSTANCE", 102, 107], ["oral fluid samples", "ORGANISM_SUBSTANCE", 112, 130], ["oral fluid samples", "ORGANISM_SUBSTANCE", 234, 252], ["PEDV WV IgG", "PROTEIN", 71, 82], ["IgA", "PROTEIN", 87, 90], ["PEDV", "SPECIES", 71, 75], ["PEDV", "SPECIES", 205, 209], ["PEDV", "SPECIES", 307, 311], ["the sensitivity", "TEST", 32, 47], ["the PEDV WV IgG", "TEST", 67, 82], ["IgA ELISAs", "TEST", 87, 97], ["serum", "TEST", 102, 107], ["oral fluid samples", "TEST", 112, 130], ["PEDV rRT", "TREATMENT", 205, 213], ["all oral fluid samples", "TEST", 230, 252], ["PEDV rRT", "TREATMENT", 307, 315], ["PCRnegative", "PROBLEM", 316, 327]]], ["On Site One, PEDV was detected in individual rectal swabs, pen fecal samples, and pen oral fluids by rRT-PCR collected for 10 weeks post exposure (Fig. 1a) , i.e., through 69 DPE (23 weeks of age).", [["rectal swabs", "ANATOMY", 45, 57], ["fecal samples", "ANATOMY", 63, 76], ["oral fluids", "ANATOMY", 86, 97], ["PEDV", "ORGANISM", 13, 17], ["rectal swabs", "ORGANISM_SUBSTANCE", 45, 57], ["fecal samples", "ORGANISM_SUBSTANCE", 63, 76], ["oral", "ORGANISM_SUBDIVISION", 86, 90], ["fluids", "ORGANISM_SUBSTANCE", 91, 97], ["PEDV", "SPECIES", 13, 17], ["PEDV", "PROBLEM", 13, 17], ["individual rectal swabs", "TEST", 34, 57], ["pen fecal samples", "TEST", 59, 76], ["pen oral fluids", "TREATMENT", 82, 97], ["PCR", "TEST", 105, 108], ["PEDV", "OBSERVATION", 13, 17], ["rectal swabs", "ANATOMY", 45, 57]]], ["An analysis of the adjusted rRT-PCR Cq values showed differences in the concentration of PEDV in the three sample types over time (p = 0.0005).", [["sample", "ANATOMY", 107, 113], ["PEDV", "CHEMICAL", 89, 93], ["PEDV", "SIMPLE_CHEMICAL", 89, 93], ["An analysis", "TEST", 0, 11], ["the adjusted rRT", "TREATMENT", 15, 31], ["Cq values", "TEST", 36, 45], ["PEDV", "PROBLEM", 89, 93], ["PEDV", "OBSERVATION", 89, 93]]], ["The concentration of PEDV was higher in pen fecal samples compared to rectal swabs (p = 0.0001) and oral fluids (p = 0.0088) at 6 DPE.", [["fecal samples", "ANATOMY", 44, 57], ["rectal swabs", "ANATOMY", 70, 82], ["oral fluids", "ANATOMY", 100, 111], ["PEDV", "CHEMICAL", 21, 25], ["PEDV", "SIMPLE_CHEMICAL", 21, 25], ["fecal samples", "ORGANISM_SUBSTANCE", 44, 57], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 70, 82], ["oral", "ORGANISM_SUBDIVISION", 100, 104], ["PEDV", "SPECIES", 21, 25], ["PEDV", "PROBLEM", 21, 25], ["rectal swabs", "TEST", 70, 82], ["oral fluids", "TREATMENT", 100, 111], ["concentration", "OBSERVATION_MODIFIER", 4, 17], ["PEDV", "OBSERVATION", 21, 25], ["higher", "OBSERVATION_MODIFIER", 30, 36], ["rectal", "ANATOMY", 70, 76]]], ["Thereafter, no difference was detected in the concentration of virus in oral fluid and pen fecal samples through 69 DPE.", [["oral fluid", "ANATOMY", 72, 82], ["fecal samples", "ANATOMY", 91, 104], ["oral fluid", "ORGANISM_SUBSTANCE", 72, 82], ["fecal samples", "ORGANISM_SUBSTANCE", 91, 104], ["virus in oral fluid", "TEST", 63, 82], ["pen fecal samples", "TEST", 87, 104], ["no", "UNCERTAINTY", 12, 14], ["difference", "OBSERVATION_MODIFIER", 15, 25], ["virus", "OBSERVATION", 63, 68]]], ["In contrast, the concentration of PEDV in rectal swab samples was significantly lower than in pen fecal samples and oral fluid samples at 13, 27, and 41 DPE (15, 17, 19 weeks of age) (p < 0.002).PEDV rRT-PCRAn analysis of the proportion of rRT-PCR positive samples (Fig. 1b) found differences among specimen types at 27, 41, and 55 DPE (17, 19, 21 weeks of age) (Fisher's Exact Test, p < 0.03).", [["rectal swab samples", "ANATOMY", 42, 61], ["fecal samples", "ANATOMY", 98, 111], ["oral fluid samples", "ANATOMY", 116, 134], ["samples", "ANATOMY", 257, 264], ["specimen", "ANATOMY", 299, 307], ["PEDV", "CHEMICAL", 34, 38], ["PEDV", "SIMPLE_CHEMICAL", 34, 38], ["rectal swab samples", "ORGANISM_SUBSTANCE", 42, 61], ["fecal samples", "ORGANISM_SUBSTANCE", 98, 111], ["oral fluid samples", "ORGANISM_SUBSTANCE", 116, 134], ["PEDV", "PROTEIN", 34, 38], ["PEDV", "SPECIES", 34, 38], ["PEDV", "SPECIES", 195, 199], ["PEDV in rectal swab samples", "TEST", 34, 61], ["pen fecal samples", "TEST", 94, 111], ["oral fluid samples", "TEST", 116, 134], ["DPE", "TEST", 153, 156], ["PEDV rRT", "TEST", 195, 203], ["PCRAn analysis", "TEST", 204, 218], ["rRT", "TEST", 240, 243], ["PCR", "TEST", 244, 247], ["specimen types", "TEST", 299, 313], ["DPE", "TEST", 332, 335], ["Fisher's Exact Test", "TEST", 363, 382], ["p", "TEST", 384, 385], ["rectal", "ANATOMY", 42, 48]]], ["No differences were found between pen fecal samples and oral fluid samples over the monitoring period, except at 55 DPE when 6 of 6 oral fluid and 1 of 6 pen fecal samples were positive (p = 0.015).", [["fecal samples", "ANATOMY", 38, 51], ["oral fluid samples", "ANATOMY", 56, 74], ["oral fluid", "ANATOMY", 132, 142], ["fecal samples", "ANATOMY", 158, 171], ["fecal samples", "ORGANISM_SUBSTANCE", 38, 51], ["oral fluid samples", "ORGANISM_SUBSTANCE", 56, 74], ["oral", "ORGANISM_SUBDIVISION", 132, 136], ["fluid", "ORGANISM_SUBSTANCE", 137, 142], ["pen fecal samples", "TEST", 34, 51], ["oral fluid samples", "TEST", 56, 74], ["6 pen fecal samples", "TEST", 152, 171]]], ["However, the proportion of positive oral fluid specimens was significantly greater than rectal swabs at 27, 41, and 55 DPE (17, 19, 21 weeks of age) (p < 0.02).", [["oral fluid specimens", "ANATOMY", 36, 56], ["rectal swabs", "ANATOMY", 88, 100], ["oral fluid", "ORGANISM_SUBSTANCE", 36, 46], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 88, 100], ["positive oral fluid specimens", "TEST", 27, 56], ["rectal swabs", "TEST", 88, 100], ["DPE", "TEST", 119, 122], ["positive", "OBSERVATION_MODIFIER", 27, 35], ["fluid specimens", "OBSERVATION", 41, 56]]], ["Likewise, the proportion of positive pen fecal samples at 41 DPE was significantly greater than rectal swabs (p = 0.0012).", [["fecal samples", "ANATOMY", 41, 54], ["rectal swabs", "ANATOMY", 96, 108], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 96, 108], ["positive pen fecal samples", "PROBLEM", 28, 54], ["DPE", "TEST", 61, 64], ["rectal swabs", "TEST", 96, 108], ["positive", "OBSERVATION_MODIFIER", 28, 36]]], ["Figures 2b and 3b show the percent positive oral fluid samples and serum samples, respectively, for three S/P cutoffs.", [["oral fluid samples", "ANATOMY", 44, 62], ["serum samples", "ANATOMY", 67, 80], ["3b", "GENE_OR_GENE_PRODUCT", 15, 17], ["oral fluid samples", "ORGANISM_SUBSTANCE", 44, 62], ["serum samples", "ORGANISM_SUBSTANCE", 67, 80], ["Figures", "TEST", 0, 7], ["the percent positive oral fluid samples", "TEST", 23, 62], ["serum samples", "TEST", 67, 80]]], ["Oral fluid (n = 972) and serum samples (n = 540) from Site Two were used as a source of PEDV negative samples for calculating cutoffs and performance estimates for the PEDV WV IgA and IgG ELISAs using the exact Binomial formula and confidence intervals (Table 1 ).DiscussionThe first objective of this study was to compare the detection of PEDV by rRT-PCR in rectal swabs, pen fecal samples, and oral fluid samples from pigs housed in commercial WTF facilities.", [["Oral fluid", "ANATOMY", 0, 10], ["serum samples", "ANATOMY", 25, 38], ["samples", "ANATOMY", 102, 109], ["rectal swabs", "ANATOMY", 359, 371], ["fecal samples", "ANATOMY", 377, 390], ["oral fluid samples", "ANATOMY", 396, 414], ["serum samples", "ORGANISM_SUBSTANCE", 25, 38], ["IgA", "GENE_OR_GENE_PRODUCT", 176, 179], ["PEDV", "SIMPLE_CHEMICAL", 340, 344], ["rectal swabs", "ORGANISM_SUBSTANCE", 359, 371], ["fecal samples", "ORGANISM_SUBSTANCE", 377, 390], ["oral fluid samples", "ORGANISM_SUBSTANCE", 396, 414], ["pigs", "ORGANISM", 420, 424], ["PEDV", "PROTEIN", 168, 172], ["IgA", "PROTEIN", 176, 179], ["IgG", "PROTEIN", 184, 187], ["PEDV", "DNA", 340, 344], ["pigs", "SPECIES", 420, 424], ["PEDV", "SPECIES", 168, 172], ["PEDV", "SPECIES", 340, 344], ["pigs", "SPECIES", 420, 424], ["Oral fluid", "TEST", 0, 10], ["serum samples", "TEST", 25, 38], ["PEDV", "PROBLEM", 88, 92], ["calculating cutoffs", "TEST", 114, 133], ["the PEDV", "TEST", 164, 172], ["IgG ELISAs", "TEST", 184, 194], ["this study", "TEST", 297, 307], ["the detection", "TEST", 323, 336], ["PEDV", "PROBLEM", 340, 344], ["rRT", "TEST", 348, 351], ["PCR", "TEST", 352, 355], ["rectal swabs", "TEST", 359, 371], ["pen fecal samples", "TEST", 373, 390], ["oral fluid samples", "TEST", 396, 414], ["fluid", "OBSERVATION", 5, 10], ["rectal", "ANATOMY", 359, 365]]], ["Specifically, comparisons were made among specimens in the duration of PEDV detection, proportion of positive samples, and concentration of virus in positive samples.DiscussionPEDV was detected by rRT-PCR in rectal swabs, pen fecal samples, and oral fluid samples, with the last rRT-PCR positive rectal swabs collected at 69 DPE, pen fecal samples at 55 DPE, and oral fluid samples at 69 DPE.", [["specimens", "ANATOMY", 42, 51], ["samples", "ANATOMY", 110, 117], ["samples", "ANATOMY", 158, 165], ["rectal swabs", "ANATOMY", 208, 220], ["fecal samples", "ANATOMY", 226, 239], ["oral fluid samples", "ANATOMY", 245, 263], ["rectal swabs", "ANATOMY", 296, 308], ["fecal samples", "ANATOMY", 334, 347], ["oral fluid samples", "ANATOMY", 363, 381], ["rectal swabs", "ORGANISM_SUBSTANCE", 208, 220], ["fecal samples", "ORGANISM_SUBSTANCE", 226, 239], ["oral fluid samples", "ORGANISM_SUBSTANCE", 245, 263], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 296, 308], ["oral fluid samples", "ORGANISM_SUBSTANCE", 363, 381], ["PEDV", "SPECIES", 71, 75], ["PEDV detection", "TEST", 71, 85], ["positive samples", "PROBLEM", 101, 117], ["virus", "PROBLEM", 140, 145], ["PCR", "TEST", 201, 204], ["rectal swabs", "TEST", 208, 220], ["pen fecal samples", "TEST", 222, 239], ["oral fluid samples", "TEST", 245, 263], ["the last rRT", "TEST", 270, 282], ["PCR", "TEST", 283, 286], ["rectal swabs", "TEST", 296, 308], ["pen fecal samples", "TEST", 330, 347], ["DPE", "TEST", 354, 357], ["oral fluid samples", "TEST", 363, 381], ["rectal", "ANATOMY", 208, 214], ["rectal", "ANATOMY", 296, 302]]], ["The fact that the cessation of PEDV detection coincided in fecal and oral fluid samples suggested that the environment did not serve as a reservoir for PEDV.", [["fecal", "ANATOMY", 59, 64], ["oral fluid samples", "ANATOMY", 69, 87], ["PEDV", "CHEMICAL", 31, 35], ["PEDV", "CHEMICAL", 152, 156], ["fecal", "ORGANISM_SUBSTANCE", 59, 64], ["oral fluid samples", "ORGANISM_SUBSTANCE", 69, 87], ["PEDV", "SIMPLE_CHEMICAL", 152, 156], ["PEDV", "PROTEIN", 31, 35], ["PEDV", "SPECIES", 31, 35], ["PEDV", "SPECIES", 152, 156], ["PEDV detection", "TEST", 31, 45], ["fecal and oral fluid samples", "TEST", 59, 87], ["a reservoir", "TREATMENT", 136, 147], ["PEDV", "PROBLEM", 152, 156], ["fecal", "ANATOMY", 59, 64]]], ["Previous publications provided data with which rectal swab data could be compared, but a comprehensive search of the literature did not find previous reports on the detection of PEDV in pen feces or pen-based oral fluid samples.", [["rectal swab", "ANATOMY", 47, 58], ["oral fluid samples", "ANATOMY", 209, 227], ["PEDV", "CHEMICAL", 178, 182], ["PEDV", "SIMPLE_CHEMICAL", 178, 182], ["pen feces", "ORGANISM", 186, 195], ["oral fluid samples", "ORGANISM_SUBSTANCE", 209, 227], ["PEDV", "SPECIES", 178, 182], ["rectal swab data", "TEST", 47, 63], ["the detection", "TEST", 161, 174], ["PEDV in pen feces", "TEST", 178, 195], ["pen-based oral fluid samples", "TEST", 199, 227]]], ["Madson et al. [7] detected PEDV in rectal swabs through 24 days post inoculation (DPI) in 5 of 8 pigs inoculated at 3 weeks of age with PEDV isolate US/Iowa/18984/ 2013.", [["rectal swabs", "ANATOMY", 35, 47], ["DPI", "CHEMICAL", 82, 85], ["PEDV", "ORGANISM", 27, 31], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 35, 47], ["pigs", "ORGANISM", 97, 101], ["pigs", "SPECIES", 97, 101], ["PEDV", "SPECIES", 27, 31], ["pigs", "SPECIES", 97, 101], ["PEDV isolate US/Iowa/18984/ 2013", "SPECIES", 136, 168], ["PEDV", "PROBLEM", 27, 31], ["rectal swabs", "TREATMENT", 35, 47], ["inoculation (DPI)", "TREATMENT", 69, 86], ["rectal", "ANATOMY", 35, 41]]], ["Thomas et al. [9] detected PEDV in rectal swabs for up to 21 DPI in 3-week-old pigs inoculated with PEDV isolate US/IN19338/2013.", [["rectal swabs", "ANATOMY", 35, 47], ["DPI", "CHEMICAL", 61, 64], ["PEDV", "ORGANISM", 27, 31], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 35, 47], ["pigs", "ORGANISM", 79, 83], ["pigs", "SPECIES", 79, 83], ["PEDV", "SPECIES", 27, 31], ["pigs", "SPECIES", 79, 83], ["PEDV", "SPECIES", 100, 104], ["PEDV", "PROBLEM", 27, 31], ["rectal swabs", "TEST", 35, 47], ["rectal", "ANATOMY", 35, 41]]], ["Crawford et al. [10] The concentration of virus, as measured by rRT-PCR, differed among specimen types.", [["specimen", "ANATOMY", 88, 96], ["The concentration of virus", "PROBLEM", 21, 47], ["rRT-PCR", "TEST", 64, 71]]], ["In particular, the concentration of PEDV nucleic acid in individual pig rectal swabs was significantly lower than oral fluid or penbased fecal samples.", [["rectal swabs", "ANATOMY", 72, 84], ["oral fluid", "ANATOMY", 114, 124], ["fecal samples", "ANATOMY", 137, 150], ["PEDV nucleic acid", "CHEMICAL", 36, 53], ["PEDV nucleic acid", "SIMPLE_CHEMICAL", 36, 53], ["pig", "ORGANISM", 68, 71], ["rectal swabs", "ORGAN", 72, 84], ["oral fluid", "ORGANISM_SUBSTANCE", 114, 124], ["fecal samples", "ORGANISM_SUBSTANCE", 137, 150], ["pig", "SPECIES", 68, 71], ["PEDV", "SPECIES", 36, 40], ["pig", "SPECIES", 68, 71], ["PEDV nucleic acid", "TEST", 36, 53], ["individual pig rectal swabs", "TEST", 57, 84], ["oral fluid", "TEST", 114, 124], ["penbased fecal samples", "PROBLEM", 128, 150], ["fluid", "OBSERVATION", 119, 124]]], ["The concentration of virus in PEDV rRT-PCR-positive oral fluid and pen-based fecal samples was not significantly different, except at 6 DPE.DiscussionDifferences were also detected among specimen types in the proportion of positive samples by time.", [["oral fluid", "ANATOMY", 52, 62], ["fecal samples", "ANATOMY", 77, 90], ["specimen", "ANATOMY", 187, 195], ["samples", "ANATOMY", 232, 239], ["oral fluid", "ORGANISM_SUBSTANCE", 52, 62], ["fecal samples", "ORGANISM_SUBSTANCE", 77, 90], ["PEDV", "SPECIES", 30, 34], ["virus", "PROBLEM", 21, 26], ["PEDV rRT", "TEST", 30, 38], ["PCR", "TEST", 39, 42], ["positive oral fluid", "PROBLEM", 43, 62], ["pen-based fecal samples", "TEST", 67, 90], ["virus", "OBSERVATION", 21, 26], ["fluid", "OBSERVATION", 57, 62], ["fecal", "ANATOMY", 77, 82], ["significantly different", "OBSERVATION_MODIFIER", 99, 122]]], ["All oral fluid samples were rRT-PCR positive (6 of 6) through 55 DPE while the number PEDV rRT-PCR-positive pen fecal samples and rectal swabs declined to \u2264 50 % at 27 DPE and later.", [["oral fluid samples", "ANATOMY", 4, 22], ["fecal samples", "ANATOMY", 112, 125], ["rectal swabs", "ANATOMY", 130, 142], ["oral fluid samples", "ORGANISM_SUBSTANCE", 4, 22], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 130, 142], ["All oral fluid samples", "TEST", 0, 22], ["rRT", "TEST", 28, 31], ["PCR", "TEST", 32, 35], ["DPE", "TEST", 65, 68], ["the number PEDV rRT", "TEST", 75, 94], ["PCR", "TEST", 95, 98], ["pen fecal samples", "TEST", 108, 125], ["rectal swabs", "TEST", 130, 142], ["rectal", "ANATOMY", 130, 136]]], ["The lower concentration and lower rate of detection in rectal swabs could be attributed to the small volume of sample retained by the swab plus the effect of diluting each rectal swab in one mL of PBS prior to testing.", [["rectal swabs", "ANATOMY", 55, 67], ["sample", "ANATOMY", 111, 117], ["swab", "ANATOMY", 134, 138], ["rectal swab", "ANATOMY", 172, 183], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 55, 67], ["The lower concentration", "TREATMENT", 0, 23], ["rectal swabs", "TREATMENT", 55, 67], ["the small volume of sample", "PROBLEM", 91, 117], ["the swab", "TEST", 130, 138], ["diluting each rectal swab", "TREATMENT", 158, 183], ["PBS", "TREATMENT", 197, 200], ["testing", "TEST", 210, 217], ["lower", "OBSERVATION_MODIFIER", 4, 9], ["concentration", "OBSERVATION_MODIFIER", 10, 23], ["lower", "OBSERVATION_MODIFIER", 28, 33], ["rectal", "ANATOMY", 55, 61], ["small", "OBSERVATION_MODIFIER", 95, 100], ["volume", "OBSERVATION_MODIFIER", 101, 107]]], ["The lower rate of detection in pen floor fecal samples may reflect the non-uniform distribution of positive samples within a pen.", [["floor fecal samples", "ANATOMY", 35, 54], ["samples", "ANATOMY", 108, 115], ["pen floor fecal samples", "TEST", 31, 54], ["positive samples", "PROBLEM", 99, 115], ["lower", "OBSERVATION_MODIFIER", 4, 9], ["non-uniform", "OBSERVATION_MODIFIER", 71, 82], ["distribution", "OBSERVATION_MODIFIER", 83, 95], ["positive samples", "OBSERVATION", 99, 115]]], ["Previously, O'Connor et al. [11] reported differences in Salmonella concentrations at various locations within a pen, i.e., the distribution of Salmonella within a pen was not uniform.DiscussionDetection of PEDV by rRT-PCR using pen-based oral fluid samples has not previously been reported in the refereed literature.", [["oral fluid samples", "ANATOMY", 239, 257], ["Salmonella", "ORGANISM", 57, 67], ["PEDV", "SIMPLE_CHEMICAL", 207, 211], ["PEDV", "DNA", 207, 211], ["Salmonella", "SPECIES", 144, 154], ["Salmonella concentrations", "PROBLEM", 57, 82], ["Salmonella", "PROBLEM", 144, 154], ["PEDV", "PROBLEM", 207, 211], ["PCR", "TEST", 219, 222], ["pen-based oral fluid samples", "TEST", 229, 257], ["Salmonella", "OBSERVATION", 144, 154]]], ["Using the described procedures, one oral fluid sample from a pen provided detection equal to, or better than, rectal swab samples from 5 pigs in the pen.", [["oral fluid sample", "ANATOMY", 36, 53], ["rectal swab samples", "ANATOMY", 110, 129], ["oral", "ORGANISM_SUBDIVISION", 36, 40], ["rectal swab samples", "ORGANISM_SUBSTANCE", 110, 129], ["pigs", "ORGANISM", 137, 141], ["pigs", "SPECIES", 137, 141], ["pigs", "SPECIES", 137, 141], ["the described procedures", "TREATMENT", 6, 30], ["one oral fluid sample", "TEST", 32, 53], ["a pen provided detection", "TEST", 59, 83], ["rectal swab samples", "TEST", 110, 129], ["rectal", "ANATOMY", 110, 116]]], ["Likewise, detection using oral fluid samples was equal to, or better than, detection using pen fecal samples.", [["oral fluid samples", "ANATOMY", 26, 44], ["fecal samples", "ANATOMY", 95, 108], ["oral fluid samples", "ORGANISM_SUBSTANCE", 26, 44], ["oral fluid samples", "TEST", 26, 44], ["pen fecal samples", "TEST", 91, 108]]], ["Thus, the data indicated that oral fluids were an effective and sensitive specimen for herd-level rRT-PCRbased detection of PEDV in commercial growing pig environments.DiscussionThe second objective of the study was to describe PEDV serum and oral fluid IgA and IgG antibody kinetics and to estimate the performance of the PEDV \"whole virus\" IgA and IgG indirect ELISAs at different cutoffs.DiscussionFor serum IgG and IgA, respectively, a cutoff of S/ P \u2265 0.80 provided diagnostic sensitivities of 0.87 (95 % (Table 1) .", [["oral fluids", "ANATOMY", 30, 41], ["specimen", "ANATOMY", 74, 82], ["serum", "ANATOMY", 233, 238], ["oral", "ANATOMY", 243, 247], ["serum", "ANATOMY", 405, 410], ["PEDV", "CHEMICAL", 124, 128], ["oral", "ORGANISM_SUBDIVISION", 30, 34], ["PEDV", "SIMPLE_CHEMICAL", 124, 128], ["pig", "ORGANISM", 151, 154], ["PEDV", "ORGANISM", 228, 232], ["serum", "ORGANISM_SUBSTANCE", 233, 238], ["oral", "ORGANISM_SUBDIVISION", 243, 247], ["fluid", "ORGANISM_SUBSTANCE", 248, 253], ["IgA", "GENE_OR_GENE_PRODUCT", 254, 257], ["PEDV", "SIMPLE_CHEMICAL", 323, 327], ["IgA", "GENE_OR_GENE_PRODUCT", 342, 345], ["serum", "ORGANISM_SUBSTANCE", 405, 410], ["IgG", "GENE_OR_GENE_PRODUCT", 411, 414], ["IgA", "GENE_OR_GENE_PRODUCT", 419, 422], ["PEDV", "PROTEIN", 228, 232], ["IgA", "PROTEIN", 254, 257], ["IgG antibody", "PROTEIN", 262, 274], ["IgA", "PROTEIN", 342, 345], ["IgG", "PROTEIN", 350, 353], ["serum IgG", "PROTEIN", 405, 414], ["IgA", "PROTEIN", 419, 422], ["pig", "SPECIES", 151, 154], ["PEDV", "SPECIES", 124, 128], ["pig", "SPECIES", 151, 154], ["PEDV", "SPECIES", 228, 232], ["PEDV", "SPECIES", 323, 327], ["the data", "TEST", 6, 14], ["oral fluids", "TREATMENT", 30, 41], ["herd", "TEST", 87, 91], ["level rRT", "TEST", 92, 101], ["PEDV", "PROBLEM", 124, 128], ["the study", "TEST", 202, 211], ["PEDV serum", "TEST", 228, 238], ["oral fluid IgA", "TEST", 243, 257], ["IgG antibody kinetics", "TEST", 262, 283], ["the PEDV", "TEST", 319, 327], ["IgA", "TEST", 342, 345], ["IgG indirect ELISAs", "TEST", 350, 369], ["serum IgG", "TEST", 405, 414], ["IgA", "TEST", 419, 422], ["a cutoff of S", "TEST", 438, 451], ["diagnostic sensitivities", "TEST", 471, 495], ["pig environments", "OBSERVATION", 151, 167]]], ["Serum IgG results declined slowly over the monitoring period, with 60 % of serum samples positive (S/P \u2265 0.80) at the final sampling on 111 DPE.", [["Serum", "ANATOMY", 0, 5], ["serum samples", "ANATOMY", 75, 88], ["DPE", "CHEMICAL", 140, 143], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["IgG", "GENE_OR_GENE_PRODUCT", 6, 9], ["serum samples", "ORGANISM_SUBSTANCE", 75, 88], ["IgG", "PROTEIN", 6, 9], ["Serum IgG", "TEST", 0, 9], ["serum samples", "TEST", 75, 88]]], ["The utility of the PEDV WV serum IgA ELISA is a question for future research.", [["serum", "ANATOMY", 27, 32], ["serum", "ORGANISM_SUBSTANCE", 27, 32], ["IgA", "GENE_OR_GENE_PRODUCT", 33, 36], ["PEDV", "PROTEIN", 19, 23], ["IgA", "PROTEIN", 33, 36], ["PEDV", "SPECIES", 19, 23], ["the PEDV WV serum IgA ELISA", "TEST", 15, 42]]], ["In particular, research is needed to determine whether the detection of serum IgA, i.e., an antibody isotype necessarily produced by the piglet in response to infection, could be used to identify infection in the face of PEDV-specific colostral (IgG) antibody or whether serum IgA response could be used in a confirmatory assay to clarify equivocal PEDV WV IgG ELISA results.DiscussionFor oral fluid IgG and IgA, respectively, a cutoff of S/P \u2265 0.80 provided diagnostic sensitivities of 0.69 (95 % CI: 0.53, 0.82) and 1.00 (95 % CI: 0.92, 1.00) and diagnostic specificities of 0.97 % (95 % CI: 0.96, 0.98) and 1.00 (95 % CI: 0.99, 1.00).", [["serum", "ANATOMY", 72, 77], ["piglet", "ANATOMY", 137, 143], ["serum", "ANATOMY", 271, 276], ["oral fluid", "ANATOMY", 389, 399], ["infection", "DISEASE", 159, 168], ["infection", "DISEASE", 196, 205], ["serum", "ORGANISM_SUBSTANCE", 72, 77], ["IgA", "GENE_OR_GENE_PRODUCT", 78, 81], ["piglet", "ORGANISM", 137, 143], ["PEDV", "GENE_OR_GENE_PRODUCT", 221, 225], ["colostral", "ORGANISM", 235, 244], ["IgG", "GENE_OR_GENE_PRODUCT", 246, 249], ["serum", "ORGANISM_SUBSTANCE", 271, 276], ["IgA", "GENE_OR_GENE_PRODUCT", 277, 280], ["oral", "ORGANISM_SUBDIVISION", 389, 393], ["IgA", "GENE_OR_GENE_PRODUCT", 408, 411], ["serum IgA", "PROTEIN", 72, 81], ["antibody isotype", "PROTEIN", 92, 108], ["PEDV", "PROTEIN", 221, 225], ["colostral (IgG) antibody", "PROTEIN", 235, 259], ["IgA", "PROTEIN", 277, 280], ["PEDV", "PROTEIN", 349, 353], ["IgG", "PROTEIN", 357, 360], ["oral fluid IgG", "PROTEIN", 389, 403], ["IgA", "PROTEIN", 408, 411], ["PEDV", "SPECIES", 221, 225], ["PEDV", "SPECIES", 349, 353], ["serum IgA", "TEST", 72, 81], ["an antibody isotype", "TEST", 89, 108], ["infection", "PROBLEM", 159, 168], ["infection", "PROBLEM", 196, 205], ["PEDV", "PROBLEM", 221, 225], ["specific colostral (IgG) antibody", "TEST", 226, 259], ["serum IgA response", "TEST", 271, 289], ["a confirmatory assay", "TEST", 307, 327], ["IgG ELISA", "TEST", 357, 366], ["oral fluid IgG", "TEST", 389, 403], ["IgA", "TEST", 408, 411], ["diagnostic sensitivities", "TEST", 459, 483], ["CI", "TEST", 498, 500], ["CI", "TEST", 529, 531], ["diagnostic specificities", "TEST", 549, 573], ["CI", "TEST", 590, 592], ["CI", "TEST", 621, 623], ["infection", "OBSERVATION", 159, 168], ["infection", "OBSERVATION", 196, 205]]], ["Although oral fluid IgG and IgA were detected by 13 DPE, the oral fluid IgA response gave better diagnostic performance than IgG.", [["oral fluid", "ANATOMY", 9, 19], ["oral fluid", "ANATOMY", 61, 71], ["oral", "ORGANISM_SUBDIVISION", 9, 13], ["fluid IgG", "ORGANISM_SUBSTANCE", 14, 23], ["IgA", "GENE_OR_GENE_PRODUCT", 28, 31], ["oral", "ORGANISM_SUBDIVISION", 61, 65], ["IgA", "GENE_OR_GENE_PRODUCT", 72, 75], ["IgG", "GENE_OR_GENE_PRODUCT", 125, 128], ["oral fluid IgG", "PROTEIN", 9, 23], ["IgA", "PROTEIN", 28, 31], ["IgA", "PROTEIN", 72, 75], ["IgG", "PROTEIN", 125, 128], ["oral fluid IgG", "TEST", 9, 23], ["IgA", "TEST", 28, 31], ["the oral fluid IgA response", "TEST", 57, 84], ["fluid IgG", "OBSERVATION", 14, 23]]], ["Notably, the oral fluid IgA response increased through 96 DPE and only began to decline at the last sampling on 111 DPE.DiscussionThere are no prior reports against which to directly compare the PEDV oral fluid antibody kinetics observed in the current study, but DeBuysscher and Berman [12] reported a large increase in IgA-secreting cells within the salivary glands of pigs following oral exposure to another coronavirus, transmissible gastroenteritis virus (TGEV).", [["oral fluid", "ANATOMY", 13, 23], ["oral", "ANATOMY", 200, 204], ["cells", "ANATOMY", 335, 340], ["salivary glands", "ANATOMY", 352, 367], ["oral", "ANATOMY", 386, 390], ["transmissible gastroenteritis", "DISEASE", 424, 453], ["DPE", "CHEMICAL", 116, 119], ["oral", "ORGANISM_SUBDIVISION", 13, 17], ["IgA", "GENE_OR_GENE_PRODUCT", 24, 27], ["oral", "ORGANISM_SUBDIVISION", 200, 204], ["IgA", "GENE_OR_GENE_PRODUCT", 321, 324], ["cells", "CELL", 335, 340], ["salivary glands", "ORGAN", 352, 367], ["pigs", "ORGANISM", 371, 375], ["oral", "ORGANISM_SUBDIVISION", 386, 390], ["coronavirus", "ORGANISM", 411, 422], ["transmissible gastroenteritis virus", "ORGANISM", 424, 459], ["TGEV", "ORGANISM", 461, 465], ["IgA", "PROTEIN", 24, 27], ["IgA", "PROTEIN", 321, 324], ["secreting cells", "CELL_TYPE", 325, 340], ["pigs", "SPECIES", 371, 375], ["coronavirus", "SPECIES", 411, 422], ["transmissible gastroenteritis virus", "SPECIES", 424, 459], ["pigs", "SPECIES", 371, 375], ["transmissible gastroenteritis virus", "SPECIES", 424, 459], ["TGEV", "SPECIES", 461, 465], ["the oral fluid IgA response", "TEST", 9, 36], ["the PEDV oral fluid antibody kinetics", "TEST", 191, 228], ["the current study", "TEST", 241, 258], ["a large increase in IgA-secreting cells", "PROBLEM", 301, 340], ["oral exposure", "PROBLEM", 386, 399], ["another coronavirus", "PROBLEM", 403, 422], ["transmissible gastroenteritis virus", "PROBLEM", 424, 459], ["increased", "OBSERVATION_MODIFIER", 37, 46], ["large", "OBSERVATION_MODIFIER", 303, 308], ["increase", "OBSERVATION_MODIFIER", 309, 317], ["IgA", "OBSERVATION", 321, 324], ["secreting cells", "OBSERVATION", 325, 340], ["salivary glands", "ANATOMY", 352, 367]]], ["On the other hand, Brandtzaeg [13] noted that enteric stimulation does not necessarily produce a strong salivary IgA response in humans.", [["salivary", "ANATOMY", 104, 112], ["salivary", "ORGAN", 104, 112], ["IgA", "GENE_OR_GENE_PRODUCT", 113, 116], ["humans", "ORGANISM", 129, 135], ["IgA", "PROTEIN", 113, 116], ["humans", "SPECIES", 129, 135], ["humans", "SPECIES", 129, 135], ["enteric stimulation", "TREATMENT", 46, 65]]], ["Because of similarities in experimental design, these data may also be compared to oral fluid IgG and IgA responses reported for porcine reproductive and respiratory syndrome virus (PRRSV) and influenza A virus (IAV) [14, 15] .", [["oral fluid", "ANATOMY", 83, 93], ["porcine reproductive and respiratory syndrome", "DISEASE", 129, 174], ["influenza A virus", "DISEASE", 193, 210], ["oral", "ORGANISM_SUBDIVISION", 83, 87], ["IgA", "GENE_OR_GENE_PRODUCT", 102, 105], ["porcine reproductive and respiratory syndrome virus", "ORGANISM", 129, 180], ["PRRSV", "ORGANISM", 182, 187], ["influenza A virus", "ORGANISM", 193, 210], ["IAV", "ORGANISM", 212, 215], ["oral fluid IgG", "PROTEIN", 83, 97], ["IgA", "PROTEIN", 102, 105], ["porcine", "SPECIES", 129, 136], ["PRRSV", "SPECIES", 182, 187], ["influenza A virus", "SPECIES", 193, 210], ["respiratory syndrome virus", "SPECIES", 154, 180], ["PRRSV", "SPECIES", 182, 187], ["influenza A virus", "SPECIES", 193, 210], ["IAV", "SPECIES", 212, 215], ["oral fluid IgG", "TEST", 83, 97], ["IgA responses", "TEST", 102, 115], ["porcine reproductive and respiratory syndrome virus", "PROBLEM", 129, 180], ["PRRSV", "PROBLEM", 182, 187], ["influenza", "PROBLEM", 193, 202], ["respiratory syndrome", "OBSERVATION", 154, 174]]], ["Kittawornrat et al. [14] evaluated PRRSV oral fluid IgG and IgA responses using pen-based field samples and experimental oral fluid samples.", [["oral", "ANATOMY", 41, 45], ["oral fluid samples", "ANATOMY", 121, 139], ["PRRSV", "ORGANISM", 35, 40], ["oral", "ORGANISM_SUBDIVISION", 41, 45], ["IgG", "ORGANISM_SUBSTANCE", 52, 55], ["IgA", "GENE_OR_GENE_PRODUCT", 60, 63], ["oral", "ORGANISM_SUBDIVISION", 121, 125], ["fluid samples", "ORGANISM_SUBSTANCE", 126, 139], ["PRRSV oral fluid IgG", "PROTEIN", 35, 55], ["IgA", "PROTEIN", 60, 63], ["PRRSV", "SPECIES", 35, 40], ["PRRSV", "SPECIES", 35, 40], ["PRRSV oral fluid IgG", "TEST", 35, 55], ["IgA responses", "TEST", 60, 73], ["pen-based field samples", "TEST", 80, 103], ["experimental oral fluid samples", "TEST", 108, 139]]], ["Using a commercial PRRS serum antibody ELISA adapted to oral fluids, IgG was readily detected and provided a diagnostic sensitivity of 0.95 (95 % CI: 0.92, 0.97) and specificity of 1.00 (95 % CI: 0.99, 1.00).", [["serum", "ANATOMY", 24, 29], ["oral fluids", "ANATOMY", 56, 67], ["PRRS", "ORGANISM", 19, 23], ["serum", "ORGANISM_SUBSTANCE", 24, 29], ["oral", "ORGANISM_SUBDIVISION", 56, 60], ["IgG", "GENE_OR_GENE_PRODUCT", 69, 72], ["IgG", "PROTEIN", 69, 72], ["PRRS", "SPECIES", 19, 23], ["a commercial PRRS serum antibody ELISA", "TEST", 6, 44], ["oral fluids", "TREATMENT", 56, 67], ["IgG", "TEST", 69, 72], ["a diagnostic sensitivity", "TEST", 107, 131], ["CI", "TEST", 146, 148], ["specificity", "TEST", 166, 177], ["CI", "TEST", 192, 194]]], ["In contrast, the IgA response in oral fluid was detectable, but weak and transient.", [["oral fluid", "ANATOMY", 33, 43], ["IgA", "GENE_OR_GENE_PRODUCT", 17, 20], ["oral fluid", "ORGANISM_SUBSTANCE", 33, 43], ["IgA", "PROTEIN", 17, 20], ["the IgA response in oral fluid", "TEST", 13, 43], ["fluid", "OBSERVATION", 38, 43], ["transient", "OBSERVATION_MODIFIER", 73, 82]]], ["Panyasing et al. [15] evaluated influenza A virus IgG and IgA responses in oral fluids.", [["oral fluids", "ANATOMY", 75, 86], ["influenza A virus", "ORGANISM", 32, 49], ["IgG", "ORGANISM_SUBSTANCE", 50, 53], ["IgA", "GENE_OR_GENE_PRODUCT", 58, 61], ["oral", "ORGANISM_SUBDIVISION", 75, 79], ["IgA", "PROTEIN", 58, 61], ["influenza A virus", "SPECIES", 32, 49], ["influenza A virus", "SPECIES", 32, 49], ["influenza", "PROBLEM", 32, 41], ["A virus IgG", "TEST", 42, 53], ["IgA responses", "TEST", 58, 71], ["oral fluids", "TREATMENT", 75, 86]]], ["Unlike the PRRSV response, both anti-IAV IgG and IgA were readily detected in oral fluids by~7 DPI and throughout the study (DPI 42).", [["oral fluids", "ANATOMY", 78, 89], ["PRRSV", "ORGANISM", 11, 16], ["anti-IAV IgG", "GENE_OR_GENE_PRODUCT", 32, 44], ["IgA", "GENE_OR_GENE_PRODUCT", 49, 52], ["oral", "ORGANISM_SUBDIVISION", 78, 82], ["anti-IAV IgG", "PROTEIN", 32, 44], ["IgA", "PROTEIN", 49, 52], ["PRRSV", "SPECIES", 11, 16], ["anti-IAV", "SPECIES", 32, 40], ["the PRRSV response", "PROBLEM", 7, 25], ["both anti-IAV IgG", "TEST", 27, 44], ["IgA", "TEST", 49, 52], ["the study", "TEST", 114, 123], ["PRRSV response", "OBSERVATION", 11, 25]]], ["These studies suggest that oral fluid IgG and IgA kinetics vary among pathogens.", [["oral", "ANATOMY", 27, 31], ["oral", "ORGANISM_SUBDIVISION", 27, 31], ["IgG", "GENE_OR_GENE_PRODUCT", 38, 41], ["IgA", "GENE_OR_GENE_PRODUCT", 46, 49], ["oral fluid IgG", "PROTEIN", 27, 41], ["IgA", "PROTEIN", 46, 49], ["These studies", "TEST", 0, 13], ["oral fluid IgG", "TEST", 27, 41], ["IgA kinetics", "PROBLEM", 46, 58], ["fluid IgG", "OBSERVATION", 32, 41]]], ["Thus, it will be critical to evaluate antibody isotype kinetics during the process of adapting antibody assays to the swine oral fluid matrix.DiscussionFor disease surveillance in swine populations, diagnostic specificity is paramount because false positives quickly erode confidence in test results.", [["oral fluid matrix", "ANATOMY", 124, 141], ["swine", "ORGANISM", 118, 123], ["oral", "ORGANISM_SUBDIVISION", 124, 128], ["fluid matrix", "CELLULAR_COMPONENT", 129, 141], ["antibody isotype", "PROTEIN", 38, 54], ["swine", "SPECIES", 118, 123], ["swine", "SPECIES", 180, 185], ["swine", "SPECIES", 118, 123], ["swine", "SPECIES", 180, 185], ["antibody isotype kinetics", "PROBLEM", 38, 63], ["adapting antibody assays", "TEST", 86, 110], ["disease surveillance", "TEST", 156, 176], ["diagnostic specificity", "TEST", 199, 221], ["false positives", "PROBLEM", 243, 258]]], ["Therefore, the investigators recommend a conservative S/P cutoff for serum and oral fluid samples, e.g., \u2265 0.80 for routine use.", [["serum", "ANATOMY", 69, 74], ["oral fluid samples", "ANATOMY", 79, 97], ["serum", "ORGANISM_SUBSTANCE", 69, 74], ["oral fluid samples", "ORGANISM_SUBSTANCE", 79, 97], ["serum and oral fluid samples", "TEST", 69, 97]]], ["However, diagnostic sensitivity and specificity were presented forConclusionThe purpose of surveillance is to provide timely information on pathogen exposure and immune responses in swine populations in order to optimize health and prevent disease.", [["swine", "SPECIES", 182, 187], ["swine", "SPECIES", 182, 187], ["diagnostic sensitivity", "TEST", 9, 31], ["specificity", "TEST", 36, 47], ["pathogen exposure", "TREATMENT", 140, 157], ["immune responses in swine populations", "TREATMENT", 162, 199], ["disease", "PROBLEM", 240, 247]]], ["Well-validated, reproducible, high-throughput nucleic acid and antibody assays are necessary to achieve this purpose.", [["nucleic acid", "CHEMICAL", 46, 58], ["nucleic acid", "TEST", 46, 58], ["antibody assays", "TEST", 63, 78], ["reproducible", "OBSERVATION_MODIFIER", 16, 28], ["high", "OBSERVATION_MODIFIER", 30, 34]]], ["This study showed that oral fluid-based testing could provide an easy and \"animal-friendly\" approach to nucleic acid and/or antibody-based surveillance of PEDV in swine populations.", [["oral", "ANATOMY", 23, 27], ["nucleic acid", "CHEMICAL", 104, 116], ["PEDV", "CHEMICAL", 155, 159], ["oral", "ORGANISM_SUBDIVISION", 23, 27], ["nucleic acid", "SIMPLE_CHEMICAL", 104, 116], ["PEDV", "SIMPLE_CHEMICAL", 155, 159], ["swine", "ORGANISM", 163, 168], ["swine", "SPECIES", 163, 168], ["PEDV", "SPECIES", 155, 159], ["swine", "SPECIES", 163, 168], ["This study", "TEST", 0, 10], ["oral fluid-based testing", "TEST", 23, 47], ["nucleic acid", "TEST", 104, 116], ["antibody", "TEST", 124, 132], ["PEDV", "PROBLEM", 155, 159]]], ["In particular, the exceptional strength and duration of the PEDV IgA antibody response in oral fluids raises the question as to its ability to serve as an indicator of protective immunity; this is a question for future research.Availability of data and materialsThe data is available upon request from the corresponding author.Availability of data and materialsAuthors' contribution JBK participated in study design, implementation of the study, analysis, and writing of the manuscript.", [["oral fluids", "ANATOMY", 90, 101], ["IgA", "GENE_OR_GENE_PRODUCT", 65, 68], ["oral", "ORGANISM_SUBDIVISION", 90, 94], ["PEDV IgA antibody", "PROTEIN", 60, 77], ["PEDV", "SPECIES", 60, 64], ["the PEDV IgA antibody response", "TEST", 56, 86], ["oral fluids", "TREATMENT", 90, 101], ["the study", "TEST", 435, 444], ["analysis", "TEST", 446, 454]]], ["KW participated in study design, implementation of the study.Availability of data and materialsLGL developed the PEDV WV ELISA, carried out immunoassays, and helped draft the manuscript.", [["PEDV", "SPECIES", 113, 117], ["the study", "TEST", 51, 60], ["the PEDV WV ELISA", "TEST", 109, 126], ["immunoassays", "TEST", 140, 152]]], ["MR participated in study design and implementation of the study.", [["MR", "PROTEIN", 0, 2], ["MR", "TEST", 0, 2], ["the study", "TEST", 54, 63]]], ["CW and YS performed statistical analyses.", [["statistical analyses", "TEST", 20, 40]]], ["PL participated in the study design and implementation of the study.", [["the study", "TEST", 19, 28], ["the study", "TEST", 58, 67]]], ["JQZ participated in the study design and writing.", [["JQZ", "CHEMICAL", 0, 3]]], ["DB carried out immunoassays.", [["immunoassays", "TEST", 15, 27]]], ["PG carried out molecular studies.", [["PG", "CHEMICAL", 0, 2], ["molecular studies", "TEST", 15, 32]]], ["RM conceived of the study, participated in study design, and implementation of the study.", [["the study", "TEST", 16, 25], ["the study", "TEST", 79, 88]]], ["JZ participated in study design, data analysis, and writing.", [["data analysis", "TEST", 33, 46]]]]}